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ABSTRACT 
Signal transduction networks comprising protein-protein interactions (PPIs) 
mediate homeostatic, diseased, and therapeutic cellular responses. Mapping these 
networks has primarily focused on identifying interactors, but less is known about the 
interaction affinity, rates of interaction or their regulation. To better understand the extent 
of the annotated human interactome, I first examined > 2500 protein interactions within 
the B cell receptor (BCR) signaling pathway using a current, cutting-edge 
bioluminescence-based platform called “NanoBRET” that is capable of analyzing 
transient and stable interactions in high throughput. Eighty-three percent (83%) of the 
detected interactions have not been previously reported, indicating that much of the BCR 
pathway is still unexplored. Unfortunately, NanoBRET, as with all other high throughput 
methods, cannot determine binding kinetics or affinities. To address this shortcoming, I 
developed a hybrid platform that characterizes > 400 PPIs quantitatively and 
simultaneously in < 1 hour by combining the high throughput and flexible nature of 
nucleic programmable protein arrays (NAPPA) with the quantitative abilities of surface 
plasmon resonance imaging (SPRi). NAPPA-SPRi was then used to study the kinetics 
and affinities of > 12,000 PPIs in the BCR signaling pathway, revealing unique kinetic 
mechanisms that are employed by proteins, phosphorylation and activation states to 
regulate PPIs. In one example, activation of the GTPase RAC1 with nonhydrolyzable 
GTP-γS minimally affected its binding affinities with phosphorylated proteins but 
increased, on average, its on- and off-rates by 4 orders of magnitude for one-third of its 
interactions. In contrast, this phenomenon occurred with virtually all unphosphorylated 
  
ii 
proteins. The majority of the interactions (85%) were novel, sharing 40% of the same 
interactions as NanoBRET as well as detecting 55% more interactions than NanoBRET. 
In addition, I further validated four novel interactions identified by NAPPA-SPRi using 
SDS-PAGE migration and Western blot analyses. In one case, we have the first evidence 
of a direct enzyme-substrate interaction between two well-known proto-oncogenes that 
are abnormally regulated in > 30% of cancers, PI3K and MYC. Herein, PI3K is 
demonstrated to phosphorylate MYC at serine 62, a phosphosite that increases the 
stability of MYC. This study provides valuable insight into how PPIs, phosphorylation, 
and GTPase activation regulate the BCR signal transduction pathway. In addition, these 
methods could be applied toward understanding other signaling pathways, pathogen-host 
interactions, and the effect of protein mutations on protein interactions.  
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PREFACE 
A comprehensive understanding of the dynamic and complex signaling networks 
within cells remains one of the grand challenges in the pursuit for precision medicine. In 
regards to cancer, therapy resistance and disease recurrence largely occur through 
multiple, yet interconnected pathways that help the diseased cell(s) to evade treatment, 
the immune response, and normal physiological cell-death signals. The identification of 
the key proteins involved in pathway crosstalk or driving disease progression and therapy 
resistance will no doubt aid in creating targeted and combinatorial therapy approaches 
that will be more effective than current treatments. For sure, the successful story of 
imatinib mesylate, sold under the trade name of “Gleevec,” in treating chronic 
myelogenous leukemia (CML) by specifically targeting the BCR-ABL protein 
underscores the potential impact of understanding diseases at the molecular level. 
Combinatorial therapy has been repeatedly proven to be more effective than single-drug 
cancer treatment over the last five decades. For instance, the FLT3 tyrosine kinase with 
an internal tandem duplication mutation (FLT3-ITD) results in constitutive activation of 
the kinase and, subsequently, acute myeloid leukemia (AML). The small-molecule drug 
sorafenib in combination with chemotherapy was recently shown in a phase II clinical 
trial to increase the 1-year survival rate in older AML-FLT3-ITD patients than standard 
chemotherapy alone (Uy et al., 2015). 
Given the importance of protein-protein interactions (PPIs), it is surprising that 
their binding kinetics and affinities have been studied only minimally. Numerous 
techniques, which are discussed in more detail in Chapter 1, have been developed to 
  
xlvi 
study PPIs. However, many of them rely on stable interactions even though protein 
interactions are known to occur over a wide range of affinities (i.e., strengths) and 
kinetics (i.e., rates). Moreover, none of the available approaches can assess unique 
binding events quantitatively in a high throughput manner, thus resulting in a paucity of 
affinity and kinetic information. The B cell receptor (BCR) signaling pathway, for 
example, is considered to be one of the most well understood pathways, involving > 100 
proteins and potentially > 2100 interactions, yet most of its interactions have been studied 
using classic equilibrium-based assays and only 12 protein interactions have been 
characterized quantitatively.  
Scientists and mathematicians have proposed that models, built from large-scale 
binding affinity information and protein abundance data, could improve our 
understanding of signaling pathways and allow prediction of cellular outcomes. Such 
models would rely on sufficient data about the participants in the pathways, their 
abundance, and their interaction characteristics to be accurate. I chose to study the BCR 
pathway because it was already well studied, still had room for additional discovery and 
because my collaborators were studying other aspects of the pathway that eventually 
would strengthen our model. I first studied the BCR signaling pathway using an 
equilibrium assay, albeit a modern one with the potential to detect some transient 
interactions.  I then developed an entirely new methodology that could detect even more 
interactions (including weak ones) and which would provide kinetic data on interaction 
rates.  
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In this thesis, > 2500 protein interactions of the BCR signaling pathway were first 
examined using a current, cutting edge technology in which transient and stable 
interactions can be detected in high throughput. Seventy-two known and 401 previously 
unreported protein interactions were identified, highlighting the fact that the BCR 
pathway – and the human interactome – remain largely unexplored. Just like other high 
throughput protein interaction methods, however, the binding rates and affinities of these 
interactions could not be characterized. To address this need, this thesis describes how a 
high throughput protein microarray platform was combined with a traditionally low 
throughput technique capable of studying binding events in real-time to analyze > 400 
protein interactions in less than an hour. The hybrid “NAPPA-SPRi” technology then 
studied > 12,000 PPIs within the BCR signaling pathway under different protein 
activation and phosphorylation states. An initial steady state model of the B cell is 
currently being built from kinetic and protein abundance data obtained from NAPPA-
SPRi  and mass spectrometry, respectively. This project represents the first high 
throughput, quantitative analyses of protein-protein interactions for any signaling 
pathway. 
In Chapter 1, the history of how protein-protein interactions were conceptualized 
is examined. Chapter 2 focuses on the current techniques to study PPIs and reviews what 
is known about the BCR signaling pathway. Chapter 3 contains the qualitative analyses 
of > 2500 protein interactions in the BCR signaling pathway as determined by a high 
throughput bioluminescence-based approach. Chapters 4 – 7 cover the development of 
the technology, methodology, and software, respectively, regarding NAPPA-SPRi 
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applications and analyses. Chapter 8 contains the quantitative analyses of the PPIs in the 
BCR signaling pathway by NAPPA-SPRi. The data are also discussed in the context of 
biology – for example, what is the biological purpose of increasing the on-rate for a 
particular PPI? Finally, in Chapter 9, a description of how the NAPPA-SPRi data can be 
incorporated into a steady state model of B cell response and a perspective on the 
potential uses and impact of NAPPA-SPRi are given
1 
 
CHAPTER 1 
1   PROTEIN-PROTEIN INTERACTIONS  
1.1   History of protein-protein interactions: from solitary molecules to protein networks  
External stimuli are transmitted through the membrane by cell surface receptors, 
and then propagated through the cell via protein-protein interactions to elicit specific 
cellular responses. Disruptions to normal signaling from aberrant proteins (e.g., from 
mutation or altered expression) or chemicals can therefore initiate disease (Gonzalez & 
Kann, 2012). However, protein interactions in homeostasis and disease were not 
appreciated until the mid- to late-20th century.  
Prior to the 1940s, proteins were largely considered to be solitary molecules 
without much function. Then, following the discovery that myosin B, a protein that had 
been studied for nearly a century, was actually a complex of myosin and actin, physical 
associations between proteins were observed with increasing frequency (Braun & 
Gingras, 2012). Proteins’ three-dimensional structures and their effect on interactions 
also became of interest. The first signal transduction pathway, which happened to also be 
a kinase cascade, was identified in 1968 during a time when phosphoproteins were 
believed to be “biologically inert and (…) uninteresting.” The Krebs laboratory showed 
that protein kinase A activated phosphorylase kinase in response to increases in cyclic 
AMP. The activation of phosphorylase kinase via phosphorylation was proven a year 
later. In the 1970s and 1980s, protein interactions became widely recognized as essential 
for most cellular responses following studies that showed their roles in homeostasis and 
disease, like the cell cycle and cancer. In 1990, the src homology domain (SH2) 
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preferentically interacted with phosphorylated proteins, providing proof that specific 
domains mediate interactions with post translational modifications. It also suggested that 
dynamic protein interactions may occur more often than originally believed. Within a 
decade, low throughput technologies became commercially available that could 
characterize the interaction strengths and the rates at which the proteins bound and 
unbound, like surface plasmon resonance and isothermal titration calorimetry (see 
Chapters 1.3 and 4.1.2). High throughput studies using yeast-2-hybrid and affinity 
purification mass spectrometry constructed the first large-scale maps of the interactome 
in the early 2000s. These data provided insights into the structural organization of protein 
networks as well as assigning biological function(s) to unknown proteins unveiled by the 
Human Genome Project.  
The importance of understanding signaling pathways was underscored in 2001 
with the first U.S. Food and Drug Administration (FDA)-approved small molecule 
“targeted therapy” kinase inhibitor, “Gleevec,” to treat chronic myelogenous leukemia 
(CML) (Kurzrock & Markman, 2008). Gleevec, also known as imatinib mesylate, was 
specifically designed to 
bind and block the activity 
of a fusion kinase, BCR-
ABL, since the active form 
results in unchecked cell 
proliferation in CML 
patients (Figure 1). Figure 1. Mechanism of action of Gleevec (imatinib mesylate) 
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Gleevec increased the percentage of complete cytogenetic responses in chronic phase 
CML patients from 5% - 25% to 50 – 60%. Further understanding of CML’s initial or 
eventual tumor resistance to Gleevec has led to the development of more powerful kinase 
inhibitors, including dasatinib, nilotinib, and bosutinib. Within 10 years of Gleevec’s 
release, drugs targeting the epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor (VEGF), and the proteasome became available to treat 
advanced non-small cell lung cancer, kidney and some gastrointestinal stromal tumors, 
and multiple myeloma, respectively.  
 
1.2   Current understanding of protein-protein interactions 
The human genome contains ~ 20,000 – 25,000 protein-coding genes that result in  
> 2 million protein species due to post-transcriptional alterations, mutations, and post 
translational modifications (PTMs) (Ponomarenko et al., 2016). Histone H4 alone, with 
combinations of its twenty PTMs, could represent > 3 million protein species with 
different protein interactions and functions (Phanstiel et al., 2008). The physical 
interactions between the 
proteins are specific and 
dynamic, resulting in signaling 
pathways that are often 
represented as independent, 
linear chain of events extending 
from the cell membrane to the 
Figure 2. Signaling pathways can converge, diverge, and crosstalk with 
each other.  
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nucleus and eliciting a specific cellular phenotype(s) (e.g., proliferation, apoptosis). 
However, signal transduction via these protein-protein interactions (PPIs) is much more 
complex and interconnected where the pathways converge, diverge, and crosstalk with 
each other (Figure 2) (Karp & Patton, 2013). Convergence is when two or more different 
pathways result in the same molecular or cellular response. Divergence is when multiple 
signaling pathways are activated from a single stimulus. Crosstalk occurs when proteins 
are involved in more than one signaling pathway. Signaling cascades can be driven by a 
small number of proteins called “driver nodes.” Thus, charting PPIs in homeostasis and 
disease would have a significant impact on medicine by identifying potential 
pharmacological targets. One of these targets, for example, could be a driver node that 
enables “disease crosstalk.” Moreover, an in-depth understanding of how signaling 
pathways crosstalk with each other – and ultimately cause treatment resistance – will be 
fundamental in designing more effective combinational therapies based on the unique 
profile of the disease or patient. 
Despite its importance, a complete PPI map of any species has proven to be a 
daunting task. The human proteome network, for instance, contains an estimated ~ 
650,000 PPIs (Stumpf et al., 2008), with 49% of these estimated PPIs annotated in the 
Biological General Repository for Interaction Datasets (BioGRID) interaction database 
(Stark et al., 2006)(319,419 unique physical and genetic human PPIs; BioGRID database 
statistics 2018). It is probable that the coverage is much less since the PPI estimate does 
not take into account multiple splice variants and is based on experiments that are 
uninformative and inherently biased toward stable PPIs and scientific interests. For 
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example, equilibrium-based assays, which are commonly employed to study protein 
interactions, generally detect interactions with high binding affinities. Many experiments 
focus on studying arbitrary subsets of proteins that are known to be involved in disease, 
in a process that can be tautological. Moreover, very few studies fully annotate the PTMs 
of the proteins involved and detection methods are biased toward detecting highly 
abundant proteins. These reasons likely contribute to the notoriously small overlap across 
interaction datasets. A comparison of high throughput yeast interactions, for instance, 
revealed that only 14% of the detected PPIs were identified across different studies and 
methods (Reguly et al., 2006). Two independent large-scale yeast-2-hybrid screens using 
the same method had < 30% overlap (Ito et al., 2001). 
Whether and how proteins physically interact with each other can be affected by 
numerous factors; for example, amino acid mutations, truncations, PTMs, co-regulators, 
intracellular location, viscosity, protein abundance, available domains, viruses, and 
conformation. Given the numerous aspects that can affect PPIs, it should come as no 
surprise that alterations to these finely-tuned protein signaling networks can lead to 
disease, including Huntington’s disease, Von Hippel-Lindau syndrome, cystic fibrosis, 
Alzheimer’s disease, and cervical cancer (Gonzalez & Kann, 2012). In autosomal 
recessive Cystic fibrosis, a mutant CFTR gene results in an amino acid deletion in the 
middle of the translated protein that renders it non-functional, resulting in the inability of 
sodium and chloride molecules to be transported across membranes (Mall & Galietta, 
2015). Amino acid substitutions in the NOD2 protein result in a 2- or 40-fold risk 
increase for acquiring Crohn’s disease depending on whether the person is heterozygous 
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or homozygous for the mutations, respectively (King et al., 2006). The mutations occur in 
regions responsible for detecting bacteria and NF-κB signaling. Estrogen (ER)-positive 
breast cancers are treated with a small molecule drug Tamoxifen. However, not all ER-
positive breast cancer patients respond similarly to the drug. For example, the 
phosphorylation of ERα at serine residue 118 results in a better clinical outcome when 
using Tamoxifen than the unphosphorylated form (de Leeuw, Neefjes, & Michalides, 
2011). On the other hand, breast cancer patients with serine phosphorylation at amino 
acid residue 305 of ERα do not respond to Tamoxifen. Finally, viral proteins can interact 
with endogenous proteins and alter homeostatic signaling networks. Human 
papillomavirus (HPV) increases the risk for developing cervical cancer because it 
encodes for E6 and E7 proteins, which bind to and inactivate the tumor suppressor 
protein TP53 (Yim & Park, 2005). 
Bi-molecular interactions are described using the equation A + B  AB where A 
and B represent two different proteins while AB represents the resulting complex 
(Goodrich & Kugel, 2007). The binding affinity, also known as the dissociation constant 
KD, is generally described as the fraction of unbound proteins to bound proteins (i.e., 
[A][B]/[AB]) at equilibrium. Lower dissociation constants refer to protein interactions 
that strongly favor binding, resulting in most of the A and B proteins in the bound state at 
equilibrium (i.e., high binding affinity).  
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Interactions are also described in 
terms of the rates that A and B bind 
together (i.e., on-rate or ka) and the rate 
at which AB dissociates into the two free 
molecules (i.e., off-rate or kd). The 
association and dissociation rates at 
which AB forms and separates into its 
individual components, respectively, can 
be further used to determine the strength of the interaction (i.e., affinity). Thus, KD can 
also be represented by the dissociation rate, kd, divided by the association rate, ka. 
Therefore, quantitative analyses of protein interactions can reveal whether the interaction 
is stable or transient, which has dissociations constants in the pM-nM and µM range, 
respectively. It is possible that protein interactions may have the same binding affinity 
but have different on- and off-rates as long as the changes to the binding rates are 
proportional (Figure 3). This raises the question about whether protein interactions are 
regulated at the level of binding strength (proportion of molecules bound at equilibrium; 
KD), binding rates or both. To date, many more binding affinities have been collected 
than the on- and off-rates, which is largely due to two reasons. First, there are more 
available methods that can measure or estimate binding affinities than methods that can 
determine binding kinetics (see next section, Chapter 1.3). Second, it has been assumed 
that reasonable estimates of off-rates can be determined from the binding affinities 
because the on-rates for most proteins are believed to occur within a narrow range of 106 
Figure 3. Same KD, different on- and off-rates 
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to 107 M-1s-1 due to diffusion and protein size (Pollard, 2010). As such, the dissociation 
rate is often regarded as the main factor that determines binding affinity.  
 
1.3   Current methods for studying protein-protein interactions 
Protein-protein interactions can be predicted and studied using in silico 
approaches (Gonzalez & Kann, 2012; Wetie et al., 2014). The first step toward computer 
modeling of PPIs is to obtain structural information about the proteins-of-interest (POIs) 
since protein conformation can drastically affect whether and how a protein can interact 
with another protein (or other molecule). Protein structure can be obtained from 
databases using experimentally-produced data like Protein Data Bank or simulated using 
homology modeling (e.g., SwissModel, M4T, Modeller), de novo modeling (e.g., I-
TASSER, Phre2), or threading (e.g., NovaFold, I-TASSER). The second step relies on 
virtual analyses of the structures and, sometimes, how the proteins behave over time 
and/or in various environments. The third and final step of in silico analyses is the 
calculation of the thermodynamics of protein complexes based on protein orientation and 
binding epitope(s). This information can help predict the likelihood that two proteins will 
interact with each other and, if so, where and when they are most likely to bind.  
Numerous “wet lab” methods have been developed to study PPIs, yet very few 
provide quantitative (i.e., kinetic, affinity) information in a high throughput way 
(Gonzalez & Kann, 2012; Meyerkord & Fu, 2015; Wetie et al., 2014; Zhou, Li, & Wang, 
2016). For example, commonly employed low throughput and qualitative methods 
include fluorescence gel retardation assay, far-Western blot, X-ray crystallography, and 
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fluorescence resonance energy transfer (FRET)(Table 1). A fluorescence gel retardation 
assay applies potential complexes-of-interest to an SDS-PAGE gel; any resulting PPIs are 
identified by a shift in their gel migration when compared to the shift of single proteins. 
In far-Western blots, proteins separated via gel and transferred onto a membrane are 
probed with a labeled query protein, which is then used to determine its interaction 
partners. X-ray crystallography studies protein-protein structures by measuring the X-ray 
diffraction pattern of the crystallized complex. FRET employs chromophore-attached 
POIs that fluoresce at a different wavelength when they are in very close proximity to 
each other; FRET measures this change in fluorescence to detect interactions. 
Table 1. Capabilities of the most common methods for analyzing protein interactions 
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Bioluminescence resonance energy transfer (BRET) measures the change in emitted 
fluorescence where the resonance energy donor species is a luciferase. 
High throughput qualitative methods for characterizing PPIs include phage 
display, mass spectrometry, 2-hybrid, protein microarrays, pull-down assays (e.g., co-
immunoprecitation), and FRET\BRET. In phage display, a POI is displayed on a 
bacteriophage and then screened against other proteins. Mass spectrometry can identify 
PPIs in a couple of ways: it can ascertain which proteins are in a pull-down assay and 
analyze the contact areas of interacting proteins that are protected from proteolytic 
cleavage. 2-hybrid approaches identify PPIs by fusing one part of a transcription factor to 
a bait protein and the other part to a prey protein. If the proteins interact with each other, 
the transcription factor can bind to and initiate the transcription of a reporter gene. The 2-
hybrid approach, however, has high false positive and negative rates that are estimated to 
be 50 – 70% and 43 – 90%, respectively (Deane, Salwinski, Xenarios, & Eisenberg, 
2002; Huang & Bader, 2009). Protein interactions can be studied using protein 
microarrays by incubating the array with a known POI fused to a detectable tag. After 
washing off non-bound proteins, the tag location is determined and, since the address of 
each arrayed protein is known, the corresponding protein partner on the array can be 
identified. Pull-down assays extract a bait protein-of-interest (primarily via an antibody) 
along with its interacting proteins from solution. Since they isolate protein interaction 
complexes, the identified proteins may not interact directly but can bind through one or 
more bridging proteins. Without the use of chemical cross-linking (explained in more 
detail on page 12), pull-down assays also require the protein interactions to be stable 
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enough to withstand the washes prior to sample elution. In FRET and BRET, the POIs 
have fluorophore or luciferase tags, respectively, that will emit at a specific wavelength 
when a PPI occurs. More specific detail about FRET and BRET is on page 37. 
Protein microarrays detect PPIs in a concentration-independent manner unlike in 
vivo methods that are biased toward detecting highly abundant proteins. Detecting 
interactions in a concentration-independent manner is advantageous because protein 
microarrays can 1) identify interactions between low abundance proteins that may 
significantly affect cellular responses, and 2) offer an unbiased detection of PPIs 
regardless of cellular state since the amount of proteins can be drastically different across 
conditions. While protein microarrays are primarily utilized for detecting strong PPIs 
(i.e., antigen-antibody interactions), transient interactions can be detected with protein 
microarrays in an indirect fashion. For example, protein targets of AMPylators can be 
determined by incubating an array with an AMPylator and N6pATP, and then identifying 
the location of the N6pATP (X. B. Yu & LaBaer, 2015). Reviews of the different types of 
protein microarrays in which I am first co-author include “Advancing translational 
research with next-generation protein microarrays” and “Advances in cell-free protein 
array methods” (X. Yu, Petritis, Duan, Xu, & LaBaer, 2018; X. B. Yu, Petritis, & 
LaBaer, 2016). I also co-authored a manuscript entitled “Multiplexed Nucleic Acid 
Programmable Protein Arrays” (X. B. Yu et al., 2017). This article describes a 
modification to Nucleic Acid Programmable Protein Arrays, or NAPPA (see also Chapter 
4.1.1), where as many as five different proteins are displayed in one feature for high 
throughput, cost-effective biomarker screening and discovery.  
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Chemical cross-linking essentially “freezes” a PPI, thus allowing the detection of 
both stable and transient interactions by SDS-PAGE, in-gel digestion, and shotgun liquid 
chromatography mass spectrometry (Tang & Bruce, 2009). The reactive groups on the 
cross-linker act as a covalent bridge between interacting proteins. Numerous cross-linkers 
are available, although all of them have two or more reactive groups separated by a 
spacer, which may or may not be cleavable. Unfortunately, this approach has its 
disadvantages (Bruce, 2012). Most cross-linkers are lysine-reactive, which can be 
problematic for mass spectrometry analyses where the proteins are usually digested by 
the protease, trypsin, that also cuts at lysine residues (Holding, 2015). The identification 
of the protein partners during mass spectrometry analyses is challenging due to the 
additional mass of the cross-linker and a fragmentation spectrum that contains product 
ions from both peptides. Cross-linkers will covalently bind to anything within their reach, 
which means that proteins that are in close proximity, but not necessarily in contact with 
each other, will be crosslinked to each other. Finally, the binding rates or affinities cannot 
be determined with cross-linked protein complexes. The false detection rate for chemical 
cross-linking is unknown, but nonspecific binding of proteins to the crosslinked 
complexes during sample processing or to the stationary phase used for protein 
purification have been documented. Stringent washing during the enrichment procedure 
and utilization of short cross-linkers is assumed to decrease the number of non-
crosslinked and nonspecific interactions that are identified, respectively.  
The most common low throughput and quantitative (i.e., affinity, kinetics) 
methods for PPI analyses include circular dichroism (CD), surface plasmon resonance 
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(SPR), isothermal titration calorimetry (ITC), nuclear magnetic resonance (NMR), 
affinity capillary electrophoresis (ACE), and fluorescence polarization assay. CD detects 
changes in the far ultraviolent spectra to quantify PPIs since the changes are proportional 
to the number of protein-protein complexes that are formed. Interactions between 
unlabeled proteins can be quantitatively observed with SPR, which detects refractive 
index changes at the surface of a gold-coated slide that occur during interactions. ITC 
measures the change in temperature following the step-wise addition of a prey protein to 
a bait protein since thermodynamically-favored protein interactions will release heat. 
Using a strong magnetic field, NMR can provide structural information of protein 
interaction contacts by observing the proton resonance frequencies of the proteins. ACE 
measures changes in electrophoretic mobility that occur upon the formation of protein 
complexes to determine the general strength (not rate) of the interaction. Moreover, ACE 
requires minimal sample amounts and each binding event can be analyzed within two 
minutes. Affinity information can be obtained with a fluorescence polarization assay by 
an increase in fluorescence polarization, which occurs when a green fluorescent protein 
(GFP)-fused protein binds to another protein. Notably, both FRET and mass spectrometry 
can also be used to determine dissociation constants of PPIs, but they are not commonly 
used and are low throughput in regards to the number of unique protein interactions that 
be analyzed at one time.  
There is no high throughput, quantitative method for analyzing PPIs. However, a 
few quantitative platforms could be adapted to large-scale studies of PPIs, such as ACE 
and an array format SPR technology called SPR imaging (SPRi). Unfortunately, the 
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throughput capability of these methods has not been appropriately tested because of their 
reliance on purified proteins, which is a labor- and time-intensive process (see also page 
67). Herein, I describe how I combined a protein microarray technology called NAPPA 
that doesn’t require purified proteins with SPRi to create a high throughput, quantitative 
platform for analyzing > 400 PPIs in less than an hour. Both stable and transient PPIs are 
detected in real-time, and their corresponding kinetics (i.e., ka, kd) and affinities (i.e., KD) 
are determined. Table 1 compares the attributes of NAPPA-SPRi with the 
aforementioned methods for analyzing PPIs. More detail about the disadvantages of 
protein purification and the methodology of this “cell-free” protein microarray is 
provided on page 67. A detailed description and comparison of SPR and SPRi is on page 
75. 
 
1.4   Modeling signaling pathways and cells 
Over the past twenty years, the human interactome has grown from a handful of 
protein interactions to a staggering 319,419 unique physical and genetic protein 
interactions (Stark et al., 2006). These data provide, for the first time, a remarkable 
opportunity to understand how the thousands of interconnecting molecular gears regulate 
homeostasis, disease, and therapeutic response. However, they also emphasize the need 
for a computational model that can identify proteins that are essential in signaling and 
predict cellular response(s) from large-scale, complex data. An accurate cell model could 
pinpoint attractive drug targets as well as determine the molecular events underlying 
disease initiation and progression. 
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Cell or protein signaling models are generally built in four steps (Henriques, 
Villaverde, Rocha, Saez-Rodriguez, & Banga, 2017; Sachs, Perez, Pe'er, Lauffenburger, 
& Nolan, 2005a; Saez-Rodriguez et al., 2011). First, reported protein interactions in 
literature and databases are curated. The modeler selects the type of information with 
which to work. For example, only protein interactions with directional binding may be 
retained for further analyses. Second, a scaffold model is constructed, which often relies 
on ON/OFF or AND/IF/THEN logic gates. An example of a logic gate is “IF protein A is 
active AND protein B is active, THEN protein C is active.” The number of scaffold 
models can be extraordinary large. In one case in which there were 78 proteins with 112 
known interactions, 1038 scaffold models were built. An advantage of scaffold models is 
that potential proteins-of-interest for perturbation experiments can be identified. Third, 
cells are exposed to various conditions and their responses annotated. Finally, the 
scaffold models are trained using these in vitro experiments to accurately represent the 
data. In other words, models are assembled, in part, by reverse engineering. Modelers 
may not follow all of the aforementioned steps; instead, some models have been built 
using only in vitro perturbation experiments. 
The disadvantage of current cell models is that they are essentially “black boxes,” 
providing little insight into molecular mechanisms taking place inside the cell. Another 
important consideration is that models are only as good as the experimental data on 
which they’re built. Unfortunately, as Chapter 1.3 discusses, current experimental data 
are biased in numerous ways. Proteins associated with disease are studied much more 
than proteins with unknown or poorly understood functions. Detection methods are 
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biased toward identifying stable interactions involving highly abundant proteins. 
Moreover, very little kinetic and affinity information has been determined, which is 
primarily due to low throughput methods for analyzing the binding rates and strengths 
(Heinrich, Neel, & Rapoport, 2002). As such, modelers are forced to build algorithms 
from qualitative-based data, resulting in “best guess” approximations that could miss 
individual, yet critical binding kinetics that regulate signaling. Calculated kinetics guided 
by cellular responses may be misassigned to particular signaling components or diluted 
across multiple proteins. An example in which binding kinetics have been experimentally 
determined but would likely be overlooked in a signaling model is actin polymerization. 
GTPases CDC42 and TC10 share 70% homology to each other, but only CDC42 can 
stimulate actin polymerization (Ou, Matthews, Pang, & Zhou, 2017; Schreiber, Haran, & 
Zhou, 2009). This is because CDC42 binds to WASp 1000-fold faster than TC10. 
Modelers, therefore, are working with incomplete, biased networks with little 
understanding of the temporal regulation of signaling. 
Models built from experimentally-produced kinetic and affinity data would have 
distinct advantages over current models. The cellular effect of converging signals could 
be determined since the different on-rates of competitive binders would be known. 
Likewise, the binding kinetics would be used to ascertain the relative effects of divergent 
signals. Signal duration and the relative availability of proteins to interact could be 
calculated. Altered binding kinetics from protein mutations could be easily incorporated. 
Proteins that were not previously known to be essential in homeostasis, disease, and 
therapeutic responses would be more accurately identified. By using experimentally-
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produced binding kinetics and affinities, models would not be “black boxes” built from 
best guesses and approximations, but a virtual computer chip reflecting the true 
molecular mechanisms taking place within a cell. An accurate cell model would likely 
have the biggest effect on the pharmaceutical industry. Drug pipelines would be 
streamlined since drug targets-of-interest with predictable responses could be identified, 
thereby increasing the number of approved drugs for public use in less time. 
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CHAPTER 2 
2   B CELLS AND THE B CELL RECEPTOR SIGNALING PATHWAY 
2.1   Introduction 
In this thesis, the protein interactions in the B cell receptor (BCR) signaling 
pathway were examined in detail. The BCR pathway was chosen as the focus of this 
study for several reasons. First, the BCR pathway has relevance in homeostasis and 
disease. It regulates B cell maturation, VDJ recombination, antibody production, 
proliferation, cell survival, somatic hypermutation, class switching, germinal center 
formation, and antigen presentation. Disruptions to normal BCR signaling can lead to 
immunodeficiencies, autoimmunity, graft-versus-host disease, and cancer. Second, my 
collaborators were also studying B cells and the BCR pathway using flow cytometry and 
mass spectrometry. Since our long-term objective is to build an accurate, predictive 
virtual cell model, their results could complement my data and strengthen our model. 
Third, as one of the more well understood signaling pathways, the BCR signaling 
pathway provided a backdrop in which to compare the data collected here. Finally, the 
current map of the protein interactions and their temporal regulation in the BCR pathway 
remains incomplete. Approximately 80% of the protein interactions have been 
determined using co-immunoprecipitation techniques, which are notorious for identifying 
only stable complexes. Moreover, protein partners identified with co-affinity methods 
may not interact directly with the target-of-interest, but through a bridging protein. The 
BCR signaling pathway includes > 100 proteins and possibly > 2100 interactions, yet only 
12 interactions have been characterized quantitatively (Table 2). These data were 
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obtained with a literature searching algorithm written by Dr. Parag Mallick of Stanford 
University. 
Table 2. Documented binding affinities of protein interactions in the BCR signaling pathway 
 
2.2   B cells in homeostasis 
Our body’s ability to protect itself from infection and disease is made possible by 
the immune system, a multi-layered defense strategy that includes physical, chemical, 
and biological barriers; signaling molecules and proteins; and white blood cells (Alberts, 
2015; Murphy & Weaver, 2016). As the only cells that produce antibodies, B cells are an 
essential part of the adaptive (or acquired) immune response, which recognize and mark 
specific pathogens for destruction. B cells are also antigen presenting cells (APCs), which 
internalize antigens, process them into fragments that are typically 8 – 11 amino acids in 
length, and then present them on their surface through class I and class II MHC proteins 
to activate T cells.  
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B cells are born in the bone marrow, arising from multipotential progenitor cells. 
From this point on, their purpose in life is to assist in adaptive immunity as an APC and 
by making specific and sensitive antibodies to non-self antigens. Late pro-B-cells in the 
bone marrow undergo a process called VDJ recombination in which the gene segments 
V, D, and J of the immunoglobulin heavy chain locus are rearranged to create the unique 
B cell receptor on the cell surface and, later, the secreted antibodies (Alberts, 2015). High 
antibody diversity is the result of recombining > 8500 VDJ gene segments and its 
associated “junctional diversification,” where nucleotides are lost or added during 
segment joining. Thus, > 1012 different antibodies could be produced in the human body!  
Pre-B cells are not immediately released from the bone marrow upon assembly. 
Instead, they are exposed to a constellation of self-antigens. This “central tolerance” test 
is extremely important since release of self-reactive B cells would result in autoimmune 
disease, in which the immune system attacks normal host cells and tissues. B cells that 
react to self-antigens become unresponsive or die through apoptosis. Other B cells 
undergo receptor editing so that they no longer bind to self-antigens.  
B cells that do not bind to self-antigens in the cellular environment of the bone 
marrow are transported to the central sinusoids, where they then enter into circulation as 
IgM+ immature B cells. They then migrate to secondary lymphoid tissues like the spleen, 
lymph nodes, and Peyer’s patches where they are considered to be “transition” B cells. It 
is in the circulation and secondary lymphoid tissues where B cells bind to their specific 
antigen and become activated mature B cells. A subset of B cells become antibody-
producing plasma cells in situ, of which 90% will undergo apoptosis after 2 – 3 days. 
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Some activated B cells, however, will migrate to secondary lymphoid tissues, where they 
will stimulate the formation of B cell islands called germinal centers. 
Within the germinal center, the B cell rapidly proliferates and becomes a 
centroblast that undergoes somatic hypermutation where nucleotide substitutions are 
made in the variable region in an attempt to make a more sensitive antibody. However, 
many of these changes are unfavorable and will result in cell death. If the changes to the 
variable region are favorable, the centrocyte will receive signals in the form of released 
cytokines from follicular dendritic cells and T follicular helper cells to promote B cell 
survival, stimulate class switch recombination (e.g., IgM to IgG), and differentiation into 
an antibody-producing machine called a plasma cell. In immature B cells, the antigen 
receptors are low-affinity IgM and IgD immunoglobulins. Upon class switch 
recombination, B cells may also express high-affinity IgG, IgA, or IgE antibodies.  
The “primary response” following the first exposure of a B cell to its specific 
antigen is weak and brief. The lag phase between antigen exposure and antibody 
production is, on average, 7 – 10 days (Institute of Medicine (U.S.). Committee to 
Review Adverse Effects of Vaccines. & Stratton, 2012). However, this phase can be 
shorter, or as long as weeks to months. The antibodies that are produced are 
predominately low-affinity IgM, with low levels that quickly fade.  
Not all centrocytes differentiate into antibody-secreting plasma cells. Some 
centrocytes are transformed into quiescent, memory B cells that are essential in long-term 
immunity. During repeat exposure to the same antigen, the primed memory B cell will 
initiate a faster and more vigorous “secondary response” than a naive B-cell would. The 
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lag phase is 1 – 3 days, with high levels of high-affinity IgG antibodies being produced 
over a long period of time. 
 The life span of a B cell depends on its activation state and type. Circulating B 
cells generally live for ~ 3 days, but some are long-lived, having a half-life of 1 – 2 
months. Memory B cells can live for many years, thus imparting long-lasting immunity 
to the host. 
 
2.3   B cells in disease 
2.3.1   Autoimmune diseases 
Autoimmune diseases occur when the immune system attacks normal host cells 
and tissues. B cells can cause and contribute to the pathology of these diseases in several 
ways: 1) produce auto-reactive antibodies; 2) secrete proinflammatory molecules like 
TNF-alpha, interferon-gamma, and macrophage migration inhibitory factor; 3) present 
self-antigens for T cell activation; and 4) aid in de novo generation of ectopic germinal 
centers that are present in chronically-inflamed tissue (Hampe, 2012).   
Poor checkpoint controls during central tolerance and somatic hypermutation can 
lead to the inappropriate production of autoantibodies. Loss of skin pigment in vitiligo is 
due to the destruction of pigment cells called “melanocytes” by antibodies 
(Gottumukkala et al., 2003). Tear and saliva glands targeted by antibodies in Sjogren’s 
syndrome cause dry eyes and mouth (Suresh, Malyavantham, Shen, & Ambrus, 2015). 
Autoantibodies in the spinal fluid of Multiple Sclerosis (MS) may contribute to the 
demyelination of nerve fibers within the central nervous system (Kolln et al., 2006). 
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Antibodies to self-antigens have also been associated with the pathology of type 1 
diabetes (Taplin & Barker, 2008). 
B cell involvement in autoimmune diseases can be independent of antibody 
production. Antigen presentation by B cells have been shown to assist in driving lupus 
and experimental autoimmune encephalomyelitis (MS model) in mice (Giles, 
Kashgarian, Koni, & Shlomchik, 2015; Pierson, Stromnes, & Goverman, 2014). B cells 
also promote chronic allergic lung disease in this manner (Lindell, Berlin, Schaller, & 
Lukacs, 2008). The B cells of rheumatoid arthritis patients expressed higher levels of an 
essential cytokine for bone-resorbing osteoclastogenesis, RANKL, than the B cells in 
healthy patients (Meednu et al., 2016). The secretion of the pro-inflammatory cytokine, 
granulocyte macrophage-colony stimulation factor (GM-CSF), by B cells has also been 
linked to driving MS and causing relapses (R. Li et al., 2015). Ectopic germinal centers 
may maintain the pathology of autoimmune diseases by supporting the plasma cells that 
secrete autoantibodies. 
 
2.3.2   Primary immunodeficiency diseases 
Primary B cell immunodeficiency diseases are characterized by insufficient 
antibody production as the result of too few or defective B cells. Individuals with X-
linked agammaglobulinemia (XLA) have a mutated protein called Bruton’s Tyrosine 
Kinase (BTK) that is necessary in B cell maturation (Mak, Saunders, & Jett, 2014). Since 
their B cells cannot mature, XLA patients have severe deficiencies in all of the antibody 
isotypes. While XLA is relatively rare (i.e., 1 out of 200,000 live births), Common 
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Variable Immune Deficiency (CVID) affects 1 out of 25,000 people (Cunningham-
Rundles, 2012). B cells in CVID also fail to mature and produce normal levels of 
antibodies, but the cause(s) is unclear. In Hyper-IgM syndrome, the B cells are unable to 
undergo class switch recombination from the low-affinity IgM isotype (Davies & 
Thrasher, 2010). Selective deficiencies in IgM, IgG or IgA subclasses can also occur 
(Asano et al., 2004; Louis & Gupta, 2014; Vidarsson, Dekkers, & Rispens, 2014). In X-
linked Severe Combined Immune Deficiency (X-SCID), a gene mutation for the common 
gamma chain abolishes B cell function since the receptors for growth factors are 
abnormal (Fischer, 2000). The diseases outlined here cover only some of the primary 
immunodeficiency diseases that arise from defects in B cell development and function. 
Not surprisingly, individuals with B cell-related primary immunodeficiency 
diseases are prone to various infections and have a higher risk of getting cancer. Their 
chance of getting cancer is increased because they can have chronic inflammation as the 
result of infection and because their immune system, which usually monitors for and 
destroys neoplastic cells, is compromised. Gastrointestinal complaints are often a 
common symptom since antibody levels are normally high in the gut; thus, primary 
immunodeficiency diseases are associated with malabsorption. 
Patients with severe B cell primary immunodeficiency diseases are treated with 
intravenous immunoglobulin replacement therapy every 1 - 4 weeks for life, depending 
on the route of administration (Fried & Bonilla, 2009). Prophylactic antibiotics also 
reduce the risk of infection by Pneumococcus, Staphylococcus, and mycobacteria. 
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2.3.3   Cancer 
As explained in the 
previous section, B cell-related 
primary immunodeficiency 
diseases can increase the risk 
of cancer. B cells can also be 
cancerous, which result in “B 
cell lymphomas.” In Hodgkin 
lymphoma, the cancer 
originates from an abnormal, 
giant B cell called a Reed-
Sternberg cell (Kuppers & 
Hansmann, 2005). The cells are 
large, multinucleated, and have 
a unique morphology. Interestingly, these cells have also been detected at low levels in 
non-Hodgkin lymphomas and infectious mononucleosis, although their role in these 
diseases is unknown. Non-Hodgkin lymphoma (NHL) is the most common hematological 
malignancy in adults, 85% of which are caused by B cells (Table 3)(Coffey, Hodgson, & 
Gospodarowicz, 2003). In 2013, non-Hodgkin lymphoma was the 8th and 11th most 
common cancer and cause of cancer deaths worldwide, respectively (Fitzmaurice et al., 
2015).  
 
Table 3. WHO classification of B cell-related NHL and percentage of 
total cases 
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2.3.4   Other B cell-related diseases 
B cells have been implicated in non-autoimmune diseases, graft-versus-host 
disease (GVHD), and the spread of human immunodeficiency virus (HIV). Altered 
cytokine profiles of B cells contribute to the pathology of non-autoimmune inflammatory 
diseases like type 2 diabetes and periodontal disease (Nikolajczyk, 2010). In comparison 
to healthy patients, B cells from type 2 diabetic patients were shown to secrete elevated 
levels of pro-inflammatory cytokine IL-10 while also being unable to secrete the anti-
inflammatory cytokine IL-10 (Jagannathan et al., 2010). A common complication 
following bone marrow tissue or cell transplantation is GVHD, in which donor immune 
cells attack host cells. This is due, in part, to a breakdown in peripheral B cell tolerance 
as well as abnormal processing of B cell activating factor (BAFF) that promotes B cell 
activation and antibody production (Sarantopoulos, Blazar, Cutler, & Ritz, 2015). Finally, 
HIV has been shown to bind directly with the B cell receptors, CD21, CD-SIGN, and 
VH3 (Haas, Zimmermann, & Oxenius, 2011). The biological consequences of these 
receptor-viral interactions remain to be elucidated. 
 
2.4   B cell receptor signaling pathway 
The interaction of a B cell to its specific antigen initiates a series of intracellular 
signaling cascades, and results in specific cellular responses at the phenotypic and genetic 
levels (Dal Porto et al., 2004; Justement & Siminovitch, 2000). The BCR signaling 
pathway begins when the immunoglobulin-based BCR at the cell membrane recognizes 
and binds to its antigen, resulting in BCR cluster formation into glycolipid-rich 
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microdomains of the plasma membrane where the Src family tyrosine kinase, LYN, is 
anchored via acylation (Figure 4)(Kanehisa, Furumichi, Tanabe, Sato, & Morishima, 
2017).  
Phosphorylation drives the B cell receptor pathway.  LYN then phosphorylates 
the immunoreceptor tyrosine-based activation motif (ITAM) on the cytoplasmic tail of 
the BCR-associated heterodimer proteins, CD79A and CD79B (or Igα and Igβ, 
respectively). CD79A and CD79B are the primary transducing structures that couple 
BCR-antigen binding to intracellular effectors. Interestingly, CD79A appears to mediate 
phosphotyrosine kinases while CD79B activates calcium mobilization and IL-2 
production.  
Figure 4. KEGG BCR signaling pathway (reprinted with permission) 
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Phosphorylation at both tyrosine residues within the ITAMs of CD79A and 
CD79B results in the binding of tyrosine kinase SYK through its phosphotyrosine-
binding Src homology 2 (SH2) domains. SYK is then phosphorylated and activated by 
the nearby phosphotyrosine kinase, LYN. SYK is now capable of facilitating the 
initiation of several different sub-signaling pathways, which will be referred here as the 
PI3K/AKT, MAPK, NF-κB, RAC, NFAT pathways. Co-receptors like CD19 are 
essential in enhancing the BCR signal, while others like CD22 decrease it. Currently, the 
BCR signaling pathway is known to involve ~ 100 proteins, some of which assist in the 
convergence, divergence, and crosstalk of the sub-signaling pathways within it. 
Phosphorylation is a post translational modification that can significantly affect 
PPIs and is often used to propagate signal through a cell, like the BCR signaling pathway. 
Phosphorylation, or the transfer of the terminal phosphate group of ATP to specific 
tyrosine, serine, and threonine residues of target proteins are mediated by a set of 
enzymes called kinases. The BCR pathway has at least 37 serine-threonine kinases and 4 
tyrosine kinases (Appendix A), thereby making phosphorylation an important 
modification in in this pathway (Bounab, Getahun, Cambier, & Daeron, 2013). Many of 
the phosphatases, which are responsible for de-phosphorylating proteins, in the BCR 
pathway are considered to be negative regulators of signal propagation. For example, 
tyrosine-protein phosphatase non-receptor type 6 (PTPN6) negatively regulates BCR 
signaling by dephosphorylating CD79A and CD79B on their ITAM motifs as well as 
LYN and SYK (among others). INPP5D, INPPL1, and PTEN are other phosphatases that 
inhibit the BCR signaling pathway. The regulation of PPIs via phosphorylation, however, 
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can be very complicated. Phosphorylation can activate and inactivate proteins, which 
depends on the site and the presence of other phosphorylation events. The modification 
can also affect protein interactions. BLNK, for example, has at least 41 phosphorylated 
residues, some of which are known to affect the interaction partners of BLNK differently 
(Koretzky, Abtahian, & Silverman, 2006; Oellerich et al., 2009). 
Adaptor proteins. Adaptor proteins, particularly BLNK, GRB2, NCK1, and 
DAPP1 (also known as Bam32), act as molecular scaffolds that bring proteins in close 
proximity to each other as to facilitate a PPI between them (Koretzky et al., 2006; 
Kurosaki & Tsukada, 2000). For example, BLNK binds to BTK and phospholipase C 
gamma 2 (PLCG2); BTK then phosphorylates and activates the key lipid metabolizing 
enzyme PLCG2. 
Pathways within the BCR signaling pathway regulate a multitide of cellular 
responses. The PI3K/AKT, MAPK, NF-κB, RAC, NFAT pathways result in overlapping 
and distinct cellular responses, which are outlined in Table 4. Very briefly, the 
PI3K/AKT pathway is initiated when PI3K is activated via phosphorylation by receptor 
tyrosine kinases like CD19 (Figure 5)(Castellano & Downward, 2011). PI3K then 
converts phosphatidylinositol (3,4)-bisphosphate (PIP2) lipids to phosphatidylinositol 
(3,4,5)- trisphosphate (PIP3), which binds to and aids in the activation of a central 
Table 4. Cellular responses of the signaling pathways within the BCR pathway 
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serine/threonine kinase, AKT. 
AKT promotes cell survival by 
inhibiting the ability of the 
pro-apoptotic protein, BAD, to 
heterodimerize with BCL2L1. 
AKT also increases nuclear 
localization of pro-survival 
transcription factors, NFAT and FOXO3A (Woyach, Johnson, & Byrd, 2012). The 
PI3K/AKT pathway mediates metabolism, growth, proliferation, survival, protein 
synthesis, transcription, and apoptosis. 
Activated PLCG2 hydrolyzes PIP2 to InsP3 and diacylglycerol (DAG); it is InsP3 
that stimulates an influx of calcium into the cytoplasm. A sustained rise in calcium level 
activates the serine/threonine phosphatases, PPP3CA, PPP3CB, PPP3CC, that then 
dephosphorylate the transcription factor, NFAT, to expose a nuclear localization signal 
(Scharenberg, Humphries, & Rawlings, 2007).  NFAT translocates into the nucleus 
where it supports cell proliferation, differentiation, and cytokine production (Mognol, 
Carneiro, Robbs, Faget, & Viola, 2016; Woyach et al., 2012).  
The MAPK pathway also contributes to BCR-induced survival (Woyach et al., 
2012). The MAPK pathway is initiated when diacylglycerol (DAG) activates protein 
kinase C directly, or when VAV and GRB2 interact with RAC and SOS, respectively. 
These events stimulate the well-known RAF/MEK/ERK kinase cascade in which RAF’s 
phosphorylation leads to the phosphorylation of MEK (known as proteins MAP2K1/2), 
Figure 5. PTEN is a negative regulator of the PI3K/AKT pathway. 
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which can then phosphorylate ERK (known as proteins MAPK1/3). Phosphorylated ERK 
enters the nucleus where it targets specific transcription factors that facilitate cell 
proliferation, survival, and apoptosis. 
The NF-κB pathway begins when the IκB kinase (i.e., IKBKA or IKBKB) is 
activated and phosphorylates inhibitors of NF-κB that complex with NF-κB homo- or 
hetero-dimers in the cytoplasm (Woyach et al., 2012). The phosphorylation marks the 
inhibitors for degradation, allowing NF-κB to translocate into the nucleus where it 
regulates the transcription of genes that are involved in cell proliferation, class switching, 
survival, and the secretion of pro-inflammatory cytokines. NF-κB consists of a protein 
with a transactivation domain (RELA, RELB, REL) and/or a transcriptional inhibitor 
(NFKB1, NFKB2). Depending on the proteins that dimerize with each other, as well as 
other associated proteins, the NF-κB complex can activate or inhibit transcription. 
GTPases have pleiotropic roles in B cells. The activation of Rho GTPases 
marks the beginning of the RAC pathway. GTPases are considered to be “activated” 
when the enzyme is bound to GTP, and “inactivated” once the GTP is hydrolyzed to GDP 
(G. P. Li & Zhang, 2004). The GTPases are capable of activating or inactivating itself, 
although these processes are generally very slow and can be accelerated with the 
assistance of guanine nucleotide exchange factors or GTPase-activating proteins, 
respectively. GTPases modulate numerous downstream effector molecules that regulate 
cell mobility, differentiation, survival, and proliferation (Guo, Velu, Grimes, & Zheng, 
2009; Nayak, Chang, Vaitinadin, & Cancelas, 2013; Walmsley et al., 2003). For instance, 
active Rho GTPases have been reported to interact with > 50 downstream proteins. 
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To note, B cell cancers can arise from constitutive activation or overexpression of 
kinases (e.g., PI3K, AKT, BTK) and GTPases within the BCR signaling pathway (Cinar 
et al., 2013; Rudelius et al., 2006; Vega & Ridley, 2008; Woyach et al., 2012). Some 
primary immunodeficiency diseases, as discussed in Chapter 2.3, stem from defects in 
BTK, which inhibits B cell development and production of specific types of antibodies. 
Cell fate is determined by external environment, cell stage, and signals from 
multiple cell surface receptors. The BCR signaling pathway regulates numerous B cell 
phenotypes (see also Chapter 2.2), which is made possible by different external 
environments, developmental stages of the B cell, and signals propagated by other cell 
surface receptors. For instance, antigen-independent pre-BCR signaling in large pre-B 
cells in the bone marrow is critical in stimulating B cell development and maintaining B 
cell specificity (i.e., “allelic exclusion”) (Martensson, Almqvist, Grimsholm, & Bernardi, 
2010). The signaling mechanism, which is still incompletely understood, inhibits further 
VDJ recombination and produces a negative feedback loop to terminate pre-BCR 
expression. Antigen-dependent pre-BCR signaling causes cell apoptosis as a part of the 
“negative selection” process to remove B cells that are reactive to self antigens. Once in 
the periphery, antigen binding activates immature B cells to become short-lived plasma 
cells or to travel to secondary lymphoid organs where they stimulate the formation of 
germinal centers (Alberts, 2015). Antigen-BCR binding of mature B cells that are in 
germinal centers can result in somatic hypermutation, class switching, or the generation 
of plasma or memory B cells. An example of how signals from other receptors affect B 
cell response is the binding of the CD40 ligand from activated immune cells (e.g., T cells, 
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granulocytes) to the B cell CD40 receptor. Co-stimulation of the BCR and CD40 produce 
signals that, depending upon their relative levels of stimulation, induce proliferation, 
immunoglobulin switching, inhibition of apoptosis, or antibody secretion.  
 
2.5   Selection of query proteins for protein interaction analyses 
2.5.1   NanoBRET and NAPPA-SPRi queries 
 Five proteins in the B cell receptor (BCR) signaling pathway were chosen as 
queries to probe the entire BCR pathway protein set in both NanoBRET and NAPPA-
SPRi analyses because they occur at key nodes in the BCR pathway and are important 
regulators of B cell response. These included an adaptor (BLNK), a tyrosine kinase 
(BTK), a lipid and serine/threonine kinase (PI3K), and two Rho GTPases (RAC1, 
RHOA). B cell-related immunodeficiencies and cancers are associated with their altered 
activity from mutations or overexpression. As such, they are attractive drug targets. In 
fact, small molecular BTK inhibitors are FDA-approved to treat certain B cell cancers 
and graft-versus-host disease. BLNK, BTK, and PI3K are also proximal to the 
membrane, mediating different signaling pathways. Therefore, their activity (or lack 
thereof) has a more profound effect on cell fate than proteins further downstream 
(Appendix A, Figure 4). The ability to test different protein types also provided insight 
into their unique methods of regulation. Inclusion of RAC1 and RHOA presented an 
opportunity to compare the binding partners and kinetic profiles of active and inactive 
GTPases.  
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BLNK.  BLNK is an adaptor that binds to many proteins, thereby bringing them 
into close proximity to each other to interact. BLNK is essential for B cell development 
and in BCR signaling. Mutations in BLNK have been demonstrated to cause 
immunodeficiences, and downregulation of BLNK occurs in mediastinal large B cell 
lymphomas and Hodgkin lymphomas. Thus, BLNK appears to act as a tumor suppressor.  
BTK. BTK is a non-receptor tyrosine kinase that mediates different pathways in 
the B cell and, as such, acts as a bottleneck. It is essential for B cell development and 
differentiation. BTK mutations are the cause of a severe immunodefiency disease called 
X-linked agammaglobulinemia (XLA) (see also Chapter 2.3.2). Increased BTK activity is 
observed in several B cell cancers, including diffuse large B cell lymphoma, mantle cell 
lymphoma (MCL), and chronic lymphocytic leukemia (CLL). Since 2013, the FDA has 
approved small molecule inhibitors of BTK to treat MCL, CLL, and graft-versus-host 
disease.  
PI3K. PI3K is most well known for its lipid kinase activity, in which it 
phosphorylates the small signaling molecule, PIP2, to PIP3. It can also phosphorylate 
serine and threonine residues, most notably on itself and AKT1. It is critical for B cell 
metabolism, cell growth, development, and survival. Activating mutations are observed 
in 30% of cancers and some immunodeficiency disorders. PI3K is a heterodimer 
consisting of a catalytic and regulatory subunit, both of which have various isoforms. In 
these studies, the alpha isoforms of both the catalytic and regulatory subunits were used 
(i.e., PIK3CA and PIK3R1, respectively). These isoforms were chosen because, unlike 
the other isoforms, both PIK3CA and PIK3R1 are ubiquitously expressed. Moreover, 
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PIK3CA is the only catalytic isoform that is frequently mutated in cancer, while PIK3R1 
is the most frequently mutated regulatory subunit in cancer (i.e., 20%) (Herrero-Gonzalez 
& Di Cristofano, 2011; J. J. Zhao et al., 2006).  
GTPases. RAC1 and RHOA are both Rho GTPases with well-documented roles 
in regulating the cytoskeleton during cell growth, adhesion, and migration. They are 
essential for B cell development, proliferation, endocytosis, and antigen presentation. 
They also regulate apoptosis and survival. Increased RAC1 expression or activity are 
implicated in the initiation and progression of several types of cancers, including those of 
the lung, breast, prostate, skin, colon, but their roles in B cell-related cancers are 
unknown. Mutations in RHOA are associated with Burkitt’s lymphoma and diffuse large 
B cell lymphoma. Both the inactive and active forms of RAC1 and RHOA were analyzed 
with GDP and GTPγS, respectively. GTPγS was used for these experiments because it is 
non-hydrolyzable; a hydrolyzable GTP would result in interactions representing a 
mixture of active and inactive states. Thus, seven queries were employed for both 
NanoBRET and NAPPA-SPRi analyses (Chapters 3 and 8). 
 
2.5.2   NanoBRET queries 
NanoBRET employs proteins that are produced in vitro without the need for 
purification. Therefore, obtaining functional and purified recombinant proteins was not a 
consideration with NanoBRET as it was with NAPPA-SPRi since any protein-of-interest 
could be studied with NanoBRET as long as the plasmid cDNA was available. In 
addition to the aforementioned queries, NanoBRET was used to analyze the protein 
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interactions with an additional five queries important in B cell regulation: AKT1, 
DAPP1, LYN, MAPK14 (i.e., p38), and SYK. AKT1 is a serine/threonine kinase that is 
activated downstream of PI3K in stimulated B cells. It promotes B cell growth, 
proliferation, survival, maturation, and survival. Increased activity of AKT1 is associated 
with a poorer prognosis in patients with diffuse large B cell lymphoma. DAPP1 is an 
adaptor protein that, via its signalosome, stimulates the RAC1/JNK pathway involved in 
B cell adhesion and spreading (Al-Alwan, Hou, Zhang, Makondo, & Marshall, 2010b; 
Ulivieri & Baldari, 2005). It is also involved in MAPK/ERK signaling, which regulates 
cell proliferation and survival. LYN is a tyrosine kinase proximal to the membrane that 
quickly becomes activated upon BCR aggregation. It then activates SYK, another 
tyrosine kinase, via phosphorylation. LYN is important in B cell differentiation and B 
cell tolerance, while SYK is essential in calcium mobilization and B cell development. 
Finally, MAPK14 is a serine/threonine kinase that promotes B cell proliferation and 
survival.  
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CHAPTER 3 
3   QUALITATIVE ANALYSES OF THE BCR SIGNALING PATHWAY USING 
NANOBRET  
3.1   Introduction 
 Mapping the human interactome has been pursued with enthusiasm following the 
first large-scale protein interaction studies in 2000 (Ito et al., 2001; Ito et al., 2000; Uetz 
et al., 2000; Walhout et al., 2000). The majority of these interactions have been 
determined using equilibrium-based assays (e.g., co-immunoprecipitation) that are 
inherently biased toward detecting stable complexes even though transient interactions 
are believed to occur with higher frequency. I therefore wondered how much of the 
protein network is still unexplored. To determine this, I decided to characterize the 
protein interactions of a “well understood” pathway, the B cell receptor (BCR) signaling 
pathway, and then compare our results to what is currently known. The identification of 
only a few new interactions, for example, would indicate that the BCR pathway and, as 
an extension, the human interactome were well annotated. Many new interactions, on the 
other hand, would suggest that much of the interactome remains unmapped. 
To accomplish this task, I searched for a method that would meet the following 
criteria: high throughput, capable of detecting stable and transient interactions, high 
signal-to-noise ratio, easy-to-use, and amenable for in vitro analyses using proteins 
produced from plasmid cDNA using a cell-free expression system. Promega’s 
NanoBRETTM fit four of the five criteria, with the exception that it has only been applied 
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in vivo. Since standard BRET has been successfully applied in vitro, I describe herein 
how NanoBRET was adapted to do the same.  
My analyses focused on the protein interactions of 12 queries in the BCR pathway 
that are critical to various B cell phenotypes, including two GTPases that were 
represented in their active and inactive forms. Over 2500 interactions were analyzed, 
identifying 490 protein interactions, 83% of which have never been previously reported. 
This study suggests that only a fraction of the protein interactions in the BCR signaling 
pathway (and human interactome) have been characterized.  
 
3.2   Promega NanoBRETTM technology 
 BRET, or “Bioluminescence resonance energy transfer,” is a common method for 
analyzing transient and stable protein-protein interactions (Pfleger, Seeber, & Eidne, 
2006; Y. Xu, Piston, & Johnson, 
1999). It relies on protein “A” 
having a luciferase tag and 
protein “B” fused to a 
fluorescent label like the yellow 
fluorescent protein (YFP) 
(Figure 6). The proteins are 
mixed together along with a 
luciferase substrate. The 
Figure 6. Schematic illustration of BRET technology.  
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oxidation of the substrate by the 
luciferase will generate light called 
“bioluminescence” around the 
luciferase tag. In the case of firefly 
luciferase, which is the most 
commonly used luciferase in 
BRET experiments, the substrate 
is a mixture of beetle D-luciferin, 
magnesium, ATP, and oxygen 
(Adams & Miller, 2014; Andreu, Zelmer, & Wiles, 2011). The oxidation of luciferin by 
firefly luciferase will produce AMP, carbon dioxide, oxy-luciferin, and “flash-type” light 
that decays over ~ 15 seconds. Other types of luciferase are derived from sea pansy (i.e., 
renilla), beetle, railroad worm, and copepod. If the proteins are in very close proximity to 
each other (< 10 nm), energy from the bioluminescence is absorbed and emitted by the 
fluorophore on protein “B” at a different wavelength. Protein interactions are detected 
when the amount of emitted light from the fluorophore (i.e., signal) is higher than that of 
the bioluminescence (i.e., noise).  
Like any system, BRET has both advantages and disadvantages, which are 
summarized in Table 5 (Pfleger & Eidne, 2006; Xie, Soutto, Xu, Zhang, & Johnson, 
2011). Its primary advantages include easy real-time measurement of PPIs in vitro and in 
vivo. It is often compared to a similar technology, fluorescence energy resonance transfer 
(FRET), in which the donor protein “A” has a fluorophore (instead of luciferase). 
Table 5. Advantages and disadvantages of BRET compared to other 
methods for analyzing PPIs 
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However, the fluorophore on protein “A" must be excited by an external light source, 
making analyses much more difficult. Furthermore, autofluorescence, photobleaching, 
and possible direct excitation of the acceptor fluorophore by the external light source 
(i.e., higher noise) may occur during FRET analyses. Both BRET and FRET are sensitive 
to protein orientation as the luciferase and fluorophores need to be < 10 nm from each 
other for the donor energy to be transferred to the acceptor fluorophore. BRET’s 
disadvantages include limited sensitivity and dynamic range, and poor luminescence 
stability. 
Promega Corporation’s NanoBRETTM technology has a few distinct differences 
and advantages compared to standard BRET (Figure 7) (Hall et al., 2012; Machleidt et 
al., 2015). First, NanoBRET uses a different luciferase than standard BRET. Firefly or 
renilla luciferases that are 36 kDa and 61 kDa, respectively, are often used in BRET, 
although their large sizes can interfere with protein interactions and can be problematic 
for certain applications; for 
example, when inserting the 
reporter genes into viruses. 
NanoBRET, on the other hand, 
employs a 19 kDa luciferase 
subunit of the shrimp Oplophorus 
gracilirostris that Promega has 
dubbed “NanoLuc”®. It is fully 
active between pH 7 – 9 and 
Figure 7. Schematic illustration of NanoBRET technology using a 
fluorophore-conjugated HaloTag ligand. 
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retains activity following 30 minutes at 55 oC. In comparison, firefly luciferase has a 
sharp decrease in activity below pH 8 and above 31 oC. Second, protein “B” is not a 
fluorescent protein, but is the HaloTag fusion protein that is fluorescently and covalently 
labeled with a fluorophore-conjugated chloroalkane ligand. Third, NanoBRET uses a 
novel luciferase coelenterazine analog substrate, furimazine, that produces high intensity, 
“glow-type” luminescence that has a signal half-life of > 2 hours. No magnesium or ATP 
is necessary for the reaction to occur. The combination of nanoLuc with furimazine 
results in a 100-fold increase in specific activity compared to that obtained with standard 
BRET using firefly and renilla luciferase. In addition, NanoBRET has a small overlap 
between the donor bioluminescence (460 nm peak) and the acceptor absorption spectra 
(618 nm). The large difference in wavelengths between the generated bioluminescence 
and emitted fluorescence during PPIs results in a sensitive NanoBRET system. In 
comparison, the spectral overlap in standard BRET is much higher than NanoBRET, 
resulting in a low signal-to-noise ratio. For example, the combination of firefly luciferase, 
D-luciferin, and red fluorescent protein result in a donor peak emission of 562 nm and an 
acceptor emission at 583 nm (Daunert & Deo, 2006). Renilla luciferase, coelenterazine, 
and enhanced YFP have a donor peak emission of 480 nm and an acceptor emission at 
527nm.  
 
3.3   Adapting NanoBRETTM technology for in vitro analyses 
NanoBRET was originally developed by Promega Corporation to analyze protein 
interactions in cells. Briefly, plasmids encoding for proteins “A” and “B” are introduced 
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into the cell-of-interest, and the resulting interaction is detected using a plate reader or 
bioluminescence microscope. In this section, the adaptation of NanoBRET technology for 
in vitro analyses of PPIs within the BCR signaling pathway is discussed.   
The following filters and mirror were added to the Perkin Elmer Envision plate 
reader to make the instrument compatible with NanoBRET: emission filter 460/50m, 
emission filter 590 nm long pass, and a luminescence -/- single mirror. To ensure that the 
set-up was correct, a recombinant NanoLuc-HaloTag fusion protein with the HaloTag® 
NanoBRETTM 618 ligand from Promega Corporation was used. The negative control was 
the recombinant protein without the ligand. Luciferase substrate was added at 1-, 10-, and 
20-fold dilutions to the protein, where the 1-fold dilution represents the dilution 
recommended by Promega (i.e., 500-fold). The noise, or luciferase emission, was read at 
410 – 510 nm for one second. The signal, or NanoBRET 618 ligand emission, was read at 
> 590 nm for 1 second. The signal-to-noise ratio was then multiplied by 1000 for the 
recombinant fusion protein with and without ligand, thus resulting in the milliBRET unit 
(mBU) (Figure 8A). The response, or corrected mBU, was obtained by subtracting the 
mBU of the recombinant protein without ligand (i.e., the negative control) from the mBU 
of the recombinant protein with ligand (Figure 8B). The Perkin Elmer Envision plate 
reader with the aforementioned modifications detected the NanoBRET system with 
Figure 8. NanoBRET calculations. A) PPI response where the acceptor, or signal, emission is 618 nm and the donor, or 
noise, emission is 460 nm. B) Mean corrected mBU calculations. 
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corrected mBUs > 100. This high response is not surprising since the luciferase and 
fluorophore are stably and covalently linked to each other; in other words, this 
configuration will result in the highest mBU possible. Real PPIs interactions analyzed in 
vivo, on the other hand, have much lower responses (i.e., 1.4 – 7 mBU range with 2 – 4 
mBU being normal; personal communication with Dr. Thomas Machleidt of Promega 
Corporation). 
To optimize NanoBRET for in vitro PPI analyses using proteins expressed in the 
cell-free expression system, the following parameters were tested: buffer compatibility 
with NanoBRET, type of buffer to block the plate from nonspecific interactions, amount 
of expression lysate per well, length of protein expression, query-to-target ratio, the 
amount of NanoBRET 618 ligand and luciferase substrate, and the incubation 
temperature for PPIs. Different proteins and PPIs require different buffer conditions. For 
example, some kinases require MgCl2 while other proteins prefer Tris buffers over 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). The NanoLuc recombinant 
Figure 9. NanoBRET signal response across different buffers using a NanoLuc-HaloTag recombinant protein. 
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protein, as well as the NanoBRET 618 ligand and luciferase substrate, is routinely diluted 
in phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4), or PBS, for assessing instrument settings for the NanoBRET assay. 
Other types of buffers have not been tested by Promega Corporation, but it is an 
important consideration since certain reagents like phenol red can contribute to 
background noise. Therefore, I compared PBS, PBS + 3 mM MgCl2, PBS + 10 mM 
MgCl2, PBS + 0.01% Tween-20, PBS + 0.05% Tween-20, PBS + 1 mM tris(2-
carboxyethyl)phosphine (TCEP), PBS + 5 mM ethylenediaminetetraacetic acid (EDTA), 
PBS + 200 µM ATP, 50 mM HEPES + 150 mM NaCl (HEPES buffer), and 50 mM Tris 
+ 150 mM NaCl (Tris buffer). All buffers were at pH 7.4. Compared to the default PBS 
buffer, all of the buffers resulted in as high or higher signal response, indicating that all of 
the buffers tested are compatible with NanoBRET (Figure 9). 
In the first step of the procedure, blocking buffer is added to the wells of the plate 
to inhibit nonspecific interactions between the proteins and plastic surface. 5% fat-free 
milk (w/v), 1% bovine serum albumin (BSA), or 1% BSA heat shock fraction (i.e., 
without immunoglobulin or proteases) in PBS with 0.1% Tween-20 (PBST) was applied 
to the wells of a half-area 96-well plate and incubated at room temperature for two hours. 
The plate was washed with PBST to remove excess blocking buffer. Target proteins, Fos 
and BTK with a C-terminal HaloTag, expressed in the in vitro transcription translation 
(IVTT) system were added to the plate and three of the six replicates were covalently 
bound to the NanoBRET 618 ligand. The query protein, Jun with a C-terminal NanoLuc, 
also expressed with IVTT, was then mixed with the target proteins, Fos or BTK, for one 
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hour at room 
temperature. 
Immediately after 
the addition of 
luciferase substrate, 
or NanoBRET 
NanoGlo, the plate 
was read with the 
Perkin Elmer 
Envision plate reader and analyzed as described above. Similar binding responses were 
obtained for the known Jun-Fos interaction across the different blocking buffers (Figure 
10). Moreover, the blocking buffers resulted in similar background for the negative 
control wells containing Jun and BTK, which do not interact with each other. 1% BSA in 
PBST was chosen to be the blocking buffer for future experiments since the BSA heat 
shock fraction is significantly more expensive and the complex protein composition of 
milk may compete with target proteins for some queries (e.g., kinases). 
In the second step of the procedure, target proteins are expressed in IVTT. 
According to the manufacturer’s instructions, protein expression can occur from 90 
minutes to 6 hours at 30 oC. Target and query proteins were expressed for 1, 1.5, 2, 3, 4, 
or 5 hours, and then processed as described above. The 1.5 hour expression resulted in 
the highest signal-to-background ratio, where signal represents the mBU from the Fos-
Figure 10. Effect of different blocking buffers on signal  
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Jun interaction and 
background 
represents the 
mBU from the 
BTK-Jun non-
interaction (Figure 
11).  
Once the target and query proteins are expressed, the target protein is diluted with 
a Tris- or HEPES-based buffer to 50 µL per well, the query and target proteins are added 
to the well, and the luciferase substrate is applied just prior to analyses. To determine the 
appropriate amounts of the aforementioned parameters (or factors), I used a design of 
experiments (DOE) approach that can easily analyze the effect of each factor on the 
response and to each other (see page 92 for a more detailed explanation of DOE). 30-, 36-
, and 45-fold dilutions of the query and target proteins were compared. These dilutions 
were chosen based on previous experiments that identified this dilution range as the 
“sweet spot” (data not shown). In NanoBRET, the amount of NanoLuc query protein 
should be at or below the amount of HaloTag target protein to decrease noise. Thus, 
query-to-target ratios of 1:2, 3:4, and 1:1 were tested. For in vivo NanoBRET, the 
suggested dilution of the luciferase substrate is 500. In this DOE experiment, the 
substrate was diluted 500, 750, and 1000-fold. The target and query proteins were the 
same as previously mentioned, and all comparisons performed in duplicate. Based on the 
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signal (Jun/Fos)-to-noise 
(Jun/BTK) ratio, 30-fold 
protein dilution, 1:1 query-to-
target ratio, and 500-fold 
dilution of the luciferase 
substrate had the maximum 
response (Figure 12). None of 
the factors interacted with each 
other (data not shown). Like the 
luciferase substrate in which 
the recommended dilution for 
in vivo PPI analyses was 
determined to be the best 
dilution for in vitro PPI analyses, 
the same was found for the NanoBRET 618 ligand dilution (i.e., 1000-fold)(data not 
shown). 
Finally, the temperature at which the query and target proteins should be 
incubated was investigated. The overall NanoBRET binding response is based on the 
accumulated light emission within the analyses window (i.e., 1 second). Thus, higher 
signal would result from more interactions and more stable interactions taking place 
during this time. Theoretically, this could be accomplished by slowing down the rate at 
which the proteins dissociate from each other with decreased temperature. To determine 
Figure 11. Contour plot of signal-to-noise (S/N) versus target dilution, 
query:target ratio, and luciferase substrate dilution. Blue = low S/N. 
Green = high S/N. 
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this, the Jun query was 
incubated with Fos 
target or no target at all 
(“water”) for 1 hour at 
15 oC, 25 oC (i.e., 
room temperature), or 
30 oC, shaking at 500 
rpm. For the stable Jun-
Fos interaction, higher response was achieved at 15 oC and 25 oC (Figure 13). In the case 
of more transient interactions in which proteins dissociate from each other at an increased 
rate, even lower temperatures may be beneficial for NanoBRET analyses. 
The final protocol for in vitro NanoBRET analyses of PPIs using proteins 
expressed in cell-free lysate is provided in Chapter 3.4.2. 
 
  
Figure 12. Incubation temperature affects NanoBRET signal.  
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3.4   Analyses of PPIs in the BCR signaling pathway using NanoBRET 
3.4.1   Introduction 
 The NanoBRET technology 
provides a high throughput method for 
analyzing both transient and stable PPIs in 
a qualitative manner. It was applied 
toward mapping the PPIs in the BCR 
signaling pathway to gain a more 
comprehensive understanding of the 
interactions that take place. 107 proteins 
in the BCR signaling pathwaywere  
represented separately with HaloTag at 
the N-terminus and C-terminus, hereafter 
called “target” (Table 6). 12 proteins in 
the BCR signaling pathway had NanoLuc 
as an N-terminal fusion tag; these proteins 
are hereafter called “query.”  
 
3.4.2   Materials & Methods 
Preparation of plasmid cDNA 
Plasmid cDNAs encoding for the genes-of-interest (GOIs) were obtained from the 
Virginia G. Piper’s Center for Personalized Diagnostics’ plasmid repository, DNASU 
Table 6. Proteins in the BCR signaling pathway analyzed 
with NanoBRET 
  
50 
(Tempe, AZ), and Open Biosystems (Lafayette, CO), and shuttled into vectors with a 
HaloTag at the N-terminus (pJFT7_nHalo), a HaloTag at the C-terminus (pJFT7_cHalo), 
or a NanoLuc at the N-terminus (pJFT7_nNanoLuc). Successful cloning of the GOIs was 
confirmed through GOI insert size analyses via DNA agarose, and GOI sequence analysis 
via Sangar sequencing using primers adjacent to the start and stop codons of the GOI. 
The Sangar sequencing was performed by the DNASU Sequencing Core at Arizona State 
University (Tempe, AZ). These vector backbones were created by Justin Saul at the VGP 
CPD and are compatible with Invitrogen’s Gateway® recombination cloning technology. 
All target genes were represented with HaloTag at the N- and C-terminus, with the 
exception of genes with HaloTag only at the N-terminus (BLNK, PPP3CC) or only at the 
C-terminus (IFITM1, MAP2K1, PPP3R2). The target genes, AKT2, IKBKB, and 
PIK3R1, were represented with two different isoforms that differed significantly in size 
(Table 7). The query genes, AKT1, BLNK, BTK, DAPP1, LYN, MAPK14, 
PIK3CA/PIK3R1, GDP-bound RAC1, GTP-bound RAC1, GDP-bound RHOA, GTP-
bound RHOA, and SYK, had an N-terminal NanoLuc. Note that GTP-bound RAC1 and 
RHOA used GTPγS (BIOLOG Life Science Institute; Germany) because GTPγS cannot 
be hydrolyzed. 
 
Reagents 
The 1-Step Human Coupled IVT Kit and Bond-BreakerTM TCEP Solution, Neutral pH, 
were from Thermo Fisher Scientific (Waltham, MA). The ATP was from Cell Signaling 
Technology (Danvers, MA). The HaloTag® NanoBRET 618 Ligand and Nano-Glo 
  
51 
Substrate were from Promega Corporation (Madison, WI). Unless otherwise noted, all 
other materials and reagents were obtained from Sigma-Aldrich (St. Louis, MO). 
 
NanoBRET analyses 
White, high binding half-area 96-well plates (Greiner Bio-One; Austria) were blocked 
overnight at 4 oC with 100 µL 1% BSA (w/v) in PBST, then washed with 100 µL PBST 
and 100 µL PBS. The HeLa lysate was spun at 10k x g for 2 min at 4 oC, and the 
insoluble pellet was discarded. Target and query proteins were expressed for 1.5 hours at 
30 oC in the 1-Step Human Coupled IVT Kit, in which the HeLa lysate, reaction mixture, 
accessory proteins, and 200 ng/µL plasmid cDNA are mixed at a 5:2:1:2 ratio, 
respectively, such that 1 µL of target mixture or 1 µL of query mixture were added per 
well. The GTPase queries were GTP- or GDP-bound with 1 mM GTPγS (BIOLOG Life 
Science Institute; Germany) or GDP, respectively, in 50 mM HEPES, 150 mM NaCl, 5 
mM MgCl2, 5 mM EDTA, 1 mM TCEP, pH 7.4, for 1 hour at room temperature. Each 
query had five 96-well plates containing targets, with each set having a specific buffer. 
The BLNK, DAPP1, and JUN queries were analyzed in 50 mM HEPES, 150 mM NaCl, 
1 mM TCEP, 0.01% Tween-20, pH 7.4. The GDP-bound RAC1, GTP-bound RAC1, 
GDP-RHOA, and GTP-RHOA queries were analyzed in 50 mM HEPES, 150 mM NaCl, 
1 mM TCEP, 5 mM MgCl2, 0.01% Tween-20, pH 7.4. The AKT1 query was analyzed in 
50 mM Tris-HCl, 150 mM NaCl, 0.01% Tween-20, 250 µM ATP, 1 mM TCEP, pH 7.4. 
The BTK query was analyzed in 50 mM Tris-HCl, 150 mM NaCl, 0.01% Tween-20, 250 
µM ATP, 1 mM TCEP, 4 mM MgCl2, pH 7.4. The LYN query was analyzed in 50 mM 
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HEPES, 150 mM NaCl, 1 mM TCEP, 0.01% Tween-20, 10 mM MgCl2, 250 µM ATP, 
pH 7.4. The MAPK14 (p38) query was analyzed in 20 mM Tris-HCl, 150 mM NaCl, 
0.01% Tween-20, 250 µM ATP, 1 mM TCEP, pH 7.4. The PIK3CA/PIK3R1 (PI3K) 
query was analyzed in 50 mM Tris-HCl, 150 mM NaCl, 0.03% Tween-20, 250 µM ATP, 
1 mM TCEP, 3 mM MgCl2, pH 7.4. The SYK query was analyzed in 60 mM HEPES, 5 
mM MgCl2, 5 mM MnCl2, 1 mM TCEP, 250 µM ATP, 0.01% Tween-20, pH 7.5. Query 
and target proteins were diluted 30-fold each in buffer, such that 1 µL of query and 1 µL 
target protein were diluted to 60 µL total per well.  One replicate received NanoBRET 
618 ligand while the second (control) replicate received DMSO at a 1000-fold dilution. 
Samples were incubated at 15 oC for 1 hour. The Nano-Glo luciferase substrate was 
added at a 500-fold dilution and the plates immediately analyzed with a Perkin Elmer 
Envision plate reader equipped with an emission filter 460/50m, emission filter 590 nm 
long pass, and a luminescence -/- single mirror. The noise, or luciferase emission, was 
read at 410 – 510 nm for one second. The signal, or NanoBRET 618 ligand emission, was 
read at > 590 nm for 1 second. A positive control, in triplicate, was placed on each plate, 
which was the Jun (query) – Fos (target) interactions with and without NanoBRET 618 
ligand. The Jun-Fos interaction was used as a quality control of the sample processing as 
well as to determine the standard deviation within each plate. Duplicate or triplicate 
negative controls were included on each plate, which were the Jun (query) with no target, 
with and without the NanoBRET 618 ligand. All pipetting steps, with the exception of 
making the GTPases GDP- or GTP-bound, were performed with the Beckman Coulter 
Biomek FX liquid handler (Brea, CA). 
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NanoBRET data analyses 
 The corrected mBU value was determined as described in Chapter 3.3 (Figure 8). 
The mean (µ) and standard deviation (Δ) of the negative controls within each plate were 
also determined. Protein interactions were identified as those having corrected mBU 
values > µ + 2Δ, or two standard deviations higher than the mean of the replicate 
negative controls in their associated 96-well plate. To determine whether the detected 
interactions were known or novel, the data were compared with the online protein 
interaction databases, Biological General Repository for Interaction Datasets (BioGRID) 
and Human Protein Reference Database (HPRD) (Appendix C). Proteins isoforms with 
the same name but different sequences (i.e., AKT2, IKBKB, PIK3R1) (Appendix A) 
were counted as different proteins. 
 
3.4.3   Results & Discussion 
 NanoBRET detected known and novel interactions. Over 2500 protein-protein 
interactions (PPIs) in the BCR signaling pathway were tested with NanoBRET using 
proteins produced with a human cell-free expression system. To determine the number of 
known and novel interactions detected with NanoBRET, the data were compared to the 
online PPI databases, Human Protein Reference Database (HPRD) and Biological 
Table 7. Known and novel PPIs detected by NanoBRET 
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General Repository for Interaction Datasets 
(BioGRID) (Prasad et al., 2009; Stark et al., 
2006). NanoBRET detected ~ 40% (81/202) of 
known PPIs across all twelve queries, with 
some queries having as low as a 11% 
(MAPK14; 2/18) and as high as 77% overlap 
(AKT1; 20/26) with known PPIs (Table 7, 
Figure 14). As an example, PI3K, which is a 
heterodimer composed of the catalytic unit PIK3CA and the regulatory unit PIK3R1, had 
a 46% overlap with known interactions. Over half (i.e., ~60%) of previously-reported 
interactions were not identified with NanoBRET. Several reasons could account for this 
discrepancy. First, a significant portion (i.e., ~76%, Table 8) of reported PPIs were 
detected using pull-down (i.e., “affinity capture”) methods. These types of methods 
feature the detection of stable protein complexes, many of which are held together by 
bridging protein. Therefore, many of these reported interactions may not be direct, and 
hence would not show up in a direct assay like this. Second, a fraction of the reported 
interactions may be false positives (other than inaccurately assigned direct interactions). 
For example, yeast-2-hybrid has a false positive rate of 25 – 40%. Third, experimental 
Figure 13. Venn diagram of known and novel 
interactions detected with NanoBRET.  
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conditions, such as buffers, can affect protein interactions. Fourth, NanoBRET requires 
the use of fusion tags, which may block binding epitopes. It is worth mentioning that 
even with similar experimental conditions, identical results will not be obtained. Two 
large-scale, independent yeast-2-hybrid screens using the same method had < 30% 
overlap (Ito et al., 2001). Detailed lists of the known PPIs and their associated 
experiments are in Appendix C. 
 Despite these potential limitations, NanoBRET detected 409 interactions not 
previously reported; these represented 83% of the total number of interactions. Although 
some of these novel interactions may be false positives, I detected a majority of them 
(64%; 167/262) using an orthogonal method, NAPPA-SPRi (see Chapter 8). The high 
number of new interactions is likely because NanoBRET can detect both transient and 
stable complexes. 
The fusion tag may have interfered with some interactions. Some protein 
interactions were detected by NanoBRET when the HaloTag was at the N- or C-terminus, 
but not both (for a detailed list of protein interactions, see Appendix D). One possible 
reason is that the relative orientation of the luciferase to the NanoBRET 618 ligand 
(covalently bound to the HaloTag) is more favorable for NanoBRET analyses with 
particular tag locations for certain interactions since the fluorophore ligand and NanoLuc 
Table 8. Most known PPIs have been detected using “pull-down” methods 
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need to be within 10 nm of each other to produce signal. This BRET phenomenon is well 
documented (Brown, Blumer, & Hepler, 2015). Please note that all query proteins had the 
NanoLuc fusion tag at the N-terminus; no interactions were assessed with the NanoLuc at 
the C-terminus. Another possible reason why a known interaction may not have been 
detected is that the tag may interfere with interactions, thus suggesting the location of the 
binding epitope on the target protein. For instance, the known LYN- SYK interaction was 
detected only when LYN as a target protein had the HaloTag at the N-terminus. The 
HaloTag at the C-terminus of LYN, near its kinase domain, may interfere with LYN’s 
ability to phosphorylate SYK at tyrosine residue 323 (Geahlen, 2009). However, not all 
PPIs demonstrate this correlation. The C-terminal C2 domain of PLCG2 binds to BLNK, 
yet only the C-terminal tagged PLCG2 interacted with BLNK in the NanoBRET analyses 
(Engelke et al., 2013).  
 Rho GTPases. Protein targets of the GTPases, RAC1 and RHOA, in both the 
GDP- and GTP-bound states were analyzed. Although GTP-bound GTPases are 
considered to be activated and the mediator of most downstream functions, GDP-bound 
GTPases can also interact with other proteins, albeit to a lesser degree. In the NanoBRET 
analyses, RAC1 GTPase had more protein partners in its activated state, with GTP-bound 
RAC1 having 47% more interactions than GDP-bound RAC1 (Table 7). Some of these 
GDP- and GTP-based interactions overlap with each other (Figure 15). For example, 
RAC1 dimerized regardless of its GTP status. Indeed, this GDP/GTP-independent 
dimerization of Rho GTPases has already been documented (B. L. Zhang & Zheng, 
1998). However, activated and inactivated RAC1 had distinct binding partners as well. 
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Only GDP-bound RAC1 interacted with ARHGEF7, a guanine nucleotide exchange 
factor (GEF) that activates RAC1 by exchanging the GDP with GTP. It also targets 
RAC1 to membrane ruffles and focal adhesions. ARHGEF7 was previously shown to 
bind to RAC1 independent of the GDP/GTP status; why ARHGEF7 only interacted with 
GDP-bound RAC1 in this analyses is unclear (ten Klooster, Jaffer, Chernoff, & Hordijk, 
2006). Notably, ARHGEF7 interacted with GDP-bound RHOA, but not GTP-bound 
RHOA. It is possible that the GEF has a nucleotide preference, which affects its ability to 
bind and release the GTPase in the absence of competing nucleotides (GTP or GDP with 
the GDP- and GTP-bound GTPase queries, respectively). GRB2, an adaptor protein, 
bound to GDP-, but not GTP-, bound RAC1. It has been associated with RAC1 through 
pull-down complexes via their mutual interactions with PAK1 and SOS1; however, a 
direct interaction between GRB2 and RAC1 has not been detected before (Oak, Zhou, & 
Jarrett, 2003; Puto, Pestonjamasp, King, & Bokoch, 2003). Only GTP-bound RAC1 was 
able to bind to TEC and VAV1, both of which are known to be involved in the activation 
of RAC1 (Kline, Moore, & Clevenger, 
2001). For a more detailed discussion 
on the GTPases, please refer to Chapter 
2.4). Novel interactions were also 
detected, although these need to be 
validated and their biological roles in 
cellular response ascertained. A similar 
preference of target proteins for the 
Figure 14. Venn diagram of shared PPIs between GDP- and 
GTP-bound RAC1 detected with NanoBRET. 
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GDP- or GTP-bound GTPase state was observed for RHOA. Both GDP- and GTP-bound 
RHOA had 36 protein partners with only 9 that interacted with RHOA regardless of 
activation state. 
 RAC1 and RHOA are well known to be involved in cytoskeleton rearrangement 
that is essential in cell mobility and proliferation (Heasman & Ridley, 2008). RAC1 and 
Rho protein family members have also been shown to promote cell survival and death 
(Jiang et al., 2003; Murga, Zohar, Teramoto, & Gutkind, 2002). In the NanoBRET 
analyses, the GTP-bound GTPases bound specifically to numerous proteins, including 
BTK, CD81, LAT2, LILRB3, NFATC3, PPP3CA, RAC2, RAF1, RAP1A, RAP1B, 
RAP2A, RASSF5, TEC, TP53, and VAV1. Moreover, they interacted with more proteins 
involved in the regulation of the actin cytoskeleton (e.g., Rap GTPases) than their GDP-
bound counterparts, thus supporting previous reports. Proteins that specifically bound to 
the GDP-bound GTPases included ARHGEF7, BCL10, BCL2, CD19, DAPP1, GSK3B, 
HRAS, and PIK3AP1. Interestingly, both CD19 and PIK3AP1 (also known as BCAP) are 
involved in decreasing the threshold for antigen receptor-dependent stimulation by 
linking BCR signaling with PI3K activation. Upon binding an antigen, the CD19 and 
BCR co-localize into lipid rafts where CD19 recruits several signaling molecules, 
including PI3K, that can further augment signal transduction. PIK3AP1, on the other 
hand, promotes the translocalization of PI3K to the cell membrane where PI3K is then 
phosphorylated and activated. The preference of the GDP-bound GTPases for CD19 and 
PIK3AP1 suggests that the inactivated GTPases may help to decrease the threshold of the 
BCR-stimulated response.  
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 Tyrosine and serine/threonine kinases. Several kinases were included as queries 
in this study. BTK, LYN, and SYK are tyrosine kinases. AKT1, MAPK14 (also known as 
p38), and PI3K are serine/threonine (S/T) kinases; PI3K also phosphorylates lipids. 
Whether their interactions with the protein substrates in the NanoBRET analyses is from 
the kinase phosphorylating them or from an interaction independent of their kinase 
activity is uncertain. AKT1 was the most promiscuous kinase, interacting with 57 unique 
proteins; on the other hand, MAPK14 was the least promiscuous, binding only 14 
partners.  
Two of the three tyrosine (Y) kinases, BTK and SYK, bound to RasGRP3 
(regardless of tag location), a GEF in the MAPK signaling pathway. It is possible that 
RasGRP3 is phosphorylated by activated BTK and SYK following BCR stimulation, 
which may assist in RasGRP3’s ability to activate the MAPK signaling pathway. Indeed, 
mass spectrometry studies have identified two tyrosine residues on RasGRP3, at tyrosine 
residues 45 and 179 (Cell Signaling Technology curation set 2234; 2007)(Bassani-
Sternberg et al., 2016). Although the function of the phosphorylated tyrosines on 
RasGRP3 have yet to be elucidated, tyrosine phosphorylation of other GEFs have been 
shown to promote the activation of downstream GTPases (DeGeer et al., 2013; Kiyono, 
Kato, Kataoka, Kaziro, & Satoh, 2000; Teramoto, Salem, Robbins, Bustelo, & Gutkind, 
1997). 
Adaptor proteins. Two of the queries, BLNK and DAPP1, were adaptor 
proteins. Adaptors facilitate PPIs between other proteins by possessing a variety of 
protein-binding motifs that bring protein partners in close proximity to each other. BLNK 
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(also known as SLP-65) is a critical protein in B cell response by binding to proximal 
kinases to downstream effectors of various signaling pathways. Without BLNK, B cells 
are unable to develop properly, with a specific block in the pro- to pre-B cell transition 
(S. L. Xu et al., 2000). DAPP1 (also known as Bam32), on the other hand, is not crucial 
for B cell development, but instead plays a role in IgG3 class switching, cytoskeletal 
rearrangements, and calcium mobilization (Al-Alwan, Hou, Zhang, Makondo, & 
Marshall, 2010a; Fournier et al., 2003). BLNK was a promiscuous adaptor in this 
NanBRET analyses by interacting with 56 unique target proteins; DAPP1 interacted with 
only 22 proteins.  
DAPP1 is phosphorylated by a Src family kinase (presumably LYN) upon antigen 
engagement with the BCR and assists in RAC1 activation, although the exact mechanism 
in which DAPP1 maintains GTP-bound RAC1 is unknown (Allam, Niiro, Clark, & 
Marshall, 2004). Allam et al. speculate that DAPP1 may interact directly with RAC1. 
Indeed, in this preliminary screen of PPIs within the BCR signaling pathway, GDP-bound 
RAC1 (and GDP-bound RHOA) interacted with DAPP1. Another possibility is that 
DAPP1 acts upstream to RAC1, interacting with proteins like VAV and SOS. However, 
these NanoBRET analyses did not detect an interaction between DAPP1 and any of the 
proteins in the VAV or SOS families. DAPP1 was the only query to interact with all three 
co-inhibitors of BCR signaling upstream to PTPN6 (also known as SHP1), which were 
CD22, CD72, and LILRB3 (also known as PIRB). PTPN6 is a negative regulator of 
cytokine signal transduction and, more recently, DAPP1 has been suggested to play a role 
in negatively regulating cytokine production as well (Kile, Nicola, & Alexander, 2001; 
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Onyilagha et al., 2015). It is possible that DAPP1’s ability to control cytokine production 
may be the result of its interaction with CD22, CD72, and LILRB3.  
Pairwise linear regression analyses to determine differences in binding 
interactions across queries. To understand whether there was a difference between two 
queries in terms of enriched biological processes and gene families in their interactions, 
targets were first defined using the Protein Analysis Through Evolutionary Relationships 
(PANTHER) and HUGO Gene Nomenclature Committee (HGNC) classification 
systems, respectively. The number of targets with different biological process or gene 
family was then determined per query and a pairwise linear regression analyses 
comparing different queries were performed (Appendix D). Enriched processes or gene 
families were defined as having more than two standardized residuals away from the 
predicted mean of the fitted linear regression line. Notably, this method of analyses 
cannot determine whether the enrichment in each group is statistically significant. 
BTK interacted with significantly more proteins involved in the G-protein 
coupled receptor signaling pathway (Gene Ontology, GO:0007186) and intracellular 
signal transduction (GO:0035556) than both of the other two tyrosine kinases that were 
studied, with standardized residuals > 2.1 (Appendix B, D). It is interesting to note that 
BTK has been demonstrated to be an integral part in intracellular signal transduction and 
the G-protein coupled receptor signaling pathway (Qiu & Kung, 2000). LYN and SYK 
were not enriched in any process when compared to the other Y kinases.  
PI3K interactions were enriched in the transmembrane receptor protein tyrosine 
kinase (TRTK) signaling pathway (GO:0007169) compared to AKT1 and MAPK14, with 
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standardized residuals > 2.5 (Appendix B, D). Protein targets of AKT1 and MAPK14, on 
the other hand, were enriched in intracellular signal transduction (GO:0035556) 
compared to PI3K, having standardized residuals > 4.3. In a general way, proteins in the 
TRTK pathway are upstream in BCR signaling compared to the proteins classified under 
intracellular signal transduction. For example, BTK, CD19, LYN, and SYK are all TRTK 
pathway proteins, while BCL2, GSK3B, MAP2K1-3, and RAC1-3 are all intracellular 
signal transduction proteins. These data support numerous experimental evidence that 
PI3K acts upstream of AKT1 and MAPK14 (p38α) (Berra, Diaz-Meco, & Moscat, 1998; 
Castellano & Downward, 2011; Stechschulte et al., 2014). 
A comparison of the proteins that interact with S/T kinases and Y kinases reveal 
that S/T kinase interactions are enriched in cell surface receptor signaling pathway 
(GO:0007166) proteins, specifically those in the “CD molecule” protein gene family 
(Appendix B, D). The standardized residuals of these results were 2.4 and 3.9, 
respectively. CD, or cluster of differentiation, molecules are often receptors or ligands 
that initiate a signaling cascade. In B cells, these types of molecules act to promote or 
inhibit BCR signaling. These results warrant further investigation. 
Compared to DAPP1, BLNK’s interactions were enriched with “SH2 domain 
containing” proteins, as reflected by a standardized residual of 4.2 (Appendix B, D). The 
Src homology 2 (SH2) domain is highly conserved, ~ 100 amino acids long, present in a 
wide array of proteins, directs PPIs, and is important in protein-protein signaling (Gan & 
Roux, 2009; Schaffhausen, 1995). It recognizes, and binds to, phosphorylated tyrosine 
motifs in a promiscuous fashion, although the surrounding amino acid residues can affect 
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the overall affinities of these interactions. BLNK contains 13 potential tyrosine 
phosphorylation sites, eight of which have previously been determined to be 
phosphorylated and six as part of YXXP motifs within BLNK’s C-terminal SH2 domain 
(Hornbeck et al., 2015; Kabak et al., 2002; Kéri & Tóth, 2003). The YXXP motif is 
considered to be a classic binding site for SH2 domains. DAPP1, on the other hand, has 
11 potential phosphotyrosine sites, none of them in a YXXP motif, with only two of them 
being experimentally observed (Y139, Y195). These results reflect the biological 
functions of these adaptor proteins in BCR signaling: BLNK’s phosphotyrosines 
essentially anchor a multimolecular complex proximal to BCR engagement called the “B 
cell signalosome” that is important in initiating multiple signaling cascades, whereas 
DAPP1 stimulates the RAC1/JNK pathway involved in B cell adhesion and spreading 
(see Chapter 2.4)(Al-Alwan et al., 2010b; Ulivieri & Baldari, 2005). 
 
3.4.4   Conclusions 
  “NanoBRET” is a BRET-based platform that was recently developed by 
Promega Corporation to study PPIs in living cells, with higher sensitivity and dynamic 
range than standard BRET assays (Machleidt et al., 2015). Here, I adapted NanoBRET 
for high throughput in vitro studies, employing proteins produced in cell-free expression 
systems and 96-well plates. I compared the effect of different buffers on blocking non-
specific adsorption to the plates and suspending the proteins for analyses. NanoBRET 
was determined to be compatible with all conditions tested, with HEPES buffer resulting 
in the highest signal-to-noise ratio. Additional parameters were examined, including the 
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length of protein expression, query-to-target ratio, the amount of NanoBRET 618 ligand 
and luciferase substrate. These results indicate that 1.5-hour protein expression, 30-fold 
protein dilution, 1:1 query-to-target ratio, 1000-fold dilution of the NanoBRET 618 
ligand, and 500-fold dilution of the luciferase substrate had the maximum response. 60 
µL per half-area well of a 96-well plate were applied in this experiment to ensure that the 
pipetting performed by an automated liquid handler was within the linear range of the 
instrument; however, a lower volume, depending on the liquid handler and the 
experimental setup, could feasibly be used (i.e., > 30 µL).  
Qualitative analyses of > 2500 potential protein interactions within the BCR 
signaling pathway were performed using NanoBRET between 12 query proteins and 107 
unique target proteins represented separately with a fusion tag at the N- and C-terminus. 
This study is the first time that NanoBRET has been used to study PPIs in vitro. Distinct 
differences in binding partners between S/T kinases, Y kinases, and GDP- and GTP-
bound GTPases were detected. The majority (83%) of the interactions have never been 
previously reported, thus indicating that much of the BCR pathway has not been mapped. 
All of the queries interacted with proteins that are known to promote and inhibit 
BCR signaling, thus highlighting possible dual roles in signal transduction. For sure, the 
BCR signaling response is tightly controlled and relatively transient with proteins that 
can amplify and/or inhibit the BCR signal. LYN, the tyrosine kinase that is activated 
immediately upon BCR-antigen binding, regulates the PI3K/AKT pathway both 
positively and negatively (H. L. Li, Davis, Whiteman, Birnbaum, & Pure, 1999). 
Stimulation of the CD40 receptor can result in cell proliferation or apoptosis, depending 
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on the differentiated state of the B cell (Billian, Mondiere, Berard, Bella, & Defrance, 
1997; Ingley, 2012). DAPP1 has also been implicated as having a dual role in inhibiting 
and promoting the BCR signaling pathway (Richards, Watanabe, Santos, Craxton, & 
Clark, 2008). 
NanoBRET identified which proteins interact with each other and provides insight 
into the relative promiscuity and function of each query. However, further analysis to 
validate these results is warranted. It is important to note that all of the proteins for this 
study were expressed in the human Hela cell-based in vitro transcription translation 
(IVTT) system, which can modify proteins post translationally, most notably 
phosphorylation. The phosphorylation status of the query and target proteins was not 
controlled; thus, the detected PPIs may only reflect those that occur (or not occur) in 
HeLa cells. In addition, NanoBRET cannot measure the kinetics and affinities of the 
PPIs. This type of quantitative information would provide a more time-resolved picture 
of signal transduction, particularly for predictive algorithms or steady state models. To 
complement these qualitative NanoBRET data in an orthogonal fashion, I developed a 
high throughput and quantitative platform, NAPPA-SPRi, which is described over the 
next few chapters. Moreover, control over target protein phosphorylation, an important 
PTM in the BCR signaling pathway, is possible with this technology. By analyzing PPIs 
under different phosphorylation states (i.e., with and without phosphorylation), the 
inactive and active BCR signaling protein interaction network can be further delineated. 
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CHAPTER 4  
4   DEVELOPMENT OF NAPPA-SPRI  
4.1   Technology overview 
4.1.1   NAPPA 
Protein microarrays generally refer to a technology that displays hundreds to 
thousands of different proteins of known address on a solid planar or bead substrate. It 
enables the high throughput analysis of proteins, and has been used in basic research and 
translational research to study protein-protein interactions, protein-drug binding, 
posttranslational modifications, and antibody biomarkers of disease. More recently, bead-
based protein microarrays and, to a lesser extent, planar arrays have been implemented in 
the clinic as in vitro diagnostic tools to test for serological protein and antibody 
biomarkers of allergies, autoimmune diseases, cancer, heart disease, infectious diseases, 
and Alzheimer’s disease (Hartmann, Roeraade, Stoll, Templin, & Joos, 2009). Protein 
microarrays are primarily defined by the method in which the proteins are produced and 
immobilized.  
Traditional protein microarrays print purified proteins expressed in Escherichia 
coli (E. coli), yeast and baculovirus insect cells (X. B. Yu et al., 2016). The use of 
nonhomologous systems to express mammalian proteins can be problematic since they 
may not have the appropriate chaperones for proper folding or ability to attach post 
translational modifications (PTMs) (Saul et al., 2014). Even if a protein were to get post 
translationally modified, it is unlikely that the type and location of the PTM would reflect 
those occurring in native systems. The purification procedure is often low throughput and 
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tedious regardless of the host system and requires additional protein manipulation that 
may negatively affect protein conformation and activity (Costa, Almeida, Castro, & 
Domingues, 2014). For example, a protein that can be expressed may not necessarily be 
able to be purified due to insoluble aggregation. Thus, it is not uncommon that individual 
proteins require separate optimizations, which involve protein denaturation and refolding, 
to increase protein recovery. Furthermore, the purification process is long and does not 
result in 100% purification. Protein purity, however, can be improved if fast pressure 
liquid chromatography (FPLC) is used. Due to the time involved in optimizing protein 
expression and purification, protein microarrays are not cheap. For example, the 
ProtoArray® Human Protein Microarrays (Thermo Fisher Scientific; Waltham, MA) that 
have > 9,000 full-length human proteins expressed with the baculovirus system were 
$1,200 per array at the time that this thesis was written (2018). This is in contrast to the 
Human GE 4x44K v2 cDNA microarray offered by Agilent Technologies, which cost 
~$55 per 9,000 transcripts. The instability of proteins when compared to DNA also 
contributes to their high cost when considering shelf-life and experimental results. 
Spotting proteins directly onto the slide may result in non-specific adsorption and 
denaturation (Karlsson, Ekeroth, Elwing, & Carlsson, 2005; X. Li & Zhou, 2013). For 
most researchers, the biggest drawback of expressing human proteins in nonhomologous 
systems and/or purifying them is that the proteins may not be properly folded or 
functional. 
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In 2004, another type of protein 
microarray based on cell-free protein 
expression, the nucleic acid 
programmable protein array (NAPPA), 
was introduced (Ramachandran et al., 
2004; Ramachandran et al., 2008; X. Yu 
et al., 2018). In the NAPPA approach, 
plasmid cDNA encoding for any 
protein-of-interest (POI) is spotted onto 
a glass surface, which then can be transcribed and translated by an in vitro expression 
system (e.g., E. coli, rabbit, insect, human, wheat germ) at the time of the experiment 
(Figure 16). The use of a cell-free expression system has many advantages over 
expressing protein in vivo. First, proteins are produced with homologous ribosomes and 
chaperones, increasing the likelihood that the proteins are folded properly and are 
functional. Several NAPPA-based experiments studying protein-protein interactions and 
kinase activity have demonstrated that NAPPA proteins are functional (Ramachandran et 
al., 2004; Ramachandran et al., 2008; Rauf et al., 2018; X. B. Yu & LaBaer, 2015). 
Second, NAPPA proteins are produced in 2 hours, requiring only a plasmid backbone 
with the appropriate promoter and enabling same-day analyses. Third, proteins that may 
be toxic to cells can be synthesized. Fourth, non-natural amino acids can be incorporated. 
Fifth, NAPPA uses a fusion tag, which minimizes substrate-induced denaturation by 
distancing the protein-of-interest from the substrate surface (Karlsson et al., 2005). Sixth, 
Figure 15. Preparation of GST-based NAPPA (VGP CPD 
website) 
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the NAPPA approach does not require the proteins to be purified in the traditional sense 
(e.g., FPLC) since the expressed GST-tagged proteins are captured to the slide in situ via 
an anti-GST antibody. Finally, additives, detergents, cofactors, and binding partners can 
be easily added to the cell-free expression system.  
When this thesis was written, NAPPA could customarily express as many as 
2,300 different proteins per standard 75 mm x 25 mm slide that are 640 µm apart (center-
to-center) with a 450 µm spot diameter. Although not in general use, others have 
increased the number of proteins to 14,000 or more using a different type of slide and 
printing method (Song et al., 2017; Takulapalli et al., 2012). Additional technical work 
implies that NAPPA could one day reach as many as 48,000 different proteins per slide 
(personal communication with owner of Engineering Arts and co-developer of high 
throughput NAPPA, Dr. Peter Wiktor). 
The plasmid cDNA employed by NAPPA is in a Gateway-compatible vector and 
encodes for a fusion gene encoding for the protein-of-interest and glutathione-S-
transferase (GST). The InvitrogenTM GatewayTM cloning system allows the transcript 
inserts to be easily shuttled between Gateway-compatible vectors with the use of enzyme 
mixtures known as “BP Clonase II” and “LR Clonase II” that contain the restriction 
enzymes Int, and IHF; and Int, Xis, and IHF, respectively (Stewart, 2016). In the first 
step, PCR products flanked by the specific attB sequence replace the ccdB (controller of 
cell division or death B) gene of a donor vector and transformed into DH5α E. coli cells 
for propagation. The ccdB gene encodes for a protein that inhibits cell division, thus cells 
containing a vector with the “death cassette” will not grow and will not be selected for 
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further use. Successful shuttling of the PCR product into the donor vector is also assured 
through an antibiotic resistance gene encoded by the donor vector. PCR inserts in the 
resulting entry clone can then be transferred to any Gateway-compatible destination 
vector, which confers different antibiotic resistance than the entry clone. For NAPPA, 
genes without a stop codon are inserted into the pANT7_cGST destination vector 
containing a T7 transcriptional start site, ampillicin resistant gene, and a GST gene at the 
3’ end of the insert.  
The plasmid cDNA is printed onto glass microscope slides of standard size (25 
mm x 75 mm x 1 mm) functionalized with 3-aminopropyltriethoxysilane 
(“aminosilane”). In other words, the slides are coated with a chemical that results in free 
amines being exposed on the surface. In addition to DNA, the printing master mix 
contains bovine serum albumin (BSA), bis(sulfosuccinimidyl)suberate (BS3), 
dimethylsulfoxide (DMSO), and an anti-GST polyclonal antibody (Ramachandran et al., 
2008). The Virginia G. Piper Center for Personalized Diagnostics (VGP CPD; Tempe, 
AZ) has found that while linear DNA binds well to the glass surface, it is not transcribed 
well in the cell-free expression systems. On the other hand, circular DNA is transcribed 
well, but has difficulty binding to the glass surface. The BS3 is a bifunctional amine-to-
amine crosslinker that binds the amine-coated slides to the lysine residues on BSA and 
the anti-GST antibody to each other and, by forming a matrix, it theoretically helps trap 
the plasmid DNA to the surface. BSA is necessary as its removal results in the significant 
decrease in DNA deposition. Whether BSA “traps” DNA physically or electrostatically is 
unclear. DMSO is used to decrease the drying time following printing to improve spot 
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shape, spot size, and matrix formation. Finally, POIs are then produced and captured 
during a two-hour incubation using a cell-free expression system. (Genes can be shuttled 
into destination vectors that are compatible with the expression system-of-interest, which 
includes those arising from E. coli, rabbit, wheat germ, human, or insect.) The anti-GST 
antibody enables the capture of the expressed fusion protein to the slide surface. Since the 
26 kDa GST fusion tag is at the C-terminus of the POI, the capture of the GST means that 
the POI was fully translated.  
Notably, the use of a tag has both advantages and disadvantages (Costa et al., 
2014; Kosobokova, Skrypnik, & Kosorukov, 2016). The primary advantage of fusion 
tags is that they minimize substrate-induced denaturation by distancing the protein-of-
interest from the substrate surface. For example, coating glass with protein A prior to 
antibody addition reduces antibody denaturation (X. Li & Zhou, 2013). Non-specific 
protein adsorption and denaturation on positively-charged amine surfaces has also been 
previously documented (Karlsson et al., 2005). On the other hand, a fusion tag may 
negatively affect the conformation and activity of the protein. It can occlude binding 
epitopes, such that a protein that would otherwise interact with the POI may not be able 
to bind to the target protein when the tag is at one terminus. The tag at the other terminus, 
however, may expose the epitope for binding. Therefore, attempts to have a GST tag at 
the N-terminus of the POI have been made; they were unsuccessful. It is speculated that 
the reason why an N-terminal GST tag is incompatible with NAPPA is that the region of 
GST to which the capturing antibody attaches is obscured. 
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NAPPA often studies protein interactions at equilibrium, primarily stable 
antibody-antigen interactions (Diez et al., 2015; Miersch et al., 2013; J. Wang et al., 
2014). After protein expression and capture, most NAPPA users subject the array to 
serum from patients having the disease-of-interest. After washing, a labeled anti-human 
antibody that can be fluorescently detected to determine the location of the antibodies and 
their target antigens probes the slide. The comparison of binding patterns between control 
(i.e., healthy) and disease samples helps to identify specific antibodies that potentially 
could be used as diagnostic biomarkers of disease. A similar approach tracks the immune 
response over time in response to infection or treatment. 
Interactions other than antibody-antigen interactions detected with NAPPA (e.g., 
Fos binding to Jun) support the conclusion that the expressed proteins are functional and 
most likely folded properly (Ramachandran et al., 2008; X. B. Yu & LaBaer, 2015). 
Other studies performed in the lab have shown that known kinases maintain their ability 
to auto-phosphorylate (Rauf et al., 2018). 
While NAPPA has numerous advantages, it still has its limitations. Like any 
equilibrium-based assay, NAPPA (in its present form) can only detect protein complexes 
with high binding affinities that can withstand numerous washes inherent to the 
procedure. Stable interactions, however, only represent a small fraction of the protein 
interactions that actually occur in vivo. Thus, NAPPA is missing interactions within 
signaling networks that may be fundamental to disease onset, progression, and response 
to treatment. The current cell-free expression system that is primarily used with NAPPA 
is lysate from human HeLa cells that is mixed with accessory proteins and a reaction 
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mixture containing various other reagents (e.g., reducing agent) to enhance transcription 
and translation. The expression system is capable of performing PTMs, with 
phosphorylation being documented the most. The type and location of these PTMs are 
likely similar to those seen in HeLa cells in vivo, but may not be relevant to the disease or 
interaction-of-interest. As previously acknowledged, PTMs often affect protein activity 
and interactions.  
NAPPA has relied on the GST tag to capture the expressed protein to the slide 
surface, which is not advantageous for some applications. First, the GST tag is 
compatible with the platform only when the GST is at the C-terminus. Since some 
epitopes on the displayed proteins may be blocked by GST, it would be advantageous to 
have the displayed proteins without a fusion tag, a smaller tag, or have the proteins also 
represented on the array with the GST at the N-terminus. Second, the antibody-GST 
capturing method is not covalent. 
To address the limitations of the GST tag, the laboratory has recently investigated 
the possibility of using a covalent capturing method using the HaloTag® fusion 
(Promega Corporation; Madison, WI)(J. Wang et al., 2013). The replacement of a single 
amino acid in a haloalkane dehalogenase enzyme originating from Rhodococcus 
rhodochrous results in a stable covalent bond between the HaloTag protein and a 
chloroalkane substrate (England, Luo, & Cai, 2015). Indeed, harsh denaturing conditions 
showed that HaloTag fusion proteins remained on the slide surface while GST fusion 
proteins were removed (see also Figure 23, page 91)(J. Wang et al., 2013). In addition, 
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proteins with HaloTag at the N- and C-terminus of the proteins-of-interest can be 
successfully captured to the NAPPA surface. 
 
4.1.2   SPR and SPRi 
The term “surface plasmon resonance” (SPR) refers both to a light-electron 
phenomenon and the sensor platform that employs it (Homola & Dostálek, 2006; 
Schasfoort & Tudos, 2008). The SPR phenomenon was first observed in 1902 by R. M. 
Wood at Johns Hopkins University, in which polarized light shone onto a metal-backed 
diffraction grating resulted in reflected light composed of dark and light bands. Nearly 
four decades later, Hugo Fano recognized that the “Wood’s anomaly” was due to the 
incident light being converted into wave-like oscillations of the free electrons within the 
metal surface. In 1983, Bo Leidberg et al. exploited the SPR phenomenon for the first 
time as a biosensor to specifically detect the interaction of human IgG with anti-human 
IgG (Liedberg, Nylander, & Lundstrom, 1983). SPR has since become recognized as a 
sensitive, label-free approach for analyzing the interactions between DNA, drugs, 
peptides, and proteins in real-time. In the pharmaceutical industry, SPR identifies and 
studies the differential binding of drugs to their pharmacological targets (Olaru, Bala, 
Jaffrezic-Renault, & Aboul-Enein, 2015). This thesis, however, will focus on the 
detection of protein-protein interactions by SPR. 
All SPR instruments have three main components: optical unit, liquid handler, 
and the sensor surface. The sensor surface is generally a portable chip or slide in which 
proteins are adhered; these captured proteins are called “ligands” or “targets.” The liquid 
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handler is essential in injecting any reagent-of-interest in buffer across the surface, 
including a purified “analyte” or “query” protein. The optical unit enables the 
measurement of protein interactions through the use of a prism, grating, or optical 
waveguide. In the case of a prism, the optical unit essentially filters out light noise (i.e., s-
polarized light) so that the p-polarized light can be properly focused and synchronized 
with the surface plasmons. 
The sensor chip is generally composed of a glass substrate coated with a thin (~50 
nm) layer of gold. Other metals, like silver, copper, tin, lead, mercury, cadmium, indium, 
and the alkali metals can also produce SPR, but have more disadvantages than gold. For 
example, copper results in a weaker signal. Mercury cannot be used with light in the 
visible range. Silver, the second most common metal used with SPR, isn’t very stable and 
is easily oxidized in air.  
The metal is then coated with an adhesion linking layer and immobilization 
matrix. The adhesion linking layer is usually composed of a > 10-carbon alkane with a 
terminal thiol group, which stacks against each other in a self-assembling monolayer that 
is oriented perpendicular to the surface via the thiol during an extended incubation (i.e., 4 
– 24 hours). (Whether the thiol-gold interaction is covalent is still up for debate.) The 
adhesion linking layer enables a bioinert, hydrophilic immobilization matrix to be 
attached to the surface, the purpose of which is to 1) reduce non-specific binding of the 
query protein to the “sticky” metal and 2) capture the target protein to the slide. Matrices 
can be 2D or 3D in structure, which are composed of polymers like dextran, 
carboxymethyldextran, poly(vinyl alcohol), poly(ethylene glycol), poly(acrylic acid), and 
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poly(L-lysine). The type of immobilization topcoat depends on the specific needs of the 
experiment. The NAPPA-SPRi platform in this thesis used a self-assembling monolayer 
that combined both the adhesion linking layer and immobilization matrix: HS-C11-
(C2H4O)6-NH2, where HS-C11 represents the adhesion linking layer and (C2H4O)6-NH2 
represents the matrix (ProChimia Surfaces; Poland). 
The target protein (usually purified) is then captured to the surface via the 
immobilization matrix. For example, a biotin-functionalized self-assembled monolayer 
will bind to proteins with a streptavidin 
tag. The addition of the immobilization 
layer and target to the slide are often 
done under flow.  
The SPR phenomenon is made 
possible by the optical unit, which 
essentially directs the incident p-
polarized light to the sensor surface so 
that plasmon resonance can occur. The 
prism-based optical unit is the most 
commonly employed optical set-up and 
is used in the SPRi platform used in my 
exeriments, thus only describe the 
“Krestchmann configuration” will be 
described here. Detailed explanations of 
Figure 16. SPR analysis of PPI. A) Kretschmann 
configuration of the SPR instrument. B) PPI causes a change 
in AMR, or critical angle. C) Binding sensorgram depicting 
a PPI over the course of the experiment. 
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the other optical units can be found elsewhere (Schasfoort & Tudos, 2008). SPR 
instruments with the Krestchmann configuration require a light source to produce the 
incident light, a prism, a sensor surface (described above), and a device to measure the 
reflected light (Figure 17A). The light source can be a laser or halogen lamp that is 
directed toward a prism at a specific angle, resulting in photons with direction and 
momentum. Both the direction and momentum of these photons will change as they move 
from different mediums (i.e., vacuum to prism). The sensor chip is coupled to the prism 
through immersion oil with a similar refractive index (RI) of the slide. The key to SPR is 
that, at the critical incident angle or “angle of minimum reflectance” (AMR), the 
direction and momentum of the photons become parallel to the surface and equal to the 
electron plasmons of the metal, respectively. This results in total internal reflection and 
SPR, such that no light is reflected (Figure 17B) (i.e., the dark band observed by Wood in 
1902). It is important to note that the momentum of the electron plasmons is sensitive to 
the RI of the medium surrounding them. Thus, an interaction between a query and target 
protein will change the local RI of the medium, resulting in a different AMR. SPR 
instruments measure the change in this angle during the association and dissociation of a 
protein-protein interaction (PPI). 
SPR has two components that are inherently linked to one another: wave-like 
oscillations in the plane of the metal layer and an electric field perpendicular to the 
surface. The electric field, or “evanescent wave,” decays exponentially from the interface 
surface, extending approximately one light wavelength (of the light source) into the 
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medium on either side of the metal layer. For most instruments, the depth of the 
evanescent wave is 200 – 300 nm.  
There are three main steps in SPR analyses (Figure 17C). In the first step of 
analyses, only buffer is injected across the surface with the captured target proteins to 
obtain a baseline signal. In the second step known as the “association phase,” a purified 
query protein in buffer is added, allowing the query to associate with the target on the 
surface. In the third and final step known as the “dissociation phase,” the addition of 
query is ceased and only buffer is injected, allowing the flowing buffer to remove query 
as it dissociates from the target. SPR sensorgrams of an interaction can look like Figure 
17B, where the change in AMR is depicted on the x-axis and the reflected light intensity 
is on the y-axis. However, the most common sensorgram format is like Figure 17C, 
where time is on the x-axis and the binding response (or, change in RI) is on the y-axis. 
The y-axis can also be interpreted as the occupancy frequency of ligand epitopes by the 
query (i.e., response). 
The buffer for SPR analyses is often phosphate- or Tris-buffered saline with 0.01 
– 0.1% Tween-20. The use of a nonionic detergent like Tween-20 decreases nonspecific 
hydrophobic interactions and helps to prevent bubble adsorption on the surface. High 
concentrations of detergent, however, may interfere with real binding events. Therefore, 
both buffer and detergent choice and amount can have drastic effects on the protein 
interactions and should be chosen carefully, taking into consideration the proteins-of-
interests and the instrument set-up. The pH of Tris-buffered saline, for example, changes 
based on temperature. The SPRi instrument that was used in the experiments described 
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herein (i.e., PlexArray® HT System) can control the temperature at the sample holding 
area and sensor surface, but the temperature of the 1 mL sample loop is not controlled. 
The flux of pH in the Tris-based buffer from 4 oC in the holding area to RT in the sample 
loop to 30 oC on the sensor slide may not be desirable. Most SPR experiments use 
phosphate-buffered saline (PBS), but this buffer may not be appropriate for the 
experiment either. The phosphate groups in PBS may interfere with studying the effects 
of phosphorylation on protein interactions. 
During the “association phase,” 
the query and target proteins are 
introduced to each other. Proteins that do 
not interact with each other, or “non-
binders,” would ideally produce a 
sensorgram with a flat horizontal line, 
but this is usually not the case. Instead, 
the sensorgrams of non-binders look like 
Figure 18A, which depict differences in 
RI between the baseline and association 
steps and resemble a blockier curve than 
binders (Figure 18B) since the RI 
quickly reverts to baseline during the “dissociation step.” The query protein should be 
buffer exchanged into the same buffer used in the baseline step; however, small 
variations in temperature or buffer composition will result in an altered RI. Although a 
Figure 17. SPR sensorgrams reflecting A) bulk refractive 
index shift and B) real PPI. 
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region-of-interest on a slide is designated as a specific protein target, it should be 
remembered that there are numerous target molecules within this region (i.e., not just one 
protein molecule). Therefore, the y-axis reflects the sum of the target residues interacting 
with the query, where the amount of protein complex increases over the length of the 
association time (or until the complex has reached equilibrium). Instead of the blocky 
shape of a simple RI change in medium observed in a sensorgram of a non-binder, an 
interaction should have an exponential binding curve. 
When the query-target on-rate is limited by the rate of flow, an issue called “mass 
transport” occurs (Schasfoort & Tudos, 2008). In other words, the query is binding to the 
target as quickly as diffusion will allow and is, therefore, dependent on the query 
concentration. Increasing the flow rate, decreasing the target concentration, increasing the 
query concentration, altering the flow chamber design above the sensor surface (to reduce 
stagnant areas), and decreasing the query size can all help minimize the mass transport 
effect. Several of these suggestions, however, may not be possible. Maximum flow rates 
are often limited. For example, the maximum flow on the PlexArray® HT System is 5 
µL/sec; above this, the flow chamber can leak for durations > 30 sec. The volume of the 
sample and injection loop will also affect the flow rate. Flow chambers are often 
commercially optimized and produced, so alterations to their design by the user are not 
realistic. Reducing the query size (by only using certain domains) so that it can diffuse 
faster to the surface can also greatly affect results. Due to diffusion constraints, higher 
flow rates increase the dynamic range of the instrument.  
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With the exception of covalent 
protein interactions, all PPIs are in flux, 
coming together and apart in varying 
degrees of on- and off-rates. During the 
association step, PPIs are constantly 
being formed and broken under flow as 
query is continually transported across 
the surface. It is only during the 
“dissociation phase” in which only 
buffer is injected that the off-rate, or 
dissociation, of the PPIs can be 
determined. Weak or transient interactions are those in which the query protein is shuttled 
quickly away from the target under flow, thus resulting in a rapid drop back down to 
baseline as fewer queries occupy the target residues (Figure 19A). Query proteins in 
stable interactions, on the other hand, tenaciously bind to their targets, as evidenced by a 
slow return to baseline (Figure 19B).  
Often, a fourth regeneration step will be used in which a high salt, acid, or base 
will be applied to the slide to disrupt any PPIs remaining following the dissociation step 
to return the sensorgram to baseline. This is especially common when working with 
surface-bound antibodies, which are generally stable under the regeneration conditions. 
Following regeneration, steps 1 – 4 can be repeated with a different query or query 
concentration. Regeneration has a couple of advantages: 1) removes molecules non-
Figure 18. Sensorgrams reflecting a A) transient interaction 
and B) stable interaction. 
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specifically bound to the surface that may cause baseline issues and 2) allows the same 
chip to be re-used, which makes the experiment more cost effective than using one chip 
per query type or concentration. Regeneration is used when the immobilized target 
molecule, like antibodies and peptides, are stable enough to withstand the harsh 
regeneration treatment without detrimentally affecting their ability to bind other 
molecules. Thus, a regeneration step may not be appropriate when the activity and/or 
conformation of less stable target proteins are important to the experiment. 
Because SPR measures the AMR for each ligand protein on the surface, it 
requires a separate light detector per ligand. This results in SPR being extremely low 
throughput with the most common platform used in academic settings (i.e., Biacore 
T100) being able to measure 4 different binding events at the same time through the use 
of 4 separate flow chambers and light detectors. Also, it is important that one of these 
analyses is used as a reference, so the interactions of interest are further decreased to 
three. Biacore also offers the Biacore A100, which can analyze as many as 20 PPIs at one 
time. 
The desire for a high throughput SPR instrument led to the development of SPR 
imaging (SPRi). Although similar to SPR, SPRi has a few distinct differences (Wong & 
Olivo, 2014). One, SPR measures the AMR while SPRi measures the reflected light 
intensity across time at a set incident angle. Two, SPRi uses only one light detector (i.e., 
charge-coupled device “CCD” camera) for an entire chip. Three, since SPRi needs only 
one camera while SPR needs a separate detector per ligand type, SPRi can be in an array 
format, thus resulting in higher throughput. The MX96 instrument from IBIS 
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Technologies (Netherlands), for example, can analyze as many as 96 PPIs at one time 
(Krishnamoorthy et al., 2010). Neumann et al. demonstrated that as many as 9216 protein 
fragments (i.e., fragment library) could be immobilized on a single SPRi array for drug 
discovery and screening (Neumann, Junker, Schmidt, & Sekul, 2007). During SPRi data 
analyses, regions-of-interest (ROIs) – or, spotted target protein – on the captured video 
can be selected and the pixel intensities, or the intensity of the reflected light, of the ROIs 
analyzed across time. One ROI will produce a corresponding sensorgram, with time on 
the x-axis and the amount of reflected light on the y-axis. While SPRi has high 
throughput capability, its measurement of reflected light rather than the AMR results in 
lower sensitivity than SPR instruments. The use of a camera also results in optical 
vignetting, which can negatively affect the quality of data around the edges of the array. 
Given the information provided above regarding SPR technology, the PPI that 
would result in the largest signal-to-noise ratio would be one where the 1) target protein 
was small (i.e., low mass), 2) target protein was very close to the surface, and 3) query 
protein was large. In actuality, most SPR instruments are not sensitive enough to detect 
binding of an analyte to queries that are less than 1 kDa. 
 
4.2   History of NAPPA-SPRi 
SPRi platforms like those from IBIS Technologies (Netherlands), GWC 
Technologies (Madison, WI), and Plexera LLC (Woodinville, WA) have the capacity of 
analyzing any type of PPI in a high throughput manner, yet most SPRi studies rely on 
antibody- or peptide-based interactions (Joshi, Peczuh, Kumar, & Rusling, 2014; 
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Stojanovic, Schasfoort, & Terstappen, 2014; Zhu et al., 2014). Even proof-of-concept 
demonstrations of SPRi throughput have been based on numerous replicates of stable 
antibody-antigen interactions rather than more biologically-relevant, non-antibody PPIs 
(Geertz, Shore, & Maerkl, 2012). In actuality, only one study has examined the kinetics 
of non-antibody, full-length proteins in high throughput. In 2016, 96 unique proteins 
from Yersinia pestis were expressed and purified from E. coli, biotinylated, and printed 
onto an SPRi chip coated with avidin using the Biacore FLEXchip and then probed with 
the same 96 proteins (Keasey et al., 2016). (Of note, the Biacore FLEXchip, which was 
reported to analyze as many as 400 binding events at one time, has been discontinued.) 
With the purported high throughput capabilities of various SPRi platforms, why then 
aren’t there more studies like those of Keasey et al.? Simply put, purifying proteins is 
costly and labor intensive (see also page 67). It is also easier from an experimental 
standpoint to use peptides or antibodies as captured targets on the SPR array since they 
are resilient to buffer changes and harsh regeneration conditions. Antibodies also bind to 
their antigens with high affinity with long half-lives. Therefore, Dr. Joshua LaBaer asked 
in 2006 whether his high throughput DNA-based NAPPA chemistry could be made 
compatible with SPRi. 
Dr. Sanjeeva Srivastava and Dr. Manual Fuentes first worked on making NAPPA 
compatible with SPRi. Their platform relied on using a C-terminal GST e-coil fusion tag 
in which the e-coil would bind very strongly via a coiled-coil interaction with a k-coil 
ligand on the surface (KD = ~60 pM
-1) (De Crescenzo, Litowski, Hodges, & O'Connor-
McCourt, 2003). E-coil and k-coil are short (< 40 amino acids) amphiphilic alpha-helical 
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peptides that form heterodimers through interhelical hydrophobic (i.e., coiled-coil) 
interactions (Aronsson et al., 2015). The k-coil and e-coil sequences were 
LKVSALKEKVSALKEKVSALKEKVSALKEKVSALKE and 
LEVSALEKEVSALEKEVSALEKEVSALEKEVSALEK, respectively. Note that the 
amino acids, leucine (L) and valine (V), are hydrophobic while the amino acids in bold, 
lysine (K) and glutamine (E), are hydrophobic.  
The use of a ~4 kDa k-coil peptide instead of a massive antibody (i.e., 150 kDa) 
as a capturing ligand will significantly reduce the surface mass and would, theoretically, 
make the SPR analysis more sensitive to binding events. Furthermore, the use of a k-coil 
appeared to eliminate the need for BSA, which has been found to be an essential reagent 
for plasmid cDNA immobilization with standard NAPPA. The GST tag was maintained 
in order to analyze protein display levels fluorescently with an anti-GST monoclonal 
antibody. Briefly, the printing master mix contained only k-coil and plasmid cDNA and 
the protein expressed with rabbit reticulocyte lysate. (At this time, no other mammalian 
cell-free expression system was available.) By 2009, antibody-antigen interactions were 
successfully detected using the e-coil//k-coil chemistry (i.e., version 1), but the data were 
never published. 
Dr. Lusheng Song, a collaborator in China at the National Center for NanoScience 
and Technology, created the second version of NAPPA-SPRi in 2012. Like standard 
NAPPA, he used a C-terminal GST tag and an anti-GST polyclonal antibody to bind the 
translated fusion protein. The antibody was not part of the printing master mix, but was 
instead bound to the entire bare gold surface through electrostatic interactions; no 
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adhesion linking layer and immobilization matrix were used. He was able to demonstrate 
the interactions of query antibodies to their target proteins, as well as between TP53 and 
MDM2. His data were not published. 
Biacore SPR instruments were, at this time, the most popular; however, they 
relied on Biacore-specific flow chamber chips that were not amenable to printing (i.e., 
NAPPA). Therefore, VGP CPD worked with Plexera® Bioscience to develop a SPRi 
instrument that would be compatible with NAPPA, which is the PlexArray® HT System. 
I worked on the first (e-coil/k-coil) and second (GST-based) versions of NAPPA-
SPRi when I first joined the laboratory (separate from the individuals mentioned above), 
but found concerning disadvantages with both. The e-coil/k-coil chemistry prompted 
further optimization. First, only the k-coil and plasmid cDNA were contained in the 
printing master mix. In other words, the k-coil was not covalently captured to the array 
surface, but rather bound nonspecifically to the positive-charged slide through non-
covalent, van der Waals forces. (The slides used the same amine-coating that I later used 
in the optimized NAPP-SPRi experiments.) Rather than adopting a vertical configuration 
where one end of the k-coil is captured to the surface, the k-coil molecules likely laid 
horizontally on the slide. It is therefore uncertain 1) whether this affected the k-coil’s 
ability to interact specifically with the e-coil of the target protein, and 2) how much of the 
target protein is captured to the slide specifically via the k-coil/e-coil interaction or 
through van der Waals forces. To determine whether the target protein is captured 
specifically to the surface through the e-coil/k-coil interaction, I printed both GST-tagged 
proteins with and without the e-coil tag on an array and then analyzed the level of 
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displayed protein 
using a mouse 
anti-GST 
monoclonal 
antibody and 
fluorophore-
conjugated 
secondary anti-
mouse antibody. The data revealed no significant difference in the level of protein 
captured between GST-tagged proteins and GST-ecoil-tagged proteins (data not shown, 
September 2010).  
Non-specific protein adsorption and their denaturation on positively-charged 
amine surfaces is a known phenomenon (Karlsson et al., 2005). I have also observed non-
specific target immobilization on NAPPA 
arrays. In fact, some antibodies bind more 
strongly to the area around the spot that has no 
capturing reagent (i.e., “the ring”) than the spot 
itself (Figure 20), which may be due to the 
antibodies having a preference for linear 
epitopes or that the antibodies’ epitopes are 
more exposed upon partial or full target 
denaturation. Therefore, it’s important to point 
Figure 19. Proteins are denatured when they bind non-specifically to the slide. 
Fluorescent analyses of A) protein display using an anti-tag antibody and B) tyrosine 
phosphorylation using an nti-phosphotyrosine antibody. False-colored rainbow images, 
where blue = low antibody binding, yellow = moderate antibody binding, red = high 
antibody binding.  
Figure 20. SPRi binding curves using a 
streptavidin and biotinylated k-coil coated slide 
surface. GST-tagged TP53, Fos, and Jun proteins 
probed with an anti-GST antibody.  
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out that while the e-coil/k-coil chemistry detects interactions between target proteins and 
query antibodies, there are no data supporting its ability to detect non-antibody PPIs that 
may rely on conformational epitopes (Figure 21). Of note, the query antibodies that were 
used (i.e., anti-JUN, anti-FOS, anti-TP53) are specific to linear epitopes, since synthetic 
peptides were used to immunize the animal hosts.  
Another major issue with the k-coil/e-coil chemistry 
was that the amount of required plasmid cDNA was five times 
that needed for standard NAPPA. For example, standard 
NAPPA needs a 1.2 mg/mL concentration of plasmid cDNA 
while the NAPPA-SPRi printing mixture required 6 mg/mL. 
Indeed, it’s been demonstrated that amphiphilic α-helical 
peptides bind to plasmid cDNA (Figure 22A)(Niidome et al., 
1997). A viscous substance formed immediately upon the 
mixture of k-coil peptide and plasmid cDNA, which was easily 
seen by eye (Figure 22B). The viscous substance captured 
approximately 20 – 40% of the DNA, making it unavailable for 
printing (as determined through spectrophotometric analyses). 
The strong interaction between the k-coil and plasmid cDNA is likely why this approach 
did not require BSA to capture DNA to the slide surface.  
Version 2 of NAPPA-SPRi using a GST antibody to capture the GST-tagged 
proteins to the slide surface was also less-than-ideal. First, the GST-antibody interaction 
was not covalent; thus, under flow, the captured target protein theoretically should be 
Figure 21. Amphiphilic α-
helical peptide forms an 
insoluble aggregate with 
plasmid cDNA. Observed by 
A) Niidome et al. with electron 
microscopy and B) me in 2010 
by eye. Reprinted with 
permission. 
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removed from the surface. Further, the use of a large 150 kDa anti-GST antibody would 
result in decreased sensitivity compared to a smaller capturing agent. In both NAPPA-
SPRi versions, the target proteins were not captured covalently to the slide and only 
represented the target with the tag at the C-terminus. The tag may block binding epitopes 
and, therefore, the additional representation of the target with a tag at the N-terminus 
would be desirable. I decided that the disadvantages of the previous versions warranted a 
new approach. 
In 2005, Promega Corporation (Madison, WI) reported for the first time a 
covalent tagging system using a modified haloalkane dehalogenase “HaloTag” enzyme 
that covalently binds to a small ~ 400 Da ligand (Los et al., 2005). In the unmodified 
version, the covalent ester interaction between the terminal chloride and aspartate residue 
on the enzyme is hydrolyzed by a nearby histidine at position 272 (England et al., 2015). 
Promega mutated the histidine to a phenylalanine, thus causing the HaloTag-ligand 
interaction to remain intact. The chloroalkane ligand can be altered to make the HaloTag 
system compatible with in vitro and in vivo platforms and numerous applications. (Please 
note that the term “ligand” can also refer to the protein captured to the sensor surface. To 
avoid confusion, the use of “ligand” in this thesis will only refer to the chloroalkane 
ligand that binds covalently to HaloTag.)  
In parallel with my colleague, Dr. Jie Wang, who was testing HaloTag with the 
standard NAPPA platform, I began working with HaloTag in the context of NAPPA-
SPRi in 2012. His interest in HaloTag was based on its ability to covalently capture 
proteins to the slide so that he could subsequently denature the proteins and probe the 
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array with patient serum to identify 
antibody biomarkers of disease (J. Wang 
et al., 2013). Although proteins are folded 
in vivo, they may become misfolded 
during disease (or occluded by the tag) 
and expose epitopes that would otherwise 
remain hidden. Dr. Wang was also 
interested in the idea of making the target 
proteins tagged at either the N- or C-
terminus. In addition to these attributes, the HaloTag offered another advantage regarding 
SPR analyses: its small capturing ligand. 
The covalent and specific capture of HaloTagged target proteins to the slide 
surface via the HaloTag-ligand interaction was elegantly demonstrated by Dr. Wang (J. 
Wang et al., 2013). The target protein, TP53, was immobilized to the array using both 
GST- and HaloTag-based chemistries. The slides were then subjected to harsh denaturing 
conditions, which included incubating the array with 125 mM Tris-HCl, 2% SDS, 100 
mM β-mercaptoethanol at 37 oC for 30 min with mild agitation. A comparison of 
captured TP53 target protein before and after denaturation revealed that TP53 continued 
to be captured only on the HaloTag-based NAPPA slide surface (Figure 23).  
Although the VGP CPD had long conceptualized synthesizing proteins in situ for 
SPR analyses, they were not the first to publicly demonstrate it. In July 2012, Seefeld et 
al. of University of California published the article, “On-Chip Synthesis of Protein 
Figure 22. HaloTag NAPPA can withstand harsh 
denaturing conditions. Captured TP53 target protein was 
assessed with an anti-TP53 antibody. Both images are false-
colored rainbow images, where blue = low antibody 
binding, yellow = moderate antibody binding, red = high 
antibody binding. Reprinted with permission. 
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Microarrays from DNA Microarrays Via Coupled In Vitro Transcription and Translation 
for Surface Plasmon Resonance Imaging Biosensor Applications,” in the Journal of 
American Chemical Society (Seefeld, Halpern, & Corn, 2012). In it, they bound linear 
dsDNA to one spot on a microfluidic SPR chip while a neighboring feature had a Cu(II)-
nitriloacetic acid (NTA) monolayer. His-tagged proteins were expressed in IVTT, 
diffused to the neighboring spot, and bound to the Cu(II)-NTA. A total of 16 features 
were on the array, with four features per protein. They demonstrated their platform by 
expressing and capturing green fluorescent protein and luciferase, then probing them with 
their specific antibodies. 
 
4.3   Optimization of NAPPA-SPRi using design of experiments (DOE) 
No binding signal can be obtained on the SPRi using the NAPPA chemistry used 
with the standard fluorescent-based protein microarrays. This incompatibility is because 
the “noise” is too high compared to the “signal;” in other words, the change in mass upon 
query binding is too little compared to the high mass of the printing master mix and target 
protein within the spot. The appropriate amounts of printing reagents for SPRi analyses 
were determined through a series of design of experiments (DOEs). 
Scientists generally use the "one-factor-at-a-time" (OFAAT) approach to optimize 
their experiments, which means that they optimize one factor before optimizing the 
setting for the next factor and so on. However, the experimental landscape is like a 3D 
surface. Locking all parameters except one will force the scientist to only investigate a 
portion of that landscape, which may never include the optimal region. Additional 
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disadvantages of OFAAT include time, expense, and the inability to determine whether 
the effect of one factor will depend on the level chosen for a different factor (i.e., “factor 
interaction”). DOE, on the other hand, analyzes different combinations of factors across 
the experimental plane (Montgomery, 2008). This allows the optimum to be found and 
factor interactions to be identified. Data interpretation is also made easy through the use 
of DOE software. Although scientists, particularly those in the research arena, rarely use 
DOE, engineers use the DOE approach all of the time. The engineers at Honeywell 
International Inc. (Morris Plains, NJ) used DOE, for example, to design a Boeing airplane 
engine (personal communication with a Honeywell employee, Dr. Don Holcomb).  
Optimization via DOE is an iterative process, requiring a cascade of experiments 
that are designed based on the results from the previous experiment. The questions when 
designing a DOE experiment are: Which and how many factors should be tested? How 
will the best parameters be determined quantitatively? How many experiments can be 
reasonably done at one time? How will the reproducibility of the experiment be 
determined? How many levels of each factor should be tested? And, finally, what levels 
of the factors should be tested? 
Herein, I describe one of the last DOE experiments that I performed to optimize 
the NAPPA-SPRi printing chemistry. The amount of the four reagents (or factors) in the 
printing master mix was tested, which included the plasmid cDNA, BSA, 
bis(sulfosuccinimidyl) suberate amine-to-amine crosslinker (BS3), and HaloTag amine 
(O4) ligand. I kept the amount of DMSO constant at 2.5%. The maximum binding 
response of the query, an anti-TP53 D01 monoclonal antibody, to the target TP53 (with a 
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C-terminal HaloTag) provided a 
quantitative value that would determine 
the optimal reagent levels. Within the 
SPRi analyses window of 1.2 cm x 1.2 
cm, 441 target proteins could be 
analyzed at one time (9 grids of 7 x 7). 
The reproducibility could have been done using replicate slides, replicate target spots on 
the array, or through the use of replicate “center points.” In a standard DOE experiment, 
there are two levels to each factor, representing a low and high value called a “corner 
point.” The center point is usually the average value between these two extremes. I 
employed a two-level factorial experiment with four center and four corner point 
replicates. Although the reproducibility could have been achieved with either type of 
replicates (i.e., center or corner point replicates), I had space on my sensor surface to 
perform both. And since the experimental landscape may not be linear across the range of 
values tested, having center points may be advantageous since they are able to provide 
more detail about the experimental plane. With 2 factor levels and four factors, there 
were 17 different printing mix combinations (i.e., center points + 2 levels 4 factors). Taking 
into consideration the replicates, the total number of target spots was 68, or 4 replicates x 
(2 levels 4 factors) + 4 center points. The levels of the corner and center points for the four 
factors are depicted in Table 9. 
Table 9. DOE factors and levels  
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The lay-out of the 17 different printing mix combinations on the slide is shown in 
Figure 24, where the combinations are given arbitrary numbers 1 – 17. Note that the 
mixes were deposited in a somewhat random manner in order to minimize any possible 
effect of location on response. Table 9 summarizes the factor levels for each printing mix, 
where “+1” represents the high factor level, “-1” represents the low factor level, and “0” 
represents a center point.  
The random print lay-out for the TP53 target protein according to the printing mix 
combination is shown in Figure 24. The DNA deposition, protein display, and refractive 
index differences (as observed by SPRi) are also shown in Figure 24. The SPRi 
“snapshot” image depicts the reflected light, where the brightness is proportional to the 
amount of mass on the surface. Figure 25 and Figure 26 show the plasmid cDNA and 
captured HaloTagged-TP53 target protein levels on the slide, respectively, determined via 
fluorescence and an anti-HaloTag antibody. Fluorescent analyses reveal that more DNA 
Figure 23. Print lay-out based on printing mix combinations. DNA deposition was determined via fluorescence using 
PicoGreen staining; green-scale false-colored image. Protein display determined via fluorescence using an anti-
HaloTag antibody; rainbow false-colored image. Original SPRi image was altered to have circular spots like the other 
images above; spots on the SPRi usually have an oval-shape. 
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deposition results in 
more protein display and 
brighter SPR spots, with 
printing mix 
combination #16 having 
highest DNA deposition 
and TP53 capture. SPRi 
analyses were still 
necessary to perform 
since fluorescent 
analyses may not 
accurately reflect binding 
response on the SPRi 
instrument.  
In addition to 
TP53, negative controls that will not bind to the anti-TP53 antibody were also included 
on the array, which included firefly luciferase and calcineurin life EF-hand protein 1 
(CHP-1). These negative controls were laid out exactly like TP53, but in supergrids on 
either side of the TP53 supergrid. Unless otherwise noted, the TP53 binding sensorgrams 
for the following results were referenced to the binding sensorgrams of CHP-1. (Similar 
results were obtained without referencing as well as with referencing to firefly luciferase 
instead of CHP-1.) 
Figure 25. Protein display of HaloTagged TP53 target protein on a gold SPRi slide 
as determined by an anti-HaloTag polyclonal antibody 
Figure 24. Deposition of TP53 plasmid cDNA on a gold SPRi slide  
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The maximum response of the binding sensorgrams was chosen for each printing 
mix combination, as denoted in Figure 27. The point at which the response value was 
chosen was at the end of the association phase where the number of anti-TP53 antibody 
molecules bound to TP53 target proteins was at a maximum for the entire NAPPA-SPRi 
analyses. The data were analyzed using the Minitab® 17 software, which is software that 
was specifically created to design and analyze DOE data.  
The normal plot is a visual way of seeing which factors or factor interactions are 
important. In general, the responses are first ranked from smallest to largest. Then, the 
Figure 26. Printing master mix combinations and their associated response on the SPRi sensorgram. A = DNA, B = 
BSA, C = Ligand, D = BS3. StdOrder = Standard order, organized by master mix combination. RunOrder was 
determined on the spot’s location on the array reading from left-to-right, top-to-bottom. TP53 response was referenced 
to CHP-1. 
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cumulative 
frequency of those 
responses is 
spread along the 
y-axis. A line is 
usually drawn 
between the 25th 
and 75th percentile 
points, which 
allows the user to identify which combinations may be significant. Negligible effects are 
normally distributed along a line where the mean is 50%. The farther away from the line, 
the more significant the factor. DNA and BSA appeared to have the most significant 
impact on response, as well as the combination of AB and ABCD (Figure 28). In other 
words, the interaction of factors A (DNA) and B (BSA) and between all of the factors 
significantly affected the SPR response. The factor with the largest impact on response is 
the amount of DNA.  
The residual plots of the referenced data looked acceptable, with expected 
randomness (Figure 29A). Interestingly, non-referenced TP53 response data did have 
reveal a nonconstant variance in observation order, showing a downward trend from the 
top to bottom of the slide (Figure 29B). A possible reason for this is due to the SPR lay-
out where the query protein passes over the slide from top to bottom. As the antibody 
binds to targets with low dissociation, less and less query is available for binding across 
Figure 27. Normal plot of standardized effects shows that DNA, BSA, and the interaction 
between the two reagents are significant. 
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the array. A variance-stabilizing 
transformation of the data to account for 
this phenomenon was applied, which 
eliminated the nonconstant variance 
(Figure 29C). The use of a reference also 
eliminated this phenomenon.  
This DOE experiment supported 
previous observations by both others and 
myself in the lab that DNA and BSA 
interact with each other. In other words, 
the effect of DNA depends on the 
amount chosen for BSA. The interaction 
between these factors is depicted in 
Figure 30, where 
interactions are 
represented as 
intersecting lines; 
the more 
perpendicular, the 
more interaction 
between the factors.  Figure 29. Interaction plot for response using average responses across replicates. 
Figure 28. Residual plots of SPR response for the anti-TP53 
antibody - TP53 protein interaction. Residual versus 
observation order for A) referenced data, B) non-referenced 
data, and C) non-referenced data that has undergone 
nonconstant variance transformation. 
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A boxplot of response shows the reproducibility of each printing mix type across 
the four replicates. It is clear that low DNA and high BSA give the highest response. The 
amount of ligand didn’t appear to make much difference, at least for the levels tested. 
The variable levels that will produce the maximum response and highest reproducibility 
are indicated (Figure 31).  
The experiment underscores the importance of analyzing the data in an 
appropriate manner for the intended application. While the fluorescent analyses favored 
the printing mix combination #16, the printing mix that had the highest binding response 
(with the highest reproducibility) on the SPRi was #11.  
The DOEs, through this example, decreased the amount of standard HaloTag-
based NAPPA printing mix from 183 µg to 40 µg in 30 µL for optimal NAPPA-SPRi 
Figure 30. Boxplot of response. 
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sensitivity, representing an 78% reduction in mass 
(Table 10). It also altered the amount of each 
reagent in comparison to each other (Figure 32).  
To summarize, the DOE approach is time- 
and cost-effective, identifies significant factors, 
and determines whether factors interact with each 
other. In a biological setting, factor interaction 
may also help to elucidate 
function and mechanisms. The 
analyses and plots presented 
here represent only a fraction 
of those that are possible with 
DOE software.  
 
 
4.4   Other parameters and methods tested 
 While Chapters 4.2 – 4.3 cover the history and development of NAPPA-SPRi, 
they only provide a small glimpse into the actual work that was required to arrive at the 
optimized surface chemistry. In this section, the different surface chemistries that were 
tested and why they weren’t ideal will be covered. The investigation of some of the other 
parameters to improve signal response and reproducibility will also be discussed.  
 
Table 10. Comparison of reagent mass for 
standard HaloTag-NAPPA and HaloTag-
NAPPA-SPRi 
Figure 31. Pie chart comparing the reagent mass and ratio differences 
between standard NAPPA and NAPPA-SPRi using HaloTag-BSA 
chemistry. 
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4.4.1   Cell-free expression systems for expressing target proteins 
 Until 2012, NAPPA employed rabbit reticulocyte lysate from Promega 
Corporation (Madison, WI) to express the target proteins because it was the only 
mammalian-based in vitro transcription translation system that was available. In 
December 2011, Thermo Fisher Scientific (Waltham, MA) launched a new mammalian 
expression system using lysate from human HeLa cells. The VGP CPD quickly adopted 
the new system once it was clear that the human target proteins were expressed at a much 
higher efficiency with HeLa cells instead of rabbit reticulocyte. As Figure 33 
demonstrates, 100% of the rabbit-based reagents recommended by Promega for one 
reaction resulted in slightly higher expression levels than 20% of the human-based 
reagents recommended for one reaction by Thermo Fisher Scientific; the cost for both 
systems are similar. At 100% HeLa lysate, the target proteins were so highly expressed 
that they began to diffuse into other spots! Another advantage of using the human 
expression system was that it was able to express some target proteins that did not 
express (or express well) in the rabbit expression system. Ultimately, both regular 
NAPPA users and I determined that the “sweet spot” for NAPPA slides was 60% of 
HeLa lysate using the standard HybriwellTM seals from Grace Bio-Labs (Bend, OR). 
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4.4.2   Chamber for protein target expression 
Target protein expression on standard NAPPA slides are always performed with 
HybriwellTM seals from Grace Bio-Labs (Bend, OR), which has a non-adhesive internal 
compartment that covers the entire NAPPA slide and has a ~ 150 µL capacity. These 
were produced specifically for NAPPA, with a chamber depth of 0.25 mm rather than the 
standard 0.15 mm. After expression is complete, the seal is removed and the slide is 
Figure 32. A comparison of the expression efficiency between rabbit reticulocyte lysate and human HeLa cell 
lysate. False-colored rainbow images. 
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washed to remove any non-specifically bound protein. The slide is kept wet throughout 
the experiment (i.e., probing with serum or antibodies) until it is dried with compressed 
air. The slide is finally analyzed in a microarray scanner.  
I also employed the HybriwellTM seals when I began working with the SPRi 
system, which had been done with the previous versions of NAPPA-SPRi. However, they 
presented two issues that needed to be addressed. First, the detectable area for SPRi is 
much smaller than that used for NAPPA (i.e., 12 mm x 12 mm for SPRi versus 21 mm x 
60 mm for NAPPA); in other words, the use of the Hybriwell required much more 
expression lysate (and money) than was necessary. Second, the SPRi flow chamber had 
to be adhered to the slide prior to SPRi analyses, which would require the slide (and 
target proteins) to be dried. Slide drying following the removal of the HybriwellTM seals, 
adherence of the SPRi flow chamber, and subsequent reconstitution of the target proteins 
in buffer could be performed in < 2 minutes, but was definitely far from ideal. 
An initial attempt to replace the Hybriwell with the SPRi flow chamber was made 
to resolve both issues when rabbit reticulocyte lysate was still being employed as the cell-
free expression system. The Plexera SPRi flow chamber is made of hard plastic with an 
internal volume of 30 µL and 0.15 mm depth and designed to distribute the query protein 
in a uniform manner across the sensor surface. However, the decrease in rabbit 
reticulocyte lysate (i.e., from 150 µL to 30 µL) resulted in a significant loss of signal, 
thus requiring the use of the larger volume Hybriwell (data not shown). A Hybriwell 
chamber with smaller surface coverage was also tested with an internal depth of 0.15 
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mm; this resulted in lower expression and reproducibility across the array (data not 
shown). 
The increased expression efficiency of the human HeLa cells compared to the 
rabbit reticulocyte lysate invited a re-examination into employing the SPRi flow chamber 
for expression. Three slides were prepared for this test: 1) Hybriwell with 60% HeLa 
lysate, 2) Flow chamber with 60% HeLa lysate, and 3) Flow chamber with 100% HeLa 
lysate. Target TP53 and firefly luciferase proteins were probed with an anti-TP53 
monoclonal antibody, and the TP53 binding sensorgrams were referenced to luciferase. 
The interaction between TP53 and anti-TP53 antibody were detected in all three methods; 
however, the use of the flow chamber with 100% HeLa lysate resulted in the highest 
signal and reproducibility (Figure 34). Please note that the Hybriwell uses 150 µL 
whereas the volume capacity of the flow chamber is only 30 µL; thus, 60% HeLa lysate 
with the Hybriwell uses 90 µL of HeLa lysate while 100% HeLa lysate with the flow 
chamber uses 30 µL HeLa lysate. The flow chamber, at both HeLa lysate concentrations, 
resulted in very good reproducibility across replicates. These data are similar to those I 
obtained at a previous laboratory that used Cy3/Cy5 in-house cDNA microarrays; 
inflexible 1 mm thick (mSeries) LifterslipsTM resulted in more consistent signal across the 
array compared to the standard flexible LifterslipsTM that are ~0.2 mm thick. 
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 Based on these results, the flow chamber was adhered to the NAPPA-SPRi slide 
prior to expression and throughout the additional steps. The switch from the Hybriwell to 
the flow chamber decreased the overall cost of the experiment because it required less 
reagent. In the case of expression, the cost was cut by ~5-fold. The target proteins were 
also able to stay in solution throughout the duration of the experiment.  
 
4.4.3   EDC-NHS surface chemistry 
 EDC-NHS refers to the covalent crosslinking between primary amines and 
carboxylic acids with the aid of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS). It is the most frequently 
employed crosslinking chemistry to couple target proteins to the immobilization matrix in 
SPR experiments. Briefly, the sensor surface is coated with an alkane-PEG self-
assembled monolayer having terminal carboxyl and hydroxyl groups at a ~ 1:50 ratio. 
When the purified target proteins are ready to be attached to the slide, the carboxyl 
groups are made into an active ester with the addition of EDC; the coupling of primary 
Figure 33. Binding response of TP53 target protein with an anti-TP53 antibody with different expression chambers, 
lysate, and lysate amount. Blue line indicates the end of the association phase and the beginning of the dissociation 
phase. 
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amines of target proteins to the active esters is made more efficient with NHS. The 
reactive NHS-ester has a half-life that is highly dependent on pH; at pH 7, the half-life is 
~5 hours while at pH 8.6, the half-life is 10 minutes (Tiwari & Uzun, 2017). Regardless, 
the EDC-NHS reagents are used immediately upon preparation for best results (i.e., 
coupling). 
 Standard fluorescent-based NAPPA arrays do not use EDC-NHS to immobilize 
the capture reagent to the slide surface. Instead, the amine-to-amine bifunctional NHS 
crosslinker, BS3, is employed. The inactive, lyophilized form of the reagent is stored in 
the dark at -20 oC. Just prior to adding the BS3 to the printing mixture, the lyophilized 
BS3 is activated by reconstituting it in water or DMSO. Various incubation lengths and 
temperature have been tested; for NAPPA, an overnight incubation (~ 16 hours) at 4 oC 
in the dark with immediate printing the following morning is not only the most 
convenient approach (compared to a 1-hour incubation at room temperature), but also 
results in the highest plasmid cDNA deposition and protein display. In short, the BS3 
crosslinks the 1) BSA lysines to each other, forming a meshwork that theoretically holds 
the plasmid cDNA in place, and 2) capturing reagent to the amine-coated slide surface. 
 The incorporation of surface chemistry similar to standard NAPPA was utilized in 
NAPPA-SPRi, where the slide surface was terminated with amines and the printing 
mixture contained BS3 crosslinker. However, I became concerned when I saw that 
components from the HeLa lysate expression system was binding strongly to the highly 
positive-charged surface as soon as it was injected over the surface. The nonspecific 
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interactions resulted in a 
wave-like image (Figure 
35A) in the direction that 
the lysate was applied to the 
sample. Preliminary results 
with the EDC-NHS 
chemistry indicated that  this 
phenomenon was 
significantly reduced (Figure 35B), so I investigated whether the surface chemistry 
should be based on EDC-NHS, rather than BS3, coupling. 
In my first experiments, the sensor surface was coated with carboxyl/hydroxyl-
terminated groups. The carboxyl groups were activated with EDC-NHS, and the slides 
were printed immediately after that with a printing mixture containing plasmid cDNA, 
HaloTag (04) amine ligand, BSA, and DMSO. Unfortunately, the short half-life of the 
reactive carboxyl group with slow print times resulted in poor protein display (data not 
shown).  
A different approach was then tried, which was to activate the carboxyl groups 
and immediately coat the slide with HaloTag (04) amine ligand, followed by spotting a 
printing mixture without the HaloTag ligand. I compared the binding responses of TP53 
Figure 34. SPRi image of an A) amine-terminated and B) EDC-NHS 
chemistry sensor surface that has been incubated with the HeLa expression 
system. Brighter areas indicate higher mass than darker areas. Same SPRi 
incident angle used for both images. 
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target protein with the anti-
TP53 antibody query across 
different carboxyl:hydroxyl 
ratios  (i.e., 1:1, 1:2, 1:5, 1:10, 
1:25, and 1:50). The responses 
were proportional to their 
carboxyl amount (Figure 36). 
The 1:1 ratio obtained the 
highest response, which was 
similar to that obtained with 
regular BS3-based chemistry. 
While the EDC-NHS 
chemistry worked for 
NAPPA-SPRi, the 
requirement to coat the slides 
with HaloTag ligand prior to printing resulted in (not too surprisingly) the diffused target 
proteins being specifically captured and displayed farther away from their printed spot 
than with standard BS3 chemistry. Figure 37 shows that the binding response of the 
target spot is the same as the response as the ring around the target spot. Moreover, slight 
binding was even observed where a non-p53 target protein, PTEN, was expressed and 
displayed, which would make the interpretation of PPIs on this surface impossible. The 
amine-terminated chemistry, on the other hand, did not have diffusion of TP53 into other 
Figure 36. Binding sensorgram of an anti-TP53 antibody query interacting 
with an expressed, immobilized TP53 target protein using a 1:1 
carboxyl:hydroxyl surface and HaloTag-BSA printing mixture. Since the 
HaloTag ligand coats the entire slide, diffused expressed TP53 protein can 
be captured specifically outside of printed spot. Referenced to CARD11. 
Figure 35. Binding responses of TP53 target protein with anti-TP53 
antibody across different carboxyl:hydroxyl ratios. Sensorgrams were 
referenced to CARD11. 
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spots, although some non-specific capture of TP53 protein around the spot was observed 
(Figure 38); this phenomenon has also been observed with standard NAPPA and is 
referred to as “the ring effect.” Due to the extreme diffusion with the EDC-NHS 
chemistry, the use of EDC-NHS as a coupling mechanism for NAPPA-SPRi was 
ultimately discarded. 
 
4.4.4   Baseline instability 
 Baseline drift during an SPR analyses can be caused by numerous sources, 
including the instrument itself. Those arising from the instrument should be accounted for 
by the manufacturer, so baseline drift is often the result of experimental conditions, 
including small fluctuations in temperature, changes in flow rate, matrix effects, loss of 
target protein over time, and improperly matched buffers (across injections). Baseline 
drifts that are occur with dextran-based sensor chips can be due to changes in the depth or 
Figure 37. Binding sensorgram of an anti-TP53 antibody query interacting with an expressed, immobilized TP53 target 
protein using an amine-terminated surface and HaloTag-lysine printing mixture. Since the HaloTag ligand coats the 
entire slide, diffused expressed TP53 protein can be captured specifically outside of printed spot. Referenced to 
CARD11. 
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extension of the dextran layer over time. Regeneration and extremely long injection times 
help to stabilize the surface and, therefore, the baseline drift. 
Baseline drift was observed with NAPPA-SPRi regardless of the buffer that was 
applied. In the example shown in Figure 39, the drift was -6.4 RU / minute during part of 
the analyses when only buffer was applied to the slide (i.e., from a 1,000 sec segment). 
The drift was also not reproducible across replicate spots on the same slide. Surface 
regeneration, as mentioned previously, was not an option. Extremely long buffer 
injections (> 5 hours) per slide were not practical since multiple chips in one block or 
batch needed to be run after an > 8-hour slide preparation (i.e., expressing, e-
phosphorylating, re-phosphorylating the target proteins). Furthermore, the non-antibody 
target proteins may not be stable in buffer for that long. 
  
Figure 38. Baseline drift with NAPPA-SPRi across duplicate spots of expressed PRCKA target protein. Sensorgram 
was zeroed at time 0 sec. 
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The addition of 5% (w/v) milk supernatant removed nonspecifically-bound 
material from the slide surface (Figure 40, Figure 41). 5% BSA (w/v) also removed mass 
from the sensor surface, but not as much as the milk supernatant (data not shown). Milk 
further helped to stabilize baselines across replicates, but did not remove drift. In the 
example given in Figure 41, the drift was 21.7 RU / minute. Interestingly, the drift 
appeared to be specific for the target protein as these baselines were similar across 
different slides (Figure 42). Based on these observations, it appears that the baseline drift 
Figure 40. Baseline drift is across duplicate spots of expressed PRCKA target protein following the addition of milk 
supernatant.  
 
Figure 39. Addition of milk supernatant to NAPPA-SPRi sensor surface removes a lot of nonspecifically-bound mass. 
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from NAPPA-SPRi may be due to spot-specific matrix effects in regards to the poly(L-
lysine), BS3, HaloTag (O4) amine ligand, plasmid cDNA, and/or displayed protein.  
Drift correction was applied on a per-spot basis during data analyses.  
 
4.4.5   Kinetic titration 
 Surface regeneration with acids, bases, nonpolar water-soluble solvents, high 
detergents, or high salts disassociates any query protein that remains bound to the target 
following dissociation, thus allowing the slide to be re-used (Andersson, Areskoug, & 
Hardenborg, 1999; Helmerhorst, Chandler, Nussio, & Mamotte, 2012). This approach is 
advantageous because it reduces cost and allows the kinetics to be better approximated 
through multiple injections of varying query concentrations. Regeneration is often used 
when the target proteins are antibodies, which are very stable protein species that remain 
functional even in the presence of regeneration buffers. However, regeneration may not 
be appropriate for other applications. In the case of this experiment, in which the PPIs of 
Figure 41. Baseline drift across different slides for the same expressed target protein following the addition of milk 
supernatant. “-C” indicates that the HaloTag is at the C-terminus of the target protein. 
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> 100 different proteins in the BCR signaling pathway are studied, most of the proteins 
are likely to be negatively affected by the regeneration buffer, either through partial or 
full denaturation. 
 Kinetic titration is an alternative option when regeneration is not possible 
(Schasfoort & Tudos, 2008). During kinetic titration, the query is added to the sensor 
surface as increasing concentrations in consecutive injections without regeneration (i.e., 
“multi-cycle kinetics”). This approach has been successfully used with 4-channel Biacore 
SPR instruments where each flow cell of a moderate-capacity carboxymethyldextran-
derivatized CM5 sensor chip routinely captures > 10 ng of target protein (Jokiranta et al., 
2001). [The sensor chip, according to the Biacore Assay Handbook, has dimensions of 
2.4 x 0.5 (l x w) with a ~ 100 nm dextran matrix coating (Murthy, Voelcker, & 
Jayaraman, 2006). It also well-established that 1 RU = 1 pg/mm2 for dextran-coated 
slides (Potyrailo & Mirsky, 2009). Jokiranta et al., for example, used CM5 sensor chips 
to immobilize C3b protein, which resulted in a 10,000 – 14,000 RU shift.]  
I explored the possibility of performing kinetic titrations with NAPPA-SPRi. 
Target proteins immobilized on the array included the HaloTag fusion target proteins, 
TP53 and AKT1, following cell-free expression and recombinant purified proteins, TP53 
and GST, which were obtained from Sigma-Aldrich, Co. (St. Louis, MO). The 
recombinant proteins were diluted to 50, 100, 200, and 400 ng/µL for printing. A mouse 
anti-TP53 monoclonal antibody (D01 clone) was applied to the array at increasing 
concentrations, ranging from 2.67 E-08 to 5.33 E-07 M. Kinetic titration was a feasible 
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approach for analyzing the binding kinetics between the antibody and recombinant 
proteins (Figure 43). However, it was not compatible with NAPPA-SPRi chemistry since 
the target protein on the surface is nearly saturated with minimal query concentration, 
indicating that amount of target protein is low.  
 
4.4.6   3D surface chemistry 
 Instead of a monolayer of target protein, a 3D hydrogel surface chemistry can be 
employed in SPR experiments to increase the amount of target protein that is 
immobilized – thus resulting in higher signal (Schasfoort & Tudos, 2008). Could a 3D-
based NAPPA-SPRi be possible? If so, it would increase signal and may make kinetic 
titration possible.  
Some NAPPA users, including myself, have successfully used a 3D hydrogel 
slide in their fluorescent-based experiments, noticing that the slide results in a higher 
Figure 42. Kinetic titration of anti-TP53 antibody to spotted TP53 recombinant proteins and displayed TP53 expressed 
and captured with the NAPPA-SPRi approach. 
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signal-to-noise ratio than regular NAPPA slides coated with aminopropyltriethoxysilane 
due to lower nonspecific binding (personal communication with Dr. Ji Qiu and Kailash 
Karthikeyan of VGP CPD). These amine-reactive, thin film 3D polymer-coated slides are 
NEXTERION® Slide H slides from Applied Microarrays, Inc. (Tempe, AZ). They 
incorporate a cross-linked, multi-component polymer layer on glass that is activated with 
NHS to covalently immobilize amine groups. Unfortunately, the funding to optimize 
making this polymer layer compatible on the SPRi chips was not available. 
A sensor chip with HC polycarboxylate hydrogel, NHS activated surface 
chemistry that is compatible with pin printing was obtained from XanTec Bioanalytics 
(Germany). It had a gold thickness of 43 nm and low fluorescence soda lime glass with 
an RI of 1.52.  
Preliminary attempts to use this chip were not successful (i.e., no binding 
response detected). Later, Dr. Lusheng Song also tried to get a 3D-based NAPPA-SPRi 
version to work; he was also unsuccessful. 
 
4.5   Optimized NAPPA-SPRi chemistry details 
As mentioned previously in Chapter 4.1.1, the printing master mix must include 
BSA to retain the plasmid cDNA to the sensor surface. Although the mechanism is only 
speculative, it is believed that the BSA essentially forms a meshwork – in which the 
DNA is captured – through its lysine residues and the amine-terminal surface via an 
amine-to-amine crosslinker. BSA is 67 kDa with 618 amino acids, 59 of which are lysine 
residues (or < 10% of the mass). While the 90% “non-necessary” mass is not an issue 
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with fluorescent-based NAPPA, it is a concern with the SPR technology in which this 
extra mass can decrease the signal-to-noise ratio of the detected binding events. How then 
could these lysines be utilized while discarding the unnecessary mass from the surface?  
BSA also had an additional disadvantage, which is discussed in more detail in 
Chapter 6.2. Very briefly, the addition of BSA in the target protein spot made analyses of 
phosphorylation events very difficult since BSA can also be phosphorylated.  
The solution for both BSA-related issues was poly(L-lysine), a positively charged 
amino acid polymer of lysines. Although the polymers are large (70 – 150 kDa), 100% of 
the residues would theoretically be useful, thus requiring less material than BSA. Another 
advantage of using poly(L-lysine) is that it is unlikely to be phosphorylated. First, lysine 
phosphorylation is not recognized as a common post translational modification when 
compared to serine, threonine, and tyrosine phosphorylation. Second, the amino acid 
residues surrounding known phosphorylation sites are generally conserved, indicating 
that phosphorylation is affected by the neighboring amino acids. The use of poly(L-
lysine) is discussed in more detail in Chapter 6.2. 
The optimized reagent amount in the printing mixture for NAPPA-SPRi was 
finally determined to be: 0.4 µg/µL plasmid cDNA, 0.0003% poly(L-lysine), 250 µm 
HaloTag amine (O4) ligand, 291 µm BS3, and 0.007% DMSO in water. Compared to the 
standard GST-based NAPPA printing master mix, this represented a 92% decrease in 
mass (Figure 44). The substitution of poly(L-lysine) instead of BSA, along with the 
subsequent DOE analyses, resulted in ~50% less mass on the surface and a 90% increase  
in SPRi signal when compared to printing master mix #11, which was chosen following 
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the DOE experiment in 
Chapter 4.3 (Figure 45). 
The inter- and intra-slide 
reproducibility for plasmid 
cDNA deposition is R2 ~ 
0.93 (Appendix J). The 
inter- and intra-slide 
reproducibility for protein 
display is R2 ~ 0.79 
(Appendix J). The 
reproducibility was 
determined with ~ 110 
unique proteins. 
This master mix 
combination was used in 
the quantitative analyses 
of the B cell receptor 
signaling pathway, which is described in more detail in Chapter 8.  
 
4.6   Potential alterations of NAPPA-SPRi 
Improvements in NAPPA-SPRi reproducibility, throughput, and protein 
immobilization should be explored. For example, the plasmid cDNA printing mixture 
Figure 43. Mass and ratio of reagents in the optimized NAPPA-SPRi printing 
mixture were significantly differently than that used in standard GST-based 
NAPPA. 
Figure 44. SPRi binding response between anti-TP53 monoclonal antibody query 
and C-HaloTagged TP53 target protein. Sensorgrams referenced to the non-binder, 
LYN target protein, with the same master mix. 
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was pin-spotted onto the arrays in this iteration of NAPPA-SPRi. Other printing methods, 
like piezoelectric printing or microfluidics, may result in more uniform sample deposition 
on the array since piezo printers have better control over the amount of sample that is 
deposited and are not as greatly affected by changes in humidity as pin spotters.  
NAPPA-SPRi throughput could also be increased. Like standard NAPPA, 
NAPPA-SPRi throughput is limited by the diffusion of expressed proteins during in vitro 
transcription translation since spots that are less than 640 µm apart (i.e., center-to-center) 
may become contaminated with proteins from neighboring features. Takulapalli et al. 
addressed the diffusion and issue through the use of silicon nanowells that were 
approximately 250 microns in diameter and 75 microns deep (Takulapalli et al., 2012). 
The nanowells physically blocked the diffusion of expressed proteins to other nanowells 
and, as such, the throughput of NAPPA increased from 2,300 to 14,000 features per slide. 
More recently, Karthikeyan et al. used a “contra capture” approach to capture the 
expressed proteins separately from the printing mixture (Karthikeyan et al., 2016). The 
printing mixture containing plasmid cDNA, amine-to-amine crosslinker, and BSA was 
deposited into microwells of a polydimethylsiloxane (PDMS) wafer. During protein 
expression, the wafer was sandwiched to a slide coated with capturing reagent. The 
expressed protein was then immobilized by the capturing slide and the PDMS wafer was 
discarded. A variation of these themes could be applied toward NAPPA-SPRi. Contra 
capture NAPPA-SPRi via the use of a nanowell wafer would increase the throughput. It 
would also reduce the mass on the SPR slide, thus increasing the sensitivity of the 
platform. Another important consideration is that DNA within each spot may not be 
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compatible with certain experiments; for example, transcription factors that bind to 
proteins and DNA cannot be used as queries because their mixed binding responses could 
not be resolved into their separate binding events (i.e., transcript factor-protein binding, 
transcription factor-DNA binding). Finally, it is likely that the contra capture approach 
would also decrease baseline drift – and therefore data analyses – because the slide 
surface would be less complex. 
The amount of immobilized protein per spot on NAPPA-SPRi is too low for 
kinetic titration (see Chapter 4.4.5). Kinetic titration is a method that allows the binding 
kinetics of multiple query concentrations to be analyzed without the need for slide 
regeneration. A possible solution to this issue would be the use of a 3D surface 
chemistry, like a carboxymethlated dextran matrix. 
 
4.7   Acknowledgements 
I am grateful to Dr. Mitch Magee and Dr. Lusheng Song for training me on the 
Plexera® SPRi instrument, as well as answering my many technical questions. Dr. 
Shaopeng Wang was also a good source of information. I thank Ian “Instrument 
Whisperer” Shoemaker for his help regarding instrument issues, which always seemed to 
crop up at the most inopportune times. Although this is mentioned in the text above, the 
ability to couple NAPPA with SPRi in its current form depended on having a chip that 
was amenable for contact printing; Plexera Bioscience LLC worked carefully with us to 
help make this happen. Lastly, the development of NAPPA-SPRi could not have been 
  
121 
possible without the financial support of the PS-OC grant and Dr. LaBaer’s discretionary 
funds.  
  
122 
CHAPTER 5  
5   PURIFED QUERY PROTEINS FOR NAPPA-SPRi  
5.1   Purified query proteins for accurate kinetic analysis 
SPR analyses must utilize one very pure query protein per injection to simplify 
data analyses. A binding response between a known target protein “A” and a query 
solution containing only one protein “B” directly reflects an interaction between proteins 
“A” and “B.” With query solutions containing two or more proteins, the delineation of 
which query (or queries) is binding to the captured target protein may not be possible. 
Query proteins that are not purified from the host expression system present an additional 
issue during data analyses. Cell lysate is markedly different than buffer alone and will 
result in a large bulk refractive index shift that may be outside the linear range or 
detection limit of the instrument. Indeed, a query-of-interest expressed in human cell 
lysate and diluted in buffer resulted in a refractive index shift that overwhelmed any real 
binding response on NAPPA-SPRi (data not shown). 
Purified recombinant proteins can either be obtained in-house or through a 
commercial source. There are two primary reasons why researchers would prefer making 
the proteins instead of purchasing them through a company: flexibility and cost. In-house 
processing means that the user can control which proteins are purified, the host system in 
which they’re expressed, the fusion tag, the location of fusion tag, and the final amount of 
material. In-house recombinant proteins can also be a cheaper option compared to 
commercially-produced proteins, which range from hundreds to thousands of dollars 
depending on the protein, purity level, and amount. However, there are two main reasons 
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why a recombinant protein from a company would be preferred: time and resources since 
protein expression and purification can require a lot of troubleshooting and optimization. 
The project may need the purified protein immediately and may not be able to wait for 
the plasmid with the gene-of-interest to be prepared and validated, the host system to be 
grown, the host to be transformed or transduced, and the protein to be purified and tested. 
The experiment may require the protein to be highly pure and functional. Whereas these 
proteins can be easily produced and tested in a company that routinely performs such 
experiments with expensive equipment like fast purification liquid chromatography 
(FPLC, ~ $50K for a new unit), research laboratories that perform small-scale protein 
purifications generally rely on more cost-effective gravity-dependent columns that have 
notoriously low resolution. It should be noted, however, that some SPR and non-SPR 
applications do not require a highly purified or functional protein. For instance, an SPR 
experiment may simply screen for query-target interactions without needing kinetics and 
affinity information.  
SPR and SPRi have traditionally relied on purified recombinant proteins to be the 
targets as well as the queries, which has ultimately limited their throughout due to the 
tedious process of protein expression and purification. With NAPPA-SPRi, the need for 
purified target proteins is no longer a requirement; however, the need for purified 
proteins as queries has not yet been abrogated. For NAPPA-SPRi, the possibility of 
expressing and purifying the query proteins in-house was investigated with the initial 
intention of using > 50 query proteins for these analyses. For the POIs in the BCR 
signaling pathway, these were, on average, ~ $300 / 10 µg. In vivo E. coli expression, 
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wheat germ cell-free expression, and human cell-free expression were pursued as options 
to produce the human proteins, which is described in more detail in the manuscript, 
“Development of a full-length human protein production pipeline,” that arose, in part, 
from this work (Saul et al., 2014). It compared the expression and purification rates of 31 
full-length human proteins ranging from 10 – 120 kDa in E. coli, the cell-free wheat germ 
expression system, and the cell-free human expression system.  
 
5.2   Producing and purifying query proteins in-house 
 The primary advantage of expressing proteins in E. coli is that a large amount of 
protein can be made with minimal cost. The use of E. coli to synthesize the BCR 
signaling pathway proteins was first pursued using the maltose binding protein (MBP) as 
an N-terminal fusion tag because MBP significantly enhances the solubility of the 
proteins-of-interest (POIs) compared to other fusion tags, which is particularly important 
since inclusion bodies are often produced during recombinant protein expression in E. 
coli (Kapust & Waugh, 1999). Protein purification was performed using an amylose 
affinity column, which bound to the MBP tag. The MBP-protein was then eluted via 
competitive exchange with the addition of maltose.  
 E. coli is known to have difficulty expressing proteins that are larger than 50 kDa. 
However, the handful of BCR signaling pathway proteins that were expressed in E. coli 
appeared to be fully translated despite being > 50 kDa (Figure 46). Of note, a fraction of 
the POIs were not fully translated, such that only the 40 kDa MBP N-terminal tag was 
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expressed. The disadvantages of using E. 
coli as an expression system and the 
purification approach became clear with 
these first attempts. First, protein 
purification using a column resulted in very 
impure samples (Figure 46). In addition, the 
MBP-amylose interaction is rather weak 
(micromolar affinity), thus causing a 
significant amount of the POI to be lost 
during the washing steps (data not 
shown)(Terpe, 2003). Both of these issues could be minimized with the optimization of 
buffers and numbers of washes, although the use of amylose affinity chromatography to 
purify MBP-tagged proteins is known to result in insufficient purity for various types of 
studies (Austin, Nallamsetty, & Waugh, 2009). Second, the use of a tag, particularly a 
larger one like MBP, could also occlude binding sites on the query. It would be necessary 
to have a small tag (like His) or a specific cleavage site between the tag and POI. Finally, 
human proteins expressed in E. coli may not be folded properly since E. coli do not have 
the same chaperone proteins as human cells that facilitate proper 3D conformation. As a 
consequence, the activity and interactions of the POIs may be affected. Taking these 
considerations in mind, it was decided that eukaryotic cell-free expression systems would 
be a preferable alternative to synthesize the query proteins for NAPPA-SPRi. 
Figure 45. Coomassie gel of purified recombinant 
proteins with N-terminal MBP tags expressed in E. 
coli. MBP is 40 kDa. 
  
126 
 The production of recombinant proteins using cell-free expression systems has 
several advantages over in vivo cell-based techniques (Zemella, Thoring, Hoffmeister, & 
Kubick, 2015). First, the only thing that is required in cell-free expression is a plasmid 
backbone with the appropriate promoter, which is mixed with the lysate mixture to 
produce proteins in < 8 hours, or more if a dialysis approach is used to increase protein 
yield. Thus, cell-free expression is much faster in synthesizing protein than cell-based 
methods because it does not require gene transfection or cell culturing. Second, proteins 
or labels that may be toxic to a cell host can be synthesized. Third, non-natural amino 
acids can be incorporated. Finally, additives, detergents, cofactors, and binding partners 
can be easily added to the cell-free expression system. One disadvantage of using a cell-
free system is that it does not produce as much protein as a cell-based system (i.e., 
micrograms to milligrams in a cell-free system versus milligrams to grams of protein in a 
cell-based system). Another important disadvantage of a cell-free expression system is 
that the cost to amount of purified protein ratio is low compared to using E. coli cells. A 
comparison of the advantages and disadvantages of the different cell-free expression 
systems are in Error! Reference source not found.. 
 Eukaryotic cell-free expression systems that were explored for this project were 
derived from wheat germ and human HeLa cells. Due to its low expression efficiency, the 
rabbit cell-free expression system was not tested to produce the query proteins (see also 
page 103, Figure 33) (L. Zhao et al., 2010).  
 Wheat germ is the vitamin-rich sprouting section (i.e., “embryo”) of a wheat 
kernel, and the use of its lysate to produce proteins was first reported in 1973 when 
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commercially available wheat germ was able to produce tobacco mosaic virus-related 
proteins and rabbit 9S globin (Roberts & Paterson, 1973). Since then, the cell-free wheat 
germ expression system has become a highly efficient protein production option, 
synthesizing 1.6 – 20 mg of protein depending on the different reaction formats (Harbers, 
Table 11. Comparison of different cell-free protein expression systems. Adapted from (Harbers, 2014) 
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2014). Various studies have highlighted its ability to successfully synthesize human 
proteins compared to both in vivo and in vitro E. coli systems (Harbers, 2014). 
 The human cell-free expression system uses lysate from HeLa cells, a cervical 
cancer cell line that was cultured in 1951. The use of HeLa cells to express recombinant 
proteins was first suggested in 1973 when Reichman et al. showed that HeLa cell extract 
was able to initiate polypeptide formation using radiolabeled N-terminal methionine 
(Reichman & Penman, 1973). As a human expression system, it offers unique advantages 
over other expression systems when producing human proteins. For example, it can 
synthesize high molecular weight human proteins due to the natural codon usage 
(Zemella et al., 2015). It also possesses the chaperone machinery to fold proteins into 
their native conformations. 
 Plasmids compatible with the wheat germ and human cell-free expression system 
were constructed by my colleague, Justin Saul, with a HaloTag at the N-terminus or C-
terminus (pJFT7_nHalo, pJFT7_cHalo). A tobacco etch virus (TEV) sequence that is 
specifically targeted for cleavage by TEV protease was placed between the POI and 
HaloTag.  
Proteins in the BCR signaling pathway were successfully synthesized with E. coli, 
wheat germ, and HeLa cells (Saul et al., 2014). The eukaryotic cell-free expression 
systems had a higher success rate of expression than E. coli across the tested proteins 
(87% vs 73%). Of the 30 – 31 POIs that were tested, only 10 proteins were soluble in E. 
coli while at least 25 were soluble in the cell-free extracts. Expression yield was variable 
across the different POIs and systems. Longer incubation times are used to increase 
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protein yield; however, this study saw that longer incubation also resulted in increased 
degradation of full-length POIs. 
The POIs were then purified using a ligand-conjugated resin and HaloTagged 
TEV protease from Promega Corporation (Madison, WI), which also bound to the resin 
and were removed from the purified fraction. More proteins were purified when they 
were expressed in the human extract, yet the yield of purified product (i.e., > 1 µg, > 90% 
purity) was the lowest of the three systems. That is, 6 proteins were purified from E. coli 
with 42% purification recovery, 10 proteins were purified from wheat germ extract with 
24% purification recovery, and 13 proteins were purified from human cell extract with 
15% recovery. The mean purification yield was dismal. With 100 µL (~ $125) of the 
human cell expression system using a dialysis format to replenish the reagents, the mean 
purification yield was only 3.5 µg. Furthermore, the cleaved HaloTag protein and 
HaloTagged TEV protease were common impurities in the samples. For a HaloTag-based 
NAPPA chemistry, these impurities are definitely causes for concern and would 
complicate SPR analyses. HaloTag can bind to unbound HaloTag ligand. The TEV 
protease could cleave target POIs from the slide since the TEV site is located between 
HaloTag and the POIs. 
 
5.3   Purchasing purified query proteins 
After this in-house effort, several considerations led us to opt to purchase the 
query proteins from commercial sources. An exhaustive search for purified proteins from 
commercial sources that could be employed as queries in the NAPPA-SPRi experiments 
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was performed. These were the criteria that had to be met: 1) human protein, 2) important 
protein in the BCR signaling pathway, 2) expressed in human or insect cells, 3) have a 
small tag (e.g., His), and, if possible, 4) tested for activity such that kinases were tested 
by their ability to phosphorylate a substrate and adaptors were tested by their ability to 
bind to a known interactor. The query proteins that fit all of these criteria included 
BLNK, BTK, and PIK3CA/PIK3R1 (PI3K). Notably, the catalytic PIK3CA protein is 
unstable without its heterodimer regulatory partner, PIK3R1, and is always found as a 
purified complex. Two major proteins in the BCR signaling pathway, SYK and DAPP1, 
were unattainable or not tested for functionality, respectively. DAPP1 was purchased 
despite not having known functionality because of its importance. Not surprisingly, it did 
not interact with any target proteins on the array.  
Two queries produced in-house, RAC1 and RHOA, were used with NAPPA-SPRi 
analyses because they are important in B cell signaling and were easily and cheaply 
obtained. They were expressed in Escherichia coli by members of Dr. Kim Orth’s 
laboratory (UT Southwestern; Dallas, TX), and have been used in various published 
experiments demonstrating their activity (Woolery, Yu, LaBaer, & Orth, 2014; 
Yarbrough et al., 2009). Moreover, the proteins were tested for functionality by Dr. 
Xiaobo Yu (personal communication; National Center for Protein Sciences; Bejing, 
China) by their ability to bind to known protein partners on NAPPA arrays. 
The purified query proteins were then used to analyze protein interactions with 
NAPPA-SPRi. The data are in Chapter 8. 
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CHAPTER 6  
6   MODULATING PROTEIN PHOSPHORYLATION ON NAPPA 
6.1   Introduction 
Numerous cellular mechanisms are mediated by protein phosphorylation, and 
aberrant phosphorylation has been linked to a range of disorders, including cancer, 
diabetes, cardiovascular disease, inflammatory diseases, and infectious diseases (Fabbro, 
Cowan-Jacob, & Moebitz, 2015). Due to the role that phosphorylation plays in disease, 
the development of effective kinase inhibitors to treat the various disorders has been 
pursued with gusto. Since the first kinase inhibitor to treat chronic myeloid leukemia was 
approved by the FDA in 2001 (i.e., Gleevec), 27 more were approved for other types of 
diseases within the next fourteen years (Wu, Nielsen, & Clausen, 2015). One of these, 
Ibrutinib, has been approved to treat B cell lymphomas, including chronic lymphocytic 
leukemia (CLL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). It 
is also used to treat chronic graft-versus-host disease, which has been associated with 
altered B cell activation and signaling (Rhoades & Gaballa, 2017). It inhibits the 
enzymatic activity of BTK, a kinase that is critical to B cell growth and survival, by 
binding covalently to a cysteine in BTK’s catalytic domain (Wu et al., 2015). Notably, 
BTK was used as a query in my NanoBRET and NAPPA-SPRi experiments.  
Phosphorylation is used as a major mechanism of signal transduction for the BCR 
signaling pathway and is generally considered to be a PTM of positive regulation (see 
also Chapter 2.4). Therefore, the study of protein interactions within the BCR signaling 
pathway should consider interactions with and without phosphorylation. Since the human 
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cell-free expression system can phosphorylate the proteins that it expresses, the de-
phosphorylation of NAPPA proteins to enable PPI analyses in the absence of 
phosphorylation is addressed in Chapter 6.2. The phosphorylation of target proteins in a 
B cell-specific manner is described in Chapter 6.3. 
 
6.2   De-phosphorylation of NAPPA proteins 
6.2.1   Standard de-phosphorylation protocol 
 NAPPA proteins are produced with a cell-free expression system based on the 
HeLa cervical cancer cell line, which has phosphorylation capability that likely reflects a 
phosphorylation pattern specific to the cells at the time that they were collected. Thus, the 
inherent phosphorylation of the target proteins was unlikely to be physiologically 
relevant for this study of the B cell receptor signaling pathway. Herein, I describe the de-
phosphorylation of target proteins, which enabled their phosphorylation in a B cell-
specific manner (see Chapter 6.3) and established a baseline to which the phosphorylated 
data could be compared.  
Target de-phosphorylation for NAPPA-SPRi analyses was first attempted 
following NAPPA chemistry optimization employing BSA (see also Chapter 4.3).  The 
standard protocol that was developed in the Virginia G. Piper Center for Personalized 
Diagnostics (VGP CPD) to de-phosphorylate standard NAPPA arrays required that the 
slide be incubated twice with 18K units of lambda protein phosphatase (LPP) for 45 min 
at 30 oC, which resulted in 36K units or $184 of LPP per slide. However, this cost was 
inhibitory in this project. Furthermore, it became apparent from the data that de-
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phosphorylation using the standard protocol was not 
complete (Figure 47). The most likely phosphorylated 
component in the printing mixture was BSA, which is 
necessary for plasmid cDNA deposition. BSA shares 
76% sequence homology with human serum albumin 
(HSA), which is well-documented to be 
phosphorylated at multiple sites. The use of BSA in 
the printing mixture, therefore, would require more 
phosphatase to completely de-phosphorylate the spots 
than displayed proteins alone. In addition to 
increasing background and complicating the analyses of kinase arrays, phosphorylation 
profiles, and de-phosphorylation optimization, BSA also presented a mass issue for 
NAPPA-SPRi since > 90% of its mass was unnecessary (see also Chapter 4.5). Poly(L-
lysine) (PL), a polymer of lysine residues, offered a possible alternative to BSA. In 
addition to providing lysines that aid in DNA retention, PL cannot be phosphorylated 
since it lacks serine, threonine, and tyrosine residues.  
A HaloTag-based NAPPA array was prepared with BSA or PL in the printing 
mixture and then expressed with the human cell-free expression system. Using an anti-
phosphotyrosine antibody and HRP-conjugated secondary antibody, the level of 
phosphorylation for the four target proteins (i.e., GRB2, RAC3, LYN, MAPK9) was 
determined via fluorescence (Error! Reference source not found.). Although it is clear 
from the image that LYN is tyrosine phosphorylated, its relative intensity within the spot 
Figure 46. Fluorescent analyses of 
phosphorylated tyrosines following de-
phosphorylation of a NAPPA array using an 
anti-phosphotyrosine antibody and HRP-
conjugated secondary antibody. False-
colored gray-scale image where black 
reflects high levels of phosphorylation, 
while white reflects low levels of 
phosphorylation. 
  
135 
to other target proteins in 
the BSA-based printing 
mixture does not reflect 
this (Figure 49). 
Alternatively, LYN 
phosphorylation is 
significantly pronounced in 
the PL printing mixture.  
A second array was 
de-phosphorylated with LPP, and then probed with an anti-phosphotyrosine antibody and 
HRP-conjugated secondary antibody (Error! Reference source not found.). De-
phosphorylation of LYN in the BSA- and PL-based printing mixtures decreased the 
phosphotyrosine level by 31% and 84%, respectively. These results demonstrated that 
Figure 48. Tyrosine phosphorylation level of displayed proteins prior to de-
phosphorylation compared to spots containing only printing master mix (no 
DNA or displayed protein). Error bars represent range of values across duplicate 
spots. 
Figure 47. Tyrosine phosphorylation of target protein, LYN, before and after the addition of LPP as 
determined with an anti-phosphotyrosine antitbody and HRP-conjugated secondary antibody. Master mix = 
printing mixture without DNA or displayed protein. Gray-scale image where black reflects high 
phosphotyrosine level. 
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BSA could be replaced by PL and, furthermore, that the use of PL resulted in lower 
phosphorylation background on NAPPA arrays. 
The HaloTag-PL printing mixture was then optimized using a DOE approach to 
maximize the signal-to-noise ratio in NAPPA-SPRi analyses. Assuming an average 
molecular weight of 110 kDa, 0.7 µg of PL could be substituted for 14.65 µg of BSA in 
30 µL of printing mixture, which helped contribute to a 90% increase in SPRi signal (see 
also Chapter 4.5).  
 
6.2.2   De-phosphorylation optimization using DOE 
 The standard de-phosphorylation protocol of BSA-based NAPPA used 36K units 
of LPP, or $184 per slide, yet still resulted in incomplete de-phosphorylation. The use of 
PL instead of BSA in the printing mixture decreased background (see previous section), 
but questions remained: Could less than 36K units of LPP be used? Was only one 
phosphatase enough? Could the addition of other phosphatases decrease the overall cost 
of de-phosphorylation? 
 Husberg et al. compared the ability of four phosphatases to de-phosphorylate 
target proteins in cardiac muscle tissue. Their work demonstrated the unique and 
overlapping substrate specificities of two generic phosphatases (i.e., alkaline 
phosphatase, LPP) and two endogenous serine/threonine phosphatases in the heart (i.e., 
protein phosphatase 1, and protein phosphatase 2) (Husberg, Agnetti, Holewinski, 
Christensen, & Van Eyk, 2012). All 22 target proteins were de-phosphorylated by LPP or 
calf intestinal alkaline phosphatase (CIP), which supports the unique preference of LPP 
  
137 
for phosphorylated serine and threonine residues and CIP for tyrosine phosphorylation 
(Table 12). 
CIP can de-phosphorylate proteins, but it is often not used in this manner in 
research laboratories. Instead, CIP is used to de-phosphorylate the 5’ and 3’ ends of DNA 
in cloning to prevent re-ligation of linearized plasmid DNA. Even in New England 
BioLab’s product description, CIP is for dephosphorylating “5’ and 3’ ends of DNA and 
RNA,” “cloning vector DNA to prevent recircularization during ligation,” “DNA prior to 
end-labeling using T4 Polynucleotide,” and “treatment of dNTPs in PCR reactions prior 
to sequencing or SNP analysis;” nowhere does it mention protein de-phosphorylation. 
This may be the reason why CIP was never used to de-phosphorylate NAPPA arrays. 
Given the overlapping and unique substrate selectivity of LPP and CIP, I decided 
to perform a DOE two-level factorial experiment to optimize the de-phosphorylation of 
HaloTag-PL NAPPA microarrays with LPP and CIP. (To learn more about DOE, please 
see Chapter 4.3, page 92.) The low (“-1”) and high (“1”) levels of LPP, CIP, and number 
of incubations are depicted in Error! Reference source not found.. Reproducibility was 
determined with the use of duplicate spots. Fluorescent responses were achieved with an 
anti-phosphotyrosine antibody and HRP-conjugated secondary antibody.  
Table 12. Protein Phosphatase Specificity Chart. Data from New England Biolabs 
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The mouse anti-phosphotyrosine monoclonal antibody (P-Tyr-100) from Cell 
Signaling Technology, Inc. (Danvers, MA) was used for all of the phosphotyrosine 
experiments herein because it detected more phosphorylation events than any of the other 
anti-phosphotyrosine antibodies on the NAPPA kinase arrays (antibody comparison 
performed by Dr. Fernanda Festa of the VGP CPD). Anti-phosphoserine and anti-
phosphothreonine antibodies were also used for this de-phosphorylation optimization 
experiment, but did not result in sufficient signal. This is unsurprising since anti-
phosphoserine and anti-phosphothreonine antibodies are sensitive to the adjacent amino 
acids, and generally must be chosen for the specific phosphorylation site. Anti-
phosphotyrosine antibodies recognize phosphorylated tyrosines more independently of 
Table 13. De-phosphorylation DOE factors, levels, and responses as determined with an anti-phosphotyrosine antibody 
and HRP-conjugated secondary antibody. 
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the surrounding amino acid sequence; even so, the detection rate for this antibody was 
~30% on the kinase arrays. 
A phosphorylated slide and a slide de-phosphorylated with the standard protocol 
using LPP were also prepared at the same time as the DOE experiment. As Figure 50 
shows, the standard protocol in which the slide was incubated twice with 18K units of 
LPP (36K units total) for 45 
min at 30 oC did not result in 
complete de-phosphorylation 
despite substituting the BSA 
with PL in the printing 
mixture. LPP decreased the 
level of phosphotyrosine by 
~ 70%. 
DOE analyses using 
the Minitab® 17 software 
indicates, through a Normal 
plot of standardized effects, 
that all factors and 
combinations are significant 
(Figure 51). As anticipated, 
both CIP and LPP de-
phosphorylated tyrosines . 
Figure 49. Fluorescent analyses of tyrosine phosphorylation of a A) 
phosphorylated slide and a B) slide de-phosphorylated using the standard 
LPP-based protocol. False-colored gray-scale image where black represents 
high phosphotyrosine level and white represents low phosphotyrosine level. 
Images analyzed with the same settings to make a direct comparison. 
Figure 50. Normal plot of standardized effects for SYK response. Similar 
plots were obtained for other tyrosine phosphorylated target proteins. Αlpha = 
0.05 
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The parameter that led to the 
most de-phosphorylation 
was the highest amount of 
LPP (36K units), the lowest 
amount of CIP (300 units), 
and three incubations of 30 
min at 30 oC. While the use 
of both phosphatases also de-
phosphorylated the slide 50% 
better than the standard LPP-
based de-phosphorylation.an 
interaction plot of the 
response means revealed that 
CIP and LPP interact with 
each other (Figure 52). This 
interaction interferes with de-phosphorylation as high levels of both phosphatases result 
in poorer de-phosphorylation than when CIP is added at a lower amount (Figure 53). This 
interaction may be the de-phosphorylation of one phosphatase by the other, which would 
affect phosphatase activity. In other words, LPP and CIP should not be mixed together, 
but rather added to the slide separately. Moreover, additional incubations with CIP did 
not significantly affect the level of de-phosphorylation. The number of incubations, 
however, was important when using LPP. 
Figure 52. Box plot of response for SYK across different factors and levels. 
Other target proteins had similar plots. 
Figure 51. Interaction plot of response means for SYK. Other target proteins 
had similar plots. 
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 To determine how much CIP 
should be used to de-phosphorylate 
the target proteins, 500 units of CIP 
(or buffer) were added for 30 min at 
30 oC, then probed with an anti-
phosphotyrosine or anti-
phosphoserine antibody. CIP 
significantly de-phosphorylated 
tyrosine residues (Figure 54), but did not appear to affect serine phosphorylation of SYK. 
These results matched the known substrate specificity of CIP for phosphorylated 
tyrosines (Table 12).  
The DOE experiment, revealed that CIP and LPP could not be mixed together 
during de-phosphorylation, and that the number of incubations with LPP made a dramatic 
impact on the response. Therefore, NAPPA microarrays were first incubated with 500 
units of CIP for 30 min at 30 oC. The arrays were then incubated 1 – 3 times with 2K, 4K, 
or 6K units of LPP for 30 min at 30 oC. Tyrosine and serine phosphorylation were 
fluorescently assessed with anti-phosphotyrosine and anti-phosphoserine antibodies, 
respectively, with an HRP-conjugated secondary antibody. Tyrosine de-phosphorylation 
was similar with 2K or 4K units of LPP across two or three incubations (Figure 55). 
Figure 53. Fluorescent analyses of tyrosine phosphorylation of 
slides incubated with CIP buffer or enzyme. False-colored gray-
scale image where black represents high phosphotyrosine level 
and white represents low phosphotyrosine level. 
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However, three incubations de-
phosphorylated serine on SYK 
much better than two 
incubations (Figure 56). Taken 
together, the most efficient and 
cost effective de-
phosphorylation approach was 
incubating the slides with 500 
units of CIP for 30 min at 30 oC, then three times with 2K units of LPP at 30 oC for 30 
min each. Compared to the standard protocol, the optimized protocol de-phosphorylated 
the proteins more effectively than the standard protocol by 45% (Figure 50, Figure 55), 
was 2 hours long instead of 1.5 hours, and was only 32% of the cost. A follow-up 
Figure 54. Fluorescent analyses of tyrosine phosphorylation of slides incubated with 500 units of CIP and then LPP 
buffer or enzyme. False-colored gray-scale image where black represents high phosphotyrosine level and white 
represents low phosphotyrosine level. 
Figure 55. Percent of SYK serine phosphorylation remaining after de-
phosphorylating the array with the standard protocol or new protocol 
using 500 units of CIP for 1 incubation and 2K units of LPP across 1 – 3 
incubations. Error bars represent range across duplicate spots. 
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experiment 
demonstrated that longer 
incubation lengths did 
not improve the level of 
de-phosphorylation (data 
not shown).  
 
 
 
6.3   Treatment of NAPPA with B cell lysate 
The human cell-free expression system that is used to express the target proteins 
on NAPPA and NAPPA-SPRi uses lysate from HeLa cells, a cervical cancer cell line, 
and is well-known to contain kinase activity. While it seems reasonable to assume that 
the expression system phosphorylates its targets in a HeLa-specific manner, the target 
phosphorylation profile has never been examined. For this project, however, it was 
necessary to determine whether the expression system’s target phosphorylation profile 
was unique or similar to B cells given the potential impact that phosphorylation can play 
in protein interactions and in the BCR signaling pathway. Briefly, the phosphorylation 
profile differences between the expression system and Ramos B cell lysate was 
performed using two HaloTag-PL NAPPA slides. The cells were rapidly proliferating 
(i.e., ~22 hour doubling rate), representing an activated, tonic signaling state. After 
expression, one slide was de-phosphorylated using the standard LPP-based de-
Figure 56. Percent of tyrosine phosphorylation remaining after de-phosphorylating 
the array with the standard protocol or optimized protocol using 500 units of CIP 
for 1 incubation and 2K units of LPP across 3 incubations. 
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phosphorylation protocol and incubated in lysate from Ramos B cells that included 
phosphatase and protease inhibitors, 200 µM ATP, and metal additives to assist in kinase 
activity at 30 oC for 1 hour.  
More specifically, Ramos RA-1 cells Ramos B cells (ATCC; Manassas, VA) 
were grown in RPMI-1640 (ATCC; Manassas, VA) supplemented with 10% HyCloneTM 
fetal bovine serum (GE Healthcare Life Sciences; Logan, UT). Cells were washed twice 
with ice-cold 1 mM Na3VO4 in TBS, then solubilized in 50 mM Tris-HCl (pH 7.7), 0.5% 
nonidet P-40, 2.5 mM EDTA, 20 mM beta-glycerophosphate, 10 mM NaF, 1 mM 
Na2MoO4, 1 mM Na3VO4, 0.25 µM PMSF, 1 µM pepstatin, 0.5 ug/mL leupeptin, 10 
ug/mL soybean trypsin inhibitor, and 1 ug/mL microcystin-LR. Cells were spun at 4k x g 
for 5 min and the supernatant stored in single-use aliquots at -80 oC such that the lysate 
from 20 million cells were in 1 mL of solubilization buffer. Slides were rinsed with 50 
mM HEPES, 150 mM NaCl, pH 7.4. B cell lysate was buffer exchanged using a 7 kDa 
MWCO Zeba desalting spin column (Thermo Fisher Scientific; Waltham, MA) into 
kinase buffer containing 20 mM HEPES, 5 mM MnCl2, 5 mM MgCl2, 0.25 µM PMSF, 
0.5 ug/mL leupeptin, 10 ug/mL soybean trypsin inhibitor, 20 mM beta-glycerophosphate, 
10 mM NaF, 1 mM Na2MoO4, 1 mM Na3VO4, 500 µM ATP, pH 7.5. Slides were 
incubated with B cell lysate in kinase buffer for 1 hour at 30 oC. Slides were rinsed with 
with 50 mM HEPES, 150 mM NaCl, pH 7.4. The arrays were then probed with an anti-
phosphotyrosine antibody and HRP-conjugated secondary antibody to fluorescently 
assess the level of phosphotyrosine.  
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Indeed, the profiles 
between the HeLa expression 
system and Ramos B cells were 
different from each other (Figure 
58), and indicated that the 
necessity of phosphorylating the 
target proteins with B cell lysate 
for this project. Note that LYN, a 
tyrosine kinase that is known to 
be tyrosine phosphorylated in B 
cells, is phosphorylated on the 
array that is incubated with B cell lysate. Moreover, VAV1, which is tyrosine-
phosphorylated in activated B cells by SYK, is also phosphorylated by the B cell lysate. 
As mentioned previously, a large-scale screen of serine and threonine phosphorylation is 
not possible since anti-phosphoserine and anti-phosphothreonine antibodies do not bind 
to phosphorylated serines and tyrosines in a general manner and cannot be used for large-
scale phosphorylation screens.   
 One of the objectives of this study is to determine the effect of B cell-specific 
phosphorylation on protein interactions in the B cell receptor signaling pathway. It is 
therefore necessary to compare the interactions with targets that are un-phosphorylated 
and phosphorylated targets. Interactions with targets of mixed phosphorylation levels will 
complicate analyses and will not allow the direct comparison of the datasets. Therefore, 
Figure 57. Tyrosine phosphorylation profile of target proteins is 
different between the HeLa cell-free expression system and Ramose B 
cell lysate on HaloTag-based NAPPA, as determined via fluorescent 
analyses using an anti-phosphotyrosine antibody. False-colored 
rainbow-scale images representing level of phosphotyrosine. Images 
were analyzed at the same settings. 
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in Chapter 6.2, the targets were de-phosphorylated completely with phosphatases. Here, 
the incubation length with the B cell lysate to achieve maximum phosphorylation was 
determined.  
The amount of phosphorylation depends on the concentration of the kinase, 
substrate, and ATP; the incubation length; and the enzyme kinetics (Bertics & Gill, 
1985). HaloTag-PL NAPPA slides compatible with SPRi were expressed, de-
phosphorylated, and incubated with B cell lysate (20 million Ramos B cells in 1 mL) in 
the HEPES buffer described above for 0.5, 1, 1.5. 2, 3, 4, and 5 hours at 30 oC. The slides 
were the probed with an anti-phosphotyrosine monoclonal antibody and an HRP-
conjugated anti-mouse secondary antibody to analyze the level of phosphorylated 
tyrosines via fluorescence. Figure 59 represents the various responses observed across the 
array, where the signal appears to plateau at 3 – 4 hours. A decrease in signal at 5 hours 
Figure 58. Fluorescent analyses of tyrosine phosphorylation of target proteins incubated with Ramos B cell lysate from 
0.5 – 5.0 hours at 30 oC. Data represents average raw intensity value of duplicate spots referenced to MAP2K2 with no 
phosphorylated tyrosine response on each array. Fluorescent images of VAV1 are in false-colored rainbow scale where 
black/blue represents low phosphorylation and red represents high phosphorylation. Images were analyzed at the same 
settings. 
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may be due to protein degradation. Based on these results, the length of B cell 
phosphorylation was set at 3 hours to achieve stable and maximum phosphorylation. 
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CHAPTER 7 
7   DEVELOPMENT OF HIGH THROUGHPUT SPR SOFTWARE 
7.1   Standard SPR data analyses and kinetic models 
The “gold standard” software for SPR data analyses is Scrubber2, a program from 
BioLogic Software (Australia). It can analyze as many as four binding curves at one time; 
a number not arbitrarily chosen since the most common SPR instrument in general 
research laboratories is the Biacore T100, an instrument with four channels. Scrubber2 
can zero and crop the data, align the injection times, reference (e.g., subtract a non-binder 
curve from a binder curve), and determine the on- and off-rates of the interactions by 
fitting the binding curves.  
Scrubber2 uses two 
conventional kinetic models to fit 
the data: Langmuir and Langmuir 
with mass transport. The Langmuir 
adsorption model is useful for 
simple 1:1 protein interactions; in 
other words, one epitope on the 
query interacts with one epitope 
on the target. Additionally, the Langmuir model is appropriate when the target protein is 
in a monolayer, the surface is uniform, and the proteins interact independently of 
neighboring residues (Edwards et al., 1995; Jonsson et al., 1991; Oshannessy, 
Brighamburke, Soneson, Hensley, & Brooks, 1993; Schasfoort & Tudos, 2008). The 
Figure 59. Equations of the Langmuir binding model assuming simple 
1:1 protein interaction. A = analyte or query. B = ligand or target 
protein immobilized on the array. Rt = response at a specific time. R0 
= response at end of association phase. 
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Langmuir model equation is shown in Figure 60. It reflects a pseudo first-order kinetic 
reaction where the on-rate is proportional to the concentration of one reactant (i.e, query), 
which is initially assumed to occur on SPR platforms where the target concentration is 
fixed while the query concentration is in excess. As detailed in Chapter 4.1.2, mass 
transport occurs when the target concentration is high and the rate of diffusion is lower 
than the on-rate (i.e., km << ka[B]) (OShannessy & Winzor, 1996; Schasfoort & Tudos, 
2008). This results in a linear, rather than an exponential, binding signal.  
The Langmuir-based models are generally sufficient for most SPR data, but there 
are PPIs in which a different kinetic model would better fit the data. A bivalent analyte 
model is appropriate when a query has two separate binding sites. For example, an 
antibody can bind to two identical antigens at the end of the arms of its Y-shaped 
structure via the variant “Fab” region. The second antibody-antigen interaction is 
dependent on the first interaction due to the proximity of the binding sites. During 
dissociation, one interaction may break while the other forms, resulting in a dissociation 
rate that represents the bivalent nature of the complex rather than a single interaction. (To 
circumvent this avidity issue of antibodies, it is recommended that antibodies are 
captured as targets rather than injected as queries.) Another example of why a non-
Langmuir model should be implemented is when there are two target species or two 
different binding locations on the target, each capable of binding to the query 
independent from each other. The heterogeneous analyte or ligand binding models may 
be used in these situations. A target that changes conformation upon binding the query 
could be explained by the two-state conformation model. Further detail on how the 
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equations were derived and the background for the Langmuir and other models are 
provided in (Edwards et al., 1995; Oshannessy et al., 1993; Schasfoort & Tudos, 2008). 
The appropriate model for the data can be obtained by knowing the PPI type a 
priori or by fitting the binding curve to various kinetic models to identify which model 
best fits the interaction; the Langmuir models, however, fit most data. Another popular 
software package is BIAevaluation software from Biacore Life Sciences, which includes 
the Langmuir, bivalent analyte, heterogeneous, and two-state conformation kinetic 
models. Like Scrubber2, this software was developed to analyze low throughput data 
only.   
 
7.2   Developing in-house software to analyze Plexera SPRi data 
The Plexera® HT PlexArray instrument that was used for the NAPPA-SPRi 
experiments has a separate Plexera Data Analysis Module software for analyzing the 
produced data. Unfortunately, it cannot reference the data or fit the data well. More 
importantly for this project, it could not handle high throughput data; the software would 
simply freeze indefinitely with the NAPPA-SPRi data. Low throughput, manual software 
packages like BIAevaluation and Scrubber2 were also not feasible options. 
In collaboration with Stanford, the “SPRite” software in Python for fitting the biosensor 
data from NAPPA-SPRi was built. The SPRite software can do the following: 1) calibrate 
data; 2) alphabetize the sample names; 3) reference; 4) determine and correct for drift; 5) 
globally fit data using the 1:1 Langmuir kinetic model; 6) export the binding curves as 
PDF figures (Figure 61); 7) export a tab delimited text file that can be properly formatted 
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in SPRuce for Scrubber2 analyses; 8) 
export a tab delimited text file with 
calibrated curves (i.e., binder, 
reference, referenced binder); and 9) 
export a tab delimited text file with the 
kinetic and affinity data.  
 To ensure that the binding 
kinetics and affinities calculated by 
SPRite are similar to those obtained 
with Scrubber2, binding curves from seven datasets analyzed with bboth software 
packages and then compared. More specifically, all of the binding curves from one 
dataset and several binding curves representing a range of binding rates and affinities 
from six other datasets were analyzed with SPRite and Scrubber2. These 7 datasets were 
chosen because they came from multiple different experiments, they had a wide range of 
binding kinetics and affinities (i.e., ka = 1.2 x 10
2 to 1.33 x 105 M-1s-1, kd = 3.74 x 10-5 to 
7.41 x 10-3 s-1, KD = 8.97 x 10
-10 to 6.0 x 10-5 M), were within the linear range of the 
instrument, did not have mass transport, the association response had some curvature, and 
the binding responses followed a single exponential. A comparison of the results from 
SPRite and Scrubber is displayed as scatter plots for ka, kd, and KD in Figure 62 where the 
R2 correlations are 0.992, 0.9974, and 0.9788, respectively. These data demonstrate the 
accuracy of SPRite. A meta-analysis of the kinetics and affinities determined with 
Scrubber2 versus SPRite indicates that there were no biases across the range of ka, kd, and 
Figure 60. An example of a PDF output file of SPRite depicting 
the raw binding curve (light green), the referenced binding curve 
(black), the fitted curve (red), and the residuals between the fitted 
curve and referenced binding curve (blue). X-axis = time (sec). 
Y-axis = response units (RU). 
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KD values (Figure 63). Moreover, SPRite is 
reproducible, calculating the same values for the same dataset across different analyses, 
thus resulting in an R2 correlation of 1 (Figure 64).  
SPRite allows the entry of fitting parameters for a group of samples by command 
line. Once this is done, it will fit ~50 curves against three different references in about 5 
minutes on a standard desktop computer. Scrubber2, in comparison, requires manual 
adjustments from the user during the curve fitting. Thus, in the same 5 minutes, 4 curves 
can be processed against one reference. This represents almost a 40-fold increase in 
throughput for curves fit globally. If the binding curves are fit with the Langmuir model 
Figure 62. Meta-analysis of the ka, kd, and KD values 
obtained with Scrubber2 and SPRite indicate that SPRite 
has no biases across the ranges of values. Values were 
obtained from the seven datasets in Figure 74. 
Figure 61. Correlation of ka, kd, and KD values obtained 
with SPRite and Scrubber2 for seven datasets. NP = targets 
are Not Phosphorylated, LT = targets are Lysate-Treated 
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without drift correction and global fitting in 
SPRite, the throughput increases to 143 
curves with three different references in 5 
minutes! A comparison of the options in 
SPRite are Scubber2 is in Figure 65. 
In SPRite, each binding curve is 
referenced separately to three non-binder 
curves in SPRite. Thus, instead of one 
generated sensorgram depicting the raw, 
referenced, and residual plots in PDF format, 
THREE PDFs are created per target protein. 
In other words, an array of 100 target proteins 
will generate a PDF file with 300 pages. In 
some cases, not all referenced data may be needed and a short python script, 
“MergePDFsOnFileNames.py,” can be used to extract PDFs with a specific reference-of-
interest, and subsequently collated together. The directions for running the 
“mergePDFsOnFileName.py” script as well as script itself can be found in Appendix H. 
SPRite will be open-source, which will make it easy for the software to be added 
to and improved upon based on the needs of the SPR community. For example, SPRite is 
currently capable of analyzing curves with the 1:1 Langmuir kinetic model one dataset at 
a time. It could, however, be altered so that it can analyzed multiple datasets 
simultaneously within one command prompt window. Moreover, other kinetic models 
Figure 63. Technical reproducibility of the SPRite 
software has an R2 correlation of 1 for ka, kd, and KD 
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could be incorporated in SPRite, like the Langmuir model with mass transport or the 
heterogeneous ligand model. Spikes in the data can occur from physical anomalies during 
the analyses (e.g., bubble) or imperfect timing alignment (or “offset”) between a binder 
and its reference since the target proteins will experience association and dissociation at 
slightly different times across the array. Scrubber2 has the ability to identify some of 
these spikes and remove them from the binding sensorgram; at the moment, SPRite does 
not (Figure 65). A generic timing “offset” file is presently created by the user (see 
Appendix E) and fed into SPRite. Since the offset will be different for each target protein, 
slide, and flow rate, a separate or an embedded script in SPRite to automatically 
determine the offset values for each experiment would be ideal. Some of this work has 
already begun.  
Two files constitute SPRite, “parseSPRandFitCurves.py” and 
“curveFittingKineticModels.py.” The command line options are first read by 
“parseSPRandFitCurves.py” which determines the general framework of SPRite. 
Figure 64. Comparison of Scrubber2 and SPRite software for analyzing SPR data 
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Software libraries like “pandas” and “numpy” are imported into SPRite via 
“parseSPRandFitCurves.py” to provide standard data structures and operations for 
python-based scripts. It also performs calibration, defines phrases, indicates where to go 
in the “curveFittingKineticModels.py,” and formats the final documents. As the file name 
suggests, “curveFittingKineticModels.py” contains the equations for fitting the binding 
curves. It also drift-corrects the data. Directions on using SPRite is given in Appendix E. 
In Appendix F and Appendix G, the script is provided for the 
“parseSPRandFitCurves.py” and “curveFittingKineticModels.py” files, respectively. 
Please note that the appropriate python package must be installed before any of these 
scripts can be run. SPRite will also be available through the Mallick Lab website at 
mallicklab.stanford.edu.  
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CHAPTER 8 
8   QUANTITATIVE ANALYSES OF THE BCR SIGNALING PATHWAY USING 
NAPPA-SPRI 
8.1   Introduction 
 Cellular responses to external stimuli are mediated through dynamic and complex 
signal transduction networks that are comprised of protein-protein interactions (PPIs). 
Signal propagation is not only dependent on which proteins interact, but how they 
interact. For instance, CDC42 and WASP must interact rapidly to stimulate actin 
polymerization (Hemsath, Dvorsky, Fiegen, Carlier, & Ahmadian, 2005). Fast 
association rates and slow dissociation rates control antibody maturation and B cell 
selection (Foote & Milstein, 1991). Mutations that lead to faster association and 
dissociation rates between Ras and Raf result in more phosphorylated ERK, a 
downstream product of the Ras-Raf interaction, compared with the wild-type interaction 
(Kiel & Serrano, 2009). Despite the biological importance of kinetics and affinities, very 
little of this quantitative space has been explored due to the low throughput nature of 
current quantitative methods (see Chapter 1.3, page 8). The B cell receptor (BCR) 
signaling pathway, for example, is considered to be one of the best understood signaling 
pathways, yet only a handful of these interactions have been quantitatively characterized 
(Table 2Error! Reference source not found.).  
I applied NAPPA-SPRi, a high throughput platform that is capable of analyzing > 
400 protein interactions quantitatively in less than an hour, toward studying > 12,000 
PPIs in the BCR signaling pathway using different query proteins (BLNK, BTK, PI3K, 
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RAC1, RHOA). Since kinase cascades play an important role in signal transduction in the 
BCR pathway, I tested these interactions under conditions where the target proteins were 
either dephosphorylated or treated with lysate from naturally proliferating B cells with 
active kinases (see Chapters 2.4, 6.2, 6.3).  In addition, the GTPase query proteins were 
tested in different activation states (i.e., GDP- versus GTPγS-bound). Interaction kinetics, 
affinities, and protein partners were affected by lysate treatment of targets, GTPase query 
activation state, and the tag location of the target proteins.  
 
8.2   Materials and Methods 
ATP was from Cell Signaling Technology (Danvers, MA). GTPγS was obtained from 
BIOLOG Life Science Institute (Germany). Brij-35; Bond-Breaker TCEP Solution, 
Neutral pH; NuPAGE Transfer Buffer; and SuperSignal West Femto were from Thermo 
Fisher Scientific (Waltham, MA). All other reagents, unless otherwise noted, were 
obtained from Sigma-Aldrich (St. Louis, MO).  
 
Plasmid cDNA 
Plasmid cDNA was obtained from the Virginia G. Piper Center for Personalized 
Diagnostics’ (VGP CPD) plasmid repository, DNASU (Tempe, AZ), and Open 
Biosystems (Lafayette, CO), and prepared as previously described using the 
pJFT7_nHalo_DC and pJFT7_cHalo_DC with the capturing fusion tag (i.e., HaloTag) at 
the N- or C-terminus (Saul et al., 2014). The list of these genes is in Appendix A with the 
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sequences publicly available at https://dnasu.org/DNASU/. Successful cloning of the 
GOIs was confirmed with Sangar sequencing at DNASU. 
 
NAPPA-SPRi slide preparation 
A 48 nm layer of gold was deposited via electron beam evaporation on low sodium 
optical D263 borosilicate slides with an index of refraction of 1.52 (Plexera LLC; 
Woodinville, WA). The slides were sonicated for 10 min in 0.1 N KOH, 100% methanol, 
washed three times in 100% ethanol, and then dried with compressed gas. 1 mM amine-
terminated polyethylene glycol [HS-C11(C2H4O)6-NH2] (Prochimia Surfaces; Poland) 
was resuspended in ethanol and applied to the slide overnight at 4 oC to create a self-
assembled monolayer. To prevent evaporation of the ethanol during the incubation, these 
slides were placed on upside-down Wheaton® stainless steel 30-slide rack (Capital 
Scientific, Inc.; Austin, TX) within a plastic Lock & Lock food storage container (Food 
Storage Mall; China) with ~ 0.5 cm of 100% ethanol on the bottom. The slides were 
washed three times in 100% ethanol and dried with compressed gas just prior to printing.  
The printing master mix included 0.0003% poly-L-lysine (Thermo Fisher 
Scientific; Waltham, MA), 0.3% DMSO, 250 µM BS3 (Thermo Fisher Scientific; 
Waltham, MA), 375 µM HaloTag® amine (O4) ligand (Promega; Madison, WI), and 0.4 
mg/mL plasmid cDNA. The printing master mixture was incubated at 4 oC overnight, 
then deposited onto the prepared slides with the QArray2 spotter (Molecular Devices, 
LLC; Sunnyvale, CA) using solid pins. The random array layout and DNA deposition 
analysis are shown in Appendix J.  
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The development of this hybrid platform, which combines the advantages of 
NAPPA and SPRi, is described in more detail in Chapter 4. 
 
Target protein expression  
Slides were blocked with Tris-based SuperBlock (Thermo Fisher Scientific; Waltham, 
MA) to minimize non-specific binding overnight at 4 oC. They were then washed in 1x 
PBS three times for 2 min each, rocking. The slides were rinsed in water and dried with 
compressed air. SPRi flow chambers (Plexera; Woodinville, WA) with 30 µL volume 
were applied onto the slides followed by 1-step human coupled in vitro protein 
expression mixture according to the manufacturer’s instructions (Thermo Fisher 
Scientific; Waltham, MA). Expression was performed for 1.5 hours at 30 oC and then 30 
min at 15 oC. Slides were rinsed in 200 µL 1x PBS. Analysis of target protein expression 
is shown in Appendix J. 
 
Query protein expression  
Three purified queries were obtained from commercial companies. BLNK and BTK had 
an N-terminal His tag (Sino Biological; Beijing, China) and tested for activity through a 
functional ELISA and kinase assay tests, respectively. BLNK was expressed in human 
cells while BTK was expressed in baculovirus insect cells. PIK3CA/PIK3R1 
(p110α/p85α) (Life Technologies Corporation; Carlsbad, CA) was expressed in 
baculovirus insect cells, tested for activity using a kinase assay, and had an N-terminal 
His tag on PIK3CA. The GTPases, RAC1 and RHOA, were expressed in Escherichia coli 
  
160 
by members of Dr. Kim Orth’s laboratory (UT Southwestern; Dallas, TX), and have been 
used in various published experiments demonstrating their activity (Woolery et al., 2014; 
Yarbrough et al., 2009). Moreover, the proteins were tested for functionality by Dr. 
Xiaobo Yu (personal communication; National Center for Protein Sciences; Bejing, 
China) by their ability to bind to known protein partners on NAPPA arrays.  
 
De-phosphorylation of target proteins 
Calf intestinal alkaline phosphatase (CIAP) (New England BioLabs; Ipswich, MA) and 
lambda protein phosphatase (New England BioLabs; Ipswich, MA) were buffer 
exchanged into 1x NEBuffer 3 or 1x NEBuffer for PMP supplemented with 1 mM MnCl2 
(New England BioLabs Ipswich, MA), respectively, using 7 kDa molecular weight cut-
off (MWCO) Zeba spin desalting columns (Thermo Fisher Scientific; Waltham, MA). 
Slides were rinsed in 200 µL 1x NEBuffer 3 and then incubated in 300 units of CIAP at 
30 oC for 30 min. Slides were rinsed in 200 µL 1x NEBuffer for PMP supplemented with 
1 mM MnCl2.  The slides were then incubated three times with 2,000 units of lambda 
protein phosphatase at 30 oC for 30 min. Slides were rinsed in the same HEPES- or Tris-
based buffer that was used for SPRi analyses (Appendix J). 
The de-phosphorylation of the array proteins is optimized and discussed in 
Chapter 6.2. 
 
Phosphorylation of target proteins with Ramos B cell lysate 
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Ramos B cells (ATCC; Manassas, VA) were grown in RPMI-1640 (ATCC; Manassas, 
VA) supplemented with 10% HyCloneTM fetal bovine serum (GE Healthcare Life 
Sciences; Logan, UT). Cells were washed twice with ice-cold 1 mM Na3VO4 in TBS, 
then solubilized in 50 mM Tris-HCl (pH 7.7), 0.5% nonidet P-40, 2.5 mM EDTA, 20 
mM beta-glycerophosphate, 10 mM NaF, 1 mM Na2MoO4, 1 mM Na3VO4, 0.25 µM 
PMSF, 1 µM pepstatin, 0.5 ug/mL leupeptin, 10 ug/mL soybean trypsin inhibitor, and 1 
ug/mL microcystin-LR. Cells were spun at 4k x g for 5 min and the supernatant stored in 
single-use aliquots at -80 oC such that the lysate from 20 million cells were in 1 mL of 
solubilization buffer. Slides were rinsed in 200 µL 50 mM HEPES, 150 mM NaCl, pH 
7.4. B cell lysate was buffer exchanged using a 7 kDa MWCO Zeba desalting spin 
column (Thermo Fisher Scientific; Waltham, MA) into kinase buffer containing 20 mM 
HEPES, 5 mM MnCl2, 5 mM MgCl2, 0.25 µM PMSF, 0.5 ug/mL leupeptin, 10 ug/mL 
soybean trypsin inhibitor, 20 mM beta-glycerophosphate, 10 mM NaF, 1 mM Na2MoO4, 
1 mM Na3VO4, 500 µM ATP, pH 7.5. Slides were incubated with B cell lysate in kinase 
buffer for 3 hours at 30 oC. Slides were rinsed with the same HEPES- or Tris-based 
buffer that was used for SPRi analyses. All slides were stored at 4 oC when not being 
analyzed. 
The phosphorylation of the array proteins in a B cell-specific manner is optimized 
and discussed in Chapter 6.3. 
 
Activation of GTPases, RAC1 and RHOA 
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Purified GTPases were incubated in 10 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 5 mM 
EDTA, 1 mM TCEP, pH 7.4, and 1 mM GTPγS or GDP for 1 hour at room temperature 
to activate or inactivate the GTPases, respectively. Samples were then buffer exchanged 
into 50 mM HEPES, 150 mM NaCl, 5 mM MgCl2, 1 mM TCEP, pH 7.4, which was the 
buffer used for SPRi analyses. 
 
NAPPA-SPRi analyses 
The Plexera HT PlexArray instrument was primed three times with filtered and degassed 
“running buffer” specific to the query (Appendix J). Each slide was subjected to the 
following runs, in consecutive order: 0.5% glycerol, 1.0% glycerol, running buffer, 
protein query, and 5.34 E-8 M anti-TP53 D01 monoclonal antibody. Glycerol in running 
buffer was injected with 100 sec association and 100 sec dissociation each and used to 
normalize inter- and intra-slide data where the change in refractive index is equal to 
0.000565 response units (RU). Kinase query runs were performed at 5 µL/sec at 30 oC. 
Running buffer, purified query protein in running buffer, and antibody in running buffer 
were injected with 180 sec association and 400 sec dissociation. Non-kinase query runs 
were performed at 3 µL/sec at RT. Running buffer, purified query protein in running 
buffer, and antibody in running buffer were injected with 300 sec association and 700 sec 
dissociation. Data were acquired in real-time with the Plexera Instrument Control 
software. 
 
NAPPA-SPRi data analyses 
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Data analyses were performed in three steps. Regions-of-interest in the AVI video format 
were first identified and analyzed with the Plexera SPR Data Analysis Module software. 
The in-house software, SPRite, calibrated the data to standard response units (RU), 
formatted the data to be compatible with Scrubber2, selected the time frame(s) of interest, 
referenced the binding curves to non-binders, drift corrected the data, and fit the curves 
using Langmuir kinetic models (with and without mass transport). Finally, the curves 
were assessed by eye. More information about the SPRite software is in Chapter 7.2. 
Specific information regarding SPRi analyses is in Appendix I. 
 
Qualitative analyses of protein interactions using NanoBRET 
See Chapter 3.4. Only the protein interactions with BLNK, BTK, PI3K, GDP-bound 
RAC1, GTP-bound RAC1, GDP-bound RHOA, and GTP-bound RHOA are considered 
in this chapter. 
 
Protein interaction validation using Phos-Tag SDS-PAGE 
Recombinant human BTK with an N-terminal His tag was obtained from Sino Biological 
(Wayne, PA). Recombinant human ETS1, JUN, and BCL2 with an N-terminal His tag 
were obtained from RayBiotech (Norcross, GA), respectively. Recombinant human 
protein PI3K, constituting PIK3CA with an N-terminal His tag and untagged PIK3R1, 
was obtained from Thermo Fisher Scientific (Waltham, MA). Recombinant human MYC 
with an eleven-arginine tag at the C-terminus was obtained from Abcam (Cambridge, 
MA). MYC was first de-phosphorylated with 1200 units of lambda phosphatase for 2 hr 
  
164 
at 30 oC, and then 2 mM sodium orthovanadate was added to inhibit any further 
phosphatase activity. Kinase and substrate were mixed together at a 3:4 ratio (w/w) in 50 
mM HEPES, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 0.01% Brij-35, 1 mM ATP, and 
incubated at 30 oC for 1 hr. BTK samples with substrate and ATP were de-
phosphorylated with 800 units of lambda protein phosphatase (New England BioLabs; 
Ipswich, MA) for 2 hrs at 30 oC. 1x Laemmli loading dye (Bio-Rad; Hercules, CA) and 
10 mM Bond-Breaker TCEP Solution, Neutral pH were added to the samples before 
heating at 65 oC for 10 min. Samples were added to SuperSep Phos-TagTM (50 umol/L), 
12.5% SDS-PAGE gels (Wako Pure Chemical Industries; Richmond, VA) using tris-
tricine running buffer containing 50 mM Tris, 50 mM N-[2-hydroxy-1,1-
bis(hydroxymethyl)ethyl] glycine (Tricine), 0.10% (w/v) SDS, 5 mM sodium bisulfite. 
Gels were run at 100 V for 1 hr, and then transferred overnight to a PVDF membrane at 4 
oC and 150 mA using the Bio-Rad Mini Trans-blot cell and 1x NuPAGE transfer buffer 
supplemented with 5 mM sodium bisulfite. Membranes were blocked with 3% BSA in 
PBST (“blocking buffer”) for 1 hr at room temperature, and then probed with rabbit anti-
human anti-c-Jun monoclonal antibody (clone 60A8; Cell Signaling Technology; 
Danvers, MA), anti-ETS1 monoclonal antibody (clone D808A; Cell Signaling 
Technology; Danvers, MA), anti-c-MYC monoclonal antibody (Abcam; Cambridge, 
MA), anti-c-MYC phospho S62 monoclonal antibody (Cell Signaling Technology; 
Danvers, MA), or mouse anti-human BCL2 monoclonal antibody (Cell Signaling 
Technology; Danvers, MA). The membrane was washed three times in PBST, incubated 
for 1 hr at room temperature with HRP-conjugated anti-rabbit IgG (Cell Signaling 
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Technology; Danvers, MA) or anti-mouse IgG (Jackson ImmunoResearch; West Grove, 
PA) at a 1:15,000 dilution in blocking buffer, and then washed again three times in 
PBST. Signal was visualized using SuperSignal West Femto chemiluminescent substrate 
using the ImageQuant LAS 4000 system (GE Healthcare Life Science; Pittsburgh, PA). 
 
8.3   Results & Discussion 
8.3.1   NAPPA-SPRi detected known and novel interactions 
To evaluate 
how many known 
interactions were 
detected with 
NAPPA-SPRi, the 
data were compared 
to human, mouse, and 
rat PPIs curated by the online databases, BioGRID and HPRD (Appendix C) (Prasad et 
al., 2009; Stark et al., 2006). Of the NAPPA-SPRi PPIs that were detected, 15% were 
known and 85% were novel (Table 14). Across the seven queries, NAPPA-SPRi detected 
72 (66%) known interactions listed in these sources while also identifying 401 previously 
unreported interactions (Table 14, Table 15).  
 The PI3K query had one of the lowest coverage of known interactions (i.e., 42%) 
with NAPPA-SPRi (Table 15). In vivo, PI3K can exist as a heterodimer consisting of one 
of five different regulatory subunits and one of four different catalytic subunits (Cheung 
Table 14. Percentage of known and novel PPIs detected by NAPPA-SPRi 
Table 15. NAPPA-SPRi detected 66% of known PPIs 
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et al., 2015). Unlike the catalytic subunits, the regulatory subunits can act as a monomer 
or homodimer. In this experiment, the PI3K query was a heterodimer, containing the 
regulatory subunit PIK3R1 and the catalytic subunit PIK3CA. Its interactions on 
NAPPA-SPRi were cross-referenced with those that are known for PIK3R1, PIK3CA, 
and the heterodimer. Most of the PI3K interactions curated by BioGRID and HPRD were 
for the PIK3R1 subunit, which may or may not have been also been interacting with 
PIK3CA or one of the other catalytic isoforms. This may explain why the known PPI 
coverage of PI3K was low. The GTPases, RAC1 and RHOA, identified more known 
proteins when they were GTP-bound (i.e., active) than when they were GDP-bound 
because they interacted with > 20% more proteins than the inactive GTPases. 
 
8.3.2   Tag locations may provide helpful insight into binding sites 
NAPPA-SPRi employed fusion tags to capture the expressed target protein to the 
slide surface. Since fusion tags may interfere with interactions by blocking binding 
epitopes or altering protein structure, particularly at the end of the protein where they are 
located, targets were represented separately on the array with the tag at the N-terminus 
and C-terminus. We observed 62.3% more interactions when the tag was at the C-
terminus. Of the 101 target proteins represented on the array with a tag in each position, 
and which interacted > 3 queries across all conditions and concentrations, 69 showed a 
preference of at least two-fold for a tag in one position or the other. Twenty (20) proteins 
had more interactions with the queries when the tag was at the N-terminus, while 49 
proteins had more interactions when the tag was at the C-terminus. Some isoforms within 
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the same protein family behaved similarly, which may account for some interaction bias 
in this study toward C-terminally tagged targets. For example, most of the interactions 
with targets in the SHIP (INPP5D, INPPL1), p38 (MAPK12, MAPK13, MAPK14), ERK 
(MAPK1, MAPK3), NFATC (NFATC1, NFATC3, NFATC4), and PKC (PRKCA, 
PRKCB) protein families occurred when the tag was the C-terminus. Other isoforms 
within the same protein family behaved differently from each other. For example, AKT1 
and AKT2 interacted with at least three times as many queries when the tag was at the C-
terminus than at the N-terminus; AKT3 had no preference, with N-terminal tagged AKT3 
binding to queries 22 times and C-terminal tagged AKT3 binding to queries 24 times. All 
four PI3K catalytic isoforms had different binding profiles with respect to tag location. 
PIK3CA had no tag preference, PIK3CB interacted with 4-fold more queries when it had 
a tag at the C-terminus, PIK3CD did not interact with any queries, and PIK3CG 
interacted with 2.3-fold more queries when it had a tag at the N-terminus. These 
dissimilarities may be the result of different protein structures despite having high 
sequence homology.  
 Protein interactions that are affected by the location of the tag may provide 
helpful insight into where a query may be binding. For example, an N-terminal tag is 
more likely to occlude binding sites toward the N-terminus. NAPPA-SPRi detected the 
known interaction between the adaptor proteins, GRB2 and BLNK. The interaction was 
altered with lysate treatment, which supports the current understanding of how GRB2 
binds to BLNK in unstimulated and stimulated B cells. BLNK only bound to NP- GRB2 
with a tag at the C-terminus, implying that BLNK is binding to GRB2 toward its N-
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terminus (Figure 66). In fact, 
BLNK binds to GRB2’s N-
terminal SH3 domain in 
unstimulated B cells where 
GRB2 is in a homodimer. 
Following lysate treatment of 
GRB2 on NAPPA-SPRi, 
BLNK interacted with GRB2 
regardless of the location of the fusion tag. These data suggest that GRB2 is indeed 
phosphorylated by the B cell lysate, resulting in a conformational or electrostatic change 
that favors a GRB2-BLNK interaction. Indeed, phosphorylation at tyrosine 160 of GRB2 
in stimulated B cells is reported to destabilize GRB2’s homodimer complex, thereby 
allowing BLNK to bind to the C-terminal SH3 domain (Ahmed et al., 2013; Justement & 
Siminovitch, 2000; S. G. Li, Couvillon, Brasher, & Van Etten, 2001; Riera et al., 2010; 
Wienands et al., 1998). BLNK also binds to GRB2’s central SH2 domain in activated B 
cells. In the lysate-treated data, either the C-terminal tag does not interfere with BLNK 
binding to GRB2’s C-terminal SH3 domain or BLNK may be binding to GRB2’s central 
SH2 domain.  
 
8.3.3   Phosphorylation affects binding partners  
Phosphorylation is a common posttranslational modification (PTM) in which a 
phosphate is covalently bound to a serine, threonine, or tyrosine residue by kinases and 
Figure 65. Binding sensorgrams of the query, BLNK, binding to NP- and 
LP-GRB2. 
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removed by phosphatases. It is estimated that one-third of all proteins within a cell are 
phosphorylated at any given time, playing important roles in intracellular signaling and 
metabolic control (Kitchen, Saunders, & Warwicker, 2008). Phosphorylation can affect 
PPIs by altering protein structure, blocking binding sites, creating new binding epitopes, 
or causing bulk electrostatic changes that are sensitive to the subcellular location (Nishi, 
Shaytan, & Panchenko, 2014; Serber & Ferrell, 2007). As such, phosphorylation has been 
traditionally viewed as a posttranslational modification that promotes or inhibits 
interactions, or activates or inactivates enzymes. Phosphosites – particularly those with 
serine and threonine – are often in regions that are flexible and disordered under native 
conditions. Since the phosphate group is dianionic at physiological pH, it can form 
extensive hydrogen bonds and salt bridges with neighboring residues (Nishi, Hashimoto, 
& Panchenko, 2011). As such, phosphorylation is generally considered to induce protein 
disorder-to-order conformational changes in the region around the phosphosite; order-to-
disorder transitions may occur elsewhere in the protein as a consequence of 
phosphorylation.  
Phosphorylation plays an important role in regulating the BCR pathway. For this 
reason, PPIs were studied using target proteins that were either de-phosphorylated (i.e., 
not phosphorylated; NP) or “phosphorylated” using lysate from activated B cells 
supplemented with kinase co-factors and phosphatase inhibitors (i.e., lysate-treated; LT). 
Fluorescence analyses using anti-phosphotyrosine antibodies to arrays before and after 
lysate treatment demonstrate that the lysate contains active kinases since proteins are 
phosphorylated (see Chapter 6.3, Figure 58). Although lysate treatment represents the 
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“phosphorylation” arm of the experiment, it should be noted that certain target proteins 
may not be phosphorylated by the lysate and that the sites of the phosphorylation, if they 
do occur, are unknown. That said, as described below, I found significant differences in 
affinity and binding rates between the de-phosphorylated and lysate-treated proteins, thus 
I inferred that the main effect of the lysate treatment was to modify phosphorylation. 
For the most part, treatment with lysate did not alter which proteins interacted; 
that is, 84% of the targets showed detectable binding to the same queries regardless of 
phosphorylation state. However, in many cases, lysate treatment had a profound effect on 
either binding affinity, interaction rates or both. Those interactions that occurred in one 
but not the other target phosphorylation state are displayed in Table 16. Notably, some 
query proteins bound to > 20% more NP- than LT-targets (Table 17). These included 
Table 16. Unique PPIs based on target phosphorylation 
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PI3K, active RAC1, inactive RHOA, and active RHOA (for Venn diagrams, refer to 
Appendix M). 
 
8.3.4   Phosphorylation affects binding kinetics 
Protein interactions that occurred regardless of phosphorylation state were 
compared with each other to determine the relative effect of lysate treatment on binding 
kinetics and binding affinity. These results are depicted as bar plots in Figure 67, Figure 
68, Figure 69, Figure 71, Figure 70, and Figure 72. On-rates, off-rates, and binding 
affinities for each protein interaction in the unphosphorylated dataset were set to “0” and 
represented as blue circles. The relative changes in log10 in binding kinetics and affinity 
for each protein pair following lysate treatment were represented as a connected orange 
circle.  For example, in Figure 67, in its interaction with BLNK, VAV2 showed an 
increase of 0.7 log10 in its kd (i.e., dissociation), almost no change in ka (i.e., 
association), and a decrease of 0.7 log10 in the KD (i.e., binding affinitiy). 
BLNK and PI3K interactions are regulated primarily through their off-rate. 
Approximately half of the targets showed higher binding affinity to the adaptor protein 
BLNK after they were lysate-treated. In these examples, this change was associated with 
small increases in on-rates or decreases in off-rates (Figure 67, Appendix Q). The other 
Table 17. Query interactions with NP- and LT-targets 
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half of the BLNK interactions had lower binding affinities with LT-targets, a result 
largely associated with faster off-rates, with little or no change in the on-rate. Lysate 
treatment generally resulted in stronger binding affinities with PI3K, which were 
associated with slower off-rates (Figure 68). 
Figure 66. Bar plots showing the relative log10 change in kd, KD, and ka with LT-targets compared to NP-targets for 
the BLNK query. 
Figure 67. Bar plots showing the relative log10 change in kd, KD, and ka of all of the PPIs of PI3K with NP- and LT-
targets. 
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BTK interactions are regulated through their on- or off-rates. For the non-
receptor tyrosine kinase, BTK, stronger affinities with LT-targets compared to NP-targets 
were associated with slower dissociation rates, whereas weaker affinities were associated 
with slower association rates (Figure 69, Appendix Q).  
Figure 68. Bar plots showing the relative log10 change in kd, KD, and ka with LT-targets compared to NP-targets for 
the BTK query. Bar plots showing all of the PPIs is in Appendix P. 
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RAC1 interactions are regulated through their on- and off-rates. Among the 
most surprising findings of this study relates to RAC1 binding to targets. GTP-bound 
RAC1, showed significantly faster on- and off-rates to lysate-treated targets compared to 
their dephosphorylated counterparts (Figure 70, Appendix Q); however, despite binding 
rate changes that sometimes exceeded several orders of magnitude, the overall affinity 
(KD) was largely unchanged. Thus, it appears that phosphorylation of some targets results 
in a dramatic form of regulation of binding rates without a significant effect on the 
fraction of molecules bound. Such an effect has never been previously reported. The LT 
→ NP transition increased the average on-rates and off-rates of active RAC1 by 220- and 
257-fold, respectively, with only a 1.48 change in affinity. In other words, the on- and 
off-rates increased or decreased proportionally with relatively little change in binding 
affinity. In contrast, both the 
binding kinetics and affinities 
of GDP-bound (“inactive”) 
RAC1 were minimally 
affected with lysate treatment 
(Figure 71). Overall, the on-
rates, off-rates, and binding 
affinities of inactive RAC1 
increased 2-fold, decreased 2-
Figure 69. Bar plots showing the relative log10 change in kd, KD, and 
ka of some of the PPIs of the RAC1(GTP) query with NP- and LT-
targets. Bar plots showing all of the PPIs is in Appendix P. 
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fold, and increased 1.5-
fold, respectively, 
compared to the binding 
kinetics and affinities with 
de-phosphorylated targets. 
RHOA 
interactions are regulated 
through minimal changes 
in their on- or off-rates. The 
majority of LT- targets bound 
to active RHOA with lower 
binding affinities than their NP 
counterparts, which was 
associated, in large part, to 
slower on-rates (Figure 72). 
However, roughly a quarter of 
the interactions resulted in 
stronger affinities, which were 
associated with slower off-
rates. Inactive RHOA interacted with only five targets that were unphosphorylated and 
lysate-treated, with no overall differences in binding kinetics and affinities between de-
phosphorylated and LT-targets (Appendix P). Taken together, the different kinetic 
Figure 71. Bar plots showing the relative log10 change in kd, KD, and ka 
of some of the PPIs of the RHOA(GTP) query with NP- and LT-targets. 
A bar plot showing all of the PPIs is in Appendix P. 
Figure 70. Bar plots showing the relative log10 change in kd, KD, and ka of 
some of the PPIs of the RAC1(GDP) query with NP- and LT-targets. Bar 
plots showing all of the PPIs is in Appendix P. 
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profiles illustrate that proteins employ different methods of regulation in their 
interactions with other proteins. They also indicate that the interactions are not an artefact 
from the NAPPA-SPRi platform. 
                                                                                                                                   
8.3.5   Pairwise analyses of low and high binding affinities 
To understand whether there was a difference of interacting targets with particular 
biological processes and gene families that had low or high binding affinities to a specific 
query, targets were first defined using the Protein Analysis Through Evolutionary 
Relationships (PANTHER) and HUGO Gene Nomenclature Committee (HGNC) 
classification systems, respectively. The number of targets with different biological 
process or gene family were then determined per query and a pairwise linear regression 
analysis was performed comparing the targets with low binding affinity to those with 
high binding affinity to the same query (Figure 73, Figure 74). Enriched processes and 
gene families were defined as having more than two standardized residuals away from 
the predicted mean of the fitted linear regression line. Residual plots of these analyses are 
in Appendix N). 
BLNK Targets. Target proteins of BLNK having > 3 x 10-9 M difference in 
binding affinities following lysate treatment were compared in terms of their biological 
processes and gene families using pairwise linear regression analyses. The biological 
process that was most enriched in targets with stronger affinities to BLNK following 
lysate treatment was the stress response. BLNK has already been demonstrated to be 
important in the stress response, mediating protein interactions for the PI3K/AKT and 
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JNK signaling pathways that regulate cell survival and apoptosis, respectively (Ding et 
al., 2000; Han et al., 2001; Kabak et al., 2002). Stress also increases tyrosine 
phosphorylation of numerous proteins that are targeted by SH2 domains (Suzuki, Ohsugi, 
& Ono, 1996). Interestingly, the SH2 domain containing gene family was enriched in this 
group as well.  
Figure 73. Radial plot of enriched HGNC gene families in PPIs that have stronger binding affinities following lysate 
treatment. Numbers represent the standard deviation away from the mean.  
 
Figure 72. Radial plots of enriched PANTHER biological processes in PPIs that have stronger binding affinities 
following lysate treatment. Numbers represent the standard deviation away from the mean. 
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BTK Targets. Twenty targets of BTK with the highest binding affinities and 
slower dissociation constants were compared against the 29 proteins with the lowest 
affinities and slower association rates following lysate treatment. One of the gene 
families that were enriched in targets with stronger affinities following lysate treatment 
was RAS type GTPases. Interestingly, BTK resembles some Ras GTPase-activating 
proteins (GAPs) through its PH domain and BTK motif (~150 amino acids); GAPs bind 
to active Ras GTPases and accelerate GTP hydrolysis (Grewal, Koese, Tebar, & Enrich, 
2011). It is possible that the lysate-treated Ras GTPases are activated by components in 
the lysate, thus resulting in a stronger interaction with BTK. Lysate treatment may have 
also resulted in the phosphorylation of Ras GTPase, which has previously been shown to 
promote GTPase activity and its association with GAPs (Bunda et al., 2014). 
RHOA Targets. The role of RHOA in cytoskeleton rearrangement and cell 
migration is well-established (Zegers & Friedl, 2014). Targets in the biological processes 
of cellular component movement, localization, and locomotion were enriched in 
interactions with higher binding affinities to active RHOA following lysate treatment. 
This target group was also enriched in the PI3K subunit gene family, which acts upstream 
of RHOA to promote cell migration (J. M. Kim, Kim, Lee, & Jeong, 2016; A. L. Zhang, 
Yan, Wang, Huang, & Liu, 2017).  
 
8.3.6   GTPase activation state affects binding partners and kinetics 
GTPases regulate a variety of biological processes, including cell proliferation, 
survival, migration, and growth. In vivo, they exist in two conformational states, an 
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inactive GDP- form and an active GTP-bound form (Kumawat, Chakrabarty, & Kulkarni, 
2017; Vetter & Wittinghofer, 2001). GTPase activation is accompanied by a structural 
change that occurs primarily by the switch I and II domains that bind to the γ-phosphate 
of GTP. The ~ 200 angstrom2 GTP-bound switch region is a focal point of most 
biomolecular interactions that mediate most downstream signaling (Dvorsky & 
Ahmadian, 2004). I therefore sought to better understand the effect of the two 
conformational states on protein partners, binding kinetics, and binding affinities. Two 
Rho GTPases sharing 60% sequence homology and that are important regulators of the 
BCR signaling pathway, RAC1 and RHOA, were chosen for this study. They were 
inactivated and activated with GDP and non-hydrolyzable GTP (i.e., GTPγS), 
respectively. Since RAC1 and RHOA have intrinsic GTP hydrolysis, the use of 
hydrolyzable GTP would have resulted in mixed signals arising from inactive and active 
GTPase interactions.  
Active GTPases interacted with more proteins than inactive GTPases. In this 
study, RAC1 and RHOA interacted with 95 and 97 targets, identifying 96% known 
interactions and 166 (86%) novel interactions. Both GTP-bound RAC1 and RHOA had 
significantly more protein 
interactions than their GDP-
bound counterparts (Figure 
75), which is consistent with 
the idea that active GTPases 
mediate most downstream 
Figure 74. Active Rho GTPases, RAC1 and RHOA, interacted with more 
proteins than inactive Rho GTPases. 
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effectors. Ninety-two percent (92%) of the targets that interacted with inactive GTPases 
also interacted with their active forms. The primary difference between the inactive and 
active states of RAC1 and RHOA is that they interacted with 38% and 171% more 
targets, respectively, when active. Additional Venn diagrams are in Appendix M. 
Some of these data are supported by a recent study by Paul et al. that examined 
the interaction partners of RAC1 and RHOA using affinity purification mass 
spectrometry (Paul et al., 2017). In short, the GTPases were expressed in E. coli with an 
N-terminal GST tag, purified with a glutathione column, loaded with GDP or GTPγS to 
inactivate or activate them, respectively, and then incubated in the lysate of mouse brain 
tissue. Mass spectrometry analyses were then performed following pull-downs in 
triplicate. Like the NAPPA-SPRi data, Paul et al. identified more novel interactions 
(82/116; 71%) than known interactions. They also observed that RAC1 and RHOA had 
8- to 3.5-fold more interactions, respectively, when active. They did not, however, detect 
the same protein partners of the inactive and active forms. This is surprising since GDP- 
and GTP-bound GTPases have been demonstrated to interact with some of the same 
proteins (Bos, Rehmann, & Wittinghofer, 2007; Cotton et al., 2007). Other differences 
between our two studies are worth mentioning. NAPPA-SPRi detected 43% more 
interactions than the study performed by Paul et al. and, since their pool of target proteins 
theoretically includes all expressed proteins, NAPPA-SPRi also detected more known 
interactions. Ninety-six percent (96%; 26/27) of the possible known interactions of RAC1 
and RHOA were detected with NAPPA-SPRi whereas Paul et al. detected 49% (34/69) of 
the protein interactions curated by the online BioGRID database for mice. Finally, their 
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affinity purification method selects for stable interactions and it cannot characterize the 
interactions in terms of their binding kinetics of affinities.  
 Inactive and active GTPases interacted with NP- and LT-targets differently. 
As discussed in sections 8.3.4 and 8.3.5, GTPase activation affected the binding 
interactions with NP- and LT-targets (Figure 76, Appendix Q). Inactive RAC1 bound to 
14% more LT- targets than NP- targets. However, active RAC1 and RHOA interacted 
with 22% and 26% more NP-targets than LT-targets. Inactive RHOA, on the other hand, 
interacted with 600% more NP-targets than LT-targets. This binding profile of inactive 
RHOA has not been reported by others, which is likely because the majority of known 
RHOA interactions are from studies employing active RHOA; for example, the study by 
Paul et al. discussed above (Paul et al., 2017). These results suggest that inactive RHOA 
may play a more significant role in regulating unphosphorylated proteins – perhaps in 
unstimulated cells where RHOA activation and protein phosphorylation are minimal – 
Figure 75. Venn diagram comparing the PPIs between inactive and active GTPases with (left) NP-target proteins and 
(right) LT-target proteins. 
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than previously believed. Inactive and active RAC1 GTPase had significantly different 
kinetic profiles with NP- and LT- targets as well (Figure 70, Figure 71). The effect of 
lysate treatment of the target proteins affected binding with GDP-bound RAC1 by 
increasing the affinity, which was mostly associated with small increases in its on-rates 
and decreases in its off-rates.  
Among the most dramatic observations in my study was the effect of lysate 
treatment on the target interactions with active RAC1. Lysate treatment significantly 
slowed both on and off rates of binding to active RAC1, but in direct proportion to each 
other. Thus, even though the magnitude of difference in binding to RAC1 between 
dephosphorylated and lysate-treated protein was often more than 220-fold, there was 
almost no change in the dissociation constant (i.e., binding affinity). This suggests that 
phosphorylation specifically regulates the interaction rates among proteins without 
changing the fraction of proteins bound!   
Lysate treatment resulted in both lower and higher binding affinities with active 
RHOA, which were primarily associated with slower on-rates or slower off-rates, 
respectively (Figure 72). Overall, the changes in binding kinetics were minimal, although 
for ~24% of the interactions, the average on- or off-rates decreased by 17-fold and 35-
fold, respectively, with a 21-fold change to the binding affinities. The binding affinities 
of inactive and active RAC1, on the other hand, were small (i.e., average 1.48-fold 
change) compared to binding kinetics that decreased, on average, > 200-fold with lysate 
treatment.  
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Similar to the effect of 
target de-phosphorylation, 
GTP-bound RAC1 interactions 
had faster on- and off-rates than 
their GDP-bound counterparts 
with moderate alterations to the 
binding affinity (Figure 77, 
Figure 78, Appendix Q). The 
increase in on- and off-rates 
were amplified upon RAC1 
activation compared to the 
effect of target de-
phosphorylation. More 
specifically, the GDP → GTP 
transition with LT- targets 
increased the average on-rates and 
off-rates by 25- and 64-fold, respectively, while the average binding affinity decreased 
3.3-fold (not including the RAC1-VAV1 interaction) (Figure 77). However, for 31% 
(17/55) of RAC1’s interactions with LT- targets, the on- and/or off-rates increased by > 2 
orders of magnitude. That is, RAC1 activation increased the overall on- and off-rates in 
this group by 4.5 and 5.1 orders of magnitude, respectively, with only a decrease in 
binding affinity by 1.3-fold. This effect was enhanced with NP- targets where the average 
Figure 76. Bar plots showing the relative log10 change in kd, KD, 
and ka of all PPIs with inactive and RAC1 to LT-targets. 
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on- and off-rates increased by 3.9 
and 4.2 orders of magnitude, 
respectively, with an average 
increase in binding affinity by 
1.9-fold for 98% of the 
interactions (Figure 78). This 
novel kinetic regulation cannot 
be detected using classic 
equilibrium-based assays. It is 
also interesting that RAC1 
activation significantly increased 
its interactions with NP- targets as well. That is, RAC1’s interactions with LT- targets 
increased only 16% after activation while increasing 61% for NP- targets. 
Surprisingly, RHOA activation did not significantly affect the binding kinetics or 
affinities with NP- targets. On average, the on-rate increased 1.8-fold, the off-rate 
decreased by 1.25-fold, and the binding affinity decreased 1.9-fold (Figure 79). This 
kinetic regulation was different from the regulation following lysate treatment, which 
either increased the on-rates or decreased the off-rates to increase the binding affinity. 
Inactive and active RHOA interacted with the same five NP- and LT-targets, resulting in 
a small group for comparison. However, changes to binding affinities following RHOA 
Figure 77. Bar plots showing the relative log10 change in kd, KD, and 
ka with inactive RAC1 compared to active RAC1 to NP-targets. Bar 
plots showing all of the PPIs with NP- and LT-targets are in Appendix 
P. 
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activation were associated with 
changes in the on-rate (Appendix 
P). Although RHOA activation 
did not significantly affect its 
binding kinetics or affinities, it 
increased RHOA’s interactions 
by 160% with NP- targets (i.e., 
91 vs 35) and 1340% with LT- 
targets (i.e., 67 vs 5). 
 In summary, RAC1 and 
RHOA are both Rho GTPases, but have different protein partners and kinetic profiles. 
RAC1 activation results in faster on- and off-rates with relatively little change in affinity. 
This effect was observed with nearly all of its interactions with unphosphorylated targets 
while only affecting 31% of lysate-treated targets. In regards to its biological 
consequences, faster association rates allow RAC1 to interact competitively with targets 
with much higher efficiency than inactive RAC1. It also allows RAC1 to sample more 
interactions in a shorter amount of time. Faster dissociation rates allow proteins like 
GAPs access to RAC1 to negatively regulate its signaling. RAC1 activation also allows it 
to interact with many more unphosphorylated targets. RHOA activation causes moderate 
alterations in its on- and off-rates and binding affinities. Notably, activated RHOA 
demonstrated binding to many more proteins than inactive RHOA, suggesting that 
activation expands its target range.  
Figure 78. Bar plots showing the relative log10 change in kd, KD, and 
ka with inactive RHOA compared to active RHOA to NP-targets. Bar 
plots showing all of the PPIs with LT-targets are in Appendix P. 
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Disorder-to-order transitions might explain faster binding rates of active 
GTPases to unphosphorylated proteins. Both active RAC1 and RHOA experienced 
faster on-rates with NP-targets than LT-targets. The dissimilar kinetics between NP- and 
LT-targets suggest that the targets are being modified by the B cell lysate, most probably 
via phosphorylation. Phosphorylation increases the local negative charge and, at least 
around the phosphosite, stimulates a disorder-to-order transition via the formation of salt 
bridges and hydrogens between the phosphate and neighboring residues (Nishi et al., 
2011; Nishi et al., 2014; Raggiaschi, Gotta, & Terstappen, 2005). This is particularly 
relevant for the phosphorylation of serine and threonine residues where the majority of 
phosphorylation occurs (i.e., 65 – 99%, depending on the source) and which are 
frequently found in disordered and flexible regions. Thus, these kinetic profiles may be 
explained by a variation of the “fly-casting” hypothesis, which was originally proposed in 
2000 by Shoemaker et al. (Shoemaker, Portman, & Wolynes, 2000). The hypothesis 
states that unfolded, intrinsically disordered proteins (IDPs), characterized by 
composition biases toward polar and charged amino acids and low sequence complexity, 
can bind to other proteins faster because they have a larger capture radius; the bound 
protein can then be “reeled in” (Uversky, 2013; Wright & Dyson, 2015). Subsequent 
experiments indicate that IDPs with some pre-formed structure generally do have faster 
on-rates and that IDPs can be very selective about their binding partners (Mollica et al., 
2016). While NP-targets are not IDPs, I speculate that the binding interfaces of NP-
targets are more disordered and flexible prior to phosphorylation with lysate treatment. 
Notably, not all of the interactions with active RAC1 and RHOA behaved this way; 
  
187 
somes on-rates did not change while others actually decreased following lysate treatment. 
A possible explanation is that the phosphorylation either does not affect the binding 
interface or induces a disorder-to-order transition at the binding site(s).                                                                                       
 
8.3.7   Comparison of protein-protein interactions between NanoBRET and NAPPA-
SPRi. 
Protein interactions identified with NAPPA-
SPRi were compared with those obtained with the 
qualitative, bioluminescence-based platform, 
NanoBRET (see Chapter 3.4.3, page 53). Forty 
percent (40%; 328/818) of all interactions and 41% 
(286/702) of novel interactions detected with 
NAPPA-SPRi were also detected with NanoBRET 
(Table 18, Figure 80) (additional Venn diagrams are 
in Appendix O). NAPPA-SPRi detected 473 unique 
interactions across all seven queries while 
NanoBRET only detected 305. NAPPA-SPRi likely 
detected 55% more interactions than NanoBRET 
because it can analyze interactions in real-time across a wide range of on-rates, off-rates, 
and binding affinities whereas NanoBRET signal is determined by the number of bound 
proteins at equilibrium.  
Figure 79. Venn diagram of protein 
interactions detected by NanoBRET and 
NAPPA-SPRi.  
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In both NAPPA-SPRi and NanoBRET analyses, GTP- bound RAC1 had more 
protein partners than GDP-bound RAC1 (38% and 43% more PPIs, respectively). 
NAPPA-SPRi also detected significantly more interactions with activated RHOA than 
inactivated RHOA (271%), although no difference between activated and inactivated 
RHOA was observed with NanoBRET (3%).  
 
Table 18. PPIs that were observed by NanoBRET and NAPPA-SPRi 
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8.3.8   Novel interactions detected by NAPPA-SPRi and NanoBRET 
BTK-ETS1 interaction. Both NAPPA-SPRi and NanoBRET detected a novel 
interaction between BTK and the transcription factor, ETS1, which inhibits B cell 
differentiation into plasma cells and decreases autoantibody tolerance (Figure 81) 
(Russell et al., 2015). Several studies have demonstrated that ETS1 downregulation in 
activated B cells is dependent upon BTK (Gutierrez, Halcomb, Coughran, Li, & 
Satterthwaite, 2010; Luo et al., 2014). In one study, transgenic mice were generated 
expressing different levels of BTK and ETS1. Increased BTK expression levels resulted 
in decreased expression of ETS1, and vice versa (Mayeux et al., 2015). Thus, a 
functional, but not physical or biochemical, relationship between BTK and ETS1 for 
maintaining plasma cell homeostasis has been established. This study shows that BTK 
and ETS1 bind to each other in vitro. It is also possible that the proteins physically 
interact with each other in vivo because they are both in the cytoplasm and nucleus. This 
interaction is discussed in more detail in the next section (Chapter 8.3.9).  
Figure 80. Novel BTK-ETS1 interaction detected by NAPPA-SPRi and NanoBRET. NAPPA-SPRi binding 
sensorgram (left) and NanoBRET response (right), where error bars represent the range of response across technical 
replicates. 
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 BLNK-PTEN interaction. Another novel interaction that was detected by 
NAPPA-SPRi and NanoBRET was between the adaptor protein, BLNK, and the 
phosphatase and tumor suppressor, PTEN (Figure 82). PTEN is a negative regulator of 
PI3K signaling and, as such, is a negative regulator of the BCR signaling pathway as 
well. More specifically, PTEN reverses PI3K’s effect by dephosphorylating the PI3K 
substrate, PIP3, back to PIP2 (Milella et al., 2015). PTEN also has roles that are 
independent from PI3K and phosphatase activity, including contributing toward 
centrosome stability in the nucleus. While the BLNK-PTEN interaction has not been 
reported previously, another phosphatase that is a negative regulator of the BCR 
signaling pathway and a PIP3 phosphatase, PTPN6, has been demonstrated to de-
phosphorylate BLNK. De-phosphorylation of BLNK by PTPN6 modulates BLNK’s 
ability to bind other proteins, which results in a decrease of MAPK8 (i.e., JNK) kinase 
activity. Therefore, it’s possible that PTEN binds to BLNK in order to alter its 
phosphorylation and PPIs. PTEN’s PI3K-independent roles in B cells have not been 
explored but may have relevance in B cell-related cancers that have PTEN deficiencies, 
Figure 81. Novel BLNK-PTEN interaction detected by NAPPA-SPRi and NanoBRET. NAPPA-SPRi binding 
sensorgram (left) and NanoBRET response (right), where error bars represent the range of response across technical 
replicates. BLNK interacted with NP- and LT-PTEN; LT-PTEN data not shown. 
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including diffuse large B cell lymphoma, mantle cell lymphoma, and primary cutaneous 
follicle center lymphomas (X. X. Wang, Huang, & Young, 2015). 
 Active RHOA-IKBKA interaction. In both NAPPA-SPRi and NanoBRET 
analyses, GTP-bound RHOA, but not GDP-bound RHOA, interacted with IKBKA 
(Figure 83). The connection between RHOA and the NFκB pathway has been well-
documented (H. J. Kim, Kim, Moon, Park, & Park, 2014; Tong & Tergaonkar, 2014). 
Central to the NF-κB pathway is the IκB complex that is composed of two 
serine/threonine kinases (IKBKA, IKBKB) and one scaffold protein (IKBKG) (Woyach 
et al., 2012). IKBKA or IKBKB activation results in the phosphorylation – and 
subsequent degradation – of proteins that bind to and sequester the transcription factor 
NFκB in the cytoplasm. Once the inhibitor proteins are degraded, NFκB translocates into 
the nucleus where it regulates the transcription of genes involved in cell proliferation, 
class switching, survival, and the secretion of pro-inflammatory cytokines (Carlberg, 
2016). RHOA, through its downstream kinases, has previously been demonstrated to 
increase the transcriptional activity of NFκB in the NFκB pathway (Shih, Tsui, Caldwell, 
& Hoffmann, 2011). These data indicate that active RHOA may have a more direct 
Figure 82. Novel RHOA-IKBKA interaction detected by NAPPA-SPRi and NanoBRET. NAPPA-SPRi binding 
sensorgram (left) and NanoBRET response (right), where error bars represent the range of response across technical 
replicates. NanoBRET response for GDP-bound RHOA and IKBKA is -0.00992. 
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involvement with the NFκB pathway by binding to IKBKA. The RHOA-IKBKA 
interaction may provide insight into the upstream events leading to non-canonical NFκB 
activation and explain why RHOA is essential in B cell development (S. M. Zhang, Zhou, 
Lang, & Guo, 2012)   
 
8.3.9   Validation of novel protein-protein interactions 
  Analyzing protein interactions with unphosphorylated and lysate-treated 
“phosphorylated” targets presented a unique opportunity to look for potential novel 
phosphorylation events based off of distinct kinetic profiles between the two datasets. In 
this section, four novel interactions that appeared to involve the phosphorylation of a 
target by BTK or PI3K were validated. The interactions were analyzed using zinc-based 
Phos-TagTM SDS-PAGE separation in which zinc attached to highly cross-linked agarose 
inhibits the migration of phosphorylated species more than standard SDS-PAGE. The 
gels were then transferred for Western blot analyses using target-specific antibodies.  
BTK-JUN interaction. On the NAPPA-SPRi platform, the on-rate and binding 
response of the BTK query 
with JUN were much higher 
with NP-JUN than LT-JUN 
(Figure 84). This suggested 
that BTK may be 
phosphorylating JUN, a 
transcription factor that controls 
Figure 83. NAPPA-SPRi binding sensorgram of the BTK query binding 
JUN with a fusion tag at the C-terminus. 
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the expression of genes involved in cell proliferation, 
apoptosis, transformation, differentiation, and 
development, were  (de Gorter, Vos, Pals, & 
Spaargaren, 2007). A migration shift was observed 
only when JUN was mixed with BTK and ATP (Figure 
85). Addition of phosphatase to the mixture ensured 
that the migration was the result of a phosphorylation 
event.  
In pre-B-lymphoblastic lymphoma cells, BTK 
knockdown inhibited JUN expression (Hiratsuka et al., 2016). Both BTK and JUN are 
also often overexpressed in splenic marginal zone lymphoma and Hodgkin disease 
(Mathas et al., 2002; Troen et al., 2004). Therefore, BTK-mediated phosphorylation may 
make JUN more resistant to proteases. Interestingly, the only tyrosine known to be 
phosphorylated on JUN, Y170, protects JUN from ubiquitination-mediated degradation 
(Gao, Lee, & Fang, 2006; Hornbeck et al., 2015). BTK may be phosphorylating JUN at 
this site. 
This interaction was not detected by NanoBRET. One possible reason is that JUN 
may have been phosphorylated by components in the cell-free expression system before 
BTK was added. Another possibility is that the interaction between BTK and JUN was 
simply too transient to be detected since NanoBRET signal, as an equilibrium-based 
assay, is determined by the number of bound proteins at equilibrium. These data also 
Figure 84. Western blot image showing 
that BTK phosphorylates JUN. Black 
triangle marks migrated JUN band due to 
phosphorylation. 
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highlight the utility of NAPPA-SPRi in detecting novel, transient interactions in regards 
to post translational modifications like phosphorylation. 
BTK-BCL2 interaction. 
BTK also interacted with BCL2, an 
important anti-apoptotic protein, on 
the NAPPA-SPRi platform with 
different binding profiles when 
BCL2 was de-phosphorylated and 
lysate-treated (Figure 86). This 
interaction was also not detected with NanoBRET, 
further demonstrating the usefulness of NAPPA-SPRi in 
detecting phosphorylation events. BCL2 
phosphorylation was validated with Phos-Tag Western 
blot analysis using an anti-BCL2 antibody and 
subsequent phosphatase treatment (Figure 87). Two 
migrated BCL2 bands, one heavy and one light in 
intensity, might reflect two different phosphorylation 
events.  
A functional relationship between BTK and BCL2 has been demonstrated using 
BTK small molecule inhibitors, in which BTK inhibition increases a cell’s sensitivity to 
the anti-apoptotic effects of BCL2 (Deng et al., 2015). Moreover, the use of BTK and 
BCL2 inhibitors in combination successfully killed chronic lymphocytic leukemia (CLL) 
Figure 85. NAPPA-SPRi binding sensorgram of the BTK query 
binding JUN with a fusion tag at the N-terminus. 
Figure 86. Western blot image that 
shows BTK phosphorylates BCL2. 
Black triangle marks migrated BCL2 
band due to phosphorylation. 
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cells ex vivo (Davids, 2017). Several clinical trials using BTK and BCL2 inhibitors in 
conjunction to treat chronic lymphocytic leukemia (CLL) are underway even though the 
biochemical relationship between BTK and BCL2 is not understood. The novel BTK-
mediated phosphorylation of BCL2 identified in this study may inhibit BCL2’s 
subcellular location or activity. Phosphorylation of other proteins in the BCL2 family 
have been demonstrated to affect their translocation to the outer mitochondrial 
membrane, interactions, and activity (Schinzel, Kaufmann, & Borner, 2004).  
BTK-ETS1 interaction. Both NanoBRET and NAPPA-SPRi detected the 
interaction between BTK and ETS1 (Figure 81). Although BTK can have kinase-
independent roles, the distinct binding profiles with unphosphorylated and lysate-treated 
ETS1 suggested that BTK may be phosphorylating ETS1, a transcription factor that is 
essential in B cell differentiation and tolerance (Figure 88) (Middendorp, Dingjan, Maas, 
Dahlenborg, & Hendriks, 2003; Russell et al., 2015; Saito et al., 2003). That is, BTK 
binds strongly to the unphosphorylated form 
and releases the lysate-treated form rapidly, 
which would be expected of a kinase binding 
its unmodified substrate, and then releasing it 
after the modification. As the Western blot 
image in Figure 88 shows, ETS1 does not 
experience any migration shifts in the 
absence of BTK or ATP. In the presence of 
BTK and ATP, however, a migrated band is 
Figure 87. Western blot image showing that BTK 
phosphorylates ETS1. Black triangle marks migrated 
ETS1 band due to phosphorylation. 
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observed. To verify that the shift was due to phosphorylation, the BTK-ETS1-ATP 
sample was treated with lambda protein phosphatase.  
Previous studies have shown that ETS1 phosphorylation events can inhibit or 
promote DNA binding, make ETS1 more protease resistant, or have no effect (Cowley & 
Graves, 2000; Lu et al., 2014). It’s already been established that BTK downregulates 
ETS1 expression in activated B cells as well as B cells in diffuse large B cell lymphoma, 
Burkitt’s lymphoma, and Hodgkin disease (Mayeux et al., 2015; Testoni, Chung, Priebe, 
& Bertoni, 2015). It is thus possible that BTK-mediated phosphorylation makes ETS1 
more prone to degradation. 
PI3K directly phosphorylates myc at serine 62.  In a manner similar to those 
examples described above, PI3K favored binding with unphosphorylated MYC over the 
lysate-treated form on the NAPPA-SPRi platform (Figure 89). This interaction was 
detected with NanoBRET as well (Figure 90). MYC is a transcription factor that is 
dysregulated in 70% of all cancers with two well-studied phosphorylation sites that affect 
its stability: serine 62 and threonine 58. Phosphorylation of serine 62 by Erk and Src 
Figure 88. NAPPA-SPRi binding sensorgram of PI3K 
query binding to MYC. 
Figure 89. PI3K-MYC interaction detected by 
NanoBRET 
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family kinases increases MYC’s half-life, 
while phosphorylation of threonine 58 by 
GSK3B promotes its degradation. Previous 
studies have shown that PI3K indirectly 
inhibits MYC’s degradation by activating 
AKT1, a serine/threonine kinase that inhibits 
GSK3B. This may account for the observation 
that sustained PI3K activity and MYC 
overexpression result in cancer. However, no 
known direct physical or biochemical relationship between the two proteins have been 
previously reported. Here, PI3K-mediated phosphorylation of MYC was validated with 
Western blot analyses, demonstrating that PI3K also inhibits MYC’s degradation by 
directly phosphorylating MYC at serine 62 (Figure 91). 
Using NAPPA-SPRi, four interactions that appeared to be novel phosphorylation 
events based on distinct binding responses with NP- and LT-targets were identified. 
These were then validated using SDS-PAGE migration and Western blot analyses. 
Notably, only two of these interactions, BTK-ETS1 and PI3K-MYC, were also observed 
with NanoBRET. The interactions, BTK-JUN, BTK-BCL2, BTK-ETS1, and PI3K-MYC, 
include proteins that are important in maintaining homeostasis. Therefore, their 
interactions have potentially real and direct applications to human health and disease. 
Follow-up experiments to determine whether these events occur in vivo, the location of 
Figure 90. Western blot demonstrating that PI3K 
phosphorylates MYC at serine 62. 
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the phosphorylation site(s), and the biological consequences of these phosphorylation 
events are needed. 
 
8.3.10   Identification of promiscuous proteins 
Proteins have traditionally been considered to be specific in which proteins they 
bind. However, protein promiscuity – or the ability to bind other proteins in a nonspecific 
or broad manner -- in biological processes and evolutionary fitness has only recently 
become appreciated. Proteins hubs essential in maintaining homeostasis and often 
disrupted in disease, like p53, p21, BRCA1, and ubiquitin, are promiscuous by definition 
because they have a disproportately high connectivity in protein networks (Patil, 
Kinoshita, & Nakamura, 2010). Lab-directed evolution experiments in 2005 and 2011 
that used error-prone PCR and gene amplification in E. coli demonstrated that evolution 
selects for promiscuous proteins and that promiscuity increases fitness (Aharoni et al., 
2005; Soo, Hanson-Manful, & Patrick, 2011). Promiscuous proteins are therefore likely 
to be more prevalent than traditionally believed, and the identification of such proteins 
may help to understand the molecular mechanisms underlying homeostasis, disease, and 
drug resistance. In this NAPPA-SPRi study, the number of interactions for each query 
and target protein widely differed from each other, thus suggesting a possible advantage 
of using this platform to identify novel protein hubs.  
This study identified target proteins that behaved promiscuously by binding to 
queries > 12 times out of the 14 different query-target conditions. The eleven targets 
included AKT1, BCL2A1, ETS1, IKBKB (Ref Seq ID: BC108694), IKBKG, MAPK1, 
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MAPK13, MYC, NCKAP1L, RAP2C, and RHOA. Six of these target proteins were also 
shown to bind to at least 5 (out of 7) different queries in the NanoBRET analyses: AKT1, 
BCL2A1, IKBKB (Ref Seq ID: BC108694), IKBKG, MAPK13, and MYC.  
At the other end of the promiscuity spectrum, there were some target proteins that 
bound to very few proteins. LIME1, NFATC3, PIK3CD, PPP3CC, and RAP1A bound to 
< 2 queries out of the fourteen query-target conditions. RAP1A also displayed non-
promiscuous behavior in the NanoBRET analyses, binding to two of the seven queries.  
To help determine whether these differences 
were real or artefacts from the experimental set-up, 
the number of previously reported PPIs curated by 
the online database, BioGRID, was determined for 
the proteins identified as “non-promiscous” (i.e., 
low number of interactions) and “promiscuous” 
(i.e., high number of interactions) using NAPPA-
SPRi (Figure 92) (Stark et al., 2006). Promiscuous 
proteins had an average of 177 unique human 
protein interactions that have been previously 
reported, with AKT1, IKBKB, MYC, and MAPK1 
having as many as 315, 327, 618, and 249 interactions, respectively. Non-promiscuous 
proteins, on the other hand, had an average of 31.4 unique protein interactions, with 
RAP1A having the most PPIs (i.e., 87) amongst this group. Some of the proteins 
identified as promiscuous, including BCL2A1, IKBKG, NCKAP1L, and RAP2C, had a 
Figure 91. Number of unique human protein 
interactors with the target proteins identified 
as promiscuous and non-promiscuous with 
NAPPA-SPRi. Horizontal line represents the 
mean data point for each group. 
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low number (< 20) of documented interactions in BioGRID. It is possible that these 
proteins bind many protein partners, but have not been studied to the same extent that 
AKT1, IKBKB, MYC, and MAPK1 have been. Taken together, these data suggest that 
the identification of novel protein hubs may be possible with NAPPA-SPRi.  
No common domain, motif, or biological function among this group of proteins 
can explain their promiscuous behavior. However, a study of 305 enzymes by 
Chakraborty et al. revealed that > 80% promiscuous proteins have > 39% polar (or > 20% 
charged) residues within 3 angstroms of the active site (p-value ~ 0.05) (Chakraborty & 
Rao, 2012). A weaker correlation was obtained regarding the features of the residues (i.e., 
basic, acidic, polar, charged) around the active site, such that the promiscuity was highest 
for charged residues and lowest for acidic residues. Thus, the promiscuity of the proteins 
in this study may be explained by the presence of charged residues around their binding 
sites rather than a specific domain or motif. 
 
8.4   Conclusions 
Here, a high throughput, quantitative method, NAPPA-SPRi, was applied toward 
studying protein interactions within the BCR signaling pathway. The platform detects 
distinct interactions, kinetics, and affinities depending on protein phosphorylation, 
GTPase activation state, protein isoform, and tag location. The differing kinetics indicate 
that the data are not the result of artefacts, but actually reflect the exquisite regulation of 
protein interactions to propagate signal. The vast majority of the interactions (85%) 
detected with NAPPA-SPRi were novel. The high overlap of novel interactions between 
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NAPPA-SPRi and NanoBRET as well as novel phosphorylation events validated with 
Western blot analyses reveal that the BCR signaling pathway – which is considered to be 
one of the better understood pathways – is still largely unmapped. Moreover, the kinetic 
profiles of RAC1 underscore the importance of measuring the on- and off-rates as this 
unique method of regulation would not be detected using methods that only measure 
binding affinity or simply determine which proteins bind to RAC1. Interestingly, the 
effect of tag location on binding may help provide information regarding binding 
epitopes and, theoretically, could help build structural networks by distinguishing which 
protein interactions are competitors or non-competitors with each other. 
As an in vitro platform, the NAPPA-SPRi data may not accurately represent what 
is occurring in vivo. First, NAPPA-SPRi allows protein interactions to occur that would 
otherwise be impossible due to the proteins’ in vivo subcellular locations. Since the 
subcellular location(s) of a vast majority of proteins have already been experimentally 
determined, however, this information could help filter out PPIs that could not, or are less 
likely to, occur in vivo. A larger concern perhaps is the high macroscopic viscosity of the 
cytoplasm, which affects the rotational movement and long-range diffusion of proteins, 
such that the concentration and location of a protein-of-interest may vary from one spot 
to another within a cell (Schreiber et al., 2009). The intracellular viscosity has also led 
scientists to estimate that the binding on-rates for most proteins to cannot exceed ~ 107 M-
1s-1 in vivo (Pollard, 2010). Therefore, interactions identified in this study with extremely 
fast on-rates are not likely to occur in vivo (e.g., active RAC1 with NP-targets). Second, 
the immobilization of the target proteins could affect their conformation and, as a 
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consequence, their binding interactions. Indeed, there is evidence that kinetic values of 
PPIs obtained with SPR may differ from those obtained in solution (Schreiber et al., 
2009). Third, NAPPA-SPRi, like many other methods that study PPIs, uses a fusion tag 
to capture the expressed target proteins to the slide surface. These could affect a protein’s 
native conformation and block binding epitopes. One of these concerns was addressed by 
representing each target protein with a tag on the N-terminus or C-terminus, such that 
binding epitopes that may be blocked in one configuration could be available in the 
second. Fourth, the aqueous environment of NAPPA-SPRi is not well-suited for 
membrane proteins, which is why our study focused particularly on soluble proteins. 
Fifth, the buffers and cofactors were selected based on the query that was used; however, 
these do not accurately represent in vivo conditions. For example, intracellular GTP is 
roughly ten times higher than GDP. The non-hydrolyzable GTP (i.e., GTPγS) was also 
used to study the interactions of active GTPases in some of these experiments; no GTP or 
GDP were supplied. While exteme conditions were used in our experiments (e.g., 
completely unphosphorylated target proteins, GTPγS-bound GTPase queries), it is 
important to mention that these were necessary so that we could document the different 
behaviors in each state. Finally, some proteins expressed as separate spots on the array 
are usually found as heterodimers or complexes in vivo. These would include the 
regulatory and catalytic subunits of PI3K and calcineurin A; the heterodimer NFKB1-
RELA; and the complex CARD11-BCL10-MALT1. It is possible, however, that proteins 
in the human cell-free expression system may bind and stabilize these monomers.  
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Standard SPR experiments generally use five to seven different concentrations of 
the query spanning as much as seven orders of magnitude to obtain absolute binding 
kinetics. These types of experiments are made possible through a cost-effective approach 
of regenerating the surface of the slide after each query concentration, which removes all 
residual query proteins from the slide. Regeneration is ideal for experiments in which 
peptides or antibodies are immobilized on the surface since these are stable to 
regeneration conditions that use acidic, basic, or high salt buffers. As such, regeneration 
may not be appropriate for some experiments as the buffers may negatively affect protein 
structure and, consequently, their protein interactions and binding kinetics. Regeneration 
was not performed in the NAPPA-SPRi experiments out of concern that the regeneration 
buffers were too harsh for the target proteins. An alternative approach called “kinetic 
titration” was explored, in which the query is added to the surface in increasing 
concentrations with no regeneration step. Unfortunately, NAPPA-SPRi is not compatible 
with kinetic titration due to the low amount of protein that is displayed (see Chapter 
4.4.5). Two different query concentrations with NAPPA-SPRi were therefore tested in 
order to keep the experimental costs within budget. Since the standard five to seven 
different query concentrations were not used and some of the kinetic values obtained in 
this study were outside the linear detection range of the SPRi instrument (ka = 103 to 107 
M-1s-1; kd = 10-5 to 10-1 s-1; KD = 10-4 to 10-12 M), these results cannot be considered to 
be absolute kinetic values. Rather, these values are relative to each other and still 
represent the altered kinetics and affinities as the result of phosphorylation and protein 
activation states.  
  
204 
In these experiments, target protein phosphorylation was controlled by de-
phosphorylating the proteins with phosphatases or phosphorylating them using B cell 
lysate from Ramos RA-1 B cells (spiked with protease and phosphatase inhibitors). 
Ramos is a Burkitt’s lymphoma cell line that is negative for the Epstein-Barr virus. As 
such, its phosphorylation of the target proteins – and their protein interactions – represent 
a diseased state at a specific point in time. It is likely that the use of a different cell line 
would result in unique PPIs and kinetics.  
Wild-type Rho GTPases were used in this experiment because I wanted to directly 
compare how GTPase activation states affected their interactions. Constitutively active or 
dominant negative mutant GTPases could have been used instead. However, they are 
structurally different than their wild-type counterparts, thereby making their kinetic 
analyses outside the scope of this study (Davis et al., 2013; Kumawat et al., 2017). 
Follow-up experiments of GTPase mutants, particularly those that are relevant in disease, 
would be interesting (Porter, Papaioannou, & Malliri, 2016). 
This large-scale study enabled a unique perspective into the effect of protein 
phosphorylation on PPIs that would not be identified in low throughput experiments. The 
NAPPA-SPRi data show that phosphorylation does not determine whether most protein 
interactions occur or not occur, but rather affects their binding kinetics. Biologically, 
alterations to the on- and off-rates would have significant effects in signal transduction. 
Faster on-rates, for example, would provide an advantage to proteins that are competing 
for the same binding epitope. Slower off-rates would lengthen the effect of the PPI, 
whether it be to activate or inhibit downstream signaling. Faster off-rates would allow 
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regulatory proteins to turn the signal off more quickly. The differential binding kinetics 
across the tested queries illustrate how proteins have different ways to regulate their 
interactions. 
Perhaps the most interesting kinetic results that were revealed in this study were 
those of RAC1. RAC1 activation did not change its binding affinities but increased its 
on- and off-rates by ~4 orders of magnitude with 31% of the LT-targets! In contrast, this 
phenomenon occurred with 98% unphosphorylated proteins. These data show that RAC1, 
a protein that regulates numerous pathways and biological outcomes, has a high 
competitive edge to propagate signaling while also being able to be turned off quickly. 
They also highlight the importance of measuring the kinetics because techniques that 
only calculate the binding affinity would not have been able to detect this important 
method of regulation. 
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CHAPTER 9 
9   CONCLUDING REMARKS 
 The term “interactome” to describe the interconnecting protein network was first 
coined by French researchers in 1999 (Ji, 2012). Since then, large-scale interaction maps 
have been constructed, illuminating the complexity of the human interactome and the 
potential to cause a paradigm shift in personalized and precision medicine by pinpointing 
attractive drug targets and determining the molecular events underlying disease initiation 
and progression. The abundance of complex information has also stimulated the 
development of mathematical models to understand the system behavior of signaling 
pathways. Unfortunately, computational models of cells and signaling pathways have 
thus far been built using qualitative experiments that are either inherently biased or 
provide little mechanistic insight. For example, proteins that are known to be involved in 
disease are studied more than proteins of unknown or poorly understood function, and 
highly abundant proteins and stable interactions are preferentially identified by current 
detection methods. With a paucity of kinetic and affinity data, modelers are forced to 
build algorithms from qualitative-based data, resulting in “best guess” approximations 
that could miss individual, yet critical binding kinetics that regulate signaling. Calculated 
kinetics guided by cellular responses may be misassigned to particular signaling 
components or diluted across multiple proteins. Finally, experiments in which proteins-
of-interest are perturbed and the cellular responses observed are essentially “black boxes” 
in which many of the molecular processes remain obscure (Aldridge, Burke, 
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Lauffenburger, & Sorger, 2006; Fumia & Martins, 2013; Heydari et al., 2017; Janes & 
Yaffe, 2006; Kirouac et al., 2012; Sachs, Perez, Pe'er, Lauffenburger, & Nolan, 2005b).   
The human interactome has been studied primarily through high throughput 
methods like yeast-2-hybrid and affinity purification mass spectrometry, which rely on 
stable protein interactions. However, transient interactions underlie important cellular 
processes, thus begging the question: How much of the interactome has been missed? To 
help answer this question, I first adapted a current, high throughput method capable of 
detecting transient and stable interactions in vivo, NanoBRETTM, to analyze protein 
interactions in vitro using proteins produced from a cell-free expression system. I then 
applied NanoBRET toward studying > 2500 interactions in the B cell receptor signaling 
pathway. Although this pathway is considered to be relatively well understood compared 
to other pathways (e.g., Hippo/Warts/FGF), 83% of the interactions detected by 
NanoBRET have not been previously reported. These data indicate that the human 
interactome is still largely unmapped. Unfortunately, NanoBRET, just like any other high 
throughput method, cannot characterize protein interactions in regards to their binding 
kinetics and affinities.  
Herein, I described the development of methods, technology, and software to 
determine the binding kinetics and affinities of protein interactions with and without 
target phosphorylation. These included: 
• Modulation of protein phosphorylation on NAPPA using phosphatases or 
activated B cell lysate. 
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• A platform that quantitatively characterizes > 400 protein-protein interactions 
simultaneously in < 1 hour by combining the high throughput and flexible 
nature of nucleic programmable protein arrays (NAPPA) with the 
quantitative ability of surface plasmon resonance imaging (SPRi). 
• Built automated “SPRite” software capable of analyzing high throughput 
SPR data. 
I then applied NAPPA-SPRi to study the kinetics and affinities of > 12,000 
protein interactions in the B cell receptor signaling pathway under different protein 
phosphorylation and GTPase activation states. NAPPA-SPRi detected 66% of known 
interactions and 401 novel interactions, 41% of which were also observed with 
NanoBRET. Notably, NAPPA-SPRi detected 55% more interactions than NanoBRET. 
NAPPA-SPRi data show that phosphorylation does not determine whether most (84%) 
protein interactions occur or not occur, but rather affects their binding kinetics and 
affinities, which appear to be uniquely modulated across proteins. Increased interactions 
upon RAC1 and RHOA GTPase activation align well with current understanding that 
active GTPases mediate most downstream pathways. RAC1 activation with 
nonhydrolyzable GTP-γS minimally affected its binding affinities but increased its 
overall on- and off-rates by ~4 orders of magnitude. This phenomenon was observed with 
31% of targets treated with activated B cell lysate capable of phosphorylation and 98% of 
unphosphorylated targets. This underscores the importance of measuring kinetics as 
equilibrium assays that simply measure binding affinities would not have detected this 
important method of regulation. 
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Four novel interactions that had significantly altered binding profiles to targets 
before and after lysate treatment were validated as phosphorylation-mediated events 
using SDS-PAGE and Western blot analyses. One of these interactions included two 
proteins that are frequently mutated in cancer, PI3K-MYC, but were not previously 
known to physically associate with each other. Instead, I show that PI3K directly 
phosphorylates MYC at serine 62, a phosphosite that is known to increase the half-life of 
MYC. Follow-up experiments are necessary to determine the phosphorylation sites of the 
other three interactions and what, if any, the biological effects of these interactions are in 
vivo.  
Target proteins are all represented equally on NAPPA-SPRi, thereby allowing 
interactions important in signal transduction to be identified that would otherwise be 
masked by interactions of highly abundant proteins in vivo. However, interactions in vivo 
are regulated in part by protein abundance. Thus, the abundance of proteins in the B cell 
receptor signaling pathway in four B cell lines, Ramos RA-1, Jeko-1, Rec-1, and Toledo, 
was determined with mass spectrometry analyses (data not shown). NAPPA-SPRi and 
mass spectrometry data are currently being incorporated into a virtual B cell model. 
Additional experiments will be required to determine whether the model can accurately 
predict proteomic – and possibly phenotypic – changes as the result of specific stimuli. It 
will be the first model of any signaling pathway built from large-scale, experimentally-
produced kinetic data. 
An accurate cell model has far-reaching consequences in medicine and science. It 
would – theoretically – be able to delineate the effects of genetic mutations on disease 
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pathology specific to the individual or tumor. Central protein hubs for signal transduction 
in homeostasis and disease would be identified. Alternate signaling pathways in treatment 
resistance would be known. With this knowledge in hand, drugs could be designed 
smarter and patients could be treated more effectively based on their unique genetic 
background, thereby resulting in a paradigm shift in personalized and precision medicine. 
Synthetic biologists interested in sustainable energy could re-engineer cyanobacteria to 
become highly efficient fuel producers. Tissue engineers could identify the components 
essential in cell-to-cell variability and signaling crosstalk. And virologists could use the 
generated information to develop safer and more effective vaccines for various diseases 
and bioterrorism incidents. 
In this thesis, NAPPA-SPRi was applied toward studying protein-protein 
interactions in the B cell receptor signaling pathway, but it could be used to study any 
interactions as long as the plasmid cDNA can be constructed. Since the proteins are 
produced using a cell-free expression system from numerous sources (e.g., human, wheat 
germ, E. coli), NAPPA circumvents disadvantages that are inherent in expressing 
proteins in vivo (e.g., toxic proteins) or in a non-homologous system. It can be imagined 
that NAPPA-SPRi could be expanded to drug screening and studying other signaling 
pathways, host-pathogen protein-protein interactions, and the effect of protein mutations 
on protein interactions. The array format would also be compatible with screening 
antibodies or validating protein functionality. Potential substrates of kinase 
phosphorylation could be screened. Altered binding based on the location of the fusion 
tag on NAPPA-SPRi may also assist in identifying binding epitopes. Membrane proteins 
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are not likely to be folded correctly on NAPPA due to their native hydrophobic 
environment, but their hydrophilic intracellular or extracellular protein domains could be 
displayed instead. I demonstrate that the phosphorylation of NAPPA proteins can be 
altered in a B cell-specific manner using lysate from activated B cells, but the methods 
developed and described herein could easily be used to study the effect of 
phosphorylation patterns from other cell types on protein interactions. Other post 
translational modifications could be studied with NAPPA-SPRi as well. Proteins 
displayed by traditional fluorescence-based NAPPA have been citrullinated and 
AMPylated for autoantibody and protein interaction studies, respectively, by adding 
peptidyl arginine deiminase 2 and AMPylators to the array (Karthikeyan et al., 2016; X. 
B. Yu & LaBaer, 2015). 
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240 
 
 
 
Table 19. Detailed list of human proteins in the BCR signaling pathway (continued on next page) 
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APPENDIX B 
PANTHER AND HGNC ANNOTATIONS 
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Table 20. Unique PANTHER biological processes, part 1 (to be cross-referenced to Table 22) 
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Table 21. Unique PANTHER biological processes, part 2 (to be cross-referenced to Table 23) 
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Table 22. Unique PANTHER biological processes, part 1 (to be cross-referenced to Tables 20 - 21) 
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Table 23. PANTHER biological processes of target proteins, part 2 (to be cross-referenced to Tables 20 - 21) 
  
247 
 
Table 24. Associated HGNC protein domains for each protein target, part 1 
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Table 25. Associated HGNC protein domains for each protein target, part 2 
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APPENDIX C 
KNOWN PROTEIN INTERACTIONS IN BIOGRID AND HPRD 
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Table 26. Known protein interactions with BLNK 
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Table 27. Known protein interactions with BTK 
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Table 28. Known protein interactions with PI3K* 
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Table 29. Known protein interactions with RAC1 
Table 30. Known protein interactions with RHOA 
  
254 
APPENDIX D 
SUPPLEMENTAL NANOBRET DATA 
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Table 31. Table of PPIs detected by NanoBRET, part 1 
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Table 32. Table of PPIs detected by NanoBRET, part 2 
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Table 33. Number of PPIs per NanoBRET query within the same PANTHER Biological Process 
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Figure 92. Enriched and under-represented PANTHER biological processes in BTK interactions compared to the other 
Y kinase queries 
 
Figure 93. Enriched and under-represented PANTHER biological processes in PI3K interactions compared to the other 
S/T kinase queries 
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Table 34. Number of PPIs per NanoBRET query within the same HGNC protein domain 
 
 
Figure 94. S/T kinases interacted with more targets in the cell surface receptor signaling pathway 
than Y kinases 
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Figure 95. S/T kinases interacted with more CD molecules than Y kinases 
 
Figure 96. BLNK interacted with more proteins with SH2 domains than DAPP1 
 
  
  
261 
APPENDIX E 
DIRECTIONS ON USING SPRITE TO ANALYZE SPR DATA 
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The SPRite script is a flexible software that can theoretically analyze an infinite 
number of protein interactions using the 1:1 Langmuir kinetic model with and without 
drift correction. This is in direct contrast to current software packages in which the 
binding curves must be fit manually in low throughput (e.g., BIAevaluation, Scrubber2). 
Although SPRite was developed to analyze high throughput NAPPA-SPRi data, it can be 
used for any SPR experiment (as long as the input file is correctly formatted). Below are 
directions on how to analyze SPR data with SPRite. 
 
Step 1: Set up computer to run SPRite 
2. Make a folder called “StanScripts” in your root directory e.g. c:\StanScripts 
3. Download the following files from the Mallick lab website, 
mallicklab.stanford.edu, and place in the “StanScripts” folder 
a. curveFittingKineticModels.py 
b. OffSets.txt 
c. parseSPRFileAndFitCurves.py 
d. StanScripts.yml 
4. Download and install Anaconda2 
5. Open Anaconda Prompt and navigate to the “StanScripts” folder 
cd c:\StanScripts 
6. Build the environment from the StanScripts.yml file 
conda env create –f StanScripts.yml –n StanScript 
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Step 2: Format data file 
1. Analyze SPR data in Plexera® Data Analysis Module software according to 
Plexera® instructions 
2. Export file as a tab delimited file. (An example of the file format is in Figure 
97.) 
a. Column A:  
i. Row 1: Name: Sample_Name   ID:    Set:    Family:    Group:    
Block: Position(must be a unique number)   Row: 1   Column: 
1 
ii. Row 2: Relative time (starts from 0 and continues to increase 
throughout the SPR analyses) 
b. Column B: 
i. Row 2: Raw intensity (This is the pixel intensity of the spot for 
each time segment) 
c. Column C: 
i. Row 2: Satellite Intensity (Sometimes regions around the spots 
are chosen by SPR users to act as a reference. The satellite 
intensity is the pixel intensity of these regions. Note that 
satellites were not used in the analyses.)  
d. Column D: 
i. Row 2: Subtracted Intensity (The Subtracted Intensity = Raw 
Intensity – Satellite Intensity) 
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e. Column E: Leave blank 
 
Figure 97. Format of input file from the Plexera® Data Analysis Module software for SPRite analyses in text tab 
delimited format. 
 
Step 3: Fit data 
1. Go to computer > SYSTEM (C:) > StanScripts 
2. Place correct input file of interest in “StanScripts” folder (see Figure 97).  
Figure 98. SPRite options displayed within the python terminal. 
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3. Go to Start > Anaconda Prompt >  
4. Type Activate StanScript 
5. Type cd c:\StanScripts 
6. To see all of the options like Figure 99 within SPRite, add the following 
command:  python parseSPRFileAndFitCurves.py –h  
For further explanations about the options, please see “Descriptions about 
SPRite Options” below 
7. Fill in the appropriate data in the command line 
a. python parse SPRFileAndFitCurves.py –i <input_filename> -o 
<OffSets.txt>-c <conc_analyte> -t 
<association_start_time_for_block1> -a 
<total_association_duration_time> -d 
<total_dissociation_duration_time>  -r 3 -s 
<ref1_block_no.1,ref_block_no.2,ref_block_no.3> -m <mass_analyte> 
-f <flow_rate> -l <model_type> -g 
<Units_to_convert_file,Start_time_of_first_calibration,End_time_of_f
irst_calibration,Start_time_of_second_calibration,End_time_of_secon
d_calibration,Conversion_factor> 
b. An example of a command line to analyze a dataset is:  
python parseSPRFileAndFitCurves.py -i SPRdatafile.txt -o OffSets.txt 
-c 0.0000001166 -t 1500 -a 300 -d 700 –p 100 -r 3 –s405,236,201 -m 
51465 -f 3 -l l –g ru,770,820,1240,1285,0.000565  
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where the inputted data file (-i)  is “SPRdatafile.txt,” the concentration 
of the query (-c) is 0.0000001166 M, the query injection time (-t) is 
1500 sec, the association length (-a) is 300 sec, the dissociation length 
(-d) is 700 sec, the seconds before the query injection  (-p) to include 
in the figures are 100, the number of reference spots (-r) to use is 3, the 
reference spots are located (-s) in positions 405, 236, and 201, the 
query mass (-m) is 51465 Da, the flow rate (-f) is 3 uL/sec, the kinetic 
model (-l) to use is Langmuir, the data will be calibrated and converted 
(-g) to RU, the start time of the first glycerol injection is 770 sec, the 
end time of the first glycerol injection is 820 sec, the start time of the 
second glycerol injection is 1240 sec, the end time of the second 
glycerol injection is 1285 sec, and the known RIU between the first 
and second glycerol injections is 0.000565. Also see calibration 
example in Figure 100 using 0.5% and 1% glycerol where the correct 
command would be –g ru,115,150,580,625,0.000565. 
Figure 99. Plateaued responses of two calibration reagents result in a known 
shift in RI. The responses on the Plexera HT PlexArray instrument are in % 
reflectivity, or arbitrary units (AU). 
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8. Output will now be in the “SPRdatafile” folder within the “StanScripts” 
folder, which will contain: 
a. Folder denoting the model used containing separate PDFs per binding 
sensorgram 
b. Text file containing all of the kinetic data 
c. Text file containing the calibrated curves over time 
d. Text file that is compatible with Scrubber2 
e. PDF file of all of the sensorgrams 
 
Descriptions about SPRite Options 
1. Required input files with flags 
a. -i ,--infile: The input text tab delimited file for processing. The file 
must be in the correct format (see also Step 2, Figure 97, page 264) 
b. -o, --tofile: Spot Time offset "txt" file 
(tab-separated). In essence, this file 
aligns the injection time for each spot. 
This file is used because only the start 
time “-t” in which any of the target spots 
first observe the query is inputted into the 
command line in SPRite, yet the target 
protein spots on a SPRi slide will be 
Figure 100. Offset file example 
where column A has the spot 
number and column B denoted the 
time offset. If the start time “-t” is 
“100” in the command line, this 
offset file tells SPRite that the real 
start time is “100” for spots 1 – 4 
and “101” for spots 5 – 7. 
  
268 
exposed to query protein at different times due to the flow of reagents 
from one end of the array to the other. The file denotes how the spots 
are exposed to the query from the start time “-t”. The file needs to be 
made by the user to fit their slide format. In the case with NAPPA-
SPRi, the targets close to the injection inlet will be exposed to query a 
few seconds before the targets close to the injection outlet. Based on 
observation of RI changes across the slide due to glycerol injections, 
the offset file was generated. The offset file should look like Figure 
101. The time offset for one particular NAPPA-SPRi dataset using the 
Plexera flow chamber is depicted in Figure 102 in which the flow was 
5 µL per second. The offset file should be changed if the flow is 
altered. For example, the time offset for a NAPPA-SPRi dataset with a 
c. flow of 3 µL per second is different than that of 5 µL per second 
(Figure 102, Figure 103).  
Figure 101. Time offsets for a 21 x 21 spotted array on a Plexera sensor chip using a 
Plexera flow cell with a dataset having 3 µL/sec flow 
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2. Required input parameters (strings) with flags 
a. -c, --aconc: Analyte concentration in Molarity.  
b. -t, --tstart: Assoctiation start time start for first array/spot. Calculate 
the start time for each array using this input and using the 
“SpotTOffsets.txt” file for each spot (Figure 101).  
c. -a ,--tassoc: Association duration time in seconds 
d. -d, --tdissoc: Dissociation duration time in seconds 
e. -p, --preassoc: Pre-Association time to include in figures 
f. -r, --refcount: Number of references. Currently, 3 references should be 
used. The response of each reference sensorgram “1, 2, or 3” will be 
subtracted from each target sensorgram “X” separately, such that “X” 
will be analyzed with “X-1,” “X-2,” and “X-3” 
Figure 102. Time offsets for a 21 x 21 spotted array on a Plexera 
sensor chip using a Plexera flow cell with a dataset having 5 µL/sec 
flow 
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g. -s, --refspots: Reference spots name - values of all the reference spot 
locations should be separated by a comma (for example: 203,350,480).  
3. Optional input parameters with flags 
a. -m, --amass: Mass of the analyte in Daltons. 
b. -f --frate: Flow rate as uL/sec.  
c. -l ,--mselect: Model selection for curve fitting. One or more models 
can be chosen at one time, each one separated using commas. 
Available options: l (default), lld, lmt, hl or all 
1. l - Langmuir 1:1; default 
2. lmts - Langmuir mass transport (currently in progress, 
not ready to be used) 
3. lld - Langmuir linear drift; PDF files do not display 
drift corrected curves 
4. mlld – Langmuir linear drift; PDF files display drift 
corrected curves 
5. mglld – Langmuir linear drift; Association and 
dissociation curves are fit globally; PDF files display 
drift corrected curves 
6. hl - Heterogeneous ligand (currently in progress, not 
ready to be used) 
7. all - For now, all runs only l and lmts 
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d. –g, --glycalib: Conversion of intensity units to AIU, RIU, or RU. Any 
type of reagent can be used to calibrate as long as the refractive index 
shift is known. Glycerol, PBS, and ethanol are common reagents for 
calibrating data. For the example given in Figure 100, the correct 
command to convert data into RU would be: -g 
ru,115,150,580,625,0.000565 
Where the first two numbers indicate the time in which the plateaued 
response of the first calibration reagent begins and ends, while the 
second two numbers indicate the time in which the plateaued response 
of the second calibration reagent begins and ends. The fifth number is 
the known RI difference between the two calibration reagents, which 
happen to be 0.5% and 1% glycerol in running buffer. 
e. –e, --driftcorr: Drift correction method (Options: d or ad). Default =No 
drift correction. Options: d (dissociation), ad (association and 
dissociation). Leave blank if no drift correction is needed. 
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APPENDIX F 
“PARSESPRANDFITCURVES.PY” SCRIPT 
#!/usr/bin/env python 
import re 
from os.path import * 
from os import getcwd, makedirs 
from optparse import * 
from pandas import * 
from numpy import * 
from scipy.optimize import curve_fit 
from PyPDF2 import PdfFileReader, PdfFileMerger 
import curveFittingKineticModels as CFM 
import matplotlib.pyplot as plt 
# Integrating SPRuce: 
# Convert to RU/RIU based on glycerol injections 
def glycerolCalibration(one_prot_au_df,\       
   one_prot_name,\ 
  glycalib_str, time_colname, riu_to_ru_factor = 1e+6): 
 #riu_to_ru_factor = 1e+6 #Domain knowledge 
 one_prot_converted_unit_df = DataFrame() 
 if glycalib_str: 
  conversion_unit, ts1, td1, ts2, td2, dRI = glycalib_str.split(",") 
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  ts1, td1, ts2, td2, dRI = int(ts1), int(td1), int(ts2), int(td2), float(dRI) 
  tend1=ts1+td1 
  tend2=ts2+td2 
  ws_t_one_prot_df_ci1 = one_prot_au_df.loc[(one_prot_au_df.time>=ts1) 
&\          
(one_prot_au_df.time<=td1)] 
  avg_au_ci1 = mean(ws_t_one_prot_df_ci1[one_prot_name]) 
  ws_t_one_prot_df_ci2 = one_prot_au_df.loc[(one_prot_au_df.time>=ts2) 
&\ 
         
(one_prot_au_df.time<=td2)] 
  avg_au_ci2 = mean(ws_t_one_prot_df_ci2[one_prot_name]) 
  CalFac = dRI / (avg_au_ci2 - avg_au_ci1) 
  one_prot_riu_df = one_prot_au_df*CalFac 
  if conversion_unit == "riu": 
    one_prot_riu_df[time_colname] = 
one_prot_au_df[time_colname] 
    one_prot_converted_unit_df = one_prot_riu_df 
  elif conversion_unit == "ru": 
    one_prot_ru_df = one_prot_riu_df*riu_to_ru_factor 
    one_prot_ru_df[time_colname] = 
one_prot_au_df[time_colname] 
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    one_prot_converted_unit_df = one_prot_ru_df 
  else: 
    print "Entered incompatible conversion unit entered:", 
conversion_unit,\ 
       ". Please select one of \"riu\", \"ru\"" 
 else: 
   one_prot_converted_unit_df = one_prot_au_df 
 return one_prot_converted_unit_df 
# Get the slope and intercept values for the preassociation time RU values 
# This is to drift-correct the data. 
def lFitData(t, response_unit): 
    lfit = polyfit(t,\ 
    response_unit,\ 
    1, full=True) 
 lcoef, lresid, lrank, lsing_values, lrcond = lfit 
 # Get slope and intercept from the fit coefs 
 response_m, response_c = lcoef 
 return response_m, response_c 
def calcSlopeIntercept(ws_t_response): 
 t = np.array(ws_t_response.iloc[:,0].astype('int')) 
 response_unit = np.array(ws_t_response.iloc[:,1]) 
 slope, intercept = lFitData(t, response_unit) 
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 return slope, intercept 
def parseTimeOffsetFile(time_offset_file, delim_operator): 
 time_offset_df = read_csv(time_offset_file, sep=delim_operator, engine = 
'python') 
 return time_offset_df 
# 0 to #refs-1 need to be looped since python follows zero-indexing 
def calcNewTimeForQueryRefsEachSpot(time_offset_df,\     
     tstart_spot1,\      
     block_name,\      
     refn_spots_list,\     
     refs_count): 
 time_offset = time_offset_df[time_offset_df['Spot']==block_name] 
 time_offset_value = int(time_offset.iloc[:,1].values) 
 query_tstart = tstart_spot1+time_offset_value 
 refn_tstarts_list = list() 
 for ref_spot_icol in range(0, refs_count): 
  ref_offset = 
time_offset_df[time_offset_df['Spot']==int(refn_spots_list[ref_spot_icol])] 
  ref_offset_value = int(ref_offset.iloc[:,1].values) 
  ref_tstart = tstart_spot1+ref_offset_value 
  refn_tstarts_list.append(str(ref_tstart)) 
 query_refn_tstarts_str = ",".join([str(query_tstart)]+refn_tstarts_list) 
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 return query_refn_tstarts_str 
# Adding time and raw columns to get total column count per protein 
# For each protein: 
# First cell in each protein column has spot information 
# Python follows zero indexing, so we split time+raw+#refs-1 
# Get rid of the row with second header 
# If protein name is missing in the header info. Just use "1" instead! 
def splitByProteins(df, time_offset_df,\ 
        analyte_conc,\ 
        analyte_mass,\ 
        flow_rate,\ 
        tstart_spot1,\ 
        t_assoc, t_dissoc,\ 
        preassoc_time, refs_count,\ 
        refn_spots_str, 
time_colname): 
 one_protein_col_count = refs_count+2 
 refn_spots_list = refn_spots_str.split(",") 
 split_cells_index = arange(0,len(df.columns),\     
         one_protein_col_count) 
 data_by_protein_dict = dict() 
 refn_spots_df = DataFrame() 
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 refn_spots_df_list = list() 
 # Get reference spots only to fill in the columns after the reference for scrubber 
format: 
 refn_spots_block_list = ["Block: " + one_ref_spot_block for one_ref_spot_block 
in refn_spots_list] 
 for one_ref_spot_block in refn_spots_block_list: 
   one_ref_spot_colname = 
df.columns[df.columns.to_series().str.contains(one_ref_spot_block)][0] 
   one_ref_spot_colname_loc = 
df.columns.get_loc(one_ref_spot_colname) 
   one_ref_spots_df = df.iloc[:,one_ref_spot_colname_loc+1] 
   refn_spots_df_list.append(one_ref_spots_df) 
 refn_spots_df = concat(refn_spots_df_list, axis=1) 
 #refn_spots_df = refn_spots_df.convert_objects(convert_numeric = True) 
 for i in split_cells_index: 
  df_by_protein = df.iloc[:,i:(i+one_protein_col_count)] 
  prot_array_info = df_by_protein.columns[0] 
  prot_block_match = re.match(r"Name: (.*?) .*Block: (.*?) .*", 
prot_array_info) 
  prot_name = "NoName" 
  block_name = "1" 
  if prot_block_match: 
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   if prot_block_match.group(1): 
    prot_name = prot_block_match.group(1) 
    prot_name = prot_name.replace(" ", "") # Might not need 
this! 
   if prot_block_match.group(2): 
    block_name = prot_block_match.group(2) 
  prot_block_name = prot_name + "_" + block_name 
  if block_name in refn_spots_list: 
    continue 
  block_name = int(block_name) 
  df_by_protein = concat([df_by_protein.iloc[:,[0,1]], refn_spots_df],axis = 
1) 
  df_by_protein = df_by_protein[1:len(df_by_protein)] 
  df_by_protein = df_by_protein.convert_objects(convert_numeric = True) 
  query_refn_tstarts_str = 
calcNewTimeForQueryRefsEachSpot(time_offset_df,\     
  tstart_spot1,\         
  block_name,\         
  refn_spots_list,\        
  refs_count) 
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  refn_spots_name_list = 
[prot_block_name+"_ref"+str(one_ref_spot+1)+"_"+str(refn_spots_list[one_ref_spot])\ 
   for one_ref_spot in range(0, refs_count)] 
  prot_block_refn_spots_name_str = 
",".join([prot_block_name]+refn_spots_name_list) 
  pro_kinetics_params_info = [prot_block_refn_spots_name_str,\  
        str(t_assoc),\ 
        str(t_dissoc),\ 
        str(preassoc_time),\ 
        str(analyte_conc),\ 
        str(analyte_mass),\ 
        str(flow_rate),\  
        query_refn_tstarts_str] 
  pro_kinetics_params_info_str = "|".join(pro_kinetics_params_info) 
  df_by_protein.columns = [time_colname, prot_block_name]+\  
          refn_spots_name_list 
  data_by_protein_dict[pro_kinetics_params_info_str] = df_by_protein 
 return(data_by_protein_dict) 
def getProKineticsParamsAndIntensities(data_by_protein_dict): 
 pro_kinetics_params_info_str = data_by_protein_dict.keys() 
 for one_pro_kinetics_params_info_str in pro_kinestics_params_info_str: 
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  df_time_raw_refs = 
data_by_protein_dict[one_pro_kinetics_params_info_str] 
  prot_name, t_start, t_assoc, t_diss,\ 
  analyte_mass, analyte_conc, p_calib, p_driftCorr,\ 
  refn_spots_tstart, ref2_tstart, ref3_tstart = 
one_pro_kinetics_params_info_str.split("_") 
 return prot_name, t_start, t_assoc, t_diss,\ 
     analyte_mass, analyte_conc, p_calib, p_driftCorr,\ 
     refn_spots_tstart, ref2_tstart, ref3_tstart, df_time_raw_refs 
def get_raw_ref_intensities(df_time_raw_refs): 
 relative_time = df_time_raw_refs.iloc[:,0] 
 time_raw_intensities = df_time_raw_refs.iloc[:,[0,1]] 
 time_refn_spots_intensities = df_time_raw_refs.iloc[:,[0,2]] 
 time_ref2_intensities = df_time_raw_refs.iloc[:,[0,3]] 
 return relative_time, time_raw_intensities,\ 
     time_refn_spots_intensities, time_ref2_intensities 
def windowSelectValues(df_time_raw_refs,\      
   preassoc_tstart,\       
   preassoc_tend,\ 
    assoc_tstart,\ 
    dissoc_tend,\ 
    one_prot_colname, time_colname): 
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 ws_t_one_prot_df_preassoc = 
df_time_raw_refs.loc[(df_time_raw_refs.time>=preassoc_tstart) &\   
     (df_time_raw_refs.time<=preassoc_tend),\ 
    [time_colname, one_prot_colname]] 
 ws_t_one_prot_df_ad = 
df_time_raw_refs.loc[(df_time_raw_refs.time>=assoc_tstart) &\ 
      (df_time_raw_refs.time<=dissoc_tend),\  
       [time_colname, one_prot_colname]] 
 ws_t_one_prot_df_pread = 
df_time_raw_refs.loc[(df_time_raw_refs.time>=preassoc_tstart) &\   
      (df_time_raw_refs.time<=dissoc_tend),\ 
       [time_colname, one_prot_colname]] 
 return ws_t_one_prot_df_preassoc,\ 
     ws_t_one_prot_df_ad,\ 
     ws_t_one_prot_df_pread 
# Zeroed time to association start time 
def bcValues(window_selected_df, t_start): 
 baseline_correction_var = 
window_selected_df[(window_selected_df.time==t_start)] 
 bc_values_df = window_selected_df-baseline_correction_var.values.squeeze() 
 bc_values_df = bc_values_df.reset_index(drop=True) 
 return bc_values_df 
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# subtract slope*(t-t0) it from the association/dissociation 
# The assoc/dissoc base correction depends on given start time 
def driftCorrectInputBased(ws_t_one_prot_df_pread,\     
      ws_t_one_prot_df_preassoc,\ 
       tstart, tend, time_colname): 
 ws_t_one_prot_df_d = 
ws_t_one_prot_df_pread[(ws_t_one_prot_df_pread.time>=tstart) &\ 
  (ws_t_one_prot_df_pread.time<=tend)] 
 preassoc_prot_m, preassoc_prot_c = 
calcSlopeIntercept(ws_t_one_prot_df_preassoc) 
 prot_td0 = 
ws_t_one_prot_df_pread.ix[ws_t_one_prot_df_pread.time==tstart,0].values 
 one_prot_dc = ws_t_one_prot_df_d.iloc[:,1]-
(preassoc_prot_m*(ws_t_one_prot_df_d[time_colname]-prot_td0)) 
 # Copy df to different variable and apply drift correction to the new variable 
 dc_t_one_prot_df_pread = ws_t_one_prot_df_pread.copy(deep=True) 
 dc_t_one_prot_df_pread.ix[(dc_t_one_prot_df_pread.time>=tstart) &\  
 (dc_t_one_prot_df_pread.time<=tend),1] = one_prot_dc 
 return dc_t_one_prot_df_pread 
# Drift correct the dissociation phase data 
# Find New start time before Zeroing data-may reset the time again but later 
# Get slope (m) and intercept (c) for the prior to assoc values 
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# Call the function to correct drift based on user input 
### Options: 1. Drift correct Assoc+Dissoc 2. Dissoc ONLY 3. NO correction! 
# Loop for the query and reference spots 
# Note: Make a copy of dataframe, then update the dissociation phase 
def dcValuesAndNewTstart(ws_t_one_prot_df_preassoc,\     
     ws_t_one_prot_df_pread,\ 
      t_assoc,\ 
      assoc_tstart, dissoc_tend,\ 
      input_dc_method, time_colname): 
 dissoc_tstart = assoc_tstart+t_assoc+1 
 if input_dc_method == "d" : 
  dc_t_one_prot_df_pread = 
driftCorrectInputBased(ws_t_one_prot_df_pread,\      
 ws_t_one_prot_df_preassoc,\ 
 dissoc_tstart, dissoc_tend, time_colname) 
 elif input_dc_method == "ad": 
  dc_t_one_prot_df_pread = 
driftCorrectInputBased(ws_t_one_prot_df_pread,\      
 ws_t_one_prot_df_preassoc,\ 
      assoc_tstart, dissoc_tend, time_colname) 
 else: 
  dc_t_one_prot_df_pread = ws_t_one_prot_df_pread 
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 return dc_t_one_prot_df_pread 
def refQuery(input_values_query, input_values_ref): 
 referenced_query = input_values_query - input_values_ref 
 return referenced_query 
# We need to subtract each reference from query 
# But since we have a df of all values, 
# Just reference the df by subtracting the entire df with the query 
# Note: query column becomes zero 
# Then negative correct the value and update the df to add time and set bc query values 
# Finally, rearrange all the columns to form the sequence=> time,query, refd1, refd2.... 
def refQueryDF(bc_t_prot_allrefs_df,\ 
        prot_block_refn_spots_name_list,\ 
        refs_count, time_colname): 
 query_prot_name = prot_block_refn_spots_name_list[0] 
 refn_spots_name_list = 
prot_block_refn_spots_name_list[1:len(prot_block_refn_spots_name_list)] 
 time_only_df = bc_t_prot_allrefs_df[time_colname].T.drop_duplicates().T # 
Remove multiple time columns! => Issues! 
 # Hack: Just incase the time series sequence breaks at some point 
 if len(time_only_df.columns) > 1 : 
  time_only_df = time_only_df.iloc[:,0] 
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 time_refd_all_df = -(bc_t_prot_allrefs_df[refn_spots_name_list].sub(\  
     bc_t_prot_allrefs_df[query_prot_name],\ 
      axis=0)) 
 time_refd_all_df[time_colname] = time_only_df.astype(int) 
 time_refd_all_df = time_refd_all_df[[time_colname]+refn_spots_name_list] 
 time_query_df = concat([time_only_df, bc_t_prot_allrefs_df[query_prot_name]], 
axis=1) 
 return time_refd_all_df, time_query_df, query_prot_name, refn_spots_name_list 
# query_tstart is assoc_start_time query_tend is dissoc_end_time 
# Make a dictionary with protein nametype (query, ref1 ..) and their corresponding start 
times 
# Reference the query protein by subtracting query values with given reference values 
def windowSelectBCRefValues(one_prot_df,\      
      preassoc_tstart,\    
      preassoc_tend,\    
      t_assoc,\     
      assoc_tstart,\     
      dissoc_tend,\     
      one_prot_colname,\ 
      input_dc_method, time_colname) : 
 ws_t_one_prot_df_preassoc,\ 
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 ws_t_one_prot_df_ad, ws_t_one_prot_df_pread = 
windowSelectValues(one_prot_df,\      
 preassoc_tstart,\         
 preassoc_tend,\         
 assoc_tstart,\          
 dissoc_tend,\          
 one_prot_colname, time_colname) 
 dc_t_one_prot_df_pread = dcValuesAndNewTstart(ws_t_one_prot_df_preassoc,\ 
        ws_t_one_prot_df_pread,\ 
        t_assoc,\   
        assoc_tstart,\   
        dissoc_tend,\ 
        input_dc_method, 
time_colname) 
 # Baseline correct/Zeroing data 
 bc_t_one_prot_df = bcValues(dc_t_one_prot_df_pread, assoc_tstart) 
 return bc_t_one_prot_df 
def callCF(df_time_allrefs_ad,\ 
      df_time_raw,\ 
      analyte_conc,\ 
      analyte_mass,\ 
      flow_rate,\ 
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      t_assoc, t_dissoc,\ 
      assoc_tstart, dissoc_tend,\ 
      plot_filename,\ 
      base_input_filename,\ 
      plots_file_path,\ 
      fit_type,\ 
      refs_spots_list,\ 
      merge_onefit_pdfs,time_colname) : 
 all_coefs_fits_df_list = list() 
 print "Curve fitting...." 
 coefs_df = DataFrame() 
 response_unit_pread = "" 
 try: 
  response_unit_pread, coefs_df = 
CFM.fitCurveModels(df_time_allrefs_ad,\      
 df_time_raw,\          
 analyte_conc,\ 
 analyte_mass,\ 
 flow_rate,\ 
 t_assoc, t_dissoc,\ 
 assoc_tstart, dissoc_tend,\ 
 plot_filename, fit_type,\ 
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 base_input_filename, plots_file_path,\ 
 refs_spots_list, merge_onefit_pdfs, time_colname) 
 except ValueError: 
  print "Skipping array protein. Data too noisy..." 
 all_coefs_fits_df_list.append(coefs_df) 
 all_coefscolumnfits_df = concat(all_coefs_fits_df_list, axis=1) 
 all_fits_coefs_df = concat(all_coefs_fits_df_list) 
 return response_unit_pread, all_fits_coefs_df, all_coefscolumnfits_df 
# Get the model type and populate "fit_types_list": 
def getFitType(input_model_selected,\ 
        fit_types_list): 
 # Basic model, in place and use with all. Make this default! 
 if input_model_selected == "l" or input_model_selected == "all": 
  fit_types_list.append("l") 
 # In place and tested but NOT included with default-"all" option yet! 
 if input_model_selected == "lld": 
  fit_types_list.append("lld") 
 # In place but not satisfied and NOT included with default-"all" option yet! 
 if input_model_selected == "mlld": 
  fit_types_list.append("mlld") 
 # In place but testing and NOT included with default-"all" option yet! 
 if input_model_selected == "mglld": 
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  fit_types_list.append("mglld") 
 # NOT in place! Weird outputs 
 if input_model_selected == "lmt": 
  fit_types_list.append("lmt") 
 # Working and validation in process! 
 if input_model_selected == "lmts" or input_model_selected == "all": 
  fit_types_list.append("lmts") 
 # In place but NOT validated! 
 if input_model_selected == "hl": 
  fit_types_list.append("hl") 
 return 0 
def processSPRFileAndFitCurves(input_filename, time_offset_file,\   
      analyte_conc, tstart_spot1,\   
      t_assoc, t_dissoc_input,\   
      preassoc_time, refs_count,\ 
      refn_spots_str, analyte_mass,\ 
      flow_rate, input_model_selected,\ 
      input_dc_method, delim_operator, 
glycalib_str): 
 # Brute force: Resetting the dissociation time by decreasing the tail by 5 seconds 
 t_dissoc = t_dissoc_input - 5 
 time_colname = "time" 
  
290 
 fit_types_list = list() 
 getFitType(input_model_selected, fit_types_list) 
 # Need to set this properly 
 current_dirpath = getcwd() 
 base_input_filename = basename(input_filename) 
 base_input_filename_noext = splitext(base_input_filename)[0] 
 results_subdir = "results_"+base_input_filename_noext 
 results_subdir_path = join(current_dirpath, results_subdir) 
 # Create a subdirectory for each file under current directory (if not present): 
 print "Creating sub-directory: \n", results_subdir_path 
 if not exists(results_subdir_path): 
  makedirs(results_subdir_path) 
 all_spots_fits_coefs_df = DataFrame() 
 all_spots_columnfits_coefs_df = DataFrame() 
 # Loop over all the fit types requested (used when "all" option is selected). 
 for fit_type in fit_types_list: 
  plots_file_path = join(results_subdir_path, fit_type) 
  print "Creating sub-directory for model: \n",\ 
     fit_type, "at:", results_subdir_path 
  if not exists(plots_file_path): 
   makedirs(plots_file_path) 
  time_offset_df = parseTimeOffsetFile(time_offset_file, delim_operator) 
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  # Read input processed prior to scrubber file 
  input_df = read_csv(input_filename, sep=delim_operator, engine = 
'python')#, skiprows=0) 
  data_by_protein_dict = splitByProteins(input_df, \    
        time_offset_df,\   
        analyte_conc,\   
       analyte_mass,\ 
        flow_rate,\ 
        tstart_spot1,\    
        t_assoc, t_dissoc,\ 
       preassoc_time,\ 
        refs_count,\    
        refn_spots_str, time_colname) 
  pro_kinetics_params_info_str = sorted(data_by_protein_dict.keys()) 
  merge_onefit_pdfs = PdfFileMerger() # open pdf merger document! 
  all_plots_merged_filename = fit_type+"_"+\     
        base_input_filename_noext+\ 
         "_all_merged.pdf" 
  bc_t_prot_allrefs_df_filt_list = list() 
  output_prot_df_list = list() 
  for one_pro_kinetics_params_info_str in pro_kinetics_params_info_str: 
  
292 
   df_time_raw_refs = 
data_by_protein_dict[one_pro_kinetics_params_info_str] 
   prot_block_refn_spots_name_str,\ 
   t_assoc, t_dissoc, preassoc_time,\ 
   analyte_conc, analyte_mass,\ 
   flow_rate, query_refn_tstarts_str = 
one_pro_kinetics_params_info_str.split("|") 
   t_assoc, t_dissoc, preassoc_time = int(t_assoc),\   
           int(t_dissoc),\ 
          int(preassoc_time) 
prot_block_refn_spots_name_list = 
prot_block_refn_spots_name_str.split(",") 
   query_refn_tstarts_list = map(int, query_refn_tstarts_str.split(",")) 
   prot_names_tstarts_dict =
 dict(zip(prot_block_refn_spots_name_list,\      
    query_refn_tstarts_list)) 
   bc_all_t_prot_df_list = list() 
   array_protein_name = prot_block_refn_spots_name_list[0] 
   one_prot_all_list = list() 
   for one_prot_colname in prot_names_tstarts_dict.keys(): 
    assoc_tstart = prot_names_tstarts_dict[one_prot_colname] 
    dissoc_tend = assoc_tstart+t_assoc+t_dissoc 
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    preassoc_tstart = assoc_tstart-preassoc_time 
    preassoc_tend = assoc_tstart-1 
    one_prot_au_df = df_time_raw_refs[[time_colname, 
one_prot_colname]] 
    one_prot_df = glycerolCalibration(one_prot_au_df,\ 
        one_prot_colname,\  
        glycalib_str, time_colname) 
    one_prot_all_list.append(one_prot_df) 
    bc_t_one_prot_df = 
windowSelectBCRefValues(one_prot_df,\       
    preassoc_tstart,\ 
    preassoc_tend,\      
    t_assoc,\ 
    assoc_tstart,\ 
    dissoc_tend,\       
    one_prot_colname,\      
    input_dc_method, time_colname) 
    bc_all_t_prot_df_list.append(bc_t_one_prot_df) 
   bc_t_prot_allrefs_df = concat(bc_all_t_prot_df_list, axis=1) # We 
will have duplicates for "time" column here 
   print "Protein=>"+array_protein_name+"....." 
   # Reference the values (query-ref1, query-ref2...) 
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   time_refd_all_df, time_query_df,\ 
   query_prot_name, refn_spots_name_list = 
refQueryDF(bc_t_prot_allrefs_df,\        
       prot_block_refn_spots_name_list,\  
        refs_count, time_colname) 
   # Reset the association start value to zero since we zeroed the data 
to start from zero 
   response_unit_pread, all_fits_coefs_df, all_coefscolumnfits_df
 = callCF(time_refd_all_df,\        
      time_query_df,\    
      float(analyte_conc),\    
      float(analyte_mass),\    
      float(flow_rate),\ 
      int(t_assoc),\     
      int(t_dissoc),\     
      int(assoc_tstart),\    
      int(dissoc_tend),\    
      query_prot_name,\    
      base_input_filename,\    
      plots_file_path,\    
      fit_type,\     
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      refn_spots_name_list,\   
      merge_onefit_pdfs,time_colname) 
   all_spots_fits_coefs_df = 
all_spots_fits_coefs_df.append(all_fits_coefs_df) 
   #### scrubber validation: START 
   #### Super crude hack! 
   # Filter patterns for Brianne: Ref1 with -C and Ref2 with -N for 
easier filtering 
   subset_col_indices = [i for i, x in 
enumerate(prot_block_refn_spots_name_list) if re.search(r'-C.*ref1|-N.*ref2', x)] 
   if len(subset_col_indices) < 1: 
     subset_col_indices = [1] 
   time_prot_block_selrefn_spots_name_list = 
[prot_block_refn_spots_name_list[i] for i in [0]+subset_col_indices] 
   time_prot_block_selrefn_spots_name_list.insert(0, time_colname) 
   bc_t_prot_allrefs_df_filt = bc_t_prot_allrefs_df 
   bc_t_prot_allrefs_df_filt[time_colname] = 
bc_t_prot_allrefs_df_filt.index 
   bc_t_prot_allrefs_df_filt = 
bc_t_prot_allrefs_df_filt[time_prot_block_selrefn_spots_name_list].T.drop_duplicates().
T 
   bc_t_prot_allrefs_df_filt.iloc[:,1] = response_unit_pread 
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   bc_t_prot_allrefs_df_filt.iloc[:,2] = 0 
   bc_t_prot_allrefs_df_filt['blank1'] = "" 
   bc_t_prot_allrefs_df_filt['blank2'] = "" 
   blank_df = DataFrame([['Relative Time','RAW 
DATA','REFERENCE DATA', 'BLANK1', 'BLANK2']],\     
     columns=bc_t_prot_allrefs_df_filt.columns.values) 
   bc_t_prot_allrefs_df_filt = concat([blank_df, 
bc_t_prot_allrefs_df_filt], ignore_index=True) 
   split_array_prot_info_list = 
bc_t_prot_allrefs_df_filt.columns.values[2].split("_") 
   #Convert the header to scrubber format: 
   scrubber_first_header_prot_col = "Name: 
"+split_array_prot_info_list[0]+"  ID:  Set:  Family: 
 Group:  Block: "+split_array_prot_info_list[1]+"  Row: 1  
Column: 1" 
   scrubber_first_header_all_cols = [scrubber_first_header_prot_col, 
"", "", "",""] 
   bc_t_prot_allrefs_df_filt.columns = scrubber_first_header_all_cols 
   bc_t_prot_allrefs_df_filt_list.append(bc_t_prot_allrefs_df_filt) 
   # Plexera output format? 
   one_prot_all_df = concat(one_prot_all_list, axis=1) # We will 
have duplicates for "time" column here 
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   one_prot_all_nodup_df = 
one_prot_all_df[prot_block_refn_spots_name_list] 
   one_prot_all_nodup_df[[time_colname]] = 
one_prot_all_df[time_colname].T.drop_duplicates().T 
   one_prot_all_nodup_df = one_prot_all_nodup_df[[time_colname] 
+ prot_block_refn_spots_name_list] 
   blank_df = DataFrame([['Relative Time','Raw Intensity','Satellite 
Intensity','Subtracted Intensity', '']],\        
     columns=one_prot_all_nodup_df.columns.values) 
   one_prot_all_nodup_df = concat([blank_df, 
one_prot_all_nodup_df], ignore_index=True) 
   one_prot_all_nodup_df.columns = scrubber_first_header_all_cols 
   output_prot_df_list.append(one_prot_all_nodup_df) 
  # Combine all pdfs for one model/fit-type into one pdf for Brianne! 
  # Slightly crude! 
  all_pdfs = plots_file_path 
  all_plots_merged_file = join(results_subdir_path, 
all_plots_merged_filename) 
  print "Merging all pdfs for the selected model:" + all_plots_merged_file 
  merge_onefit_pdfs.write(all_plots_merged_file) 
  # Get raw baselined data, reference spot data out for Brianne+Ian to cross-
check with scrubber: 
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  scrubber_format_df = concat(bc_t_prot_allrefs_df_filt_list, axis=1) 
  output_prot_df = concat(output_prot_df_list, axis=1) 
  ### Write an output file in scrubber format with only the binding curve 
data for validation 
  scrubber_format_file = join(results_subdir_path,\    
        input_model_selected+\ 
        "_ScrubberFormat_"+\ 
       base_input_filename) 
  scrubber_format_df.to_csv(scrubber_format_file,\    
       index=False, sep="\t") 
  ### Write an intermediate output file in plexera format? with input data 
for validation across multiple platforms 
  output_prot_file = join(results_subdir_path,\     
        input_model_selected+\ 
       "_OutputData_"+\   
        base_input_filename) 
  output_prot_df.to_csv(output_prot_file,\     
      index=False, sep="\t") 
  ####Scrubber validation hack: END! 
 all_spots_fits_coefs_file = join(results_subdir_path,\ 
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     input_model_selected+\ 
     "_Format1coefs_"+\      
     base_input_filename) 
 print "Creating all in one file-Format1:" + all_spots_fits_coefs_file 
 all_spots_fits_coefs_df.to_csv(all_spots_fits_coefs_file,\    
           index=False, 
sep="\t") 
 print "Results located at:", all_spots_fits_coefs_file 
 return 0 
# 
# Read command line options 
# 
def readAndParseCommandlineArgs(): 
 usage = "usage: %prog [options]  (Use -h or --help to see all options)" 
 cl=OptionParser(usage=usage) 
 cl.add_option('--infile', '-i', action='store', 
   help="input \"Processed Prior to scrubber\" csv file 
(REQUIRED)", 
   dest="infile") 
 cl.add_option('--glycalib', '-g', action='store', 
   help="Glycerol calibration parameter string - format: 
units,ts1,td1,ts2,td2,dRI\ 
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     Accepted value for units: \"au, ru, riu\"For example 
-g ru,780,825,1245,1290,0.000565", 
     dest="glycalib", default="") 
 cl.add_option('--tofile', '-o', action='store', 
     help="Spot Time offset \"txt\" file (REQUIRED)", 
     dest="tofile") 
 cl.add_option('--aconc', '-c', action='store', 
     help="Analyte CONCENTRATION 
(REQUIRED)", 
     dest="aconc") 
 cl.add_option('--tstart', '-t', action='store', 
     help="Time start for SPOT-1 (REQUIRED)", 
     dest="tstart") 
 cl.add_option('--tassoc', '-a', action='store', 
     help="Association duration time (REQUIRED)", 
     dest="tassoc") 
 cl.add_option('--tdissoc', '-d', action='store', 
     help="Dissociation duration time (REQUIRED)", 
     dest="tdissoc") 
 cl.add_option('--preassoc', '-p', action='store', 
     help="Pre Association time for drift correction 
(REQUIRED)", 
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     dest="preassoc") 
 cl.add_option('--refcount', '-r', action='store', 
     help="Number of references (REQUIRED)", 
     dest="refcount") 
 cl.add_option('--refspots', '-s', action='store', 
     help="Reference spots name - \ 
     values of all the reference\ 
     spot locations should be separated by a comma", 
     dest="refspots") 
 cl.add_option('--amass', '-m', action='store', 
     help="Analyte MASS (OPTIONAL)", 
     dest="amass") 
 cl.add_option('--frate', '-f', action='store', 
     help="Flow Rate", 
     dest="frate") 
 cl.add_option('--mselect', '-l', action='store', 
     help="Model select (Options: l , lld, lmts, hl or 
all)", 
     dest="mselect", default="l") 
 cl.add_option('--driftcorr', '-e', action='store', 
     help="Drift correction method (Options: d or ad)", 
     dest="driftcorr") 
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 cl.add_option('--sep', '-n', action='store' 
     help="Separation method for input file (Options: , 
or \t or \s)", 
     dest="delimsep", default="\t") 
 (options, args) = cl.parse_args() 
### Need to add defaults for flexibility 
 # 
 # Check the command line options 
 if options.infile: 
  if isfile(options.infile): 
   input_filename = options.infile 
   glycalib_str = str(options.glycalib) 
   time_offset_file = options.tofile 
   analyte_conc = float(options.aconc) 
   tstart_spot1 = int(options.tstart) 
   t_assoc = int(options.tassoc) 
   t_dissoc = int(options.tdissoc) 
   preassoc_time = int(options.preassoc) 
   refs_count = int(options.refcount) 
   refn_spots_str = str(options.refspots) 
   analyte_mass = options.amass 
   flow_rate = options.frate 
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   model_select = options.mselect 
   input_dc_method = options.driftcorr 
   delim_operator = str(options.delimsep) 
   return(input_filename, time_offset_file,\ 
       analyte_conc, tstart_spot1,\ 
       t_assoc, t_dissoc,\ 
       preassoc_time, refs_count,\ 
       refn_spots_str, analyte_mass,\ 
       flow_rate, model_select,\ 
       input_dc_method, delim_operator,\ 
       glycalib_str) 
 else: 
  cl.error("Please specify an input \"Processed Prior to scrubber\" csv 
file to run the search. Use -h for more information.\n") 
# Any line with "bc_ws_t_one_prot_df" variable part is only temporary for now. 
# This is to check total raw biacore units with drift corrected values 
def main(): 
 input_filename, time_offset_file,\ 
 analyte_conc, tstart_spot1,\ 
 t_assoc, t_dissoc_input,\ 
 preassoc_time, refs_count,\ 
 refn_spots_str, analyte_mass,\ 
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 flow_rate, input_model_selected,\ 
 input_dc_method, delim_operator, glycalib_str = 
readAndParseCommandlineArgs() 
 process_results = processSPRFileAndFitCurves(input_filename, time_offset_file,\ 
         analyte_conc, 
tstart_spot1,\         
 t_assoc, t_dissoc_input,\        
  preassoc_time, refs_count,\       
   refn_spots_str, analyte_mass,\ 
        flow_rate, 
input_model_selected,\ 
        input_dc_method, 
delim_operator, glycalib_str) 
 print process_results, "Done!" 
if __name__ == "__main__": 
  # stuff only to run when not called via 'import' here 
  main() 
#### Script command example: 
##### python parseSPRFileAndFitCurves.py -i ../SPR\ analyses/Additional\ 
Data/BTK_Deph_TEMP.csv -o ../SPR\ analyses/20150527_SpotTOffsets.csv -c 9e-08 -t 
2570 -a 180 -d 400 -s 100,100,100 -p 100 -m 77800 -r 3 -f 5 -l all -e d -n , (or -n $'\t' or -n 
$'\s') 
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##### python parseSPRFileAndFitCurves.py -i ../SPR\ 
analyses/20151028ASU/20151009_RAC1_reproducibility/09102015_RAC1_GTP_4ug_
deph_3.txt \ 
#####           -o 
../SPR\ analyses/20150527_SpotTOffsets.csv -c 1.78174E-07 -m 22450 \ 
#####           -r 3 -f 
3 -l l -t 2806 -a 300 -d 700 -s 405,201,236 -p 100 -n $'\t' 
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APPENDIX G 
“CURVEFITTINGKINETICMODELS.PY” SCRIPT 
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#!/usr/bin/env python 
import re 
from pandas import * 
from numpy import * 
from os.path import join, exists 
from os import makedirs 
from scipy.optimize import curve_fit#, leastsq 
from scipy.integrate import odeint 
from scipy.stats import chisquare 
from collections import OrderedDict 
import matplotlib.pyplot as plt 
from PyPDF2 import PdfFileReader, PdfFileMerger 
from parseSPRFileAndFitCurves import lFitData 
def assocEqLang1(t, Req, kobs, X): 
 t0 = t[0] 
 r_assoc = (Req*(1-exp(-kobs*(t-t0))))+X 
 return r_assoc 
def dissocEqLang1(t, R0, kd, X): 
 t0 = t[0] 
 #t = t-t0 #=> Zeroing dissoc so they go from 0 to 699 instead of 301-1000 
 r_dissoc = (R0*exp(-kd*(t-t0)))+X 
 return r_dissoc 
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def assocEqLLD(t, Req, kobs, Y, X): 
 t0 = t[0] 
 t_assoc = t-t0 
 r_assoc = (Req*(1-exp(-kobs*t_assoc)))+(Y*t_assoc)+X 
 return r_assoc 
def dissocEqLLD(t, R0, kd, Y, X): 
 t0 = t[0] 
 t_dissoc = t-t0 
 #t = t-t0 # Zeroing dissoc so they go from 0 to 699 instead of 301-1000 
 r_dissoc = (R0*exp(-kd*t_dissoc))+(Y*t_dissoc)+X 
 return r_dissoc 
## Langmuir 1:1 with linear drift global equation 
def solveAssocDissocEqsGLLD(assoc_init, dissoc_init,\     
        analyte_conc, fit_type, 
plot_prefix): 
 t_assoc_only, ru_assoc_only, Req0, ka0, Y0_assoc, X0_assoc = assoc_init 
 t_dissoc_only, ru_dissoc_only, R0, kd0, Y0_dissoc, X0_dissoc = dissoc_init 
 t_assoc_dissoc = np.concatenate([t_assoc_only, t_dissoc_only]) 
 ru_assoc_dissoc = np.concatenate([ru_assoc_only, ru_dissoc_only]) 
 #ru_assoc_dissoc = ru_assoc_dissoc-ru_assoc_dissoc[0] 
 assoc_slope_limit = (Req0*20)/(100*t_assoc_only[len(t_assoc_only)-1]) 
 ## Add R0 params for dissoc => last element from calc assoc values 
  
309 
 dissoc_slope_limit = (Req0*10)/(100*t_dissoc_only[0]) 
 assoc_dissoc_param_bounds = ((0, 0, 0,-assoc_slope_limit,-np.inf),(np.inf, np.inf, 
np.inf, assoc_slope_limit, np.inf)) 
 assoc_dissoc_init_params = [Req0, ka0, kd0, Y0_assoc, Y0_dissoc] 
 t_assoc_start = t_assoc_only[0] 
 t_assoc_end = t_assoc_only[len(t_assoc_only)-1] 
 t_dissoc_start = t_assoc_end+1 
 t_dissoc_end = t_dissoc_only[len(t_dissoc_only)-1] 
 #print t_assoc_start, t_assoc_end, t_dissoc_start, t_dissoc_end 
 def assocdissocEqGLLD(t, Req, ka, kd, Y_assoc, Y_dissoc): 
  t_assoc_only = t[t_assoc_start:t_assoc_end+1] 
  t_assoc = t_assoc_only-t_assoc_only[0] 
  t_dissoc_only = t[t_dissoc_start:t_dissoc_end+1] 
  t_dissoc = t_dissoc_only-t_dissoc_only[0] 
  #r_assoc = (Req*(1-exp(-kobs*t_assoc)))+(Y_assoc*t_assoc) 
  r_assoc = (Req*(1-exp(-
(ka*analyte_conc+kd)*t_assoc)))+(Y_assoc*t_assoc) 
  R0 = r_assoc[len(r_assoc)-1] 
  r_dissoc = (R0*exp(-kd*t_dissoc))+(Y_dissoc*t_dissoc) 
  r_assoc_dissoc = np.concatenate([r_assoc, r_dissoc]) 
  return r_assoc_dissoc 
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 adfit_params, adcov = curve_fit(assocdissocEqGLLD,\    
      t_assoc_dissoc,\    
      ru_assoc_dissoc,\ 
      assoc_dissoc_init_params,\ 
      bounds=assoc_dissoc_param_bounds,\ 
      #gtol = 1e-20,\ 
      #xtol = 1e-20, ftol = 1e-20,\ 
      max_nfev=5000000) 
 Req_pred, ka_pred, kd_pred, Y_assoc_pred, Y_dissoc_pred = adfit_params 
 assoc_dissoc_values_pred = assocdissocEqGLLD(t_assoc_dissoc, Req_pred, 
ka_pred, kd_pred, Y_assoc_pred, Y_dissoc_pred) 
 #assoc_dissoc_values_pred = assoc_dissoc_values_pred - 
assoc_dissoc_values_pred[0] 
 # Reverse calculating from the equation => kobs = kd+(ka*analyte_conc); Req = 
[A]*Rmax/([A]+KD) 
 kobs_pred = (ka_pred*analyte_conc)+kd_pred 
 kD_pred = kd_pred/ka_pred 
# Rmax_pred = (Req_pred/analyte_conc)*(analyte_conc+kD_pred) 
 glld_coefs_df = DataFrame([{'ka'      : ka_pred,\ 
     'kd'      : kd_pred,\ 
     'kD'      : kD_pred,\ 
     'kobs'     : kobs_pred,\ 
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     'Y_assoc_pred' : Y_assoc_pred,\ 
     'Y_dissoc_pred': Y_dissoc_pred,\ 
     'Rmax'     : R0}]) 
 assoc_values_pred = assoc_dissoc_values_pred[t_assoc_start:t_assoc_end+1] 
 dissoc_values_pred = assoc_dissoc_values_pred[t_dissoc_start:t_dissoc_end+1] 
 #print len(assoc_values_pred), len(dissoc_values_pred), len(t_assoc_only), 
len(t_dissoc_only), len(ru_assoc_only), len(ru_dissoc_only)  
 return ru_assoc_only, assoc_values_pred,\ 
     ru_dissoc_only, dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, glld_coefs_df,\ 
     adfit_params 
def assocEqMT(Rt, t, Rmax,\ 
       ka_analyte_conc,\ 
       kobs, kakt_ratio): 
 dRdt = (((ka_analyte_conc*Rmax)-(kobs*Rt))/(1+(kakt_ratio*(Rmax-Rt)))) 
 return dRdt 
def dissocEqMT(Rt, t, Rmax, kd, kakt_ratio): 
 dRdt = ((-kd*Rt)/(1+(kakt_ratio*(Rmax-Rt)))) 
 return dRdt 
def assocEqHL(t, C1, C2, kobs1, kobs2, X): 
 r_assoc = C1*(1-exp(-kobs1*t))+C2*(1-exp(-kobs2*t))+X 
 return r_assoc 
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def dissocEqHL(t, D1, D2, kd1, kd2, X): 
 t0 = t[0] 
 t = t-t0 # Zeroing dissoc so they go from 0 to 699 instead of 301-1000 
 r_dissoc = (D1*exp(-kd1*t))+(D2*exp(-kd2*t))+X 
 return r_dissoc 
# Calculate Residuals + Residual sum of squares/deviance 
# Calculate Residual degree of freedom + Residuals Stdev 
# Residual variance => reduced chisquare 
def calcResidualsSsqSD(input_response, pred_response, params_count): 
 resids = input_response-pred_response 
 input_response_var = var(input_response) 
 resid_ssq = sum(resids**2) 
 resid_dof = len(input_response)-params_count 
 resid_var = resid_ssq/resid_dof 
 resid_sd = sqrt(resid_var) 
 chisq_value, chisq_p_value = calcChisq(input_response,\    
      pred_response,\ 
      params_count) 
 return resids, resid_ssq, resid_sd, chisq_value 
# Calculate chisquare and p-values 
# delta degrees of freedom (ddof): p-k-1 
# p = #parameters, k = #data points 
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def calcChisq(input_response, pred_response, params_count): 
 chisq_ddof = len(input_response)-params_count-1 
 chisq_value, p_value = chisquare(f_obs=input_response,\    
 f_exp=pred_response,\ 
 ddof=chisq_ddof) 
 #print "Chi>", chisq_value, p_value 
 return chisq_value, p_value 
# Hard coding most of the params for now (other than Rmax) 
def getAssocDissocParams(t, response_unit, \      
       analyte_conc, t_assoc,\ 
      t_dissoc, t_assoc_start,\ 
      t_dissoc_end, fit_type): 
 # set common assoc-dissoc params 
 ka0, kd0, kt0 = 1e5, 1e-3, 1e8 
 ka10, kd10, ka20, kd20 = 1e5, 1e-3, 1e-4, 0.1 
 analyte_surf_conc0 = 0 
 X0 = 0 
 Y0 = 0 #0.01 suggested by biaeval documentation 
 # t_assoc_end = t_assoc time (since t starts from zero) 
 t_assoc_end = t_assoc_start+t_assoc 
 t_dissoc_start = t_assoc_end+1 
 # Adding one to extract the values because python is zero indexing! 
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 t_assoc_only = t[t_assoc_start:t_assoc_end+1] 
 ru_assoc_only = response_unit[t_assoc_start:t_assoc_end+1] 
 t_dissoc_only = t[t_dissoc_start:t_dissoc_end+1] 
 ru_dissoc_only = response_unit[t_dissoc_start:t_dissoc_end+1] 
 # Common association phase calcs 
 # Median of last 10 seconds of association phase: 
 ru_assoc_end = len(ru_assoc_only)-1 #t_assoc_end+1? 
 Rmax0 = float64(median(ru_assoc_only[(ru_assoc_end-10):ru_assoc_end])) 
#float(max(response_unit)) 
 #Rmax0 = float64(ru_assoc_only[ru_assoc_end] - ru_assoc_only[0]) 
 #Rmax0 = float(max(response_unit)) 
 kobs0 = kd0+(ka0*analyte_conc) 
 ### set assoc and dissoc params for each model 
 # Langmuir 1:1 
 if fit_type == "l": 
  assoc_all_init = [t_assoc_only, ru_assoc_only,\    
       Rmax0, kobs0, X0] 
  dissoc_noD_init = [t_dissoc_only, ru_dissoc_only,\    
        Rmax0, kd0, X0] 
 # Langmuir 1:1 with linear drift 
 elif fit_type == "lld": 
  # Works but might not use it! 
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  assoc_all_init = [t_assoc_only, ru_assoc_only,\    
      Rmax0, kobs0, Y0, X0] 
  dissoc_noD_init = [t_dissoc_only, ru_dissoc_only,\    
       Rmax0, kd0, Y0, X0] 
 # Langmuir 1:1 with linear drift multimodel correcting for drift 
 elif fit_type == "mlld": 
  # Work in progress - troubleshooting 
  assoc_all_init = [t_assoc_only, ru_assoc_only,\    
       Rmax0, kobs0, Y0, X0] 
  dissoc_noD_init = [t_dissoc_only, ru_dissoc_only,\    
        Rmax0, kd0, Y0, X0] 
 # Langmuir 1:1 with linear drift multimodel correcting for drift 
 elif fit_type == "mglld": 
  # Work in progress - troubleshooting 
  assoc_all_init = [t_assoc_only, ru_assoc_only,\    
      Rmax0, ka0, Y0, X0] 
  dissoc_noD_init = [t_dissoc_only, ru_dissoc_only,\    
       Rmax0, kd0, Y0, X0] 
 # Langmuir 1:1 with mass transport 
 elif fit_type == "lmt": 
  # Need to fix this! Might not need it! 
  kakt_ratio0 = ka0/kt0 
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  ka_analyte_conc0 = ka0*analyte_conc#*rmax 
  assoc_all_init = [t_assoc_only, ru_assoc_only,\    
      Rmax0, ka_analyte_conc0, kd0,\ 
      kobs0, kakt_ratio0, X0] 
  dissoc_noD_init = [t_dissoc_only, ru_dissoc_only,\    
      Rmax0, kd0, kakt_ratio0, X0] 
 # Langmuir 1:1 with mass transport by surface conc. prediction: 
 elif fit_type == "lmts": 
  assoc_all_init = [t_assoc_only, ru_assoc_only,\    
  Rmax0, analyte_surf_conc0,\ 
  kt0, ka0, kd0, X0] 
  dissoc_noD_init = [t_dissoc_only, ru_dissoc_only,\ 
  kd0, X0] 
 # Heterogeneous ligand 
 elif fit_type == "hl": 
  # NOT validated yet and might not use it! 
  # Setting all second params to 10% of first. Need to fix this? 
  #==>TESTING! 
  kobs10 = kd10+(ka10*analyte_conc) 
  kobs20 = kd20+(ka20*analyte_conc) 
  #<==TESTING! 
  Rmax10 = Rmax0 
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  Rmax20 = Rmax10*(10/100) 
  assoc_all_init = [t_assoc_only, ru_assoc_only,\    
  Rmax10, kobs10, Rmax20, kobs20, X0] 
  dissoc_noD_init = [t_dissoc_only, ru_dissoc_only,\ 
   kd10, kd20, X0] 
 return assoc_all_init, dissoc_noD_init 
########################################################################
######## 
############ Experimental hidden params START. Don't these models from CLI 
### FUNCTIONAL MODELS: 
## Langmuir 1:1 with R0 (R0) NOT constant constant during dissociation! 
def solveAssocDissocEqsLang1R0AsParam(assoc_all_init, dissoc_noD_init,\  
       analyte_conc, fit_type, plot_prefix): 
 t_assoc_only, ru_assoc_only, Req0, kobs0, X0 = assoc_all_init 
 afit_params, acov = curve_fit(assocEqLang1, t_assoc_only,\   
       ru_assoc_only,\ 
       p0=[Req0, kobs0, X0],\ 
       maxfev=2000000) 
 Req_pred, kobs_pred, X_pred = afit_params 
 assoc_values_pred = assocEqLang1(t_assoc_only, Req_pred,\   
        kobs_pred, X_pred) 
 ## Add R0 for dissoc => last element from calc assoc values? 
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 t_dissoc_only, ru_dissoc_only, R0, kd0, X0 = dissoc_noD_init 
 # Reset R0 since we are trying to use it as a parameter in this model and not 
constant! 
 #R0 = assoc_values_pred[len(assoc_values_pred)-1] 
 dfit_params, dcov = curve_fit(dissocEqLang1, t_dissoc_only,\   
      ru_dissoc_only,\ 
      p0=[R0, kd0, X0],\ 
      maxfev=5000000) 
 Rmax_pred, kd_pred, X_pred = dfit_params 
 dissoc_values_pred = dissocEqLang1(t_dissoc_only, Rmax_pred, kd_pred, 
X_pred) 
 # Reverse calculating from the equation => kobs = kd+(ka*analyte_conc) 
 ka_pred = (kobs_pred-kd_pred)/analyte_conc 
 kD_pred = kd_pred/ka_pred 
 l_coefs_df = DataFrame([{'ka': ka_pred,\      
     'kd': kd_pred,\      
      'kD': kD_pred, 'kobs' : kobs_pred}]) 
 return ru_assoc_only, assoc_values_pred,\ 
     ru_dissoc_only, dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, l_coefs_df,\ 
     afit_params, dfit_params 
## Langmuir 1:1 with linear drift NOT constant constant during dissociation! 
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def solveAssocDissocEqsLLDR0AsParam(assoc_init, dissoc_init,\    
     analyte_conc, fit_type, plot_prefix): 
 t_assoc_only, ru_assoc_only, Req0, kobs0, Y0, X0 = assoc_init 
 afit_params, acov = curve_fit(assocEqLLD, t_assoc_only,\    
     ru_assoc_only,\ 
     p0=[Req0, kobs0, Y0, X0],\ 
     maxfev=1000000) 
 Req_pred, kobs_pred, Y_assoc_pred, X_assoc_pred = afit_params 
 assoc_values_pred = assocEqLLD(t_assoc_only, Req_pred,\   
     kobs_pred, Y_assoc_pred, X_assoc_pred) 
 ## Add R0 params for dissoc => last element from calc assoc values 
 t_dissoc_only, ru_dissoc_only, R0, kd0, Y0, X0 = dissoc_init 
 #R0 = assoc_values_pred[len(assoc_values_pred)-1] 
 dfit_params, dcov = curve_fit(dissocEqLLD, t_dissoc_only,\   
     ru_dissoc_only,\ 
     p0=[R0, kd0, Y0, X0],\ 
     maxfev=1000000) 
 Rmax_pred, kd_pred, Y_dissoc_pred, X_dissoc_pred = dfit_params 
 dissoc_values_pred = dissocEqLLD(t_dissoc_only, Rmax_pred,\   
     kd_pred, Y_dissoc_pred, X_dissoc_pred) 
 # Reverse calculating from the equation => kobs = kd+(ka*analyte_conc) 
 ka_pred = (kobs_pred-kd_pred)/analyte_conc 
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 kD_pred = kd_pred/ka_pred 
 lld_coefs_df = DataFrame([{'ka': ka_pred,\      
     'kd': kd_pred,\ 
     'kD' : kD_pred, 'kobs' : kobs_pred}]) 
 return ru_assoc_only, assoc_values_pred,\ 
     ru_dissoc_only, dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, lld_coefs_df,\ 
     afit_params, dfit_params 
############ Experimental hidden params END ############ 
########################################################################
######## 
## Langmuir 1:1 with R0 constant during dissociation! 
def solveAssocDissocEqsLang1(assoc_init, dissoc_init,\     
     analyte_conc, fit_type, plot_prefix): 
 t_assoc_only, ru_assoc_only, Req0, kobs0, X0 = assoc_init 
 afit_params, acov = curve_fit(assocEqLang1, t_assoc_only,\   
     ru_assoc_only,\ 
     p0=[Req0, kobs0, X0],\ 
     maxfev=2000000) 
 Req_pred, kobs_pred, X_pred = afit_params 
 assoc_values_pred = assocEqLang1(t_assoc_only, Req_pred,\   
     kobs_pred, X_pred) 
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 ## Add R0 for dissoc => last element from calc assoc values? 
 t_dissoc_only, ru_dissoc_only, R0, kd0, X0 = dissoc_init 
 #R0 = ru_dissoc_only[0] 
 #R0 = assoc_values_pred[len(assoc_values_pred)-1] 
 def dissocEqLang1_R0constant(t, kd, X): 
  t0 = t[0] 
  r_dissoc = (R0*exp(-kd*(t-t0)))+X 
  return r_dissoc 
 dfit_params, dcov = curve_fit(dissocEqLang1_R0constant,\   
    t_dissoc_only,\ 
    ru_dissoc_only,\ 
    p0=[kd0, X0],\ 
    maxfev=5000000) 
 kd_pred, X_pred = dfit_params 
 dissoc_values_pred = dissocEqLang1_R0constant(t_dissoc_only,\ 
    kd_pred, X_pred) 
 # Reverse calculating from the equation => kobs = kd+(ka*analyte_conc) 
 ka_pred = (kobs_pred-kd_pred)/analyte_conc 
 kD_pred = kd_pred/ka_pred 
 Rmax_pred = (Req_pred/analyte_conc)*(analyte_conc+kD_pred) 
 l_coefs_df = DataFrame([{'ka'   : ka_pred,\    
    'kd'   : kd_pred,\ 
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    'kD'   : kD_pred,\ 
    'Rmax'  : Req0, 'kobs' : kobs_pred}])#Rmax_pred}]) 
 return ru_assoc_only, assoc_values_pred,\ 
     ru_dissoc_only, dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, l_coefs_df,\ 
     afit_params, dfit_params 
## Langmuir 1:1 with linear drift 
def solveAssocDissocEqsLLD(assoc_init, dissoc_init,\     
     analyte_conc, fit_type, plot_prefix): 
 t_assoc_only, ru_assoc_only, Req0, kobs0, Y0_assoc, X0_assoc = assoc_init 
 t_dissoc_only, ru_dissoc_only, R0, kd0, Y0_dissoc, X0_dissoc = dissoc_init 
 assoc_slope_limit = (R0*20)/(100*t_assoc_only[len(t_assoc_only)-1]) 
 assoc_param_bounds = ((0,0,-assoc_slope_limit,-
np.inf),(np.inf,np.inf,assoc_slope_limit,np.inf)) 
 assoc_init_params = [Req0, kobs0, Y0_assoc, X0_assoc] 
 afit_params, acov = curve_fit(assocEqLLD,\      
      t_assoc_only,\ 
      ru_assoc_only,\ 
      assoc_init_params,\ 
      bounds=assoc_param_bounds,\ 
      #xtol = 1e-20, ftol = 1e-20,\ 
      max_nfev=1000000) 
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 Req_pred, kobs_pred, Y_assoc_pred, X_assoc_pred = afit_params 
 assoc_values_pred = assocEqLLD(t_assoc_only, Req_pred,\   
      kobs_pred, Y_assoc_pred,\ 
      X_assoc_pred) 
 ## Add R0 params for dissoc => last element from calc assoc values 
 dissoc_slope_limit = (R0*10)/(100*t_dissoc_only[0]) 
 dissoc_param_bounds = ((0,-np.inf,-np.inf),(np.inf,np.inf,np.inf)) 
 dissoc_init_params = [kd0, Y0_dissoc, X0_dissoc] 
 def dissocEqLLD_R0constant(t, kd, Y, X): 
   t0 = t[0] 
   t_dissoc = t-t0 
   r_dissoc = (R0*exp(-kd*t_dissoc))+(Y*t_dissoc)+X 
   return r_dissoc 
 dfit_params, dcov = curve_fit(dissocEqLLD_R0constant,\    
    t_dissoc_only,\ 
    ru_dissoc_only,\ 
    dissoc_init_params,\ 
    bounds=dissoc_param_bounds,\ 
    #gtol = 1e-20,\ 
    #xtol = 1e-20, ftol = 1e-20,\ 
    max_nfev=5000000) 
 kd_pred, Y_dissoc_pred, X_dissoc_pred = dfit_params 
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 dissoc_values_pred = dissocEqLLD_R0constant(t_dissoc_only,\ 
    kd_pred, Y_dissoc_pred,\ 
    X_dissoc_pred) 
 # Reverse calculating from the equation => kobs = kd+(ka*analyte_conc); Req = 
[A]*Rmax/([A]+KD) 
 ka_pred = (kobs_pred-kd_pred)/analyte_conc 
 kD_pred = kd_pred/ka_pred 
# Rmax_pred = (Req_pred/analyte_conc)*(analyte_conc+kD_pred) 
 lld_coefs_df = DataFrame([{'ka'      : ka_pred,\ 
   'kd'      : kd_pred,\ 
   'kD'      : kD_pred,\ 
   'kobs'     : kobs_pred,\ 
   'Y_assoc_pred' : Y_assoc_pred,\ 
   'Y_dissoc_pred': Y_dissoc_pred,\ 
   'Rmax'     : R0}])#Rmax_pred}]) 
 return ru_assoc_only, assoc_values_pred,\ 
     ru_dissoc_only, dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, lld_coefs_df,\ 
     afit_params, dfit_params 
## Langmuir 1:1 with linear drift multimodel correcting for drift 
def solveAssocDissocEqsMLLD(assoc_init, dissoc_init,\     
    t_preassoc, ru_preassoc,\ 
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    analyte_conc, fit_type, plot_prefix): 
 lfit = polyfit(t_preassoc,\ 
         ru_preassoc,\ 
         1) 
 preassoc_drift = polyval(lfit, t_preassoc) 
 ru_drift_corr_preassoc_only = (ru_preassoc - preassoc_drift)# + preassoc_drift[0] 
 ru_assoc_only, assoc_values_pred,\ 
 ru_dissoc_only, dissoc_values_pred,\ 
 t_assoc_only, t_dissoc_only, lld_coefs_df,\ 
 lld_afit_params, lld_dfit_params = solveAssocDissocEqsLLD(assoc_init,\ 
     dissoc_init,\ 
     analyte_conc,\ 
     fit_type,\ 
     plot_prefix) 
 Req_pred, kobs_pred, Y_assoc_pred, X_assoc_pred = lld_afit_params 
 kd_pred, Y_dissoc_pred, X_dissoc_pred = lld_dfit_params 
 #Rmax_pred = (Req_pred*(analyte_conc+kD_pred))/analyte_conc 
 assoc_drift = Y_assoc_pred*t_assoc_only 
 dissoc_drift = Y_dissoc_pred*t_dissoc_only 
 # Correct association + dissociation drifts by subtracting predicted drifts from the 
referenced data 
 ru_drift_corr_assoc_only = (ru_assoc_only - assoc_drift) - X_assoc_pred 
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 ru_drift_corr_assoc_only = (ru_drift_corr_assoc_only - 
ru_drift_corr_assoc_only[0]) + 
ru_drift_corr_preassoc_only[len(ru_drift_corr_preassoc_only)-1] 
 #ru_drift_corr_assoc_only = ru_assoc_only-ru_assoc_only[0]-assoc_drift - 
X_assoc_pred+ru_drift_corr_preassoc_only[len(ru_drift_corr_preassoc_only)-1] 
 ru_drift_corr_dissoc_only = (ru_dissoc_only - dissoc_drift) - X_dissoc_pred 
 ru_drift_corr_dissoc_only = (ru_drift_corr_dissoc_only - 
ru_drift_corr_dissoc_only[0]) + ru_drift_corr_assoc_only[len(ru_drift_corr_assoc_only)-
1] 
 #ru_drift_corr_dissoc_only=ru_dissoc_only-ru_dissoc_only[0]-
dissoc_drift+ru_drift_corr_assoc_only[len(ru_drift_corr_assoc_only)-1] 
 #print ru_drift_corr_assoc_only[0], ru_drift_corr_dissoc_only[0] 
 t_assoc_only, ru_assoc_only, Req0, kobs0, Y0, X0 = assoc_init 
 t_dissoc_only, ru_dissoc_only, R0, kd0, Y0, X0 = dissoc_init 
 #print lld_afit_params, lld_dfit_params  
 ru_drift_corr_assoc_end = len(ru_drift_corr_assoc_only)-1 
 Rmax_drift_corr = 
float64(median(ru_drift_corr_assoc_only[(ru_drift_corr_assoc_end-
10):ru_drift_corr_assoc_end])) 
 mlld_assoc_init = [t_assoc_only, ru_drift_corr_assoc_only, Req_pred, kobs_pred, 
Y_assoc_pred, X0] 
  
327 
 mlld_dissoc_init = [t_dissoc_only, ru_drift_corr_dissoc_only, R0, kd_pred, 
Y_dissoc_pred, X0] 
 #print type(t_assoc_only), type(ru_drift_corr_assoc_only), type(t_dissoc_only), 
type(ru_drift_corr_dissoc_only) 
 ru_mlld_assoc_only, mlld_assoc_values_pred,\ 
 ru_mlld_dissoc_only, mlld_dissoc_values_pred,\ 
 t_assoc_only, t_dissoc_only, mlld_coefs_df,\ 
 mlld_afit_params, mlld_dfit_params = 
solveAssocDissocEqsLLD(mlld_assoc_init,\ 
      mlld_dissoc_init,\ 
      analyte_conc,\ 
      fit_type, plot_prefix) 
 #print mlld_afit_params, mlld_dfit_params 
 return ru_drift_corr_assoc_only, mlld_assoc_values_pred,\ 
     ru_drift_corr_dissoc_only, mlld_dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, mlld_coefs_df,\ 
     mlld_afit_params, mlld_dfit_params, 
ru_drift_corr_preassoc_only 
## Langmuir 1:1 with linear drift GLOBAL multimodel correcting for drift 
def solveAssocDissocEqsMGLLD(assoc_init, dissoc_init,\     
     t_preassoc, ru_preassoc,\ 
     analyte_conc, fit_type, plot_prefix): 
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 lfit = polyfit(t_preassoc,\ 
         ru_preassoc,\ 
         1) 
 preassoc_drift = polyval(lfit, t_preassoc) 
 ru_drift_corr_preassoc_only = (ru_preassoc - preassoc_drift)# + preassoc_drift[0]  
 t_assoc_only, ru_assoc_only, Req0, ka0, Y0_assoc, X0_assoc = assoc_init 
 t_dissoc_only, ru_dissoc_only, R0, kd0, Y0_dissoc, X0_dissoc = dissoc_init 
 kobs0 = (ka0*analyte_conc)+kd0  
 assoc_init = [t_assoc_only, ru_assoc_only, Req0, kobs0, Y0_assoc, X0_assoc] 
 t_assoc_start = t_assoc_only[0] 
 t_assoc_end = t_assoc_only[len(t_assoc_only)-1] 
 t_dissoc_start = t_assoc_end+1 
 t_dissoc_end = t_dissoc_only[len(t_dissoc_only)-1] 
 t_assoc_dissoc = np.concatenate([t_assoc_only, t_dissoc_only]) 
 ru_assoc_dissoc = np.concatenate([ru_assoc_only, ru_dissoc_only]) 
 def assocdissocEqLLD_global(t, Req, ka, kd, Y_assoc, Y_dissoc): 
  t_assoc_only = t[t_assoc_start:t_assoc_end+1] 
  t_assoc = t_assoc_only-t_assoc_only[0] 
  t_dissoc_only = t[t_dissoc_start:t_dissoc_end+1] 
  t_dissoc = t_dissoc_only-t_dissoc_only[0] 
  r_assoc = (Req*(1-exp(-(ka*analyte_conc+kd)*t_assoc))) + 
(Y_assoc*t_assoc) 
  
329 
  R0 = r_assoc[len(r_assoc)-1] 
  r_dissoc = (R0*exp(-kd*t_dissoc)) + (Y_dissoc*t_dissoc) 
  r_assoc_dissoc = np.concatenate([r_assoc, r_dissoc]) 
  return r_assoc_dissoc   
 assoc_slope_limit = (R0*20)/(100*t_assoc_only[len(t_assoc_only)-1]) 
 #assoc_param_bounds = ((0,0,-assoc_slope_limit,-
np.inf),(np.inf,np.inf,assoc_slope_limit,np.inf)) 
 lld_global_assoc_dissoc_init_params = [Req0, ka0, kd0, Y0_assoc, Y0_dissoc] 
 lld_global_assoc_dissoc_param_bounds = ((0, 0, 0, -assoc_slope_limit, -
np.inf),(np.inf, np.inf, np.inf, assoc_slope_limit,np.inf)) 
 #print max(ru_assoc_dissoc), max(ru_drift_corr_assoc_only) 
 lld_global_adfit_params, lld_global_adcov = 
curve_fit(assocdissocEqLLD_global,\       
     t_assoc_dissoc,\ 
     ru_assoc_dissoc,\ 
     lld_global_assoc_dissoc_init_params,\ 
     bounds=lld_global_assoc_dissoc_param_bounds,\ 
     #gtol = 1e-20,\ 
     #xtol = 1e-20, ftol = 1e-20,\ 
     max_nfev=5000000) 
 Req_pred, ka_pred, kd_pred, Y_assoc_pred, Y_dissoc_pred = 
lld_global_adfit_params 
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 #print lld_global_adfit_params   
 #ru_assoc_only, assoc_values_pred,\ 
 #ru_dissoc_only, dissoc_values_pred, t_assoc_only, t_dissoc_only, 
glld_coefs_df,\ 
 #glld_adfit_params = solveAssocDissocEqsGLLD(assoc_init,\ 
 #           
     dissoc_init,\ 
 #           
     analyte_conc,\ 
 #           
     fit_type,\ 
 #           
     plot_prefix) 
 #Req_pred, ka_pred, kd_pred, Y_assoc_pred, Y_dissoc_pred = glld_adfit_params 
 #ru_assoc_only, assoc_values_pred,\ 
 #ru_dissoc_only, dissoc_values_pred,\ 
 #t_assoc_only, t_dissoc_only, lld_coefs_df,\ 
 #lld_afit_params, lld_dfit_params = solveAssocDissocEqsLLD(assoc_init,\ 
 #           
     dissoc_init,\ 
 #           
     analyte_conc,\ 
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 #           
     fit_type,\ 
 #           
     plot_prefix) 
 #Req_pred, kobs_pred, Y_assoc_pred, X_assoc_pred = lld_afit_params 
 #kd_pred, Y_dissoc_pred, X_dissoc_pred = lld_dfit_params 
 assoc_drift = Y_assoc_pred*t_assoc_only 
 dissoc_drift = Y_dissoc_pred*t_dissoc_only 
 ru_drift_corr_assoc_only = (ru_assoc_only - assoc_drift) 
 ru_drift_corr_assoc_only = (ru_drift_corr_assoc_only + 
ru_drift_corr_assoc_only[0]) #+ 
ru_drift_corr_preassoc_only[len(ru_drift_corr_preassoc_only)-1]  
 #print ru_assoc_only 
 #print ru_drift_corr_assoc_only 
 ru_drift_corr_dissoc_only = (ru_dissoc_only - dissoc_drift) 
 ru_drift_corr_dissoc_only = (ru_drift_corr_dissoc_only - 
ru_drift_corr_dissoc_only[0]) + ru_drift_corr_assoc_only[len(ru_drift_corr_assoc_only)-
1]  
 ##print ru_dissoc_only 
 #print ru_drift_corr_dissoc_only 
 #ru_drift_corr_assoc_only = ru_drift_corr_assoc_only - 
ru_drift_corr_assoc_only[0] 
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 #print ru_drift_corr_assoc_only[0:10], ru_drift_corr_dissoc_only[0:10] 
 #ru_drift_corr_dissoc_only = ru_drift_corr_dissoc_only - 
ru_drift_corr_assoc_only[0]  
 ru_drift_corr_assoc_end = len(ru_drift_corr_assoc_only)-1 
 Rmax_drift_corr = 
float64(median(ru_drift_corr_assoc_only[(ru_drift_corr_assoc_end-
10):ru_drift_corr_assoc_end]))  
 #kobs_pred = (ka_pred*analyte_conc)+kd_pred 
 #ka_pred = (kobs_pred-kd_pred)/analyte_conc 
 #print ka_pred 
 #print glld_adfit_params 
 #print lld_afit_params, lld_dfit_params  
 def dissocEqLang1_R0constant(t, kd): 
  t0 = t[0] 
  r_dissoc = (Rmax_drift_corr*exp(-kd*(t-t0))) 
  return r_dissoc 
 l1_dissoc_param_bounds = ((0),(np.inf)) 
 l1_dfit_params, l1_dcov = curve_fit(dissocEqLang1_R0constant,\   
     t_dissoc_only,\ 
     ru_drift_corr_dissoc_only,\ 
     bounds=l1_dissoc_param_bounds,\ 
     p0=[kd0],\ 
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     max_nfev=5000000) 
 kd_l1_pred = l1_dfit_params 
 #print l1_dfit_params 
 kobs_l1_pred = (ka_pred*analyte_conc)+kd_l1_pred  
 def assocdissocEqL_kdfixed(t, Req, ka): 
  #t_assoc_only = t[t_assoc_start:t_assoc_end+1] 
  #t_assoc = t_assoc_only-t_assoc_only[0] 
  #t_dissoc_only = t[t_dissoc_start:t_dissoc_end+1] 
  #t_dissoc = t_dissoc_only-t_dissoc_only[0] 
  r_assoc = (Req*(1-exp(-(ka*analyte_conc+kd_l1_pred)*t))) 
  #r_assoc = (Req*(1-exp(-
(ka*analyte_conc+kd_l1_pred)*t_assoc)))+X_assoc 
  #r_dissoc = (Req*exp(-kd_l1_pred*t_dissoc))+X_dissoc 
  #r_assoc_dissoc = np.concatenate([r_assoc, r_dissoc]) 
  #return r_assoc_dissoc 
  return r_assoc 
 lkdf_assoc_dissoc_param_bounds = ((0, 0),(np.inf, np.inf)) 
 lkdf_assoc_dissoc_init_params = [Rmax_drift_corr, ka0]   
 lkdf_adfit_params, lkdf_adcov = curve_fit(assocdissocEqL_kdfixed,\  
    t_assoc_only,\ 
    ru_drift_corr_assoc_only,\ 
    lkdf_assoc_dissoc_init_params,\ 
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    bounds=lkdf_assoc_dissoc_param_bounds,\ 
    #gtol = 1e-20,\ 
    #xtol = 1e-20, ftol = 1e-20,\ 
    max_nfev=5000000) 
 Req_lkdf_pred, ka_lkdf_pred = lkdf_adfit_params 
 #print lkdf_adfit_params 
 def assocdissocEqL_kdRelaxed(t, Req, ka, kd): 
  t_assoc_only = t[t_assoc_start:t_assoc_end+1] 
  t_assoc = t_assoc_only-t_assoc_only[0] 
  t_dissoc_only = t[t_dissoc_start:t_dissoc_end+1] 
  t_dissoc = t_dissoc_only-t_dissoc_only[0] 
  r_assoc = (Req*(1-exp(-(ka*analyte_conc+kd)*t_assoc))) 
  R0 = r_assoc[len(r_assoc)-1] 
  r_dissoc = (R0*exp(-kd*t_dissoc)) 
  r_assoc_dissoc = np.concatenate([r_assoc, r_dissoc]) 
  return r_assoc_dissoc 
 lkdr_assoc_dissoc_init_params = [Rmax_drift_corr, ka_lkdf_pred, kd_l1_pred] 
 lkdr_assoc_dissoc_param_bounds = ((0, 0, 0),(np.inf, np.inf, np.inf)) 
 #print max(ru_assoc_dissoc), max(ru_drift_corr_assoc_only) 
 ru_drift_corr_assoc_dissoc = np.concatenate([ru_drift_corr_assoc_only, 
ru_drift_corr_dissoc_only]) 
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 lkdr_adfit_params, lkdr_adcov = curve_fit(assocdissocEqL_kdRelaxed,\  
    t_assoc_dissoc,\ 
    ru_drift_corr_assoc_dissoc,\ 
    lkdr_assoc_dissoc_init_params,\ 
    bounds=lkdr_assoc_dissoc_param_bounds,\ 
    #gtol = 1e-20,\ 
    #xtol = 1e-20, ftol = 1e-20,\ 
    max_nfev=5000000) 
 Req_lkdr_pred, ka_lkdr_pred, kd_lkdr_pred = lkdr_adfit_params 
 #print lkdr_adfit_params 
 mlld_assoc_dissoc_values_pred = assocdissocEqL_kdRelaxed(t_assoc_dissoc, 
Req_lkdr_pred, ka_lkdr_pred, kd_lkdr_pred)  
 # Temp for output purposes: 
 mlld_adfit_params = lkdr_adfit_params 
 t_assoc_only = t_assoc_dissoc[t_assoc_start:t_assoc_end+1] 
 mlld_assoc_values_pred = 
mlld_assoc_dissoc_values_pred[t_assoc_start:t_assoc_end+1] 
 ru_mlld_assoc_only = ru_drift_corr_assoc_dissoc[t_assoc_start:t_assoc_end+1]  
 t_dissoc_only = t_assoc_dissoc[t_dissoc_start:t_dissoc_end+1] 
 mlld_dissoc_values_pred = 
mlld_assoc_dissoc_values_pred[t_dissoc_start:t_dissoc_end+1] 
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 ru_mlld_dissoc_only = 
ru_drift_corr_assoc_dissoc[t_dissoc_start:t_dissoc_end+1]  
 kD_lkdr_pred = kd_lkdr_pred/ka_lkdr_pred 
 kobs_lkdr_pred = (ka_lkdr_pred*analyte_conc)+kd_lkdr_pred 
 mlld_coefs_df = DataFrame([{'ka'      : 
ka_lkdr_pred,\ 
  'kd'      : kd_lkdr_pred,\ 
  'kD'      : kD_lkdr_pred,\ 
  'kobs'     : kobs_lkdr_pred,\ 
  'Y_assoc_pred' : Y_assoc_pred,\ 
  'Y_dissoc_pred': Y_dissoc_pred,\ 
  'Rmax'     : Req_lkdr_pred}]) 
 #mlld_assoc_init = [t_assoc_only, ru_drift_corr_assoc_only, Rmax_drift_corr, 
ka0, 0, 0] 
 #mlld_dissoc_init = [t_dissoc_only, ru_drift_corr_dissoc_only, Rmax_drift_corr, 
kd0, 0, 0] 
 #ru_mlld_assoc_only, mlld_assoc_values_pred,\ 
 #ru_mlld_dissoc_only, mlld_dissoc_values_pred, t_assoc_only, t_dissoc_only, 
mlld_coefs_df,\ 
 #mlld_adfit_params = solveAssocDissocEqsGLLD(mlld_assoc_init,\ 
 #           
       mlld_dissoc_init,\ 
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 #           
       analyte_conc,\ 
 #           
       fit_type, plot_prefix) 
 #print mlld_adfit_params 
 return ru_mlld_assoc_only, mlld_assoc_values_pred,\ 
     ru_mlld_dissoc_only, mlld_dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, mlld_coefs_df,\ 
     mlld_adfit_params, mlld_adfit_params, 
ru_drift_corr_preassoc_only 
## Langmuir 1:1 with mass transfer using 
## analyte surface concentration 
def solveAssocDissocEqsAsurfLMT(assoc_all_init,\ 
    dissoc_noD_init,\ 
    analyte_conc,\ 
    fit_type,\ 
    plot_prefix): 
 #print assoc_all_init 
 ## Asurf calculation 
 t_assoc_only, ru_assoc_only,\ 
  Rmax0, analyte_surf_conc0,\ 
  kt0, kd0, ka0, X0 = assoc_all_init 
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 t_dissoc_only, ru_dissoc_only,\ 
 kd0, X0 = dissoc_noD_init 
 def calcAnalyteSurfConcMT(R, t, Rmax,      
      analyte_surf_conc,\ 
      kt, X): 
dAsdt = (kt*(analyte_conc-analyte_surf_conc))-X 
  #dAsdt = (kt_analyte_conc-kt_analyte_surf_conc))-
(ka*analyte_surf_conc*(Rmax-R))+(kd*R) 
  return dAsdt 
 def solveAnalyteSurfConcMT(t, Rmax, analyte_surf_conc,\   
           kt, ka, kd): 
  X = (ka*analyte_surf_conc*(Rmax-
ru_assoc_only[0]))+(kd*ru_assoc_only[0]) 
  analyte_surf_conc_pred = odeint(calcAnalyteSurfConcMT,\ 
      ru_assoc_only[0], t,\ 
      args=(Rmax,\ 
      analyte_surf_conc,\ 
      kt, X)) 
  return analyte_surf_conc_pred[:,0].ravel() 
 asurf_params, asurf_cov = curve_fit(solveAnalyteSurfConcMT,\ 
      t_assoc_only, \ 
      ru_assoc_only,\ 
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      p0=[Rmax0,\ 
      analyte_surf_conc0,\ 
      kt0, ka0,\ 
      kd0]) 
 #print "As---->", asurf_params 
 Rmax_pred, analyte_surf_conc_pred,\ 
 kt_pred, ka_pred, kd_pred = asurf_params 
 asurf_pred = solveAnalyteSurfConcMT(t_assoc_only,\    
      analyte_surf_conc_pred,\ 
      kt_pred, ka_pred,\ 
      kd_pred, Rmax_pred) 
 #print "Asurf Pred=>", asurf_pred[len(asurf_pred)-1] 
 kobs_pred = (ka_pred*analyte_surf_conc_pred)+kd_pred 
 kobs0= (ka0*analyte_surf_conc_pred)+kd0 
 assoc_init = [t_assoc_only, ru_assoc_only,\ 
        Rmax0, kobs0, X0] 
 dissoc_noD_init = [t_dissoc_only, ru_dissoc_only,\ 
        kd_pred, Rmax0, X0] 
 ru_assoc_only, assoc_values_pred,\ 
 ru_dissoc_only, dissoc_values_pred,\ 
 t_assoc_only, t_dissoc_only, l_coefs_df = 
solveAssocDissocEqsLang1(assoc_init,\ 
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        dissoc_noD_init,\ 
         analyte_surf_conc_pred,\ 
        fit_type,\ 
        plot_prefix) 
 lmts_coef_df_init = 
DataFrame([{'analyte_surf_conc_pred':analyte_surf_conc_pred,\    
        'kt':kt_pred}]) 
 lmts_coef_df = concat([lmts_coef_df_init, l_coefs_df], axis=1) 
 return ru_assoc_only, assoc_values_pred,\ 
     ru_dissoc_only, dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, lmts_coef_df,\ 
     afit_params, dfit_params 
## Langmuir 1:1 with mass transfer 
def solveAssocDissocEqsLMT(assoc_all_init, dissoc_noD_init,\    
     analyte_conc, fit_type,\    
     plot_prefix): 
 ## Assoc phase--> 
 t_assoc_only, ru_assoc_only,\ 
  Rmax_assoc0, ka_analyte_conc0, kd0,\ 
  kobs0, kakt_ratio_assoc0, X0 = assoc_all_init 
 #print "Init Assoc=> ", Rmax, ka_analyte_conc_rmax0, kd0,\ 
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 #            
kobs0, kakt_ratio_assoc0, X0 
 # Solve ODE for association phase: 
 def solveAssocEqsLMT(t, Rmax, ka_analyte_conc,\ 
            kobs, 
kakt_ratio_assoc): 
  Rt_pred = odeint(assocEqMT, ru_assoc_only[0], t,\ 
           args=(Rmax, 
ka_analyte_conc,\          
  kobs, kakt_ratio_assoc)) 
  return Rt_pred[:,0].ravel() 
 afit_params, acov = curve_fit(solveAssocEqsLMT,\     
    t_assoc_only,\ 
    ru_assoc_only,\ 
    p0=[Rmax_assoc0,\ 
    ka_analyte_conc0,\ 
    kobs0, kakt_ratio_assoc0],\     
    maxfev=1000000) 
 print "LMT ASSOC PARAMS=>",afit_params 
 Rmax_assoc_pred,\ 
 ka_analyte_conc_pred,\ 
 kobs_pred, kakt_ratio_assoc_pred = afit_params 
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 assoc_values_pred = solveAssocEqsLMT(t_assoc_only,\ 
       Rmax_assoc_pred,\ 
       ka_analyte_conc_pred,\ 
       kobs_pred,\ 
       kakt_ratio_assoc_pred) 
 ## Dissoc phase--> 
 t_dissoc_only, ru_dissoc_only,\ 
  Rmax_dissoc0, kd0, kakt_ratio_dissoc0, X0 = dissoc_noD_init 
 #print "Init Dissoc=>", Rmax, kd0, kakt_ratio_dissoc0, X0 
 # Solve ODE for dissociation phase: 
 def solveDissocEqsLMT(t, Rmax, kd, kakt_ratio_dissoc): 
  Rt_pred = odeint(dissocEqMT,\      
    ru_dissoc_only[0],\ 
    t,\ 
    args=(Rmax, kd, kakt_ratio_dissoc)) 
  return Rt_pred[:,0].ravel() 
 dfit_params, dcov = curve_fit(solveDissocEqsLMT,\ 
    t_dissoc_only,\ 
    ru_dissoc_only,\ 
    p0=[Rmax_dissoc0, kd0,\     
    kakt_ratio_dissoc0],\ 
    maxfev=1000000) 
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 print "LMT DISSOC PARAMS=>", dfit_params 
 Rmax_dissoc_pred, kd_pred,\ 
 kakt_ratio_dissoc_pred = dfit_params 
 dissoc_values_pred = solveDissocEqsLMT(t_dissoc_only,\ 
        Rmax_dissoc_pred,\ 
        kd_pred,\ 
        kakt_ratio_dissoc_pred) 
 # Return the required coefficients 
 ka_pred = (kobs_pred-kd_pred)/analyte_conc 
 kt_assoc = ka_pred/kakt_ratio_assoc_pred 
 ka_from_rmax_conc_pred = ka_analyte_conc_pred/(analyte_conc) 
 kt_from_rmax_conc_pred = ka_from_rmax_conc_pred/kakt_ratio_assoc_pred 
 kt_dissoc = ka_pred/kakt_ratio_dissoc_pred 
 kD_pred = kd_pred/ka_pred 
 lmt_coefs_df = DataFrame([{'ka': ka_pred,\      
   #'ka_from_rmax_conc_pred' : ka_from_rmax_conc_pred,\ 
   #'kt_from_rmax_conc_pred' : kt_from_rmax_conc_pred,\ 
   #'rmax_assoc_pred' : Rmax_assoc_pred,\ 
   #'rmax_dissoc_pred' : Rmax_dissoc_pred,\ 
   'kd': kd_pred,\ 
   'kD': kD_pred,\ 
   'kt_dissoc': kt_dissoc,\ 
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   'kt_assoc': kt_assoc}]) 
 return ru_assoc_only, assoc_values_pred,\ 
     ru_dissoc_only, dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, lmt_coefs_df,\ 
     afit_params, dfit_params 
## Heterogeneous Ligand 
def solveAssocDissocEqsHL(assoc_all_init,\ 
 dissoc_noD_init,\ 
 analyte_conc,\ 
 fit_type, plot_prefix): 
 t_assoc_only, ru_assoc_only,\ 
 C10, kobs10, C20, kobs20, X0 = assoc_all_init 
 afit_params, acov = curve_fit(assocEqHL,\ 
    t_assoc_only,\ 
    ru_assoc_only,\ 
    p0=[C10, kobs10, C20, kobs20, X0],\ 
    maxfev=1000000) 
 C1_pred, kobs1_pred, C2_pred, kobs2_pred, X_pred = afit_params 
 assoc_values_pred = assocEqHL(t_assoc_only,\     
     C1_pred, kobs1_pred,\ 
     C2_pred, kobs2_pred,\ 
     X_pred) 
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 ## Add R0 for dissoc => last element from calc assoc values 
 t_dissoc_only, ru_dissoc_only, kd10, kd20, X0 = dissoc_noD_init 
 D10 = assoc_values_pred[len(assoc_values_pred)-1] 
 D20 = D10*(30/100) 
 dfit_params, dcov = curve_fit(dissocEqHL, t_dissoc_only,\ 
    ru_dissoc_only,\ 
    p0=[D10, kd10, D20, kd20, X0],\ 
    maxfev=1000000) 
 D1_pred, kd1_pred, D2_pred, kd2_pred, X_pred = dfit_params 
 dissoc_values_pred = dissocEqHL(t_dissoc_only,\ 
      D1_pred, kd1_pred,\ 
      D2_pred, kd2_pred,\ 
      X_pred) 
 # Reverse calculating from the equation => kobs = kd+(ka*analyte_conc) 
 ka1_pred = (kobs1_pred-kd1_pred)/analyte_conc 
 kD1_pred = kd1_pred/ka1_pred 
 ka2_pred = (kobs2_pred-kd2_pred)/analyte_conc 
 kD2_pred = kd2_pred/ka2_pred 
 hl_coefs_df = DataFrame([{'ka1': ka1_pred, 'kd1': kd1_pred,\ 
  'kD1' : kD1_pred,\ 
  'ka2': ka2_pred, 'kd2': kd2_pred,\ 
  'kD2' : kD2_pred}]) 
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 return ru_assoc_only, assoc_values_pred,\ 
     ru_dissoc_only, dissoc_values_pred,\ 
     t_assoc_only, t_dissoc_only, hl_coefs_df,\ 
     afit_params, dfit_params 
def combineAndPlot(response_unit_pread, t_pread,\ 
 t_assoc_dissoc,\ 
 assoc_dissoc_values_pred,\ 
 assoc_dissoc_values_resids,\ 
 raw_time,\ 
 raw_response,\ 
 prot_block_name, 
 plot_file_path): 
 plot_filenamepath = join(plot_file_path, prot_block_name + '.pdf') 
 plt.plot(raw_time, raw_response, 'y-',label='raw_dc') 
 plt.plot(t_pread, response_unit_pread, 'k-',\ 
      label='data', linewidth=0.5) 
 plt.plot(t_assoc_dissoc, assoc_dissoc_values_pred, 'r-',\ 
      label='fitted') 
 plt.plot(t_assoc_dissoc, assoc_dissoc_values_resids, 'b-',\ 
      label='residuals', linewidth=0.5) 
 plt.title(prot_block_name) 
 plt.legend(loc='best') 
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 plt.savefig(plot_filenamepath) 
 plt.close() 
 return plot_filenamepath 
def fitCurveModels(df_time_refdall,\ 
          df_time_raw,\ 
          analyte_conc,\ 
          analyte_mass,\ 
          flow_rate,\ 
          t_assoc, t_dissoc,\ 
          assoc_tstart, 
dissoc_tend,\ 
          prot_block_name, 
fit_type,\ 
        base_input_filename, 
        plot_file_path,\  
        refn_spots_name_list,\ 
         merger, time_colname): 
 # Reset the association start value to zero since we zeroed the data to start from 
zero 
 # Zero Association start time since the dataframe is already zeroed to association 
start time 
 assoc_tstart_new = assoc_tstart-assoc_tstart 
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 dissoc_tend_new = dissoc_tend-assoc_tstart 
 raw_response = np.array(df_time_raw.iloc[:,1]) 
 raw_time = np.array(df_time_raw.iloc[:,0]) 
 df_time_refdall_preassoc = df_time_refdall.loc[(df_time_refdall[time_colname] < 
assoc_tstart_new)] 
 df_time_refdall_ad = df_time_refdall.loc[(df_time_refdall[time_colname] >= 
assoc_tstart_new) & (df_time_refdall[time_colname] <= dissoc_tend_new)] 
 refs_count = len(refn_spots_name_list) 
 t_pread = np.array(df_time_refdall[time_colname]) 
 t_preassoc = np.array(df_time_refdall_preassoc[time_colname]) 
 t = np.array(df_time_refdall_ad[time_colname]) 
 one_spot_all_coefs_df = DataFrame() 
 coefs_df = DataFrame() 
 all_plot_filenames_by_fittype = list() 
 term_refd_response_unit_pread = "" 
 for icol in range(0, refs_count): 
  response_icol = icol+ 
  ref_spot_name = refn_spots_name_list[icol] 
  print "Reference#", response_icol, "=>", ref_spot_name 
  plot_prefix = str(ref_spot_name) + '_' + fit_type 
  response_unit_preassoc = 
np.array(df_time_refdall_preassoc.iloc[:,response_icol]) 
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  response_unit_pread = np.array(df_time_refdall.iloc[:,response_icol]) 
  response_unit = np.array(df_time_refdall_ad.iloc[:,response_icol]) 
  ### get initial assoc + dissoc specific params 
  assoc_all_init,\ 
  dissoc_noD_init = getAssocDissocParams(t,\ 
       response_unit,\ 
       analyte_conc,\ 
       t_assoc, t_dissoc,\ 
       assoc_tstart_new, dissoc_tend_new,\ 
       fit_type) 
  spot_info_df = DataFrame([{'array_protein_spot' : prot_block_name,\ 
      'reference_no' : response_icol,\ 
      'reference_spot' : ref_spot_name,\ 
      'input_filename' : base_input_filename,\ 
      'flow_rate' : flow_rate,\ 
      'analyte_conc': analyte_conc,\ 
      'analyte_mass': analyte_mass,\ 
      'assoc_tstart': assoc_tstart,\ 
      'assoc_time' : t_assoc,\ 
      'dissoc_time': t_dissoc,\ 
      'type_of_fit' : fit_type}]) 
  try: 
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   if fit_type == "l": 
    #print "Fitting langmuir 1:1 ...." 
     ru_assoc_only, assoc_values_pred,\ 
    ru_dissoc_only, dissoc_values_pred,\ 
    t_assoc_only, t_dissoc_only, coefs_df,\ 
    afit_params, dfit_params = 
solveAssocDissocEqsLang1(assoc_all_init,\ 
    dissoc_noD_init,\ 
    analyte_conc,\ 
    fit_type, plot_prefix) 
   elif fit_type == "lld": 
    #print "Fitting langmuir 1:1 with drift...." 
     ru_assoc_only, assoc_values_pred,\ 
    ru_dissoc_only, dissoc_values_pred,\ 
    t_assoc_only, t_dissoc_only, coefs_df,\ 
    afit_params, dfit_params = 
solveAssocDissocEqsLLD(assoc_all_init,\ 
    dissoc_noD_init,\ 
    analyte_conc,\ 
    fit_type, plot_prefix) 
   elif fit_type == "mlld": 
    #print "Fitting langmuir 1:1 with drift...." 
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     ru_assoc_only, assoc_values_pred,\ 
    ru_dissoc_only, dissoc_values_pred,\ 
    t_assoc_only, t_dissoc_only, coefs_df,\ 
    afit_params, dfit_params, ru_drift_corr_preassoc_only = 
solveAssocDissocEqsMLLD(assoc_all_init,\ 
    dissoc_noD_init,\ 
    t_preassoc, response_unit_preassoc,\ 
    analyte_conc,\ 
    fit_type, plot_prefix) 
     response_unit_pread = 
np.concatenate([ru_drift_corr_preassoc_only, ru_assoc_only, ru_dissoc_only]) 
   elif fit_type == "mglld": 
    #print "Fitting langmuir 1:1 with drift...." 
     ru_assoc_only, assoc_values_pred,\ 
    ru_dissoc_only, dissoc_values_pred,\ 
    t_assoc_only, t_dissoc_only, coefs_df,\ 
    afit_params, dfit_params, ru_drift_corr_preassoc_only = 
solveAssocDissocEqsMGLLD(assoc_all_init,\ 
    dissoc_noD_init,\ 
    t_preassoc, response_unit_preassoc,\ 
    analyte_conc,\ 
    fit_type, plot_prefix) 
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     response_unit_pread = 
np.concatenate([ru_drift_corr_preassoc_only, ru_assoc_only, ru_dissoc_only]) 
   elif fit_type == "lmt": 
    #### Might not need to use this! 
    #print "Fitting langmuir 1:1 with mass transfer...." 
     ru_assoc_only, assoc_values_pred,\ 
    ru_dissoc_only, dissoc_values_pred,\ 
    t_assoc_only, t_dissoc_only, coefs_df,\ 
    afit_params, dfit_params = 
solveAssocDissocEqsLMT(assoc_all_init,\ 
    dissoc_noD_init,\ 
    analyte_conc,\ 
    fit_type,\ 
    plot_prefix) 
   elif fit_type == "lmts": 
    #print "Fitting langmuir 1:1 with mass transfer (Area surface 
conc.)...." 
     ru_assoc_only, assoc_values_pred,\ 
    ru_dissoc_only, dissoc_values_pred,\ 
    t_assoc_only, t_dissoc_only, coefs_df,\ 
  
353 
    afit_params, dfit_params = 
solveAssocDissocEqsAsurfLMT(assoc_all_init,\ 
    dissoc_noD_init,\ 
    analyte_conc,\ 
    fit_type,\ 
    plot_prefix) 
   elif fit_type == "hl": 
    #rint "Fitting Heterogeneous ligand...." 
     ru_assoc_only, assoc_values_pred,\ 
    ru_dissoc_only, dissoc_values_pred,\ 
    t_assoc_only, t_dissoc_only, coefs_df,\ 
    afit_params, dfit_params = 
solveAssocDissocEqsHL(assoc_all_init,\ 
    dissoc_noD_init,\ 
    analyte_conc,\ 
    fit_type, plot_prefix) 
  # Calculate assoc and dissoc residuals 
  # resids, resid_ssq, resid_sd 
  # Add 1 to dissoc params since one value is missing till we fit assoc phase 
   assoc_params_count = len(assoc_all_init) 
   dissoc_params_count = len(dissoc_noD_init) 
   assoc_resids, assoc_resid_ssq,\ 
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   assoc_resid_sd, assoc_chisq = 
calcResidualsSsqSD(ru_assoc_only,\ 
     assoc_values_pred,\ 
     assoc_params_count) 
   dissoc_resids, dissoc_resid_ssq,\ 
   dissoc_resid_sd, dissoc_chisq = 
calcResidualsSsqSD(ru_dissoc_only,\       
   dissoc_values_pred,\ 
   dissoc_params_count) 
   t_assoc_dissoc = np.concatenate([t_assoc_only, t_dissoc_only]) 
   assoc_dissoc_values_pred = np.concatenate([assoc_values_pred,\ 
   dissoc_values_pred]) 
   assoc_dissoc_values_resids = np.concatenate([assoc_resids,\ 
   dissoc_resids]) 
   add_coefs_df = DataFrame([{'assoc_resid_sd' : assoc_resid_sd,\ 
   'dissoc_resid_sd' : dissoc_resid_sd,\ 
   'fit_quality' : 'SUCCESS'}]) 
   coefs_df = concat([spot_info_df, add_coefs_df, coefs_df], axis=1) 
   plot_filenamepath = combineAndPlot(response_unit_pread, 
t_pread,\ 
     t_assoc_dissoc,\ 
     assoc_dissoc_values_pred,\ 
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     assoc_dissoc_values_resids,\ 
     raw_time,\ 
     raw_response,\ 
     plot_prefix, plot_file_path) 
   merger.append(PdfFileReader(plot_filenamepath, "rb")) 
  except ValueError: 
   print "Skipping ", ref_spot_name, ". Data might be too noisy..." 
   add_coefs_df = DataFrame([{'fit_quality' : 'NO FIT'}]) 
   coefs_df = concat([spot_info_df, add_coefs_df], axis=1) 
  one_spot_all_coefs_df = one_spot_all_coefs_df.append(coefs_df) 
  if re.search(r'-C', prot_block_name) and response_icol == 1: 
   term_refd_response_unit_pread = response_unit_pread 
  elif re.search(r'-N', prot_block_name) and response_icol == 2: 
   term_refd_response_unit_pread = response_unit_pread 
 return term_refd_response_unit_pread, one_spot_all_coefs_df 
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APPENDIX H 
“MERGEPDFSONFILENAME.PY” DIRECTIONS AND SCRIPT 
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DIRECTIONS 
Below are the directions for running the “mergePDFsOnFileName.py” script: 
1. Make folder in the C: drive labeled “MergePDFs” 
2. Place script “mergePDFsOnFileNames.py” in folder 
3. Copy separate PDFs generated for one SPRi analyses into the folder 
4. Open Anaconda Prompt 
a. cd c:\MergePDFs 
b. activate stanscript 
c. python mergePDFsOnFileNames.py -p c:\MergePDFs 
5. When script is complete, delete the separate PDFs and move the merged files into 
the appropriate folder 
6. Repeat steps 3, 4b, and 5 until all PDF datasets that you want to make are 
completed 
 
SCRIPT 
import re 
from os.path import * 
from os import listdir 
from PyPDF2 import PdfFileReader, PdfFileMerger 
from optparse import * 
def mergePDFsInFolder(input_folder_path,\ 
                      merged_ref1ref2_pdfname="Ref1_Ref2_merged.pdf", 
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                      merged_ref3_pdfname="Ref3_merged.pdf"): 
    pdf_merger_ref1ref2 = PdfFileMerger() 
    pdf_merger_ref3 = PdfFileMerger() 
    for one_file in sorted(listdir(input_folder_path)): 
        if one_file.endswith(".pdf"): 
            #print one_file 
            ref1c_ref2n_pattern = re.match(".*-C.*ref1.*|.*-N.*ref2.*", one_file) 
            ref3_pattern = re.match(".*ref3.*", one_file) 
            if(ref1c_ref2n_pattern and ref1c_ref2n_pattern.group(0)): 
                #print ref1c_ref2n_pattern.group(0) 
                #print one_file 
                pdf_merger_ref1ref2.append(PdfFileReader(join(input_folder_path, one_file), 
"rb")) 
            else: 
                pass 
            if(ref3_pattern and ref3_pattern.group(0)): 
                #print ref3_pattern.group(0) 
                #print one_file 
                pdf_merger_ref3.append(PdfFileReader(join(input_folder_path, one_file), 
"rb")) 
            else: 
                pass 
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        else: 
            pass 
    pdf_merger_ref1ref2.write(join(input_folder_path, merged_ref1ref2_pdfname)) 
    pdf_merger_ref3.write(join(input_folder_path, merged_ref3_pdfname)) 
    return(merged_ref1ref2_pdfname, merged_ref3_pdfname) 
# Read input folder path, output filename and pass to rquired function 
def main(): 
  input_folder_path,\ 
  merged_ref1ref2_pdfname,\ 
  merged_ref3_pdfname = readAndParseCommandlineArgs() 
  merged_pdf_names = mergePDFsInFolder(input_folder_path,\ 
                                      merged_ref1ref2_pdfname,\ 
                                      merged_ref3_pdfname) 
  print merged_pdf_names, "Done!" 
# 
# Read command line options 
# 
def readAndParseCommandlineArgs(): 
  usage = "usage: %prog [options]   (Use -h or --help to see all options)" 
  cl=OptionParser(usage=usage) 
  cl.add_option('--pdfpath', '-p', action='store', 
                help="FULL PATH to input subdirectory", 
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                dest="pdfpath") 
  cl.add_option('--outpdf1', '-1', action='store', 
                help="Merged PDF filename (NO PATH)", 
                default="Ref1_Ref2_merged.pdf", 
                dest="outpdf1") 
  cl.add_option('--outpdf2', '-2', action='store', 
                help="Merged PDF filename (NO PATH)", 
                default="Ref3_merged.pdf", 
                dest="outpdf2") 
  (options, args) = cl.parse_args() 
### Need to add defaults for flexibility 
  # 
  # Check the command line options 
  if options.pdfpath: 
    if isdir(options.pdfpath): 
      input_folder_path = options.pdfpath 
      merged_ref1ref2_pdfname = options.outpdf1 
      merged_ref3_pdfname = options.outpdf2 
      return(input_folder_path, merged_ref1ref2_pdfname, merged_ref3_pdfname) 
  else: 
    cl.error("Please enter a filepath containing the PDFs\n") 
if __name__ == "__main__": 
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   # stuff only to run when not called via 'import' here 
   main() 
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APPENDIX I 
SUPPLEMENTAL NAPPA-SPRI DATA ANALYSES INFORMATION 
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NAPPA-SPRi data analyses 
Guidelines used for determining protein interactions with NAPPA-SPRi 
1.) Affinity had to be within the detection limits of the instrument: 1E-05 to 1E-14 
2.) The curve had to look real by eye, while taking into account what the raw curve 
looked like. 
3.) Had to be represented by at least two interactions across the four replicates (two 
duplicates for two concentrations).  
Rule exceptions: 1) Interactions that were seen at least twice (by eye), but there was 
something wrong with all but one curve. For example, the kinetics were outside the range 
of the instrument or something weird happened during the dissociation phase that 
screwed up the numbers -- like a bubble. 2) PI3K had very few interactions. Therefore, 
some interactors identified with PI3K were only identified by one binding curve. 3) Some 
interactions that were observed in the RHOA dataset once were also selected if the 
response was high  (> 100 RU after referencing). 
 
Additional notes on NAPPA-SPRi analyses 
 The kinetic data (ka, kd) was averaged within duplicates, then the KD was 
determined from these data. If the query interacted with the target protein with the fusion 
tag at the N- and C-terminus, then the interaction with the strongest affinity was selected 
to represent the interaction. 
BLNK, PI3K, RAC1, and RHOA data were referenced to LIME1. Array proteins 
with an N-terminal HaloTag were referenced to N-terminally tagged LIME1, and array 
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proteins with a C-terminal HaloTag were referenced to C-terminally tagged LIME1. BTK 
data were similarly referenced to N- or C-terminally tagged LUC2 (i.e., luciferase). Spot 
numbers refer to the spot location used from the Plexera Data Module software files. 
All data was analyzed with SPRite “MGLLD” parameters except for the 
following: 1) RAC1 curves that had mass transport were processed with SPRite, but the 
kinetics were determined with Scrubber.  
All data was analyzed with the lower-bound and upper-bound limits for drift 
correction as -/+ 20% except for the following: BTK and RHOA datasets. In these 
datasets, the lower-bound limit for drift correction was changed to 0% to +20%. In the 
curveFittingKineticModels.py script (Appendix G), the line 
“lld_global_assoc_dissoc_param_bounds = ((0, 0, 0, -assoc_slope_limit, -np.inf),(np.inf, 
np.inf. np.inf, assoc_slope_limit,np.inf))” under the “def assocdissocEqLLD_global” sub 
routine was changed to “lld_global_assoc_dissoc_param_bounds = ((0, 0, 0, 0, -
np.inf),(np.inf, np.inf. np.inf, assoc_slope_limit,np.inf))”. The original bounds resulted in 
binding curves with strange-looking dissociation curves (e.g., curves that were 0 or 
negative kd).  
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APPENDIX J 
NAPPA-SPRI LAY-OUT, PLASMID DNA DEPOSITION, AND PROTEIN DISPLAY 
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Lay-out of plasmid cDNA on SPR slide 
Figure 103. Lay-out of plasmid cDNA and expressed proteins on SPR slide. The plasmid cDNAs encoding for genes-
of-interest were deposited on the array in a random manner using a pin spotter. 
 
Plasmid cDNA deposition on SPR slide 
 The quality of the printing onto the SPR slide was assessed using a fluorescent 
nucleic stain, PicoGreen® (Thermo Fisher Scientific; Waltham, MA). First, the slides 
were blocked with Tris-based SuperBlock (Thermo Fisher Scientific; Waltham, MA) to 
minimize non-specific binding overnight at 4 oC. Then, 
PicoGreen® diluted in SuperBlock at 1:500 was 
applied to the slide, incubated in the dark for 10 min, 
washed three times in 1x PBS, rinsed in water, and 
dried under compressed air. Fluorescence was 
determined using the PowerScanner MicorarrayTM from 
Tecan Group Ltd. (Switzerland). 
Figure 104. False-colored image of DNA 
deposition using PicoGreen 
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Figure 105. Reproducibility of plasmid cDNA deposition across duplicates 
 
 
Protein expression on SPR slide 
The expression and subsequent capture of target proteins onto the SPR slides were 
assessed fluorescently. First, the slides were blocked with Tris-based SuperBlock 
(Thermo Fisher Scientific; Waltham, MA) to minimize non-specific binding overnight at 
4 oC. They were then washed in 1x PBS three times for 2 min each, rocking. The slides 
were rinsed in water and dried with compressed air. SPRi flow chambers (Plexera; 
Figure 106. Reproducibility of plasmid cDNA deposition across slides 
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Woodinville, WA) with 30 µL volume were applied onto the slides followed by 1-step 
human coupled in vitro protein expression mixture according to the manufacturer’s 
instructions (Thermo Fisher Scientific; Waltham, MA). Expression was performed for 1.5 
hours at 30 oC and then 30 min at 15 oC. To remove the flow cells, the slides were placed 
at -80 oC for 30 sec. Slides were rinsed in 200 µL 1x PBS and blocked for 1 hour at RT 
with 5% milk in 1x PBST (“blocking buffer”). The slides were incubated in rabbit anti-
HaloTag polyclonal antibody (Promega; Madison, WI) diluted 1:250 in blocking buffer 
for 1 hour at RT, rocking. After washing the slides three times in blocking buffer, the 
slides were incubated in Alexa Fluor 555 goat anti-rabbit IgG (Thermo Fisher Scientific; 
Waltham, MA) diluted 1:500 in blocking buffer for 1 hour at RT, rocking. The slides 
were then washed three times in 1x PBS, rinsed in water, and dried under compressed air. 
Fluorescence was determined using the PowerScanner MicorarrayTM from Tecan Group 
Ltd. (Switzerland). 
Figure 107. Target protein expression on an SPR slide as determined with an anti-HaloTag antibody. False-colored 
rainbow image where black represents low protein expression and red represents high protein expression. Note that the 
HaloTag binds preferentially to proteins with an N-terminal HaloTag. 
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Figure 109. Reproducibility of displayed protein across different slides. 
Figure 108. Reproducibility of displayed protein across duplicates. 
Table 35. Buffer conditions used for NAPPA-SPRi 
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Figure 110. NAPPA-SPRi image on the Plexera SPRi biosensor. 
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APPENDIX K 
PROTEIN INTERACTIONS DETECTED BY NAPPA-SPRI  
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Table 36. PPIs detected by NAPPA-SPRi, part 1 
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Table 37. PPIs detected by NAPPA-SPRi, part 2 
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APPENDIX L 
TABLES OF NAPPA-SPRI KINETIC DATA 
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Table 38. BLNK and BTK queries: KD, ka, and kd data, part 1 
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Table 39. BLNK and BTK queries: KD, ka, and kd data, part 2  
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Table 40. PI3K query: KD, ka, and kd data 
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 Table 41. RAC1 query: KD, ka, and kd data 
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Table 42. RHOA query: KD, ka, and kd data 
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APPENDIX M 
NAPPA-SPRI: VENN DIAGRAMS OF NP- AND LT-TARGET INTERACTIONS  
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Figure 112. Venn diagram comparing the PPIs between 
BTK and NP- and LT-targets 
Figure 111. Venn diagram comparing the PPIs 
between BLNK and NP- and LT-targets 
Figure 113. Venn diagram comparing the PPIs 
between PI3K and NP- and LT-targets 
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Figure 117. Venn diagram comparing the PPIs between 
GTP-bound RHOA and NP- and LT-targets 
Figure 116. Venn diagram comparing 
the PPIs between GDP-bound RHOA 
and NP- and LT-targets 
Figure 115. Venn diagram comparing the PPIs 
between GTP-bound RAC1 and NP- and LT-targets 
Figure 114. Venn diagram comparing the PPIs between 
GDP-bound RAC1 and NP- and LT-targets 
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Figure 118. Venn diagram comparing the PPIs with active RAC1 
and RHOA 
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APPENDIX N 
NAPPA-SPRI: STANDARDIZED RESIDUAL PLOTS 
  
  
385 
  
 
Figure 119. Residual plot comparing the binding of NP- and LT-targets. 
Queries preferentially bound to NP-VAV3 compared to LT-VAV3. 
Figure 120. Residual plot comparing the HGNC gene families that interacted with 
BLNK with stronger and weaker binding affinities following lysate treatment. 
Figure 121. Residual plot comparing the HGNC gene families that interacted with 
BTK with stronger and weaker binding affinities following lysate treatment. 
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Figure 123. Residual plot comparing the HGNC gene families that 
interacted with RHOA(GTP) with stronger and weaker binding affinities 
following lysate treatment. 
Figure 122. Residual plot comparing the HGNC gene families that 
interacted with RAC1(GTP) with stronger and weaker binding affinities 
following lysate treatment. 
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Figure 125. Residual plot comparing the PANTHER biological 
processes that interacted with BTK with stronger and weaker binding 
affinities following lysate treatment. 
Figure 124. Residual plot comparing the PANTHER biological processes that 
interacted with BLNK with stronger and weaker binding affinities following lysate 
treatment. 
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Figure 126. Residual plot comparing the PANTHER biological processes 
that interacted with RAC1(GTP) with stronger and weaker binding 
affinities following lysate treatment. 
Figure 127. Residual plot comparing the PANTHER biological processes 
that interacted with RHOA(GTP) with stronger and weaker binding 
affinities following lysate treatment. 
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APPENDIX O 
VENN DIAGRAMS OF NAPPA-SPRI AND NANOBRET INTERACTIONS  
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 Figure 129. Venn diagram comparing BTK’s PPIs identified similarly and uniquely with the 
NanoBRET and NAPPA-SPRi platform  
Figure 128. Venn diagram comparing BLNK’s PPIs identified similarly and uniquely 
with the NanoBRET and NAPPA-SPRi platform 
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Figure 130. Venn diagram comparing PI3K’s PPIs identified similarly and uniquely with 
the NanoBRET and NAPPA-SPRi platform 
Figure 131. Venn diagram comparing GDP-bound RAC1’s PPIs identified similarly and 
uniquely with the NanoBRET and NAPPA-SPRi platform 
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Figure 132. Venn diagram comparing GTP-bound RAC1’s PPIs identified similarly and uniquely 
with the NanoBRET and NAPPA-SPRi platform 
Figure 133. Venn diagram comparing GDP-bound RHOA’s PPIs identified similarly 
and uniquely with the NanoBRET and NAPPA-SPRi platform 
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Figure 134. Venn diagram comparing GTP-bound RHOA’s PPIs identified similarly and uniquely with the 
NanoBRET and NAPPA-SPRi platform 
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APPENDIX P 
BAR PLOTS OF RELATIVE BINDING KINETICS 
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Figure 135. Bar plots showing the relative log10 change in kd, KD, and ka of all PPIs 
between NP- and LT-targets and the BTK query. 
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Figure 136. Bar plots showing the relative log10 change in kd, KD, and ka of all PPIs between NP- and LT-targets and 
the RAC1(GDP) query. 
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Figure 137. Bar plots showing the relative log10 change in kd, KD, and ka of all 
PPIs between NP- and LT-targets and the RAC1(GTP) query. 
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Figure 138. Bar plots showing the relative log10 change in kd, KD, and ka of all PPIs between NP- and LT-targets and 
the RHOA(GDP) query. 
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Figure 139. Bar plots showing the relative log10 change in kd, KD, and ka of all PPIs between NP- and LT-targets and 
the RHOA(GTP) query. 
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Figure 140. Bar plots showing the relative log10 change in kd, KD, and ka of all PPIs with inactive and active RAC1 
to NP-targets. 
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Figure 141. Bar plots showing the relative log10 change in kd, KD, and ka of all PPIs with inactive and active RHOA 
to NP-targets. 
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APPENDIX Q 
NAPPA-SPRI BINDING SENSORGRAMS 
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Figure 142. BLNK’s interactions are largely regulated by their off-rates 
Figure 143. BTK’s interactions are largely regulated by their A) off-rates or B) on-rates. 
Figure 144. Inactive RAC1’s interactions are largely 
regulated by their on- AND off-rates.  
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Figure 145. Active RAC1’s interactions are largely regulated by their 
on- AND off-rates. 
Figure 146. RAC1 activation increases its on- and off-rates with little 
change in binding affinities with LT-targets 
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Figure 147. RAC1 activation significantly increases its on- and off-rates 
with little change in binding affinities with NP-targets 
Figure 148. RAC1 activation minimally affects binding kinetics and affinities 
